[
  {
    "question": "Are there microbes in human breast milk?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are there microbes in human breast milk?', I first consider the biological context. Human breast milk is known to provide nutrition and immune support to infants. Research in recent years has shown that breast milk contains a microbiome, including beneficial bacteria such as Lactobacillus and Bifidobacterium, which play a role in the infant's gut health and immune system development. These microbes are naturally present and transferred to the infant during breastfeeding. There is substantial scientific evidence supporting the presence of microbes in breast milk, so the answer should reflect this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can breastfeeding confer protection from type I diabetes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether breastfeeding can confer protection from type I diabetes, I first consider the nature of type I diabetes, which is an autoimmune condition typically diagnosed in childhood or adolescence, involving the destruction of insulin-producing cells in the pancreas. The causes are multifactorial, including genetic predisposition and environmental triggers. I recall that breastfeeding is often associated with various health benefits for infants, including potential protective effects against certain diseases due to the presence of antibodies and other immune-modulating factors in breast milk. I think there is some research suggesting that breastfeeding might reduce the risk of type I diabetes, possibly by influencing the immune system or delaying exposure to potential dietary triggers like cow's milk proteins, which have been hypothesized to play a role in the development of the disease. However, I also consider that the evidence might not be conclusive, as type I diabetes has a strong genetic component, and environmental factors are complex. Upon reflection, I remember that some studies, including meta-analyses, have indicated a modest protective effect of breastfeeding, particularly if it is exclusive and prolonged for at least a few months. Given this, I lean towards a positive association, though I acknowledge the evidence is not definitive. Therefore, I will answer 'yes', with the understanding that it is based on current research trends rather than absolute certainty.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can pets affect infant microbiomed?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether pets can affect an infant's microbiome, I first consider the concept of the microbiome, which refers to the community of microorganisms living in and on the human body, particularly in the gut, and its importance for health and development. Infants develop their microbiome early in life through various exposures, including birth method, diet, and environment. Pets, as part of the household environment, can introduce different microbes through fur, dander, saliva, or even outdoor elements they bring in. Studies suggest that exposure to pets may influence the diversity of an infant's microbiome, potentially offering protective effects against allergies or asthma by promoting a more varied microbial environment. However, the exact impact can vary based on factors like the type of pet, hygiene practices, and the infant's overall environment. Given the evidence from research indicating a connection between pet exposure and microbial diversity in infants, I conclude that pets can indeed affect an infant's microbiome.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any association between the human gut microbiome and depression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about the association between the human gut microbiome and depression, I first consider the growing body of research in this area. The gut microbiome refers to the trillions of microorganisms living in the digestive tract, which play a role in various aspects of health, including mental health via the gut-brain axis. Studies have shown that the composition of gut bacteria can influence brain function and behavior through mechanisms like inflammation, neurotransmitter production, and stress response. Research, including meta-analyses and clinical studies, has identified differences in the gut microbiome of individuals with depression compared to healthy controls, often showing reduced microbial diversity or altered levels of specific bacteria. Additionally, interventions like probiotics or dietary changes have shown potential in alleviating depressive symptoms in some cases, though causality is not fully established. While the evidence suggests a correlation, it is important to note that the field is still evolving, and more longitudinal studies are needed to confirm direct causation. Based on current scientific understanding, there appears to be an association between the gut microbiome and depression, even if the exact nature of this relationship is not fully understood. Therefore, my answer will reflect this association.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is pembrolizumab effective against Ewing's sarcoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether pembrolizumab is effective against Ewing's sarcoma, I first consider that pembrolizumab is a checkpoint inhibitor, specifically a PD-1 inhibitor, used primarily in cancers with high PD-L1 expression or specific genetic profiles. Ewing's sarcoma is a rare bone and soft tissue cancer, mostly affecting children and young adults, and is typically driven by EWSR1-FLI1 gene fusion. Current standard treatments for Ewing's sarcoma involve chemotherapy, surgery, and radiation, not immunotherapy. I recall that immunotherapy, including pembrolizumab, has shown limited success in sarcomas compared to other cancers like melanoma or lung cancer. Research and clinical trials on pembrolizumab for Ewing's sarcoma are sparse, and there is no strong evidence or FDA approval for its use in this specific cancer. Some studies suggest that Ewing's sarcoma may not express high levels of PD-L1, which could limit the effectiveness of PD-1 inhibitors. Therefore, based on the available knowledge, pembrolizumab is unlikely to be effective as a standard treatment for Ewing's sarcoma.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can gene therapy restore auditory function?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Gene therapy is a promising field in medical science that involves modifying or introducing genes to treat or prevent diseases. In the context of auditory function, research has shown potential for gene therapy to address certain types of hearing loss, particularly those caused by genetic mutations. For instance, conditions like congenital deafness due to defects in specific genes (e.g., GJB2 mutations) have been targeted in preclinical studies using gene therapy to restore or improve auditory function. Animal models, such as mice, have demonstrated successful restoration of hearing through the delivery of corrected genes via viral vectors to the inner ear. Clinical trials in humans are still in early stages, but initial results are encouraging for specific genetic hearing impairments. However, not all types of hearing loss can be addressed with current gene therapy techniques, especially those caused by environmental factors or non-genetic damage to auditory structures. Therefore, while gene therapy can restore auditory function in certain cases, it is not universally applicable yet. Based on the current evidence and potential, the answer leans toward affirmative for specific scenarios.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does vesatolimod inhibit TLR7?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether vesatolimod inhibits TLR7, I first consider the nature of vesatolimod. Vesatolimod is an investigational drug known to be a toll-like receptor 7 (TLR7) agonist, meaning it activates TLR7 to stimulate immune responses, particularly in the context of antiviral or anticancer therapies. Since agonists activate receptors rather than inhibit them, vesatolimod should not inhibit TLR7. I double-check this understanding by recalling that inhibition would imply a blocking or reduction of TLR7 activity, which contradicts the known mechanism of vesatolimod as a stimulator of TLR7. Therefore, the answer should be no, vesatolimod does not inhibit TLR7.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can simvastatin alleviate depressive symptoms?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether simvastatin can alleviate depressive symptoms, I first consider its primary use. Simvastatin is a statin drug primarily prescribed to lower cholesterol levels and reduce the risk of cardiovascular disease. However, there has been some research exploring the potential anti-inflammatory and neuroprotective effects of statins, which could theoretically influence mental health conditions like depression. I recall that inflammation is implicated in some cases of depression, and statins have anti-inflammatory properties. There are studies suggesting a potential link between statin use and reduced depressive symptoms, particularly in patients with co-morbid conditions like heart disease. However, the evidence is not conclusive, and simvastatin is not an approved treatment for depression. Clinical guidelines and major health organizations do not recommend statins as a primary treatment for depressive symptoms. The question asks if it 'can' alleviate symptoms, which implies possibility rather than established treatment. Given some evidence of potential benefit, even if not primary or widely accepted, I lean towards 'yes', but I must be cautious as the primary purpose of simvastatin is not for depression, and results may vary. After weighing this, I conclude that while there is some supportive evidence, it is not definitive or standard practice, but the question's phrasing allows for a positive response based on possibility.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does gepotidacin activate bacterial topoisomerase?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether gepotidacin activates bacterial topoisomerase, I first consider the role of bacterial topoisomerase, which is an enzyme involved in DNA replication and repair by managing DNA supercoiling. Gepotidacin is a novel antibiotic that targets bacterial DNA gyrase and topoisomerase IV, which are types of topoisomerases. However, the key point is whether it 'activates' these enzymes or inhibits them. From my understanding, gepotidacin works by inhibiting the activity of bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and leading to bacterial cell death. Activation would imply stimulating or enhancing the enzyme's function, which is not the mechanism of action for gepotidacin. Therefore, the answer should be based on this inhibitory effect rather than activation.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is obesity related to cognitive decline?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether obesity is related to cognitive decline, I first consider the scientific consensus and available evidence. Obesity is a condition characterized by excessive body fat, often linked to various health issues like diabetes and cardiovascular disease. Cognitive decline refers to the deterioration of mental functions such as memory, attention, and problem-solving, often associated with aging or neurodegenerative diseases. Research suggests a connection between obesity and cognitive decline, as obesity can contribute to inflammation, insulin resistance, and vascular problems, all of which may negatively impact brain health. Numerous studies, including meta-analyses, have shown that obesity, especially in midlife, is a risk factor for cognitive impairment and dementia later in life. However, the relationship is complex and may be influenced by other factors like genetics, lifestyle, and comorbidities. While the evidence leans toward a correlation, causation is not fully established in all cases. Given the weight of evidence, I conclude that obesity is related to cognitive decline.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are whole-genome duplications more divergent than small-scale duplications in yeast?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether whole-genome duplications (WGDs) are more divergent than small-scale duplications (SSDs) in yeast, I need to consider the biological context. WGDs involve the duplication of an entire genome, leading to a sudden increase in gene content across all chromosomes, while SSDs involve the duplication of smaller segments, such as individual genes or chromosomal regions. Divergence can refer to sequence divergence (mutations accumulating over time) or functional divergence (changes in gene function). In yeast, particularly Saccharomyces cerevisiae, WGD is a well-studied event that occurred approximately 100 million years ago, leading to significant gene loss and functional divergence among retained duplicates. SSDs, on the other hand, occur more frequently and may not experience the same evolutionary pressures as WGDs. Research suggests that WGDs often result in greater divergence due to the potential for subfunctionalization and neofunctionalization across many gene pairs simultaneously, as well as the larger evolutionary time scale since the event. SSDs might show less divergence because they are more recent or constrained by local genomic context. Therefore, based on this analysis, I conclude that WGDs are generally more divergent than SSDs in yeast.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do yeast LTR give rise to circular DNA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether yeast Long Terminal Repeats (LTRs) give rise to circular DNA, I need to consider the biological context. LTRs are sequences typically associated with retrotransposons, which are mobile genetic elements in yeast, such as Saccharomyces cerevisiae. These elements can replicate via an RNA intermediate and integrate into the genome, but the question specifically asks about the formation of circular DNA. Circular DNA can arise in various contexts, such as extrachromosomal circular DNA (eccDNA) or through specific recombination events. In yeast, Ty elements (a type of retrotransposon with LTRs) are known to occasionally form circular intermediates during their replication cycle, particularly through recombination between LTRs. Studies have shown that such circular forms can be detected, though they are not the primary mode of transposition. Therefore, while it is not the most common outcome, yeast LTRs associated with retrotransposons can give rise to circular DNA under certain conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Copy Number Variants (CNVs) depleted in regions of low mappability?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Copy Number Variants (CNVs) are depleted in regions of low mappability, I first consider the definition of CNVs and mappability. CNVs are structural variations in the genome where sections of DNA are duplicated or deleted, leading to variations in copy number. Mappability refers to the ability to uniquely map sequencing reads to a specific genomic region; regions of low mappability often include repetitive sequences or areas with high similarity to other parts of the genome, making it difficult to accurately assign reads. It is plausible that CNVs might be underrepresented in such regions because the detection of CNVs relies on accurate read mapping. In low mappability regions, the ambiguity in read placement could lead to under-detection of CNVs, suggesting depletion. However, this could also be a technical artifact rather than a biological phenomenon. Upon reflection, studies in genomics often report challenges in detecting structural variants in repetitive regions, supporting the idea of depletion in low mappability areas. Therefore, I conclude that CNVs are likely depleted in such regions.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can mitochondria be inherited by both parents in humans?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether mitochondria can be inherited from both parents in humans, I need to consider the biological mechanism of mitochondrial inheritance. Mitochondria are organelles in cells that produce energy, and they contain their own DNA, separate from nuclear DNA. In humans, mitochondria are typically inherited maternally, meaning they are passed down through the egg from the mother to the offspring. During fertilization, the sperm contributes nuclear DNA but usually does not contribute mitochondria, as the mitochondria in sperm are generally not incorporated into the embryo or are degraded. There are rare cases and exceptions where paternal mitochondrial DNA might be detected, but these are not the norm and often involve specific conditions or experimental contexts. For the purpose of this question, which seems to ask about the general case in humans, the standard understanding is that mitochondria are inherited only from the mother. Therefore, the answer should be 'no', as mitochondria are not typically inherited from both parents.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Have machine learning methods been used to predict the severity of major depressive disorder(MDD)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider whether there is evidence or research indicating that machine learning methods have been applied to predict the severity of major depressive disorder (MDD). Machine learning is widely used in healthcare for predictive modeling, including mental health applications. There are studies and papers that discuss the use of machine learning algorithms to analyze data such as patient symptoms, brain imaging, or electronic health records to predict outcomes in depression, including severity. Based on this, it is reasonable to conclude that such methods have indeed been used for this purpose.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any association between suicide and autism in adolescents, yes or no?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about an association between suicide and autism in adolescents, I first consider the available research and data on this topic. Studies have indicated that individuals with autism spectrum disorder (ASD) may be at a higher risk for suicidal thoughts and behaviors compared to the general population. Factors such as social isolation, bullying, anxiety, depression, and difficulties in emotional regulation, which are often more prevalent in individuals with autism, can contribute to this risk. Specific research, including meta-analyses and cohort studies, has shown that adolescents with autism have a significantly higher rate of suicidal ideation and attempts. For instance, a 2019 study published in the Journal of Autism and Developmental Disorders highlighted that adolescents with ASD are at an elevated risk for suicide-related outcomes. While correlation does not imply causation, the consistent findings across multiple studies suggest a notable association. Therefore, based on this analysis, there appears to be evidence supporting an association between suicide and autism in adolescents.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does allele phasing improve the phylogenetic utility of ultraconserved elements?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether allele phasing improves the phylogenetic utility of ultraconserved elements (UCEs), I first consider the role of allele phasing and UCEs in phylogenetics. UCEs are highly conserved genomic regions used as markers for reconstructing evolutionary relationships due to their low mutation rates and presence across diverse taxa. Allele phasing refers to the process of determining the specific combination of alleles on each chromosome, which can help in distinguishing heterozygous sites and understanding genetic variation more accurately. In phylogenetics, accurate resolution of genetic variation can improve tree reconstruction by providing clearer signals of divergence and reducing noise from ambiguous or unresolved heterozygous sites. Studies suggest that phasing can enhance the accuracy of haplotype inference, potentially leading to better resolution in phylogenetic analyses, especially in cases of recent divergence or complex evolutionary histories. However, the impact might be limited for UCEs specifically, as they are highly conserved and may not exhibit sufficient variation for phasing to make a significant difference in some cases. On balance, given the potential for improved resolution of genetic variation, it is reasonable to conclude that allele phasing can improve the phylogenetic utility of UCEs, at least in certain contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are ultraconserved enhancers important for normal development?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ultraconserved enhancers are important for normal development, I first consider what ultraconserved enhancers are. These are highly conserved non-coding DNA sequences that often act as enhancers, regulating gene expression critical for development. Research indicates that many ultraconserved elements are associated with genes involved in embryonic development, and mutations or deletions in these regions can lead to developmental abnormalities in model organisms. While some studies suggest redundancy or non-essential roles for certain ultraconserved enhancers, the majority of evidence points to their importance in ensuring proper gene regulation during development. Therefore, I conclude that they are indeed important for normal development.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Bobble head doll syndrome associated with hydrocephalus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Bobble head doll syndrome is a rare neurological condition characterized by repetitive, involuntary head movements, often resembling the motion of a bobblehead doll. It is frequently associated with hydrocephalus, a condition involving an accumulation of cerebrospinal fluid in the brain, which can cause ventricular enlargement and pressure on brain structures. Research and medical literature indicate that hydrocephalus, particularly when it involves the third ventricle or aqueductal stenosis, is a common underlying cause of bobble head doll syndrome. Therefore, there is a recognized association between the two conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Tisagenlecleucel effective for B-Cell Lymphoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Tisagenlecleucel is effective for B-Cell Lymphoma, I first consider that Tisagenlecleucel is a CAR-T cell therapy approved for certain types of B-cell malignancies. It is specifically indicated for relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), based on clinical trials like the JULIET trial, which demonstrated significant response rates in patients who had failed prior treatments. The therapy works by modifying a patient's T-cells to target CD19 on B-cell lymphoma cells, leading to tumor reduction in many cases. While effectiveness can vary based on individual patient factors, the overall evidence supports its efficacy in this context. Therefore, the answer should reflect this established medical consensus.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is durvalumab used for lung cancer treatment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Durvalumab is an immunotherapy drug, specifically a PD-L1 inhibitor, used in the treatment of certain types of cancer. It is approved for use in non-small cell lung cancer (NSCLC) under specific conditions, such as unresectable Stage III NSCLC after chemoradiation therapy. Therefore, durvalumab is indeed used for lung cancer treatment.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does epidural anesthesia for pain management during labor affect the Apgar score of the the infant?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether epidural anesthesia for pain management during labor affects the Apgar score of the infant, I first consider the purpose of the Apgar score, which is a quick assessment of a newborn's health at 1 and 5 minutes after birth, evaluating factors like heart rate, respiratory effort, muscle tone, reflex response, and color. Epidural anesthesia is a common method for pain relief during labor, but it can potentially influence labor progression or maternal pushing efforts, which might indirectly affect the infant's condition at birth. Research and clinical studies suggest that while epidurals may slightly increase the risk of instrumental delivery or prolonged labor, most evidence indicates no significant direct impact on Apgar scores when properly managed. Factors like dosage, timing, and individual maternal response to the epidural could play a role, but overall, the consensus in medical literature leans toward minimal to no adverse effect on Apgar scores. Therefore, I conclude that epidural anesthesia does not generally affect the Apgar score of the infant.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) been reported to be a plasminogen receptor in pathogenic bacteria?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the role of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in pathogenic bacteria and whether it has been documented as a plasminogen receptor. GAPDH is a well-known enzyme involved in glycolysis, but research has shown that in some pathogenic bacteria, such as Streptococcus species, GAPDH can be surface-exposed and multifunctional. Studies have reported that GAPDH on the bacterial surface can bind to host proteins, including plasminogen, facilitating the conversion of plasminogen to plasmin, which aids in tissue invasion and immune evasion. For instance, literature on Streptococcus pyogenes indicates that GAPDH acts as a plasminogen-binding protein. Therefore, there is evidence supporting GAPDH as a plasminogen receptor in pathogenic bacteria.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can exposure to heavy metals like lead(Pb) or cadmium(Cd) cause changes in DNA methylation patterns in Isoetes sinensis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the biological context and existing scientific knowledge. Isoetes sinensis is a type of aquatic fern, and DNA methylation is an epigenetic modification that can influence gene expression without altering the DNA sequence. Heavy metals like lead (Pb) and cadmium (Cd) are known environmental pollutants that can induce stress in plants, potentially leading to epigenetic changes as a response mechanism. Research in other plant species has shown that heavy metal exposure can alter DNA methylation patterns as a stress response or adaptation mechanism. Although specific studies on Isoetes sinensis may not be widely documented, the general principle of heavy metal-induced epigenetic changes in plants suggests that such an effect is plausible. Therefore, it is reasonable to conclude that exposure to heavy metals could cause changes in DNA methylation patterns in Isoetes sinensis.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "In clinical trials, the H3 R antagonist CEP-26401 has a positive effect on cognition, yes or no?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the H3 R antagonist CEP-26401 has a positive effect on cognition in clinical trials, I need to consider the available scientific evidence. H3 receptor antagonists are known to be investigated for their potential to enhance cognitive function, as histamine H3 receptors are involved in regulating neurotransmitter release in the brain, which can influence memory and learning. CEP-26401, also known as irdabisant, is a specific H3 receptor antagonist that has been studied for its effects on cognition, particularly in conditions like Alzheimer's disease or attention deficit disorders. I recall that preclinical studies in animal models have shown promising results, with improvements in memory and attention. However, in clinical trials, the results have been mixed or inconclusive. For instance, some early-phase trials suggested potential benefits in specific cognitive domains, but larger or later-phase trials did not consistently demonstrate significant improvements over placebo. Given the lack of definitive, robust evidence from clinical trials confirming a positive effect on cognition, I lean towards a negative answer. However, I must acknowledge the possibility of emerging data or specific contexts where a positive effect was observed. Since the question is phrased broadly and based on the most current general knowledge, I will conclude with 'no' due to insufficient conclusive evidence in clinical settings.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the role of yeast prions in scientific research, particularly in relation to human amyloid diseases. Yeast prions are protein-based infectious agents in yeast that can adopt misfolded conformations and propagate these states. They share similarities with amyloids, which are misfolded protein aggregates implicated in human diseases like Alzheimer's and Parkinson's. Research has shown that yeast prions, due to their simpler systems and ease of genetic manipulation, have been used as models to study protein misfolding, aggregation, and transmission mechanisms that are relevant to human amyloid diseases. Studies on yeast prions have provided insights into the structural and functional aspects of amyloid formation and the cellular mechanisms that regulate these processes. Therefore, it seems that yeast prions have indeed become important models for understanding the basic mechanisms of human amyloid diseases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay, I first consider the role of BCL11B. BCL11B is a transcription factor critical for brain development, particularly in the formation of cortical neurons and connections. Haploinsufficiency refers to a condition where a single functional copy of a gene is insufficient to maintain normal function, often leading to disease. Recent studies and clinical reports have identified that mutations or deletions leading to BCL11B haploinsufficiency are associated with neurodevelopmental disorders, including intellectual disability, speech delay, and other syndromic features. These conditions often present as syndromic neurodevelopmental delay, characterized by multiple congenital anomalies alongside developmental issues. Therefore, there appears to be a documented connection in medical literature between BCL11B haploinsufficiency and such delays.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is the PINES framework being used for the prediction of coding variants?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the PINES framework is being used for the prediction of coding variants, I first need to consider what PINES refers to. PINES (Protein Interaction Network-based Evaluation of Significance) is a computational framework often associated with evaluating the significance of genetic variants, particularly in the context of protein interactions. Coding variants are changes in the DNA sequence that affect the protein-coding regions of genes, and tools like PINES could theoretically be applied to predict or assess their impact by leveraging protein interaction networks. However, I must confirm if PINES is specifically designed or widely recognized for this purpose. Upon reflection, PINES seems more focused on prioritizing non-coding variants based on network properties rather than directly predicting coding variants. Many other tools like SIFT, PolyPhen, or ANNOVAR are more commonly used for coding variant prediction. Therefore, I believe PINES is not primarily used for this specific task.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Tecovirimat effective for smallpox?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Tecovirimat is effective for smallpox, I first consider the context of the question. Smallpox is a highly contagious and deadly disease caused by the variola virus, which has been eradicated globally due to vaccination efforts. However, concerns about bioterrorism or accidental release persist, making antiviral treatments relevant. Tecovirimat, also known as TPOXX, is an antiviral drug specifically developed to treat orthopoxvirus infections, including smallpox. Research and clinical data indicate that Tecovirimat inhibits the viral envelope protein, preventing the virus from spreading within the host. It has been approved by the FDA for the treatment of smallpox under specific conditions, based on animal studies and human safety data, as direct clinical trials on smallpox patients are not feasible due to the disease's eradication. While it has not been tested in active human smallpox cases, the available evidence from animal models and its mechanism of action strongly suggest effectiveness. Therefore, I conclude that Tecovirimat is considered effective for smallpox based on current scientific understanding and regulatory approvals.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cabozantinib effective for hepatocellular carcinoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether cabozantinib is effective for hepatocellular carcinoma (HCC), I am considering the available medical knowledge and clinical evidence. Cabozantinib is a tyrosine kinase inhibitor that targets multiple pathways involved in tumor growth and angiogenesis. Clinical trials, such as the CELESTIAL trial, have demonstrated that cabozantinib significantly improves overall survival in patients with advanced HCC who have previously been treated with sorafenib, compared to placebo. The trial showed a median overall survival of 10.2 months with cabozantinib versus 8.0 months with placebo. Additionally, it has been approved by regulatory bodies like the FDA for this indication. Therefore, based on this evidence, cabozantinib can be considered effective for hepatocellular carcinoma in certain patient populations.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Baloxavir effective for influenza?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Baloxavir is effective for influenza, I am considering the available information on this antiviral medication. Baloxavir marboxil, marketed under the brand name Xofluza, is a relatively new antiviral drug approved for the treatment of influenza in certain populations. It works by inhibiting the cap-dependent endonuclease enzyme, which is essential for viral replication, thus reducing the duration of flu symptoms. Clinical trials and studies, such as those published in medical journals, have shown that Baloxavir can reduce the duration of influenza symptoms by about one day when taken within 48 hours of symptom onset, compared to placebo. It has also been shown to reduce viral shedding, potentially decreasing transmission. However, its effectiveness can vary based on factors like the timing of administration, the specific strain of influenza, and patient factors such as age and health status. While it is not a cure, it is considered effective in managing uncomplicated influenza in otherwise healthy individuals aged 12 and older, as per approvals by regulatory bodies like the FDA. There are also considerations of resistance development in some cases, but overall, the consensus in medical literature supports its efficacy for influenza treatment under the right conditions. Therefore, I conclude that Baloxavir is effective for influenza.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ibudilast effective for multiple sclerosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ibudilast is effective for multiple sclerosis (MS), I first consider the context of the disease and the drug. Multiple sclerosis is a chronic autoimmune condition affecting the central nervous system, leading to inflammation and damage to the myelin sheath. Treatments for MS often focus on reducing inflammation, slowing disease progression, and managing symptoms. Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory and neuroprotective properties, primarily used in Japan for asthma and post-stroke complications. Recent studies, particularly a phase 2 clinical trial (SPRINT-MS), have investigated its potential in MS, showing a reduction in brain atrophy in patients with progressive MS, suggesting a neuroprotective effect. However, it did not significantly impact relapse rates or disability progression in all cases. While promising, ibudilast is not yet widely approved or established as a standard treatment for MS globally, and further research is needed to confirm its efficacy and safety. Given the evidence of some positive outcomes in progressive MS, I lean toward a cautious affirmative, but recognize the limitations. Since the question asks for a binary 'yes' or 'no' without qualifiers, and considering the evidence of effectiveness in specific contexts, I will answer 'yes' with the understanding that it is not universally conclusive.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Adar3 involved in learning and memory?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Adar3 is involved in learning and memory, I first consider the context of Adar3. Adar3 is a member of the ADAR (Adenosine Deaminases Acting on RNA) family of enzymes, which are involved in RNA editing by converting adenosine to inosine in double-stranded RNA. While Adar1 and Adar2 have been more extensively studied for their roles in various physiological processes, including neural functions, Adar3 is less characterized. Research suggests that Adar3 is predominantly expressed in the brain, and some studies indicate it may act as a negative regulator of RNA editing by competing with Adar2. There is emerging evidence linking RNA editing to neural plasticity, learning, and memory processes, as these functions often depend on precise regulation of gene expression in the brain. However, direct evidence specifically implicating Adar3 in learning and memory is limited or inconclusive in current literature. Some studies suggest a potential indirect role through its influence on RNA editing balance, but it is not as clearly established as for other ADAR enzymes. Therefore, while there is a plausible connection due to its brain expression and regulatory role, I lean towards a cautious answer based on the lack of definitive evidence.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is deletion at 6q24.2-26 associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether deletion at 6q24.2-26 is associated with longer survival in patients with high-grade serous ovarian carcinoma (HGSOCs), I first consider the context of genetic deletions and their potential impact on cancer prognosis. Deletions in specific chromosomal regions can affect tumor suppressor genes or other regulatory elements, potentially influencing cancer progression and patient outcomes. In the case of HGSOCs, a common and aggressive form of ovarian cancer, genetic alterations are often studied for their prognostic significance. I recall that some studies have investigated chromosomal aberrations in ovarian cancer, including deletions in the 6q region. Specifically, deletion at 6q24.2-26 has been noted in literature as a region of interest. Based on available data and studies, such as those from The Cancer Genome Atlas (TCGA) or other genomic analyses, there is evidence suggesting that deletion in this region may be associated with altered gene expression that could impact survival. I believe research has indicated that this deletion might correlate with better outcomes or longer survival in HGSOC patients, possibly due to the loss of certain oncogenic drivers or interactions with treatment response. However, I must acknowledge the complexity of cancer genomics, where the effect of a deletion can vary based on other genetic or environmental factors. After weighing this, I conclude that the answer leans toward an association with longer survival based on current understanding and reported findings in scientific literature.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is  LRP1 interacting with Urokinase receptor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether LRP1 (Low-density lipoprotein receptor-related protein 1) interacts with the Urokinase receptor (uPAR), I am considering the biological context and known interactions. LRP1 is a large endocytic receptor involved in the clearance of various ligands, including proteases and their complexes. The Urokinase receptor (uPAR) is a cell surface receptor that binds urokinase-type plasminogen activator (uPA), facilitating its activity in fibrinolysis and cell migration. Research indicates that LRP1 can interact with uPAR indirectly through the uPA-PAI-1 (plasminogen activator inhibitor-1) complex. When uPA binds to uPAR and is inhibited by PAI-1, the resulting complex can be internalized via LRP1 for degradation. This suggests a functional interaction between LRP1 and uPAR, mediated by other molecules. Therefore, while there may not be a direct physical binding between LRP1 and uPAR, they are part of the same pathway and interact functionally.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is chlorotoxin a peptide?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether chlorotoxin is a peptide, I first consider the definition of a peptide, which is a short chain of amino acids linked by peptide bonds, typically smaller than proteins. Chlorotoxin is a molecule derived from the venom of the deathstalker scorpion and is known for its use in medical research, particularly in targeting cancer cells. Upon recalling, chlorotoxin is indeed composed of 36 amino acids, making it a small protein or peptide. Since peptides are often defined as chains of fewer than 50 amino acids, chlorotoxin fits this criterion. Therefore, it is accurate to classify chlorotoxin as a peptide.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is selenocysteine an aminoacid?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Selenocysteine is a naturally occurring amino acid that is incorporated into proteins during translation. It is often referred to as the 21st amino acid and contains selenium instead of sulfur, distinguishing it from cysteine. It is found in certain proteins across various organisms and is essential for their function. Therefore, it is indeed considered an amino acid.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is phospholipid hydroperoxide glutathione peroxidase a selenoprotein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether phospholipid hydroperoxide glutathione peroxidase (PHGPx) is a selenoprotein, I need to consider the definition of a selenoprotein and the characteristics of PHGPx. A selenoprotein is a protein that contains the amino acid selenocysteine, which is incorporated into the protein during translation and often plays a critical role in the protein's function, especially in antioxidant enzymes. PHGPx is an enzyme involved in protecting cells from oxidative damage by reducing lipid hydroperoxides. I recall that PHGPx, also known as GPx4, is indeed a member of the glutathione peroxidase family, and it is well-documented in scientific literature that GPx4 contains selenocysteine at its active site, making it a selenoprotein. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is P. gingivalis bacteria found in brain?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether P. gingivalis bacteria is found in the brain, I first consider the nature of P. gingivalis, which is a gram-negative bacterium primarily associated with periodontal disease in the oral cavity. It is known to cause inflammation and tissue destruction in the gums. Recent research has explored links between oral health and systemic diseases, including neurodegenerative conditions like Alzheimer's disease. Studies have suggested that P. gingivalis or its byproducts, such as gingipains, may be detected in the brains of individuals with Alzheimer's, potentially contributing to neuroinflammation and plaque formation. For instance, a 2019 study published in Science Advances found P. gingivalis DNA and gingipains in the brains of Alzheimer's patients, indicating a possible translocation from the oral cavity to the brain, perhaps via the bloodstream or neural pathways. However, this does not mean it is universally present in all brains or that it directly causes brain pathology in healthy individuals. The presence seems to be associated with specific disease states rather than a general occurrence. Given the evidence, I conclude that P. gingivalis can be found in the brain under certain conditions, particularly in the context of neurodegenerative diseases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"The question asks whether there is no drug available to prevent HIV infection, specifically mentioning Pre-exposure prophylaxis (PrEP). PrEP is a well-established medical intervention involving the use of antiretroviral drugs to prevent HIV infection in high-risk individuals. Since PrEP exists and is widely used for this purpose, the statement 'there is no drug available to prevent HIV infection' is incorrect. Therefore, the answer should be 'no' to indicate that the statement is false, as a drug (PrEP) does exist for prevention.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is cariprazine effective for treatment of bipolar disorder?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether cariprazine is effective for the treatment of bipolar disorder, I first consider the context of the question. Cariprazine is an atypical antipsychotic medication, and I recall that it has been studied and approved for certain psychiatric conditions. I believe it is FDA-approved for the treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the maintenance treatment of bipolar I disorder. Clinical trials have shown its efficacy in managing symptoms of bipolar disorder, particularly in stabilizing mood during manic episodes and preventing relapse. However, effectiveness can vary based on individual patient factors, and it may not be suitable for all types of bipolar disorder or all patients. Since the question is general and does not specify a particular context or subtype, I will base my answer on the general evidence and approved indications. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Groucho related gene 5 (GRG5) have a role only in late development?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Groucho related gene 5 (GRG5) has a role only in late development, I need to consider the biological context of GRG5, also known as AES (Amino-terminal Enhancer of Split). GRG5 is a member of the Groucho/Transducin-like Enhancer of Split (TLE) family of transcriptional co-repressors, which are involved in various developmental processes through their interaction with transcription factors in signaling pathways like Notch, Wnt, and others. Research indicates that GRG5 is expressed and functional in multiple stages of development, not just late stages. For instance, it plays roles in early embryonic patterning and organogenesis by modulating signaling cascades. Additionally, its expression has been observed in adult tissues, suggesting functions beyond development. Therefore, it does not appear to be restricted to late development.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the yeast (Saccharomyces cerevisiae) genome organized into topologically associated domains (TADs)?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the yeast (Saccharomyces cerevisiae) genome is organized into topologically associated domains (TADs), I first consider the definition of TADs. TADs are regions of the genome that are spatially organized into distinct domains where DNA sequences interact more frequently with each other than with sequences outside the domain. These structures are well-documented in higher eukaryotes, such as mammals, where they play a role in gene regulation. However, yeast, being a unicellular eukaryote, has a much smaller and less complex genome compared to mammals. Research on yeast genome organization suggests that while there is some level of chromosomal organization, such as clustering of certain genomic regions (e.g., centromeres and telomeres), the presence of well-defined TADs, as seen in higher eukaryotes, is not a prominent feature. Studies using Hi-C and other chromosome conformation capture techniques in yeast indicate that the genome exhibits a more uniform interaction pattern without clear TAD boundaries. Therefore, based on current understanding, the yeast genome is not organized into TADs in the same way as in higher eukaryotes.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there any role for HUWE1 in MYC signalling?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether there is any role for HUWE1 in MYC signaling, I first consider the biological context. HUWE1 is an E3 ubiquitin ligase known to regulate protein stability by targeting proteins for degradation. MYC, on the other hand, is a proto-oncogene and transcription factor critical for cell growth and proliferation, often dysregulated in cancer. I recall that MYC stability and activity are tightly controlled by ubiquitination and degradation pathways. Research suggests that HUWE1 can ubiquitinate MYC, marking it for proteasomal degradation, thereby negatively regulating MYC levels and its signaling activity. Studies have shown that HUWE1-mediated degradation of MYC can impact cellular processes like proliferation and apoptosis, indicating a direct role in MYC signaling regulation. Therefore, there appears to be a significant role for HUWE1 in MYC signaling.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is TIAM1 favoring tumor progression in colorectal cancer (CRC)?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether TIAM1 favors tumor progression in colorectal cancer (CRC), I need to consider the biological role of TIAM1. TIAM1 (T-cell lymphoma invasion and metastasis 1) is a guanine nucleotide exchange factor (GEF) that activates Rho GTPases, particularly Rac1. It is known to play a role in cell migration, invasion, and metastasis by regulating cytoskeletal dynamics and cell adhesion. In the context of colorectal cancer, studies have shown that TIAM1 is often overexpressed in CRC tissues compared to normal tissues. This overexpression is associated with increased tumor invasiveness, metastasis, and poor prognosis. Additionally, TIAM1 has been implicated in promoting epithelial-to-mesenchymal transition (EMT), a key process in cancer progression. While there might be context-dependent roles or conflicting studies, the majority of evidence suggests that TIAM1 contributes to tumor progression in CRC by enhancing migratory and invasive capabilities of cancer cells. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are de novo mutations in regulatory elements responsible for neurodevelopmental disorders?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether de novo mutations in regulatory elements are responsible for neurodevelopmental disorders, I first consider the role of regulatory elements in gene expression. Regulatory elements, such as promoters and enhancers, control when, where, and how much a gene is expressed. Mutations in these regions can disrupt normal gene function without altering the coding sequence. De novo mutations are genetic changes that occur spontaneously in an individual and are not inherited from either parent. Neurodevelopmental disorders, including autism spectrum disorder and intellectual disability, have been linked to genetic factors. Research has shown that de novo mutations in coding regions can contribute to these disorders, but there is also growing evidence that mutations in non-coding regulatory regions can affect gene expression critical for brain development. Studies, such as those using whole-genome sequencing, have identified de novo mutations in regulatory elements associated with altered expression of genes involved in neuronal function. While not all neurodevelopmental disorders are caused by such mutations, there is sufficient evidence to suggest they play a significant role in some cases. Therefore, I conclude that de novo mutations in regulatory elements can indeed be responsible for neurodevelopmental disorders.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are recessive coding variants responsible for the majority of undiagnosed nonconsanguineous individuals?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the role of recessive coding variants in genetic disorders, particularly in nonconsanguineous individuals (those not closely related by blood). Recessive variants require two copies (one from each parent) to cause a disease, and they are often associated with rare genetic disorders. In nonconsanguineous populations, the likelihood of inheriting two copies of a rare recessive variant is lower compared to consanguineous populations, where shared ancestry increases the chance of such events. Recent studies in genetics, such as those involving exome sequencing, suggest that while recessive variants do contribute to undiagnosed genetic conditions, the majority of cases in nonconsanguineous individuals are more likely to be caused by de novo mutations, dominant variants, or complex genetic interactions rather than recessive coding variants alone. Therefore, I conclude that recessive coding variants are not responsible for the majority of undiagnosed cases in this population.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the NLM medical text indexer (MTI) still useful and relevant?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the NLM Medical Text Indexer (MTI) is still useful and relevant, I need to consider its purpose and current context. MTI is a tool developed by the National Library of Medicine to assist in indexing biomedical literature by automatically suggesting MeSH (Medical Subject Headings) terms for articles. It supports indexing for databases like MEDLINE. Given the increasing volume of biomedical literature, automated tools like MTI are crucial for efficient categorization and retrieval of information. Additionally, while machine learning and AI technologies are advancing, MTI remains integrated into workflows at NLM and is regularly updated to incorporate new methodologies. It also serves as a benchmark for other indexing tools. Therefore, despite the emergence of newer technologies, MTI's role in supporting indexing for a vast and critical database like MEDLINE suggests it retains relevance and utility.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cohesin linked to myeloid differentiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether cohesin is linked to myeloid differentiation, I first consider the role of cohesin, a protein complex crucial for chromosome segregation and gene regulation through chromatin looping. Myeloid differentiation refers to the process by which hematopoietic stem cells develop into myeloid lineage cells like macrophages and granulocytes. Research indicates that cohesin mutations are frequently associated with myeloid malignancies, such as acute myeloid leukemia (AML), suggesting a role in regulating differentiation. Studies have shown that cohesin dysfunction can disrupt normal gene expression patterns critical for myeloid lineage commitment, often leading to impaired differentiation or leukemogenesis. Therefore, there appears to be a significant link between cohesin and myeloid differentiation through its impact on genomic organization and transcriptional control.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is erythropoietin effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether erythropoietin (EPO) is effective for the treatment of amyotrophic lateral sclerosis (ALS), I first consider the nature of ALS, a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and paralysis. Erythropoietin is a hormone primarily known for stimulating red blood cell production, but it also has neuroprotective properties, which have been studied in various neurological conditions. I recall that there have been preclinical studies suggesting EPO might have potential benefits in ALS due to its anti-inflammatory and anti-apoptotic effects. However, I also consider clinical evidence. Upon reflection, I remember that clinical trials, including a notable Phase II/III trial, have been conducted to evaluate EPO in ALS patients. The results of these trials, particularly a 2013 study published in a reputable journal, indicated that EPO did not significantly slow disease progression or improve survival in ALS patients compared to placebo. While there might be some theoretical benefits, the clinical evidence does not support its effectiveness for ALS treatment at this time. Therefore, based on the lack of positive outcomes in human trials, my answer leans towards 'no'. I double-check if there are any newer studies or meta-analyses that might contradict this, but I am not aware of any recent data overturning the earlier findings. Thus, I conclude that erythropoietin is not considered effective for the treatment of ALS.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can mogamulizumab be used for the treatment of cutaneous T-cell lymphoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether mogamulizumab can be used for the treatment of cutaneous T-cell lymphoma (CTCL), I first consider the nature of the drug and its approved indications. Mogamulizumab is a monoclonal antibody targeting CCR4, a protein often overexpressed on the surface of certain cancer cells, including those in CTCL. I recall that it has been approved by regulatory bodies like the FDA for the treatment of relapsed or refractory mycosis fungoides or Sézary syndrome, which are subtypes of CTCL, based on clinical trial data demonstrating efficacy in these conditions. Therefore, it is reasonable to conclude that mogamulizumab is indeed used for treating CTCL in specific cases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has ivosidenib been FDA approved for use against acute myeloid leukemia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I need to consider whether ivosidenib has been approved by the FDA for treating acute myeloid leukemia (AML). I recall that ivosidenib is a targeted therapy drug, specifically an IDH1 inhibitor, used for certain types of cancer. I believe it was approved by the FDA in 2018 for adult patients with relapsed or refractory AML with a specific IDH1 mutation. Additionally, I think it was later approved for newly diagnosed AML patients with the same mutation who are ineligible for intensive chemotherapy. Based on this, it seems that ivosidenib is indeed FDA-approved for AML under specific conditions. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can CPX-351 be used for the treatment of tuberculosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether CPX-351 can be used for the treatment of tuberculosis, I first need to consider what CPX-351 is and its intended medical use. CPX-351 is a liposomal formulation of cytarabine and daunorubicin, primarily used in the treatment of certain types of acute myeloid leukemia (AML). It is designed to target cancer cells and is not indicated for infectious diseases. Tuberculosis, on the other hand, is a bacterial infection caused by Mycobacterium tuberculosis, typically treated with a regimen of antibiotics like isoniazid, rifampin, ethambutol, and pyrazinamide. There is no clinical evidence or guideline suggesting that CPX-351, a chemotherapy drug, has any efficacy against bacterial infections such as tuberculosis. Therefore, it is not appropriate for this use.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does lucatumumab bind to CD140?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether lucatumumab binds to CD140, I first need to clarify what lucatumumab and CD140 are. Lucatumumab is a monoclonal antibody that targets CD40, a protein on the surface of certain cells, often used in the context of cancer immunotherapy. CD140, on the other hand, typically refers to platelet-derived growth factor receptors (PDGFR), specifically PDGFR-alpha (CD140a) and PDGFR-beta (CD140b), which are involved in cell growth and division. Since lucatumumab is specifically designed to bind to CD40, and there is no evidence or documentation suggesting it has affinity for CD140 or PDGFR, it is unlikely to bind to CD140. Therefore, the answer should be based on this specificity of binding.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is lucatumumab a polyclonal antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether lucatumumab is a polyclonal antibody, I first need to understand what lucatumumab is and the definition of a polyclonal antibody. A polyclonal antibody is a mixture of antibodies produced by different B cell clones, recognizing multiple epitopes on an antigen. In contrast, a monoclonal antibody is derived from a single B cell clone and targets a specific epitope. Lucatumumab is a drug, specifically a monoclonal antibody designed to target CD40, a protein on the surface of certain cells, often used in cancer therapy research. Since it is a monoclonal antibody, it is not polyclonal as it originates from a single clone and targets a specific epitope. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can midostaurin inhibit angiogenesis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether midostaurin can inhibit angiogenesis, I first consider the nature of midostaurin. It is a multi-targeted kinase inhibitor, primarily used in the treatment of acute myeloid leukemia (AML) with FLT3 mutations. Angiogenesis, the formation of new blood vessels, is often driven by signaling pathways involving vascular endothelial growth factor (VEGF) and related receptors. Midostaurin is known to inhibit several tyrosine kinases, including FLT3, KIT, and PDGF receptors, which are implicated in cell proliferation and survival. Notably, platelet-derived growth factor (PDGF) signaling can contribute to angiogenesis by supporting pericyte recruitment and vessel stabilization. Therefore, inhibiting PDGF receptors could indirectly affect angiogenesis. However, midostaurin's primary mechanism and clinical use are not directly tied to angiogenesis inhibition, and while it may have some indirect effects through PDGF receptor inhibition, it is not specifically recognized as an anti-angiogenic agent in the same way as drugs like bevacizumab, which directly target VEGF. After analyzing this, I conclude that midostaurin is not primarily or directly an inhibitor of angiogenesis.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can enasidenib be used for the treatment of acute myeloid leukemia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Enasidenib is a targeted therapy drug that inhibits the mutated IDH2 enzyme, which is present in some patients with acute myeloid leukemia (AML). It has been approved by the FDA for the treatment of adult patients with relapsed or refractory AML who have an IDH2 mutation. Therefore, enasidenib can indeed be used for the treatment of AML in specific cases where the IDH2 mutation is present. The answer to the question is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is lithium effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether lithium is effective for the treatment of amyotrophic lateral sclerosis (ALS), I first consider the context of ALS as a progressive neurodegenerative disease with limited treatment options. Lithium, primarily used for bipolar disorder, has been studied for its potential neuroprotective effects. Initial research, including a 2008 study, suggested that lithium might slow ALS progression by promoting autophagy and reducing neuronal death. However, subsequent larger clinical trials and meta-analyses, such as those reported in 2012 and later, have largely failed to replicate these findings, showing no significant benefit in slowing disease progression or improving survival rates. Current clinical guidelines and reviews, including those from the ALS Association and recent literature, do not recommend lithium as a standard treatment for ALS due to insufficient evidence of efficacy and potential side effects. Therefore, based on the most reliable and up-to-date data, lithium is not considered effective for ALS treatment.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is celecoxib effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether celecoxib is effective for the treatment of amyotrophic lateral sclerosis (ALS), I first consider the nature of ALS, which is a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and atrophy. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-2, primarily used for pain and inflammation in conditions like arthritis. I then evaluate if there is evidence linking celecoxib to ALS treatment. Research suggests inflammation plays a role in ALS progression, so anti-inflammatory drugs like celecoxib could theoretically be beneficial. However, I recall that clinical trials and studies, such as those referenced in medical literature up to my knowledge cutoff in 2023, have not shown celecoxib to be effective in slowing ALS progression or improving outcomes. For instance, a notable study published in the early 2000s tested celecoxib in ALS patients and found no significant benefit. Without new evidence post-2023, I conclude that celecoxib is not considered effective for ALS treatment.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is pacritinib effective for treatment of myelofibrosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether pacritinib is effective for the treatment of myelofibrosis, I first consider the context of myelofibrosis, a type of blood cancer affecting the bone marrow, often treated with JAK inhibitors due to JAK-STAT pathway involvement. Pacritinib is a JAK2 inhibitor specifically developed for myelofibrosis, particularly for patients with thrombocytopenia, a common issue in this condition. Clinical trials, such as the PERSIST-1 and PERSIST-2 studies, have shown that pacritinib can reduce spleen volume and improve symptoms in patients with myelofibrosis, even in those with low platelet counts, where other JAK inhibitors like ruxolitinib may not be suitable. The FDA approved pacritinib in 2022 for adults with intermediate or high-risk myelofibrosis with platelet counts below 50,000 per microliter, indicating recognized efficacy in a specific patient subset. However, effectiveness can vary based on individual patient factors, and side effects like gastrointestinal issues or bleeding risks must be considered. Overall, based on clinical evidence and regulatory approval, pacritinib appears to be effective for certain myelofibrosis patients.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do raspberries improve postprandial glucose and acute and chronic inflammation in adults with type 2 Diabetes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether raspberries improve postprandial glucose and acute and chronic inflammation in adults with type 2 diabetes, I first consider the nutritional profile of raspberries. Raspberries are rich in fiber, antioxidants, and polyphenols, which are known to have potential benefits for blood sugar control and inflammation reduction. Research suggests that dietary fiber can slow glucose absorption, potentially improving postprandial glucose levels. Additionally, polyphenols and antioxidants may reduce oxidative stress and inflammation, which are key factors in type 2 diabetes. There are studies, such as those published in journals like 'Nutrition & Metabolism,' indicating that berry consumption can positively impact glucose metabolism and inflammatory markers in diabetic patients. However, the specific effects of raspberries alone may vary, and clinical evidence might not be conclusive for all populations or consistent across studies. Given the general positive indications from berry-related research, I lean towards a positive response, but I must note that individual results can depend on various factors like dosage, diet, and personal health conditions. After weighing this, I conclude that there is a basis to suggest raspberries can help, though not guaranteed for every case.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has Hesperidin any role as a Neuroprotective Agent?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Hesperidin has a role as a neuroprotective agent, I first consider the nature of Hesperidin, which is a flavanone glycoside found in citrus fruits, known for its antioxidant and anti-inflammatory properties. Neuroprotective agents are substances that protect neurons from injury or degeneration, often by combating oxidative stress, inflammation, or other damaging processes. Research suggests that Hesperidin may have potential neuroprotective effects due to its ability to cross the blood-brain barrier, reduce oxidative stress, and modulate inflammatory pathways, which are implicated in neurodegenerative diseases like Alzheimer's and Parkinson's. Studies, including preclinical trials on animal models, have shown promising results in protecting against neuronal damage and improving cognitive function. However, while these findings are encouraging, clinical evidence in humans is still limited, and more research is needed to confirm its efficacy and safety as a neuroprotective agent. Based on the available scientific literature and the properties of Hesperidin, it appears to have a potential role, so my answer leans toward affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there tools for visualizing and processing long-read sequencing data?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are there tools for visualizing and processing long-read sequencing data?', I first consider the context of long-read sequencing, which refers to technologies like PacBio and Oxford Nanopore that generate longer DNA or RNA reads compared to short-read sequencing. The question asks specifically about tools for visualization and processing of such data. I recall that there are indeed specialized tools for handling long-read data due to its unique characteristics, such as higher error rates and longer read lengths. For visualization, tools like IGV (Integrative Genomics Viewer) support long-read data, and for processing, tools like minimap2 and Canu are designed for alignment and assembly of long reads. Additionally, platforms like Galaxy offer workflows for long-read data analysis. Based on this, it is clear that such tools exist in the bioinformatics field. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a deep-learning algorithm for protein solubility prediction?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether there is a deep-learning algorithm for protein solubility prediction, I first consider the context of deep learning in bioinformatics. Deep learning has been increasingly applied to various biological problems, including protein structure prediction, function annotation, and property prediction. Protein solubility, which refers to the ability of a protein to dissolve in a solvent, is a critical factor in biotechnology and drug development. Given the complexity of protein-solvent interactions, traditional methods often rely on sequence-based features or physicochemical properties, but these may not capture all nuances. Deep learning, with its ability to learn hierarchical features from raw data like amino acid sequences or structural information, seems well-suited for this task. I recall that there are indeed studies and tools that utilize deep learning for predicting protein solubility. For instance, models based on convolutional neural networks (CNNs) or recurrent neural networks (RNNs) have been developed to predict solubility from sequence data. Specific tools like DeepSol and others have been published in scientific literature, demonstrating the application of deep learning to this problem. Therefore, I conclude that such algorithms do exist.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cabozantinib effective for Hepatocellular Carcinoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether cabozantinib is effective for Hepatocellular Carcinoma (HCC), I first consider the context of HCC as a common type of liver cancer often treated with targeted therapies when surgery or other local treatments are not viable. Cabozantinib is a tyrosine kinase inhibitor known to target multiple pathways involved in tumor growth and angiogenesis, such as MET, VEGFR, and AXL. I recall that clinical trials, particularly the CELESTIAL trial, have investigated cabozantinib in patients with advanced HCC who previously received sorafenib. The trial results showed that cabozantinib significantly improved overall survival compared to placebo, with a median survival of 10.2 months versus 8.0 months. Additionally, it demonstrated benefits in progression-free survival and objective response rate. Based on this data, cabozantinib is considered effective for HCC, especially in second-line treatment after sorafenib. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is dupilumab effective for treatment of asthma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether dupilumab is effective for the treatment of asthma, I first consider the nature of dupilumab as a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, thereby inhibiting IL-4 and IL-13 signaling, which are key drivers of type 2 inflammation. Asthma, particularly moderate-to-severe asthma, often involves type 2 inflammation, so dupilumab could theoretically be effective. I recall that clinical trials, such as those published in major medical journals, have demonstrated that dupilumab reduces asthma exacerbations and improves lung function in patients with uncontrolled asthma, especially those with elevated eosinophil levels. Regulatory bodies like the FDA have approved dupilumab for asthma treatment in specific cases, further supporting its efficacy. However, it may not be effective for all asthma phenotypes, particularly non-type 2 driven asthma. Since the question is general and does not specify a subtype, and given the evidence of efficacy in a significant subset of asthma patients, I lean towards a positive response. After weighing this, I conclude that the answer should be affirmative based on current medical consensus.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is verubecestat effective for Alzheimer’s Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether verubecestat is effective for Alzheimer’s Disease, I need to consider the available scientific evidence and clinical trial results. Verubecestat is a BACE1 inhibitor developed to reduce amyloid-beta production, a key factor in Alzheimer’s pathology. However, clinical trials, particularly Phase 3 studies like the EPOCH trial, showed that verubecestat did not improve cognitive decline in patients with mild-to-moderate Alzheimer’s Disease and was associated with adverse effects. A subsequent trial in prodromal Alzheimer’s was also terminated early due to lack of efficacy. Based on this, the evidence suggests that verubecestat is not effective for Alzheimer’s Disease.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does Eucommia ulmoides leaf extract ameliorates steatosis/fatty liver induced by high-fat diet?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Eucommia ulmoides leaf extract ameliorates steatosis or fatty liver induced by a high-fat diet, I first consider the context of the question. Steatosis, commonly known as fatty liver, is a condition characterized by the accumulation of fat in liver cells, often induced by a high-fat diet in experimental models. Eucommia ulmoides is a traditional medicinal plant, and its leaf extract has been studied for various health benefits, including potential effects on lipid metabolism and liver health. Research suggests that compounds in Eucommia ulmoides, such as chlorogenic acid and flavonoids, may have antioxidant, anti-inflammatory, and lipid-lowering properties. Several studies in animal models have indicated that this extract can reduce hepatic lipid accumulation, improve liver function markers, and mitigate oxidative stress caused by a high-fat diet. While human studies may be limited, the preclinical evidence supports a positive effect. Therefore, based on the available scientific literature, it is reasonable to conclude that Eucommia ulmoides leaf extract likely ameliorates fatty liver induced by a high-fat diet.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there ultraconserved regions in the budding yeast (Saccharomyces cerevisiae)?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether there are ultraconserved regions in the budding yeast Saccharomyces cerevisiae, I first consider the definition of ultraconserved regions. These are DNA sequences that are highly conserved across different species, showing little to no variation over long evolutionary periods. In the context of budding yeast, a single-celled eukaryotic organism, I need to determine if such highly conserved sequences exist within its genome, either compared to other yeast species or within its own genetic framework. Research indicates that while yeast genomes do exhibit conserved regions, particularly in essential genes like those involved in basic cellular functions (e.g., ribosomal proteins or metabolic enzymes), the term 'ultraconserved' is more commonly applied to vertebrates or higher eukaryotes where sequences remain identical over vast evolutionary distances. In yeast, conservation exists but often at a lower degree due to faster evolutionary rates and shorter generation times. Comparative genomics studies of Saccharomyces species show conserved synteny and gene order, but ultraconservation at the nucleotide level is less pronounced. Therefore, while there are conserved regions, labeling them as 'ultraconserved' might not be entirely accurate in the strictest sense of the term as used in other organisms. After this analysis, I conclude that the answer should be 'no' in the context of the strict definition of ultraconserved regions.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are there graph kernel libraries available implemented in JAVA?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are there graph kernel libraries available implemented in JAVA?', I need to consider whether there are existing libraries or frameworks in JAVA that specifically support graph kernels, which are methods used in machine learning to compute similarities between graphs. Graph kernels are often used in areas like bioinformatics and social network analysis. I recall that JAVA has libraries for graph processing, such as JGraphT and GraphStream, but I need to evaluate if these include graph kernel implementations. Additionally, there might be machine learning libraries like Weka or Deeplearning4j that could have graph kernel functionalities. Upon reflection, I realize that graph kernel implementations are more common in languages like Python (e.g., GraKeL library) and C++, and I am not immediately aware of a widely recognized JAVA library dedicated to graph kernels. However, there could be lesser-known libraries or research projects that implement graph kernels in JAVA. After considering this, I believe the answer leans towards 'no' based on the lack of prominent, widely-used libraries, but I acknowledge there might be niche or academic implementations. For the purpose of this question, I will conclude with 'no' as the most accurate response based on common knowledge.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can you computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about computationally predicting Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs), I first need to consider the current state of bioinformatics and computational biology. MoRFs are short, disordered regions in proteins that become structured upon binding to a partner molecule, playing a critical role in molecular interactions. IDPs, by nature, lack a fixed structure, making prediction challenging but feasible with specialized algorithms. There are established computational tools and methods, such as MoRFpred, ANCHOR, and DISOPRED, which use machine learning, sequence analysis, and physicochemical properties to predict these regions. These tools have been developed based on known MoRFs and IDP datasets, indicating that it is indeed possible to predict MoRFs computationally with reasonable accuracy, though limitations and false positives exist depending on the method and dataset used. Therefore, the answer should affirm the possibility of such predictions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there tools for reviewing variant calls?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I am considering the question: 'Are there tools for reviewing variant calls?' Variant calls refer to the identification of genetic variants from sequencing data, often in the context of genomics or bioinformatics. Reviewing variant calls typically involves visualizing, validating, or analyzing the calls to ensure accuracy. I know that there are several tools and software platforms designed for this purpose, such as the Integrative Genomics Viewer (IGV), which allows users to visualize variant calls alongside raw sequencing data, and other tools like GATK's VariantFiltration or VCFtools for filtering and reviewing variant data. Additionally, platforms like Ensembl Variant Effect Predictor (VEP) help in annotating and interpreting variant calls. Given this, it is clear that tools for reviewing variant calls do exist.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is baricitinib effective for rheumatoid arthritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether baricitinib is effective for rheumatoid arthritis, I am considering the available medical knowledge up to my last update. Baricitinib is a Janus kinase (JAK) inhibitor, a class of drugs used to treat autoimmune conditions by modulating the immune response. Clinical studies and regulatory approvals indicate that baricitinib has been shown to reduce symptoms and improve physical function in patients with moderate to severe rheumatoid arthritis, particularly in those who have not responded well to other treatments like methotrexate. It has been approved by regulatory bodies such as the FDA and EMA for this indication. Therefore, based on this analysis, the answer should affirm its effectiveness.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is galcanezumab effective for treatment of migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether galcanezumab is effective for the treatment of migraine, I first consider the context of the question. Galcanezumab is a monoclonal antibody used as a preventive treatment for migraine. It works by targeting calcitonin gene-related peptide (CGRP), which is involved in migraine pathophysiology. Clinical trials and studies, such as those published in medical journals, have demonstrated that galcanezumab significantly reduces the frequency of migraine days in patients with episodic and chronic migraine compared to placebo. It has been approved by regulatory bodies like the FDA for this indication. Therefore, based on available evidence, it is effective for migraine treatment.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Lasmiditan effective for migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Lasmiditan is effective for migraine, I first consider the context of the question. Lasmiditan is a medication specifically developed for the acute treatment of migraine. It is a selective serotonin receptor agonist, working differently from traditional triptans by targeting 5-HT1F receptors without causing vasoconstriction. Clinical studies, such as those leading to its FDA approval in 2019 under the brand name Reyvow, have demonstrated its efficacy in providing pain relief and reducing migraine-associated symptoms like nausea and sensitivity to light and sound in a significant percentage of patients within two hours of administration. While effectiveness can vary based on individual patient response and specific migraine characteristics, the general evidence supports its efficacy for acute migraine treatment. Therefore, based on this analysis, I conclude that Lasmiditan is effective for migraine.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is pimavanserin effective for Parkinson's disease psychosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether pimavanserin is effective for Parkinson's disease psychosis, I first consider the context of the condition and the drug. Parkinson's disease psychosis involves hallucinations and delusions, which can significantly impact quality of life. Pimavanserin is a medication specifically developed to treat psychosis in Parkinson's disease, acting as a selective serotonin inverse agonist, primarily targeting 5-HT2A receptors, without affecting dopamine receptors, which is crucial to avoid worsening motor symptoms in Parkinson's patients. Clinical trials, such as the pivotal Phase 3 trial published in 2014, demonstrated that pimavanserin significantly reduced psychotic symptoms compared to placebo, with a good safety profile. It was approved by the FDA in 2016 for this indication under the brand name Nuplazid. While there may be individual variations in response and some ongoing discussions about long-term effects or specific patient subgroups, the evidence supports its efficacy for the intended use. Therefore, based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does an interferon (IFN) signature exist for SLE patients?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether an interferon (IFN) signature exists for SLE (Systemic Lupus Erythematosus) patients, I first consider the context of SLE as an autoimmune disease characterized by immune system dysregulation. Interferons, particularly type I interferons, are cytokines involved in immune responses and have been implicated in autoimmune conditions. Research indicates that many SLE patients exhibit an 'IFN signature,' which refers to a pattern of upregulated interferon-stimulated genes (ISGs) in their blood or tissues, detectable through gene expression profiling. Studies have shown that this signature is present in a significant proportion of SLE patients and is associated with disease activity and severity. While not all SLE patients may display this signature, its presence is well-documented in the literature. Therefore, it is reasonable to conclude that an IFN signature does exist for SLE patients as a recognized biomarker in many cases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Diazepam be beneficial  in the treatment of  traumatic brain injury?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Diazepam can be beneficial in the treatment of traumatic brain injury (TBI), I first consider the nature of TBI and the pharmacological effects of Diazepam. TBI involves damage to the brain from an external force, often leading to symptoms like seizures, anxiety, and agitation. Diazepam, a benzodiazepine, is primarily used for its anxiolytic, sedative, muscle relaxant, and anticonvulsant properties. It works by enhancing the effect of the neurotransmitter GABA, which can help in calming brain activity. In the context of TBI, Diazepam might be beneficial in managing acute symptoms such as seizures or severe agitation, which are common complications. However, its use must be approached with caution due to potential side effects like sedation, respiratory depression, and the risk of dependency. Additionally, long-term use might interfere with cognitive recovery post-TBI. Clinical guidelines and studies suggest that while Diazepam can be used for short-term symptom management in TBI, it is not a primary treatment for the injury itself. Therefore, it can be beneficial in specific contexts related to TBI symptom management.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are genes that escape X-chromosome inactivation related to mental impairment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether genes that escape X-chromosome inactivation are related to mental impairment, I first consider the biological context. X-chromosome inactivation is a process in females where one of the two X chromosomes is silenced to balance gene expression with males, who have only one X chromosome. However, some genes on the inactive X chromosome escape this silencing and remain active. These 'escapee' genes can have significant functional roles. Research suggests that some of these genes are involved in brain development and function. For instance, disruptions or abnormal expression of escapee genes have been linked to neurodevelopmental disorders. Conditions like Turner syndrome and Klinefelter syndrome, which involve X chromosome abnormalities, often show cognitive or mental impairments, and escapee genes may contribute to these phenotypes. There is evidence in scientific literature indicating a connection between the dysregulation of these genes and mental impairment, particularly in the context of X-linked intellectual disabilities. Therefore, it seems plausible that there is a relationship.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether major brain gangliosides are a target for the treatment of Alzheimer's disease as of February 2019, I need to consider the scientific context and research up to that date. Gangliosides are sialic acid-containing glycosphingolipids abundant in the brain, involved in cell signaling and neuroprotection. In Alzheimer's disease, there is evidence of altered ganglioside metabolism and potential roles in amyloid-beta aggregation or clearance. Some studies prior to 2019 explored ganglioside-based therapies, such as GM1 ganglioside, for their potential neuroprotective effects or ability to reduce amyloid-beta toxicity. However, as of February 2019, while there was interest and preclinical research, there was no widely accepted or clinically approved treatment targeting gangliosides for Alzheimer's disease. Clinical trials and consensus in the field did not establish gangliosides as a primary therapeutic target at that time. Therefore, the answer should reflect the lack of definitive clinical application or consensus on gangliosides as a treatment target for Alzheimer's disease as of that date.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is pazopanib an effective treatment of glioblastoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether pazopanib is an effective treatment for glioblastoma, I first consider the nature of glioblastoma, which is an aggressive brain cancer with limited treatment options. Pazopanib is a tyrosine kinase inhibitor primarily used for renal cell carcinoma and soft tissue sarcoma. It targets vascular endothelial growth factor receptors (VEGFR), which are involved in angiogenesis, a process critical to tumor growth. Glioblastomas are highly vascularized tumors, so inhibiting angiogenesis could theoretically be beneficial. However, I recall that clinical trials and studies on pazopanib for glioblastoma have shown limited efficacy. While it may have some anti-angiogenic effects, the blood-brain barrier and the complex biology of glioblastoma often reduce the drug's effectiveness. Most data suggest that pazopanib does not significantly improve overall survival or progression-free survival in glioblastoma patients compared to standard treatments like temozolomide or radiation. Therefore, based on current evidence, it is not considered an effective treatment for glioblastoma.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is avelumab effective for bladder cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether avelumab is effective for bladder cancer, I first consider the context of the drug. Avelumab is a monoclonal antibody, a type of immune checkpoint inhibitor that targets PD-L1, often used in cancer immunotherapy. I recall that it has been studied and approved for certain types of cancer, including urothelial carcinoma, which is the most common type of bladder cancer. Specifically, avelumab has been approved by regulatory bodies like the FDA for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Clinical trials, such as the JAVELIN Bladder 100 trial, have shown that avelumab, when used as a maintenance therapy after chemotherapy, can significantly improve overall survival in patients with advanced urothelial carcinoma who have not progressed on first-line platinum-based chemotherapy. Therefore, based on this information, avelumab can be considered effective for certain stages and types of bladder cancer under specific conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can pazopanib be used for treatment von Hippel-Lindau disease?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether pazopanib can be used for the treatment of von Hippel-Lindau (VHL) disease, I first need to consider the nature of VHL disease and the indications for pazopanib. VHL disease is a rare genetic disorder characterized by the formation of tumors and cysts in various parts of the body, including the brain, spinal cord, kidneys, and eyes. It is caused by mutations in the VHL gene, leading to abnormal blood vessel growth and tumor development, such as renal cell carcinoma (RCC) and hemangioblastomas. Pazopanib is a tyrosine kinase inhibitor primarily approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. It works by inhibiting vascular endothelial growth factor (VEGF) receptors, which are involved in angiogenesis, a process critical to tumor growth in VHL disease. Given that VHL disease often leads to RCC and other vascular tumors, pazopanib's mechanism of action suggests potential efficacy. However, I must check if it is specifically indicated or studied for VHL disease. Upon reflection, while pazopanib is used for RCC, which is a common manifestation of VHL, its use in the broader context of VHL disease (beyond RCC) may not be universally established or approved. Clinical guidelines and studies often recommend other agents like belzutifan, a HIF-2α inhibitor, as a more targeted therapy for VHL-associated tumors. There is limited direct evidence or specific approval for pazopanib in the comprehensive management of VHL disease itself. Therefore, while it may be used in specific cases (e.g., for RCC in VHL patients), it is not a primary or standard treatment for the disease as a whole.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Miller-Dieker syndrome associated with abnormalities of chromosome 1?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Miller-Dieker syndrome is a rare genetic disorder characterized by lissencephaly (smooth brain), developmental delays, and other neurological issues. It is primarily associated with a deletion in the short arm of chromosome 17, specifically in the 17p13.3 region, which includes the LIS1 gene critical for brain development. There is no widely recognized or documented association between Miller-Dieker syndrome and abnormalities of chromosome 1 in medical literature or genetic databases. Therefore, the answer should reflect that there is no connection to chromosome 1.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should dacomitinib be used for treatment of glioblastoma patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether dacomitinib should be used for the treatment of glioblastoma patients, I first considered the nature of dacomitinib and its approved uses. Dacomitinib is a tyrosine kinase inhibitor primarily used for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Glioblastoma, on the other hand, is a type of brain cancer with different molecular characteristics, often involving EGFR amplification or mutations, but not necessarily the same actionable mutations as in NSCLC. I then analyzed whether there is clinical evidence or guideline support for using dacomitinib in glioblastoma. Current research and clinical trials do not widely support its use for glioblastoma, and it is not approved or recommended in major guidelines (like NCCN) for this indication. Most studies focus on other EGFR inhibitors like gefitinib or erlotinib, with limited success. Without substantial evidence of efficacy or safety in glioblastoma patients, it is not appropriate to recommend dacomitinib for this condition at this time.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is inositol effective for trichotillomania?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether inositol is effective for trichotillomania, I first consider the nature of trichotillomania, which is a mental health disorder characterized by the compulsive urge to pull out one's hair. Treatment often involves therapy, such as cognitive-behavioral therapy, and sometimes medication. Inositol, a naturally occurring compound, has been studied for its potential benefits in various mental health conditions, including anxiety and obsessive-compulsive disorder (OCD), due to its role in serotonin signaling. Trichotillomania is sometimes linked to OCD, so there might be a theoretical basis for inositol's effectiveness. I recall that a small study published in the American Journal of Psychiatry in 1996 suggested that inositol might reduce symptoms of OCD. However, specific research on trichotillomania is limited. A 2016 review in the Journal of Clinical Psychopharmacology noted a lack of robust evidence for inositol in treating hair-pulling disorders specifically, and larger, controlled trials are needed. Given the current evidence, while there is some anecdotal and theoretical support, there is no conclusive data to confirm inositol's effectiveness for trichotillomania. Therefore, I lean toward a negative answer but acknowledge the uncertainty due to limited research.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is eculizumab used for treatment of myasthenia gravis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Eculizumab is a monoclonal antibody that inhibits the complement protein C5, which plays a role in the immune response. It is primarily used for conditions involving complement-mediated damage, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In the context of myasthenia gravis (MG), a neuromuscular disorder caused by autoantibodies against the acetylcholine receptor, the complement system is involved in the destruction of the neuromuscular junction. Recent studies and clinical approvals have indicated that eculizumab is indeed used for the treatment of generalized myasthenia gravis in patients who are anti-acetylcholine receptor (AChR) antibody-positive and have not responded adequately to other therapies. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Semagacestat effective for treatment of Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Semagacestat is effective for the treatment of Alzheimer's disease, I need to consider the available scientific and clinical evidence. Semagacestat is a gamma-secretase inhibitor that was developed to reduce amyloid-beta production, a key factor in Alzheimer's pathology. However, clinical trials, particularly the Phase III trials, showed that Semagacestat not only failed to improve cognitive function in patients with Alzheimer's disease but also worsened cognitive decline and was associated with significant side effects, including an increased risk of skin cancer and infections. The trials were halted due to these adverse outcomes. Based on this, it appears that Semagacestat is not effective for the treatment of Alzheimer's disease.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does simvastatin improve outcomes of aneurysmal subarachnoid hemorrhage?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether simvastatin improves outcomes of aneurysmal subarachnoid hemorrhage (aSAH), I am considering the context of the question, which likely pertains to clinical outcomes such as mortality, neurological recovery, or prevention of complications like vasospasm. Simvastatin is a statin drug primarily used for cholesterol management, but it has been studied for potential neuroprotective and anti-inflammatory effects in conditions like aSAH. Research, including clinical trials, has explored whether statins can reduce vasospasm or improve functional outcomes after aSAH. Some studies suggest a potential benefit in reducing delayed cerebral ischemia, while others show inconclusive or no significant improvement in overall outcomes. Given the mixed evidence, with some meta-analyses indicating possible benefits but lacking definitive consensus in guidelines, I lean toward a cautious interpretation. The most recent and comprehensive reviews suggest that while there may be some positive effects, the evidence is not strong enough to universally recommend simvastatin for aSAH outcomes. Therefore, I will answer 'no' to reflect the lack of definitive, widely accepted evidence supporting its routine use for improving outcomes in this condition.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does tremelimumab improve survival of mesothelioma patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether tremelimumab improves survival in mesothelioma patients, I first consider the nature of tremelimumab as an immune checkpoint inhibitor, specifically a CTLA-4 inhibitor, used in cancer immunotherapy. Mesothelioma is a rare and aggressive cancer often linked to asbestos exposure, with limited treatment options and poor prognosis. I recall that tremelimumab has been studied in clinical trials for mesothelioma, particularly in combination with other drugs like durvalumab. A key study, the DETERMINE trial, evaluated tremelimumab as a second- or third-line treatment for malignant mesothelioma but did not show a significant improvement in overall survival compared to placebo. However, more recent studies, such as the NIBIT-MESO-1 trial, combining tremelimumab with durvalumab, have shown some promise in terms of disease control and survival in smaller cohorts, though results are not yet conclusive across larger populations. Given the mixed evidence, with the largest trial indicating no survival benefit as a single agent, I lean towards a negative response, acknowledging that combination therapies might hold potential but are not definitively proven to improve survival broadly at this stage.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Axitinib prolongs survival in pancreatic cancer patients, I first consider the nature of Axitinib. It is a tyrosine kinase inhibitor primarily used for advanced renal cell carcinoma, not pancreatic cancer. I analyze if there is clinical evidence or studies supporting its use in pancreatic cancer. Upon reflection, I recall that Axitinib has been investigated in some phase II trials for pancreatic cancer, often in combination with other therapies like gemcitabine. However, the results have generally not shown a significant overall survival benefit compared to standard treatments. Major guidelines and reviews, such as those from the National Comprehensive Cancer Network (NCCN), do not list Axitinib as a recommended treatment for pancreatic cancer due to insufficient evidence of efficacy in extending survival. Therefore, based on current knowledge, it does not appear to significantly prolong survival in pancreatic cancer patients.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does Panitumumab prolong survival of biliary tract cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Panitumumab prolongs survival in biliary tract cancer patients, I first consider the nature of Panitumumab, which is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is primarily used in colorectal cancer with specific genetic profiles (e.g., KRAS wild-type). Biliary tract cancer, including cholangiocarcinoma and gallbladder cancer, is a different malignancy with distinct molecular characteristics. I recall that EGFR overexpression can occur in biliary tract cancers, suggesting a potential role for EGFR inhibitors like Panitumumab. However, I must evaluate if there is clinical evidence supporting its efficacy in this context. Upon reflection, I note that clinical trials and guidelines for biliary tract cancer primarily focus on chemotherapy regimens like gemcitabine and cisplatin, as per studies such as the ABC-02 trial. Targeted therapies, including EGFR inhibitors, have been investigated, but results are mixed. Specifically for Panitumumab, I believe there are limited data or small studies, and it is not a standard of care for biliary tract cancer. I consider if there are any phase III trials or meta-analyses showing survival benefit, but I do not recall definitive evidence supporting prolonged survival. Therefore, based on current knowledge, it is unlikely that Panitumumab has a proven role in prolonging survival for biliary tract cancer patients.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the enzyme ERAP2 associated with the disease birdshot chorioretinopathy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the enzyme ERAP2 is associated with birdshot chorioretinopathy, I first consider the nature of the disease and the role of ERAP2. Birdshot chorioretinopathy is a rare autoimmune eye disorder characterized by inflammation of the choroid and retina, often linked to genetic factors such as the HLA-A29 gene. ERAP2, or Endoplasmic Reticulum Aminopeptidase 2, is an enzyme involved in trimming peptides for presentation by MHC class I molecules, which are critical in immune responses. Given its role in antigen processing, ERAP2 could plausibly be associated with autoimmune conditions. Research indicates that variations in ERAP2 have been linked to several autoimmune diseases, including ankylosing spondylitis and psoriasis. Specifically for birdshot chorioretinopathy, studies have identified a strong genetic association with ERAP2 variants, alongside HLA-A29, suggesting that ERAP2 contributes to disease susceptibility by altering peptide presentation to T-cells. Therefore, based on this analysis, there is evidence supporting an association between ERAP2 and birdshot chorioretinopathy.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ADP-ribosylation a PTM?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ADP-ribosylation is a post-translational modification (PTM), I first need to recall the definition of PTM. PTM refers to the chemical modifications of proteins after their synthesis, which can alter their function, localization, or stability. ADP-ribosylation involves the addition of ADP-ribose units to proteins, typically catalyzed by enzymes like PARPs (poly ADP-ribose polymerases). This modification occurs after the protein is translated, fitting the definition of a PTM. It plays roles in DNA repair, gene regulation, and cell signaling. Therefore, it should be classified as a PTM. I see no reason to doubt this based on standard biochemical knowledge.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is collagen the most abundant human protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether collagen is the most abundant human protein, I need to consider what is known about human proteins and their abundance. Collagen is a major structural protein found in connective tissues like skin, bones, and cartilage, and it is often cited as the most abundant protein in the human body, making up about 30% of the body's protein content. However, I should verify if there is any other protein that might surpass it. Actin, for example, is a key protein in muscle tissue and is also very abundant, but I believe collagen still outweighs it in terms of total mass due to its widespread presence in various tissues. After reflecting on this, I recall that scientific literature and educational resources consistently state collagen as the most abundant protein in humans. Therefore, I conclude that the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Mesenchymal stem cells (MSC) multipotent cells?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Mesenchymal stem cells (MSCs) are multipotent cells, I first need to recall the definition of multipotent cells. Multipotent cells are stem cells that have the ability to differentiate into multiple, but not all, cell types within a specific lineage or tissue. MSCs are a type of adult stem cell found in various tissues like bone marrow, adipose tissue, and umbilical cord. They are known to differentiate into cells of the mesodermal lineage, such as osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). Since MSCs can differentiate into multiple cell types within the mesodermal lineage but not into all cell types (like pluripotent stem cells can), they fit the definition of multipotent cells. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is TIM-3 a target for cancer immunotherapy in NSCLC?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether TIM-3 is a target for cancer immunotherapy in non-small cell lung cancer (NSCLC), I need to consider the role of TIM-3 in immune regulation and its relevance in NSCLC. TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) is an immune checkpoint receptor expressed on T cells, which can inhibit immune responses when activated, contributing to immune evasion by cancer cells. Research indicates that TIM-3 is often overexpressed in NSCLC tumor microenvironments, correlating with T-cell exhaustion and poor prognosis. Clinical studies and preclinical data suggest that targeting TIM-3, often in combination with other checkpoint inhibitors like PD-1/PD-L1, can enhance anti-tumor immunity. Several ongoing clinical trials are investigating TIM-3 inhibitors in NSCLC, showing promising early results. Therefore, based on current scientific understanding, TIM-3 is indeed considered a potential target for cancer immunotherapy in NSCLC.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are phagosomal proteins ubiquitinated?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are phagosomal proteins ubiquitinated?', I first consider the biological context. Phagosomes are vesicles formed during phagocytosis, engulfing pathogens or debris, and they contain various proteins involved in membrane dynamics and pathogen degradation. Ubiquitination is a post-translational modification where ubiquitin is attached to proteins, often marking them for degradation or altering their function. Research indicates that ubiquitination plays a role in phagosomal maturation and pathogen clearance. For instance, ubiquitination of phagosomal membrane proteins or engulfed pathogens can recruit autophagy machinery or signal for degradation. Studies have shown that certain phagosomal proteins, like those involved in bacterial recognition, can be ubiquitinated to regulate immune responses. Therefore, it is reasonable to conclude that some phagosomal proteins are indeed ubiquitinated, even if not all of them are.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any approved treatment for NAFLD?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Is there any approved treatment for NAFLD (Non-Alcoholic Fatty Liver Disease)?', I first need to consider the current medical understanding of NAFLD. NAFLD is a condition characterized by excessive fat build-up in the liver not caused by alcohol. It ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis or liver cancer. As of the latest medical guidelines and research up to my knowledge cutoff in 2023, there is no specific drug universally approved by major regulatory bodies like the FDA or EMA solely for the treatment of NAFLD or NASH. Current management primarily focuses on lifestyle interventions such as weight loss, diet, and exercise, which are effective in reducing liver fat and inflammation. Some medications, like pioglitazone or vitamin E, have shown benefits in specific cases of NASH, but they are not universally approved for NAFLD treatment and are often used off-label with careful consideration of risks. There are also ongoing clinical trials for potential therapies, but none have been definitively approved for widespread use as of now. Therefore, while there are management strategies, there is no specific 'approved treatment' in the form of a drug specifically licensed for NAFLD.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are tumour specific antigens originating from known protein coding genes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether tumour specific antigens originate from known protein coding genes, I first consider the definition of tumour specific antigens (TSAs). TSAs are proteins or peptides expressed uniquely in tumour cells and not in normal cells, making them potential targets for immunotherapy. The question is whether these antigens come from genes already identified as protein-coding in the human genome. I recall that many TSAs arise from mutations in known protein-coding genes, leading to neoantigens, which are novel peptides not present in normal tissues. Additionally, some TSAs may result from aberrant expression of genes that are normally silent or from alternative splicing, but these genes are still part of the known protein-coding repertoire. However, there could be cases where TSAs originate from non-coding regions or novel transcripts due to genomic instability in cancer cells, though this is less common. Upon reflection, the majority of TSAs studied and targeted in therapies are derived from mutations or altered expression of known protein-coding genes. Therefore, I conclude that the answer is affirmative, though not exclusively in all cases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is treatment with Bacillus Calmette Guerin used for bladder cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I am considering the question about whether Bacillus Calmette Guerin (BCG) treatment is used for bladder cancer. BCG is a type of immunotherapy derived from a weakened strain of Mycobacterium bovis, and I recall that it is commonly used in the treatment of non-muscle invasive bladder cancer. It is administered directly into the bladder to stimulate an immune response against cancer cells. Based on this, I believe the answer should be affirmative, as BCG is a well-established treatment for certain stages of bladder cancer. I will confirm this understanding, and since the question is straightforward without any specific context or exceptions mentioned, I think 'yes' is the appropriate response.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Rhamnose have any effect on aging?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Rhamnose has any effect on aging, I first consider what Rhamnose is. Rhamnose is a naturally occurring sugar found in plants and some bacteria, often used in cosmetics for its potential skin benefits. I recall that some studies and skincare products claim Rhamnose can improve skin elasticity and reduce signs of aging by stimulating collagen production or protecting skin cells. However, I must evaluate if there is solid scientific evidence supporting these claims. Upon reflection, while there are promising studies, particularly in dermatology, the evidence might not be conclusive across all contexts of aging (e.g., systemic aging or internal health). The question is broad, covering any effect on aging, so even a localized effect on skin could qualify as a 'yes.' I lean towards 'yes' based on its reported benefits in skincare, but I acknowledge the need for more comprehensive research to confirm broader anti-aging effects.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether apoE mimetics are being considered as a treatment against Alzheimer's disease, I first need to consider the role of apoE in the context of Alzheimer's. ApoE, or apolipoprotein E, is a protein involved in lipid metabolism and is known to play a significant role in brain health. Certain variants of the apoE gene, particularly apoE4, are associated with an increased risk of developing Alzheimer's disease due to their impact on amyloid-beta clearance and other pathological processes. ApoE mimetics are synthetic compounds or peptides designed to mimic the beneficial functions of apoE, such as promoting amyloid-beta clearance, reducing inflammation, or protecting neurons. Research in this area is ongoing, with preclinical studies and some early-phase clinical trials exploring apoE mimetics as potential therapeutic agents. Given the scientific interest and the plausible mechanism of action, it is reasonable to conclude that apoE mimetics are indeed being considered as a potential treatment for Alzheimer's disease, even if they are not yet widely used or approved.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is L-4F an apoE mimetic peptide?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether L-4F is an apoE mimetic peptide, I first need to understand the terms. ApoE (apolipoprotein E) is a protein involved in lipid metabolism, and mimetic peptides are synthetic peptides designed to mimic the function or structure of a natural protein. An apoE mimetic peptide would therefore be a peptide that replicates some functional or structural aspects of apoE. L-4F is a well-known synthetic peptide often studied for its potential in treating cardiovascular diseases. It is designed to mimic the lipid-binding properties of apolipoprotein A-I (apoA-I), not apoE. ApoA-I is a major component of HDL (high-density lipoprotein) and is involved in cholesterol efflux. Research indicates that L-4F primarily functions by enhancing HDL functionality and reducing inflammation, which aligns more with apoA-I's role rather than apoE's broader roles in lipid transport and clearance. While there might be some overlap in lipid-binding capabilities, L-4F is not specifically described in scientific literature as an apoE mimetic. Therefore, based on this analysis, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can oleuropein aglycone interfere with amyloid aggregation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether oleuropein aglycone can interfere with amyloid aggregation, I first consider the context of amyloid aggregation, which is a process linked to neurodegenerative diseases like Alzheimer's, where proteins misfold and form plaques. Oleuropein aglycone is a compound derived from olive oil, known for its antioxidant and anti-inflammatory properties. I recall that some studies suggest polyphenols, like those found in olive oil, may have protective effects against amyloid formation by inhibiting aggregation or disrupting existing aggregates. Specifically, oleuropein aglycone has been investigated in scientific literature for its potential to interfere with amyloid-beta aggregation. Based on this, it seems plausible that it can interfere with the process. Therefore, my answer leans towards 'yes,' pending confirmation from specific studies or data. After this analysis, I conclude that the answer should be 'yes' based on the reported bioactivity of oleuropein aglycone.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Crocus sativus compounds are being considered against Alzheimer's disease, I first need to recall that Crocus sativus is the scientific name for saffron, a spice known for its medicinal properties. Saffron contains active compounds like crocin, crocetin, and safranal, which have been studied for various health benefits. I remember that there is growing interest in natural compounds for neurodegenerative diseases like Alzheimer's due to their potential antioxidant, anti-inflammatory, and neuroprotective effects. Research has indeed explored saffron's compounds for cognitive benefits, with some studies suggesting that crocin and other components may help improve memory and reduce amyloid-beta accumulation, a hallmark of Alzheimer's. Clinical trials and preclinical studies have shown promising results, indicating that these compounds are being considered as potential therapeutic agents. Therefore, the answer should reflect this consideration in scientific and medical research.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do Crocus sativus extracts loosen the blood-brain barrier?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Crocus sativus extracts loosen the blood-brain barrier, I first consider the context of the question. Crocus sativus, commonly known as saffron, is a plant whose extracts are studied for various medicinal properties, including antioxidant and anti-inflammatory effects. The blood-brain barrier (BBB) is a protective layer that regulates the passage of substances into the brain. 'Loosening' the BBB could imply increasing its permeability, which might be beneficial or harmful depending on the context. I recall that some studies suggest saffron's active compounds, like crocin, may have neuroprotective effects, but I am unsure if they directly affect BBB permeability. There is limited direct evidence in scientific literature specifically stating that Crocus sativus extracts alter BBB integrity or permeability. Some studies indicate potential modulation of brain function, but loosening the BBB is not explicitly confirmed. Given the lack of conclusive evidence in my knowledge base, I lean towards a negative answer but acknowledge the need for specialized research to confirm. After analysis, I conclude that without specific studies directly supporting this effect, the answer should be 'no' based on current general understanding.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Netrin-1 a secreted protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Netrin-1 is a secreted protein, I first consider the biological context. Netrin-1 is a well-studied protein known for its role in axon guidance during neural development. It acts as a signaling molecule that can attract or repel axons, which suggests it must be released into the extracellular space to function. Proteins that function outside the cell are typically secreted. I recall that Netrin-1 is indeed produced by cells and secreted to create gradients that guide neuronal growth. There is no evidence or recollection of Netrin-1 being exclusively intracellular or membrane-bound; it is primarily known as a diffusible factor. Therefore, based on this analysis, Netrin-1 should be classified as a secreted protein.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Have apolipoprotein mimetics been used in clinical trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Have apolipoprotein mimetics been used in clinical trials?', I need to consider the current state of research on apolipoprotein mimetics. Apolipoprotein mimetics are synthetic peptides or compounds designed to mimic the function of apolipoproteins, which are proteins that bind lipids to form lipoproteins and play a role in lipid metabolism. These mimetics are often investigated for their potential in treating cardiovascular diseases, dyslipidemia, and other metabolic disorders due to their ability to modulate cholesterol levels and reduce atherosclerosis. I recall that some apolipoprotein mimetics, such as ApoA-I mimetics (which mimic apolipoprotein A-I, a major component of HDL or 'good cholesterol'), have been developed and tested in preclinical studies. For instance, compounds like 4F and other ApoA-I mimetic peptides have shown promise in animal models for reducing plaque buildup. The question is whether these have progressed to human clinical trials. Upon reflection, I believe there have been early-phase clinical trials for certain ApoA-I mimetics, such as CSL112, which is a formulation of ApoA-I derived from human plasma, though it may not be a synthetic mimetic in the strictest sense. However, synthetic peptides like the 4F peptide have been discussed in the context of clinical testing for safety and efficacy in humans, particularly for cardiovascular indications. Given this, I think the answer is likely 'yes', as there is evidence of clinical trials involving apolipoprotein mimetics or closely related compounds. To be precise, I should confirm that synthetic mimetics, not just natural ApoA-I infusions, have been tested. On balance, I believe the term 'apolipoprotein mimetics' generally includes synthetic analogs, and trials have indeed been conducted with such agents. Therefore, my final answer will be 'yes'.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has strimvelis been approved by the European Medicines Agency?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Strimvelis has been approved by the European Medicines Agency (EMA), I first consider that Strimvelis is a gene therapy treatment for a rare disease called ADA-SCID (Adenosine Deaminase Severe Combined Immunodeficiency). I recall that it was developed by GlaxoSmithKline and received approval in Europe. Upon further reflection, I confirm that Strimvelis was indeed granted marketing authorization by the EMA in May 2016, making it one of the first gene therapies approved in Europe. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the protein Asporin related to disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the protein Asporin is related to disease, I first consider the biological role of Asporin. Asporin is a protein belonging to the small leucine-rich proteoglycan family, primarily found in cartilage and other connective tissues. It is known to play a role in regulating chondrogenesis and cartilage maintenance by inhibiting TGF-beta signaling. Research indicates that Asporin is associated with osteoarthritis, a degenerative joint disease, where certain genetic variants of the Asporin gene (ASPN) increase susceptibility to the condition. Specifically, a polymorphism in the ASPN gene leading to a variable number of aspartic acid repeats (D-repeats) in the protein structure has been linked to a higher risk of osteoarthritis in some populations. Additionally, Asporin may be implicated in other conditions like intervertebral disc degeneration. Given this evidence, it is clear that Asporin is related to disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is lactotransferrin a tumour suppressor?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether lactotransferrin is a tumor suppressor, I first consider the definition of a tumor suppressor, which is a protein or gene that inhibits cancer development by regulating cell growth, division, or death. Lactotransferrin, also known as lactoferrin, is an iron-binding glycoprotein found in milk and other bodily fluids, known for its antimicrobial and immune-modulating properties. I recall that some studies suggest lactoferrin has anti-cancer effects, such as inhibiting tumor cell proliferation, inducing apoptosis, and preventing metastasis in certain cancer models. However, I am unsure if it is officially classified as a tumor suppressor, as this term typically applies to specific genes or proteins like p53 or Rb that directly regulate the cell cycle or DNA repair. Upon reflection, while lactoferrin shows promising anti-tumor activity, it may not fit the strict definition of a tumor suppressor since its primary role is not cell cycle regulation but rather immune defense and iron homeostasis. I lean towards 'no' but acknowledge the need for precision. After weighing the evidence, I conclude that lactotransferrin is not classified as a tumor suppressor in the conventional sense, despite its potential anti-cancer properties.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Has the protein SIRT2 been associated to cervical cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the protein SIRT2 has been associated with cervical cancer, I am considering the current scientific literature and known biological roles of SIRT2. SIRT2 is a member of the sirtuin family of proteins, which are involved in regulating cellular processes such as aging, metabolism, and stress response through deacetylation of target proteins. There is evidence in recent studies suggesting that SIRT2 may play a role in cancer by influencing cell cycle progression, apoptosis, and tumor suppression or promotion depending on the context. Specifically, some research indicates that SIRT2 expression levels or activity might be altered in cervical cancer cells, potentially contributing to tumorigenesis through pathways like p53 regulation or epithelial-mesenchymal transition (EMT). While the association is not as well-established as for other proteins like HPV oncoproteins, there are studies that suggest a link between SIRT2 dysregulation and cervical cancer progression. Therefore, based on this analysis, the answer should reflect that there is an association, even if it is still under investigation.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does RUNX2 inhibit astrocyte differentiation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether RUNX2 inhibits astrocyte differentiation, I first consider the role of RUNX2, a transcription factor primarily known for its involvement in osteoblast differentiation and bone development. Astrocytes are a type of glial cell in the central nervous system, and their differentiation is regulated by various signaling pathways and transcription factors. I recall that RUNX2 is not typically associated with neural or glial cell development but is more specific to mesenchymal lineage differentiation. However, there could be indirect effects or context-specific roles in certain cell types or conditions. Upon reflection, I remember studies suggesting that RUNX2 might play a role in inhibiting non-osteogenic lineages in specific contexts, but I am not aware of direct evidence linking RUNX2 to astrocyte differentiation inhibition. Given the lack of specific knowledge or evidence in my training data about RUNX2 directly inhibiting astrocyte differentiation, I lean towards a negative answer but acknowledge the need for precise data. After analyzing, I conclude that there is no widely established or direct evidence supporting that RUNX2 inhibits astrocyte differentiation.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can miR-122 target RUNX2?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether miR-122 can target RUNX2, I first consider the biological context. miR-122 is a microRNA predominantly expressed in the liver, involved in regulating lipid metabolism and liver function. RUNX2, on the other hand, is a transcription factor critical for bone development and osteoblast differentiation. MicroRNAs typically target mRNAs by binding to their 3' untranslated regions (UTRs), leading to translational repression or degradation. For miR-122 to target RUNX2, there must be complementary binding sites in the RUNX2 mRNA's 3' UTR. Based on current knowledge, miR-122's primary targets are related to hepatic functions, and there is limited evidence suggesting direct targeting of RUNX2, which is more associated with bone-related pathways. However, bioinformatics tools like TargetScan or miRanda could predict potential binding sites, though experimental validation (e.g., luciferase assays, qPCR) would be needed to confirm this interaction. Given the tissue-specific expression patterns—miR-122 in liver and RUNX2 in bone—it seems unlikely they interact directly under normal physiological conditions. Without specific studies confirming this targeting, I lean towards a negative answer, but I acknowledge the possibility of indirect regulation or context-specific interactions not widely documented.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can antisense threapy be used for Huntington's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether antisense therapy can be used for Huntington's disease, I first need to consider the nature of the disease and the mechanism of antisense therapy. Huntington's disease is a genetic disorder caused by a mutation in the huntingtin gene, leading to the production of a toxic protein that damages nerve cells in the brain. Antisense therapy involves using synthetic nucleic acid strands to bind to specific mRNA sequences, thereby preventing the translation of faulty proteins or degrading the mRNA. Given that Huntington's disease results from a known genetic mutation, antisense therapy could theoretically target the mutant huntingtin mRNA to reduce the production of the toxic protein. Research and clinical trials have indeed explored antisense oligonucleotides (ASOs) for this purpose, with some promising results in reducing huntingtin protein levels. Therefore, it appears that antisense therapy can be used as a potential treatment approach for Huntington's disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can prevnar 13 be used in children?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Prevnar 13 is a pneumococcal conjugate vaccine designed to protect against 13 strains of Streptococcus pneumoniae. It is approved for use in children from 6 weeks of age through 17 years, as well as in adults. The vaccine is commonly administered to infants and young children as part of routine immunization schedules to prevent pneumococcal diseases such as pneumonia, meningitis, and bacteremia. Therefore, it is appropriate to confirm that Prevnar 13 can indeed be used in children.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Was stelara developed by Amgen?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Stelara was developed by Amgen, I need to recall or research the origin of Stelara. Stelara is a biologic medication used for conditions like psoriasis and Crohn's disease. I believe it was developed by Janssen Biotech, a subsidiary of Johnson & Johnson, not Amgen. Amgen is a different biotechnology company known for drugs like Enbrel and Neulasta. After confirming my understanding, I can conclude that Stelara was indeed developed by Janssen, not Amgen. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is ustekinumab a polyclonal antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ustekinumab is a polyclonal antibody, I first need to recall that polyclonal antibodies are a mixture of antibodies produced by different B cells, recognizing multiple epitopes on an antigen. In contrast, monoclonal antibodies are derived from a single B cell clone and target a specific epitope. Ustekinumab is a biologic drug used to treat conditions like psoriasis and Crohn's disease. I believe it is a monoclonal antibody specifically targeting interleukin-12 and interleukin-23. Upon double-checking my understanding, ustekinumab is indeed a human monoclonal antibody, not polyclonal, as it is engineered to bind to a specific target. Therefore, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do tumour-associated macrophages have a prognostic role in gliomas?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether tumour-associated macrophages (TAMs) have a prognostic role in gliomas, I first consider the biological context. Gliomas are a type of brain tumor, and TAMs are immune cells within the tumor microenvironment that can influence tumor progression. Research suggests that TAMs can promote tumor growth, invasion, and angiogenesis in gliomas, often correlating with worse outcomes. Studies have shown that a higher density of TAMs, particularly those with an M2-like pro-tumor phenotype, is associated with poorer prognosis in glioblastoma, the most aggressive glioma subtype. However, the exact role can vary depending on TAM polarization (M1 vs. M2) and specific glioma subtypes. While there is evidence supporting a prognostic role, it is not universally conclusive across all studies due to heterogeneity in research methods and patient cohorts. Based on the majority of current literature, I lean towards affirming their prognostic significance.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can cardiospheres be produced from skin fibroblasts?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether cardiospheres can be produced from skin fibroblasts, I first need to consider the biological context. Cardiospheres are three-dimensional clusters of cardiac progenitor cells typically derived from heart tissue, used in regenerative medicine for heart repair. Skin fibroblasts, on the other hand, are connective tissue cells from the skin, which are not naturally cardiac in origin. However, advances in cellular reprogramming, such as induced pluripotent stem cells (iPSCs), allow skin fibroblasts to be reprogrammed into various cell types, including cardiac lineages. Research has shown that skin fibroblasts can be converted into iPSCs and then differentiated into cardiomyocytes or cardiac progenitor cells, which could potentially form cardiospheres under the right culture conditions. There are studies demonstrating the formation of cardiosphere-like structures from iPSC-derived cardiac cells. Therefore, while not directly derived, it seems feasible through an intermediate reprogramming step. I conclude that the answer should be affirmative based on current scientific capabilities.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does the interaction of MOV10 and RNASEH2 promote L1 retrotransposition?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the interaction of MOV10 and RNASEH2 promotes L1 retrotransposition, I first consider the biological context. MOV10 is a RNA helicase known to inhibit retrotransposition of LINE-1 (L1) elements by interfering with their replication or integration. RNASEH2, on the other hand, is involved in removing RNA-DNA hybrids, which are intermediates in L1 retrotransposition. If MOV10 and RNASEH2 interact, it might suggest a coordinated mechanism. However, MOV10's primary role is inhibitory, while RNASEH2 could potentially facilitate retrotransposition by clearing RNA-DNA hybrids, aiding the process. There is no direct evidence or widely accepted study indicating that their interaction promotes L1 retrotransposition; in fact, MOV10's inhibitory effect likely dominates. Therefore, their interaction is unlikely to promote L1 retrotransposition.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Tocilizumab is an anti-TNF antibody, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Tocilizumab is a monoclonal antibody used primarily in the treatment of rheumatoid arthritis and other inflammatory conditions. However, it targets the interleukin-6 (IL-6) receptor, not tumor necrosis factor (TNF). Anti-TNF antibodies, such as adalimumab or infliximab, work by inhibiting TNF-alpha, a different cytokine involved in inflammation. Therefore, classifying Tocilizumab as an anti-TNF antibody is incorrect based on its mechanism of action.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Velocardiofacial syndrome, also known as DiGeorge syndrome, is a genetic disorder. I need to verify the chromosomal abnormality associated with it. I recall that DiGeorge syndrome is typically caused by a deletion in chromosome 22, specifically in the 22q11.2 region, not chromosome 21. Chromosome 21 is associated with Down syndrome. Therefore, the statement that it is caused by a deletion in chromosome 21 is incorrect.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I am considering the question about Anaplasma phagocytophilum, which asks if it is an obligate gram-negative, intracellular bacterium. First, I know that Anaplasma phagocytophilum is a bacterium responsible for causing human granulocytic anaplasmosis. It is indeed gram-negative, as it belongs to the family Anaplasmataceae, which are gram-negative bacteria. Additionally, it is an obligate intracellular bacterium, meaning it can only survive and replicate within the host cells, specifically in granulocytes. Therefore, the description provided in the question seems accurate. I will confirm this by ensuring there are no exceptions or misclassifications, but based on standard microbiological knowledge, it fits the description. My answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are cardenolides inhibitors of Na+/K+ ATPase?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Cardenolides are a class of naturally occurring compounds, often found in plants like foxglove (Digitalis). They are known for their cardiac effects and have been used in medicine to treat heart conditions. To answer whether they are inhibitors of Na+/K+ ATPase, I recall that Na+/K+ ATPase is an enzyme critical for maintaining the sodium and potassium ion gradients across cell membranes, especially in cardiac muscle cells. Cardenolides, such as digoxin, are known to bind to and inhibit this enzyme, which leads to an increase in intracellular calcium and a stronger heartbeat. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is it possible to analyze exosomes with FACS?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether it is possible to analyze exosomes with FACS (Fluorescence-Activated Cell Sorting), I first need to consider what exosomes are and the capabilities of FACS. Exosomes are small extracellular vesicles, typically ranging from 30 to 150 nanometers in size, released by cells and involved in intercellular communication. FACS is a specialized type of flow cytometry used to sort and analyze cells based on their fluorescence and light scatter properties. However, standard FACS instruments are generally optimized for larger particles, such as cells, which are in the micrometer range. Exosomes are much smaller, often below the detection limit of conventional flow cytometers due to limitations in laser sensitivity and scatter detection. That said, recent advancements in high-resolution flow cytometry and specialized equipment have made it possible to detect and analyze nanoparticles like exosomes, especially with the use of specific fluorescent labeling to enhance signal detection. Therefore, while traditional FACS may struggle with exosome analysis, modern adaptations and techniques do allow for it under certain conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can mitochondria transfer from cell to cell?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Can mitochondria transfer from cell to cell?', I first consider the biological context. Mitochondria are organelles within eukaryotic cells, primarily responsible for energy production. Traditionally, they are thought to be confined within the cell and passed down through cell division or inherited maternally via the egg cell during reproduction. However, recent research has suggested that under certain conditions, such as cellular stress or injury, mitochondria can be transferred between cells through mechanisms like tunneling nanotubes, extracellular vesicles, or direct cell-to-cell contact. Studies have shown this transfer can occur in specific contexts, such as in the rescue of damaged cells by healthy mitochondria from neighboring cells. Therefore, while not a common occurrence, there is evidence supporting the possibility of mitochondrial transfer between cells in specific situations.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can mitochondria pass through membrane nanotubes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether mitochondria can pass through membrane nanotubes, I first consider the nature of membrane nanotubes, which are thin, tubular structures that connect cells and facilitate the transfer of various cellular components, including organelles. Mitochondria are relatively large organelles, and their ability to pass through these nanotubes depends on the diameter of the nanotube and the mechanisms of transport. Research indicates that membrane nanotubes can vary in size, but many are narrow (50-200 nm in diameter), while mitochondria are typically larger (0.5-1.0 µm in width). However, some studies suggest that mitochondria or mitochondrial fragments can be transferred through wider nanotubes or under specific conditions where they are actively transported. There is evidence from scientific literature, particularly in studies of cellular stress or immune responses, showing mitochondrial transfer via nanotubes. Therefore, while not universally possible due to size constraints, it does occur in certain contexts. Based on this analysis, I conclude that mitochondria can pass through membrane nanotubes under specific conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is TNF-α an activator of pancreatic stellate cells?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether TNF-α (Tumor Necrosis Factor-alpha) is an activator of pancreatic stellate cells (PSCs), I need to consider the role of TNF-α in inflammation and tissue repair, as well as the specific functions of PSCs in the pancreas. PSCs are key players in pancreatic fibrosis and are activated in response to injury or inflammation, transitioning from a quiescent to a myofibroblast-like state. TNF-α is a pro-inflammatory cytokine known to be involved in various cellular processes, including activation of fibroblasts in other tissues. Research suggests that TNF-α can contribute to the activation of PSCs by promoting inflammatory signaling pathways and interacting with other cytokines or growth factors in the pancreatic microenvironment. Studies have shown that TNF-α can induce PSC proliferation and extracellular matrix production, which are hallmarks of activation. Therefore, it appears that TNF-α does play a role in activating PSCs.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are protamines ubiquitously expressed?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether protamines are ubiquitously expressed, I first need to consider what protamines are and their typical expression patterns. Protamines are small, arginine-rich proteins that replace histones during spermatogenesis in many species, aiding in DNA packaging in sperm cells. Their expression is generally specific to the testes and is temporally regulated during sperm development. Ubiquitous expression would imply that protamines are expressed across all cell types and tissues, which does not align with their specialized role in sperm formation. Based on this, it seems unlikely that protamines are ubiquitously expressed. I conclude that the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can therapeutic levels of  Vedolizumab be found in the breast milk of nursing mothers following treatment for Inflammatory bowel disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the nature of Vedolizumab, a monoclonal antibody used to treat inflammatory bowel disease (IBD). Monoclonal antibodies are large molecules, and their transfer into breast milk is typically minimal due to their size. However, some studies suggest that small amounts of such drugs can be detected in breast milk, though often at levels that are not clinically significant. Vedolizumab specifically targets the gut, with limited systemic absorption, which might further reduce its presence in breast milk. Research and clinical guidelines, such as those from the American Gastroenterological Association, indicate that Vedolizumab is considered compatible with breastfeeding due to low transfer risk. However, I must confirm if therapeutic levels—meaning concentrations high enough to have a clinical effect—are actually found in breast milk. Based on available data, while trace amounts may be present, therapeutic levels are unlikely due to the drug's pharmacokinetics. Therefore, my answer leans towards 'no,' but I acknowledge that definitive studies might be limited.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether there are any anti-amyloid antibodies approved as drugs for Alzheimer's disease treatment, I first consider the current state of Alzheimer's research and drug approvals. Alzheimer's disease is characterized by the accumulation of amyloid-beta plaques in the brain, and anti-amyloid antibodies are designed to target and clear these plaques. I recall that in recent years, there have been significant developments in this area. Specifically, I remember that the FDA approved Aducanumab (brand name Aduhelm) in June 2021, which is an anti-amyloid antibody for the treatment of Alzheimer's disease. Additionally, Lecanemab (brand name Leqembi) received FDA approval in January 2023 under the accelerated approval pathway, and later full approval in July 2023, for the same purpose. These approvals confirm that there are indeed anti-amyloid antibodies approved as drugs for Alzheimer's treatment. Therefore, the answer to the question should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is subdural empyema a complication of sinusitis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether subdural empyema is a complication of sinusitis, I first consider the medical context. Sinusitis is an inflammation or infection of the sinuses, often caused by bacteria or viruses. Subdural empyema is a collection of pus between the dura mater and the arachnoid mater of the brain, which is a serious intracranial infection. I recall that sinusitis, particularly when untreated or severe, can lead to complications by spreading infection to nearby structures, including the brain. This can occur through direct extension or hematogenous spread. Subdural empyema is indeed recognized as a rare but serious complication of sinusitis, especially frontal sinusitis, due to the proximity of the sinuses to the brain and the potential for infection to breach the bony barriers. Medical literature and clinical guidelines often list subdural empyema among the intracranial complications of sinusitis. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are artificial blood cells available?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether artificial blood cells are available, I need to consider the current state of medical technology. Artificial blood cells, often referred to as blood substitutes or synthetic blood, are being researched to mimic the oxygen-carrying capacity of real blood cells. There are products like hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon-based solutions that have been developed as alternatives to blood transfusions. Some of these have been tested in clinical trials, and a few have been approved for limited use in certain countries or under specific conditions (e.g., for emergency situations). However, they are not widely available or used as a complete replacement for natural blood cells due to side effects, limited efficacy, and regulatory challenges. As of the latest general knowledge, no fully functional artificial blood cells that replicate all functions of natural blood cells (like red blood cells, white blood cells, and platelets) are commercially available for widespread medical use. Therefore, while partial solutions exist, the answer leans toward 'no' for a fully available and widely accepted product.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is actin present in the nucleus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether actin is present in the nucleus, I need to consider the biological context. Actin is a protein primarily known for its role in the cytoskeleton, contributing to cell structure and movement in the cytoplasm. However, research over the years has shown that actin can also be found in the nucleus, where it plays roles in processes like chromatin remodeling, transcription, and nuclear structure maintenance. Studies have identified nuclear actin in various cell types, often in a monomeric form or as part of complexes, distinct from its filamentous form in the cytoplasm. Therefore, despite its primary association with the cytoplasm, actin is indeed present in the nucleus.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Philadelphia chromosome a fusion between parts of chromosomes 1 and 9?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"The Philadelphia chromosome is a well-known genetic abnormality associated with chronic myelogenous leukemia (CML). It is formed by a translocation between chromosomes 9 and 22, not chromosomes 1 and 9. Specifically, it involves the fusion of the BCR gene on chromosome 22 with the ABL gene on chromosome 9, creating the BCR-ABL fusion gene. Therefore, the statement in the question is incorrect.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is collagen matrix of human articular cartilage changing with disease?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the collagen matrix of human articular cartilage changes with disease, I first consider the role of articular cartilage in joints, which is to provide a smooth, low-friction surface for movement. The collagen matrix, primarily composed of type II collagen, is a critical structural component of this tissue. Diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA) are known to affect cartilage. In OA, there is progressive degradation of cartilage, including the collagen network, due to enzymatic activity and mechanical stress, leading to loss of structural integrity. Studies show that collagen fibers become disorganized, and there is a decrease in collagen content as the disease progresses. Similarly, in RA, inflammatory processes can lead to cartilage destruction, affecting the collagen matrix. Therefore, it is reasonable to conclude that the collagen matrix does change with disease, as both composition and organization are altered in pathological conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can TAD disruption lead to disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether TAD (Topologically Associating Domain) disruption can lead to disease, I first consider the role of TADs in genome organization. TADs are regions of the genome where DNA interactions are more frequent within the domain than outside it, playing a critical role in gene regulation by ensuring that enhancers and promoters interact appropriately. Disruption of TAD boundaries, often through structural variations like deletions, duplications, or inversions, can lead to misregulation of gene expression. For instance, it can cause enhancers to interact with the wrong promoters, potentially activating oncogenes or silencing tumor suppressors. Research has linked TAD disruptions to diseases such as cancer, developmental disorders, and congenital anomalies (e.g., limb malformations due to altered gene expression from TAD boundary disruptions). Therefore, there is substantial evidence that TAD disruption can indeed lead to disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Estrogen lead to forkhead FoxA1 activation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Estrogen leads to Forkhead FoxA1 activation, I first consider the biological context. Estrogen is a steroid hormone that binds to estrogen receptors (ERs) in cells, influencing gene expression by acting as a transcription factor. FoxA1, a member of the Forkhead box family, is a pioneer transcription factor that facilitates the binding of other transcription factors, including ER, to chromatin. Research indicates that FoxA1 is often co-expressed with ER in tissues like breast cancer cells, and it plays a critical role in ER-mediated gene regulation. Studies suggest that Estrogen, through ER, can enhance FoxA1 activity by recruiting it to specific genomic sites, effectively leading to its activation in certain contexts. However, FoxA1 can also function independently of ER in some scenarios. Given the predominant evidence of a cooperative relationship between Estrogen-ER signaling and FoxA1 in regulating target genes, it seems reasonable to conclude that Estrogen does lead to FoxA1 activation, particularly in ER-positive cells. Therefore, my answer is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Apelin usually decreased in diabetes?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Apelin is usually decreased in diabetes, I first considered the role of Apelin, which is a peptide involved in regulating glucose metabolism, insulin sensitivity, and cardiovascular functions. Research suggests that Apelin levels can vary depending on the type of diabetes and the stage of the disease. In type 2 diabetes, studies often indicate that Apelin levels are decreased due to insulin resistance and impaired glucose regulation. However, in type 1 diabetes, the relationship might differ. Additionally, factors like obesity, which often coexists with type 2 diabetes, can also influence Apelin levels. After reviewing the general trend in scientific literature, it appears that in the context of type 2 diabetes, which is more common, Apelin levels are frequently reported to be reduced. Therefore, I conclude that Apelin is usually decreased in diabetes, particularly in the most prevalent form of the condition.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is Pim-1 a protein phosphatase?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Pim-1 is a protein phosphatase, I first need to recall that protein phosphatases are enzymes that remove phosphate groups from proteins, playing a key role in regulating cellular processes by counteracting protein kinases. Pim-1, on the other hand, is a proto-oncogene that encodes a serine/threonine kinase, meaning it adds phosphate groups to proteins rather than removing them. I am considering if there is any evidence or context where Pim-1 might function as a phosphatase, but based on my understanding, Pim-1 is consistently classified as a kinase in scientific literature, involved in cell survival and proliferation pathways. There is no indication that it has phosphatase activity. Therefore, the answer should be based on its primary and well-documented function as a kinase.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the crystal structure of Pim-1 available?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the crystal structure of Pim-1 is available, I need to consider the context of structural biology and protein databases. Pim-1 is a proto-oncogene serine/threonine-protein kinase involved in cell survival and proliferation. Crystal structures of proteins like Pim-1 are often determined through X-ray crystallography and deposited in databases such as the Protein Data Bank (PDB). Given that Pim-1 is a well-studied protein due to its role in cancer research, it is highly likely that its crystal structure has been solved and published. A quick mental check suggests that multiple structures of Pim-1, often in complex with inhibitors, are indeed available in the PDB. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is myc a tumour suppressor gene?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether myc is a tumor suppressor gene, I need to recall the function of the myc gene. Myc is a proto-oncogene, which means it has the potential to cause cancer when mutated or overexpressed. It is involved in cell growth and proliferation, and its dysregulation is associated with many types of cancer. Tumor suppressor genes, on the other hand, are genes that normally inhibit cell division and prevent tumor formation. Since myc promotes cell growth rather than suppresses it, it does not fit the definition of a tumor suppressor gene. Therefore, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is CD63 an exosomal marker?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether CD63 is an exosomal marker, I first consider the role of CD63 in cellular biology. CD63 is a tetraspanin protein commonly associated with the membranes of intracellular vesicles, including exosomes. Exosomes are small extracellular vesicles released by cells, and they carry various proteins, lipids, and nucleic acids. Markers like CD63, along with CD81 and CD9, are often used to identify and characterize exosomes in research because they are enriched on exosomal membranes. Studies and literature in the field of extracellular vesicles frequently reference CD63 as a standard marker for exosomes, detectable through techniques like Western blotting or flow cytometry. However, it's worth noting that CD63 is not exclusively found on exosomes and can be present on other vesicles or cell membranes, which might lead to some ambiguity. Despite this, in the context of exosome research, CD63 is widely accepted and utilized as a marker. Therefore, based on this analysis, I conclude that CD63 is indeed considered an exosomal marker.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does association with the nuclear pore promote gene silencing?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether association with the nuclear pore promotes gene silencing, I first consider the role of the nuclear pore complex (NPC) in cellular processes. The NPC is a gateway for molecular transport between the nucleus and cytoplasm, but it also plays a role in gene regulation. Research indicates that in some organisms, like yeast, association with the nuclear pore can enhance gene expression by facilitating mRNA export or creating an environment conducive to transcription. However, in other contexts, particularly in higher eukaryotes, positioning near the nuclear periphery, where NPCs are located, is often associated with heterochromatin and gene repression. There is evidence suggesting that certain genes, when tethered to the nuclear pore, can be silenced due to proximity to repressive chromatin environments or interactions with silencing factors. For instance, studies in yeast have shown that some silenced regions, like telomeres, can interact with the nuclear periphery. Yet, the primary function of NPCs seems more tied to active gene regulation than silencing. Given the question's general nature and the mixed evidence, I lean toward a negative answer, as the predominant role of nuclear pores appears to be in facilitating gene expression rather than silencing, though context-specific silencing can occur.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the process of DNA loop-extrusion independent of ATP?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the process of DNA loop-extrusion is independent of ATP, I first need to consider the biological mechanism involved. DNA loop-extrusion is a process primarily mediated by cohesin and condensin complexes, which are part of the Structural Maintenance of Chromosomes (SMC) family. These complexes are known to form loops in DNA, which are crucial for chromosome organization and segregation during cell division. The key question is whether this process requires energy input from ATP. I recall that SMC complexes, including cohesin, are ATPases, meaning they hydrolyze ATP to perform their functions. Studies suggest that ATP hydrolysis is necessary for the dynamic activity of these complexes, including the extrusion of DNA loops. For instance, in the case of cohesin, ATP binding and hydrolysis are thought to drive conformational changes that enable loop formation and maintenance. Therefore, it seems that DNA loop-extrusion is dependent on ATP, as the energy from ATP hydrolysis powers the molecular machinery involved. There is no substantial evidence to suggest that loop-extrusion can occur without ATP in vivo under normal conditions. Thus, the process is not independent of ATP.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are lamina-associated domains (LADs) associated with transcriptional activation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether lamina-associated domains (LADs) are associated with transcriptional activation, I first consider the biological context. LADs are regions of the genome that are physically associated with the nuclear lamina, a structure at the inner nuclear membrane. These domains are typically characterized by low gene density and are often linked to gene repression or heterochromatin, which is transcriptionally inactive. Research indicates that LADs are generally associated with transcriptional silencing rather than activation, as genes within LADs tend to be expressed at low levels. However, there might be exceptions or context-specific cases where LADs could be linked to activation, but the predominant evidence suggests a repressive role. Therefore, the answer should reflect the general understanding of LAD function.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are the members of the KRAB-ZNF  gene family promoting gene repression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether members of the KRAB-ZNF gene family promote gene repression, I first consider the biological context. The KRAB-ZNF family refers to Krüppel-associated box (KRAB) domain-containing zinc finger proteins, which are a large group of transcription factors in mammals. The KRAB domain is known to interact with co-repressors like KAP1, which recruits histone deacetylases and other chromatin-modifying complexes to silence gene expression. Research indicates that many KRAB-ZNF proteins are involved in transcriptional repression, particularly in regulating endogenous retroelements and maintaining genomic stability. While some members might have context-specific roles or evolved different functions, the primary and most well-documented role of the KRAB domain is in gene repression. Therefore, it is reasonable to conclude that, in general, members of this family promote gene repression.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does deletion of cohesin change gene expression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether deletion of cohesin changes gene expression, I first consider the role of cohesin in cells. Cohesin is a protein complex crucial for holding sister chromatids together during cell division, but it also plays a significant role in regulating gene expression by organizing chromatin structure and facilitating long-range interactions between enhancers and promoters through loop formation. If cohesin is deleted, these loops may be disrupted, potentially altering the spatial organization of the genome and affecting how genes are transcribed. Studies in various organisms have shown that cohesin mutations or depletion can lead to changes in gene expression, often due to misregulation of these interactions. Therefore, it is reasonable to conclude that deletion of cohesin would indeed change gene expression in most contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SATB1 expressed in thymocytes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SATB1 is expressed in thymocytes, I need to consider the biological context. SATB1 (Special AT-rich sequence-binding protein 1) is a chromatin organizer and transcription factor known to play a critical role in T-cell development. Thymocytes are immature T-cells located in the thymus, where T-cell maturation occurs. Research indicates that SATB1 is indeed expressed in thymocytes, particularly during specific stages of T-cell development, where it regulates gene expression and chromatin structure to facilitate proper differentiation. Studies have shown that SATB1 is essential for the development of T-cells in the thymus, and its expression has been detected in thymocytes at various developmental stages, such as double-negative and double-positive stages. Therefore, based on this understanding, SATB1 is expressed in thymocytes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there negative enhancers?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are there negative enhancers?', I first need to interpret the term 'negative enhancers' in a likely context, as it could refer to different fields such as biology, technology, or even psychology. In biology, enhancers are DNA sequences that increase the transcription of genes, so 'negative enhancers' might refer to elements that suppress or reduce gene expression, which are more commonly called silencers. However, some literature might use 'negative enhancers' to describe regulatory elements with inhibitory effects. In other contexts, like audio or image processing, negative enhancers could imply something that degrades quality, though this is less common. Given the ambiguity, I lean toward the biological context where negative regulatory elements exist, even if the term might not be standard. Therefore, I conclude that there are elements that could be described as negative enhancers in certain contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SATB1 necessary for T-cell maturation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SATB1 is necessary for T-cell maturation, I first consider the role of SATB1 in T-cell development. SATB1 (Special AT-rich sequence-binding protein 1) is a chromatin organizer and transcription factor known to regulate gene expression during T-cell development. Research indicates that SATB1 is critical for the proper differentiation and maturation of T-cells in the thymus, particularly in the transition from double-negative to double-positive stages and in the regulation of T-cell receptor expression. Studies, including knockout models in mice, have shown that the absence of SATB1 leads to impaired T-cell development, with significant defects in positive selection and lineage commitment. Therefore, based on this analysis, SATB1 appears to be necessary for proper T-cell maturation.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does SATB1 regulate the RAG1 and RAG2 genes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SATB1 regulates the RAG1 and RAG2 genes, I am considering the biological context. SATB1 (Special AT-rich sequence-binding protein 1) is a transcription factor known to play a role in chromatin organization and gene regulation, particularly in T-cell development. RAG1 and RAG2 (Recombination Activating Genes 1 and 2) are crucial for V(D)J recombination, a process essential for generating diversity in T-cell and B-cell receptors. Research indicates that SATB1 is involved in regulating gene expression during lymphocyte development, and studies have shown that it binds to specific regions of the genome to facilitate chromatin looping and gene activation or repression. Specifically, SATB1 has been implicated in the regulation of RAG1 and RAG2 expression by organizing the chromatin structure at the RAG locus in thymocytes, enabling proper recombination. Therefore, based on this understanding, SATB1 does regulate RAG1 and RAG2 genes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is CTCF bound at nucleosome free regions?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether CTCF is bound at nucleosome-free regions, I need to consider the biological context. CTCF is a transcription factor known for its role in regulating gene expression and chromatin organization, often binding to specific DNA sequences to act as an insulator or boundary element. Nucleosome-free regions (NFRs) are areas of DNA not occupied by nucleosomes, often found at promoters or regulatory elements, making the DNA more accessible for protein binding. Research indicates that CTCF binding sites are frequently located in accessible chromatin regions, which are often nucleosome-free, as nucleosomes can block access to DNA. Studies using techniques like DNase-seq and ATAC-seq have shown that CTCF binding correlates with open chromatin, supporting the idea that CTCF binds to nucleosome-free regions. However, there might be exceptions or context-specific cases where CTCF binding occurs in less accessible regions. Overall, the general consensus in the field is that CTCF predominantly binds to nucleosome-free or accessible regions. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does metformin alleviate atherosclerosis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether metformin alleviates atherosclerosis, I first consider the context of the question. Metformin is a widely used medication for type 2 diabetes, primarily known for its role in controlling blood sugar levels by improving insulin sensitivity and reducing glucose production in the liver. Atherosclerosis, on the other hand, is a condition characterized by the buildup of plaques in the arteries, leading to cardiovascular issues. There is ongoing research into whether metformin has protective effects on the cardiovascular system beyond its glucose-lowering effects. Some studies suggest that metformin may have anti-inflammatory and antioxidant properties, which could potentially reduce the progression of atherosclerosis by improving endothelial function and reducing vascular inflammation. Clinical evidence, such as meta-analyses and observational studies, indicates a possible benefit in reducing cardiovascular events in diabetic patients, which might indirectly point to an effect on atherosclerosis. However, direct evidence proving that metformin specifically alleviates atherosclerosis (i.e., reverses or significantly reduces plaque buildup) is not conclusively established in humans, as most data are associative or based on animal models. Given the question's phrasing, which implies a direct effect, and considering the lack of definitive clinical guidelines or consensus stating that metformin is a treatment for atherosclerosis itself, I lean towards a cautious interpretation. Therefore, while there is promising evidence, it is not sufficient to definitively state that metformin alleviates atherosclerosis.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does GRHL2 over-expression lead to EMT?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether GRHL2 over-expression leads to EMT (Epithelial-Mesenchymal Transition), I first consider the biological context. GRHL2 (Grainyhead-like 2) is a transcription factor known to play a role in epithelial cell identity and maintenance of epithelial characteristics. EMT is a process where epithelial cells lose their characteristics and gain mesenchymal traits, often associated with cancer metastasis and tissue development. Research suggests that GRHL2 typically suppresses EMT by maintaining epithelial integrity and inhibiting mesenchymal gene expression. Over-expression of GRHL2 would likely reinforce epithelial traits rather than promote EMT. However, context-specific factors such as cell type, signaling pathways, or interactions with other regulators could potentially alter this effect. Based on the predominant evidence in literature, GRHL2 over-expression is more commonly associated with the suppression of EMT rather than its induction. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is PRDM9 essential for meiosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether PRDM9 is essential for meiosis, I first consider its role in the process. PRDM9 is a protein that plays a critical role in determining the locations of recombination hotspots during meiosis by binding to specific DNA sequences and marking them for double-strand breaks, which initiate recombination. This is crucial for proper chromosome segregation and genetic diversity. Research, particularly in mammals like mice and humans, shows that PRDM9 is highly influential in hotspot determination. However, I recall that in some organisms, such as certain yeast species or PRDM9 knockout mice, meiosis can still occur, albeit with altered recombination patterns or reduced fertility. In PRDM9-deficient mice, for instance, meiosis proceeds but often results in sterility due to improper synapsis and recombination. This suggests that while PRDM9 is important, it may not be absolutely essential for meiosis to initiate or complete in all contexts. However, in many species, its absence severely disrupts the process. Given the question's general phrasing, I lean towards affirming its essentiality in most studied cases, especially mammals. Thus, my answer will reflect that PRDM9 is generally considered essential for proper meiosis.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does the chromatin remodeling complex, RSC target H2A.Z nucleosomes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the chromatin remodeling complex RSC targets H2A.Z nucleosomes, I first consider the role of RSC and H2A.Z in chromatin dynamics. RSC (Remodels the Structure of Chromatin) is a yeast chromatin remodeling complex involved in nucleosome sliding and eviction, playing a key role in gene expression and DNA repair. H2A.Z is a histone variant often associated with nucleosomes near transcription start sites and is linked to transcriptional regulation. Research suggests that RSC interacts with H2A.Z-containing nucleosomes, particularly in promoter regions, to facilitate nucleosome remodeling or eviction. Studies have shown that RSC is recruited to H2A.Z nucleosomes to maintain accessible chromatin states. Therefore, it seems that RSC does target H2A.Z nucleosomes as part of its function in chromatin remodeling.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the tyrosine kinase BTK implicated in autoimmunity?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the tyrosine kinase BTK (Bruton’s tyrosine kinase) is implicated in autoimmunity, I first consider its role in the immune system. BTK is a key signaling molecule in B cells, crucial for B-cell receptor signaling, development, and activation. Dysregulation of B-cell activity is often associated with autoimmune diseases, where the immune system attacks self-tissues. Research indicates that BTK inhibitors, such as ibrutinib, have been explored for treating autoimmune conditions like rheumatoid arthritis and lupus, suggesting that BTK overactivity or dysfunction may contribute to autoimmunity. Additionally, mutations in BTK are linked to X-linked agammaglobulinemia, which primarily causes immunodeficiency but also highlights its critical role in immune regulation. Given this, it seems plausible that aberrant BTK signaling could lead to loss of immune tolerance and autoimmunity. Therefore, BTK is indeed implicated in autoimmunity.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is induction of interferon by TLR7 higher in males?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the induction of interferon by TLR7 is higher in males, I need to consider the biological context. TLR7 (Toll-like receptor 7) is involved in the innate immune response, recognizing single-stranded RNA and triggering the production of interferons, which are critical antiviral cytokines. Research suggests that there are sex-based differences in immune responses, often linked to genetic and hormonal factors. TLR7 is encoded on the X chromosome, and females, having two X chromosomes, might have a different expression pattern due to X-inactivation escape. Some studies indicate that females may have a higher TLR7 expression or responsiveness, potentially leading to stronger interferon production. However, I recall specific research, such as studies on plasmacytoid dendritic cells, showing that TLR7-mediated interferon production can be influenced by sex hormones like estrogen, which might enhance responses in females. On the other hand, there is evidence suggesting that in certain contexts, males might exhibit different immune activation profiles. After analyzing this, the general trend in literature leans towards females having a higher induction of interferon via TLR7 due to genetic and hormonal influences. Therefore, it is likely not higher in males.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does CXorf21 escape X chromosome inactivation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether CXorf21 escapes X chromosome inactivation, I need to consider the biological context. X chromosome inactivation (XCI) is a process in mammals where one of the two X chromosomes in females is silenced to balance gene dosage with males, who have only one X chromosome. However, some genes on the X chromosome are known to escape this inactivation and remain active on both X chromosomes. CXorf21 is a gene located on the X chromosome, and research suggests that it is one of the genes that may escape XCI in certain contexts or tissues, based on studies of X-linked gene expression. After analyzing this, I conclude that CXorf21 does escape X chromosome inactivation.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SATB1 positioned close to AT-rich sequences?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SATB1 is positioned close to AT-rich sequences, I first consider the role of SATB1. SATB1 (Special AT-rich sequence-binding protein 1) is a nuclear protein known for its involvement in chromatin organization and gene regulation. It binds to specific DNA sequences, particularly AT-rich regions, which are often found in matrix attachment regions (MARs) or scaffold attachment regions (SARs). These regions help in anchoring chromatin loops to the nuclear matrix. Given this, SATB1 is indeed associated with AT-rich sequences as part of its function in organizing chromatin structure. Therefore, it is reasonable to conclude that SATB1 is positioned close to AT-rich sequences.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Niraparib effective for ovarian cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Niraparib is effective for ovarian cancer, I first consider the context of the question. Niraparib is a PARP inhibitor, a type of targeted therapy used in cancer treatment. It is specifically approved for the treatment of ovarian cancer in certain cases, particularly for patients with BRCA mutations or as maintenance therapy after chemotherapy. Clinical trials and medical guidelines, such as those from the FDA and NCCN, indicate that Niraparib has shown efficacy in improving progression-free survival in patients with advanced ovarian cancer, especially in those with homologous recombination deficiency (HRD). However, effectiveness can vary based on individual patient factors, cancer stage, and specific genetic profiles. Since the question is general and does not specify a particular context or patient group, I will base my answer on the established medical consensus that Niraparib is effective for ovarian cancer in approved indications. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is palbociclib effective for glioblastoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether palbociclib is effective for glioblastoma, I first consider that palbociclib is a CDK4/6 inhibitor primarily used in the treatment of certain types of breast cancer. Glioblastoma, on the other hand, is a highly aggressive brain tumor. I recall that CDK4/6 pathways can be dysregulated in glioblastoma, suggesting a potential therapeutic role for inhibitors like palbociclib. However, I also note that clinical evidence might be limited. Upon reflection, I remember that while preclinical studies have shown some promise, clinical trials have not yet conclusively demonstrated significant efficacy of palbociclib in glioblastoma patients, often due to challenges like blood-brain barrier penetration and tumor heterogeneity. Therefore, based on current knowledge, it is not considered a standard or highly effective treatment for glioblastoma.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can LB-100 sensitize ovarian carcinoma to cisplatin?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether LB-100 can sensitize ovarian carcinoma to cisplatin, I first consider the context of the question. LB-100 is a small molecule inhibitor of protein phosphatase 2A (PP2A), which is involved in regulating cellular processes like apoptosis and DNA damage response. Cisplatin is a chemotherapeutic drug commonly used for ovarian carcinoma, but resistance to cisplatin is a significant clinical challenge. Sensitization would mean that LB-100 enhances the effectiveness of cisplatin, potentially by overcoming resistance or increasing cancer cell death. Research suggests that inhibiting PP2A with LB-100 can disrupt DNA damage repair mechanisms, making cancer cells more vulnerable to DNA-damaging agents like cisplatin. Preclinical studies, including those in ovarian cancer models, have shown that LB-100 can enhance the cytotoxic effects of cisplatin by promoting apoptosis and inhibiting survival pathways. While clinical data may still be limited, the mechanistic rationale and existing preclinical evidence support the potential for LB-100 to sensitize ovarian carcinoma to cisplatin. Therefore, based on this analysis, the answer should be affirmative, acknowledging that further clinical validation may be needed.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has LB-100 been tested in clinical trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether LB-100 has been tested in clinical trials, I need to consider the context and available information. LB-100 is a drug candidate known for its potential as a protein phosphatase 2A (PP2A) inhibitor, often studied for cancer treatment and other conditions. Clinical trials are formal studies conducted to evaluate the safety and efficacy of drugs in humans. Given that LB-100 is a relatively well-known investigational drug, it is likely that it has progressed to clinical testing. I recall that there have been Phase 1 and possibly Phase 2 trials involving LB-100, particularly in cancer patients, to assess its safety and preliminary efficacy. Therefore, I believe the answer is affirmative, but I must ensure I'm not confusing it with preclinical studies. Upon reflection, I confirm that LB-100 has indeed been tested in clinical trials, as there are documented studies and ongoing research listed in clinical trial databases like ClinicalTrials.gov. Thus, my final answer is 'yes'.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can LB-100 downregulate miR-33?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether LB-100 can downregulate miR-33, I first consider the nature of LB-100 and miR-33. LB-100 is a small molecule inhibitor of protein phosphatase 2A (PP2A), which is involved in various cellular processes including gene regulation. miR-33 is a microRNA that regulates lipid metabolism and other cellular functions. Downregulation of miR-33 would imply a reduction in its expression or activity. I analyze if there is a direct or indirect mechanism by which LB-100, through PP2A inhibition, could affect miR-33 expression. PP2A is known to regulate transcription factors and signaling pathways that could influence microRNA expression. However, there is no widely documented evidence or specific study directly linking LB-100 to miR-33 downregulation. Research on LB-100 primarily focuses on its role in cancer therapy and cell cycle regulation, not specifically on microRNA modulation like miR-33. Given the lack of direct evidence or established mechanism in the literature connecting LB-100 to miR-33, I conclude that it is unlikely or not confirmed that LB-100 downregulates miR-33.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can PRL3-zumab inhibit PRL3+ cancer cells in vitro and in vivo?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether PRL3-zumab can inhibit PRL3+ cancer cells in vitro and in vivo, I first need to consider the context. PRL3-zumab appears to be a targeted therapy, likely an antibody (given the '-zumab' suffix), designed to target PRL3, a protein tyrosine phosphatase often overexpressed in certain cancers (PRL3+ cancer cells). The question asks about its inhibitory effects in two settings: in vitro (cell cultures in a lab) and in vivo (within a living organism). Without specific data or studies provided, I must rely on general knowledge about targeted therapies. Typically, antibodies like PRL3-zumab are designed to bind specifically to their target (PRL3 in this case), potentially inhibiting its activity or marking cells for immune destruction. If PRL3-zumab is developed for this purpose, it is reasonable to assume it could inhibit PRL3+ cancer cells in both settings, assuming successful design and testing. However, real-world efficacy depends on factors like binding affinity, delivery, and tumor microenvironment, which are not specified here. Since the question seems to imply a straightforward inquiry about capability and given the naming convention, I will lean towards a positive response, acknowledging that this is a hypothetical or generalized assessment without concrete evidence provided in the query.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can discharge destinations be accurately predicted using the Risk Assessment and Prediction Tool (RAPT)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether discharge destinations can be accurately predicted using the Risk Assessment and Prediction Tool (RAPT), I first consider the purpose and functionality of RAPT. RAPT is a clinical tool primarily used in healthcare settings, especially for patients undergoing elective surgeries like joint replacements, to predict post-surgical rehabilitation needs and discharge destinations. It assesses factors such as age, gender, walking distance, gait aid use, and social support to generate a score that helps predict whether a patient is likely to be discharged home or to a rehabilitation facility. Studies and clinical evidence suggest that RAPT has been validated for its predictive accuracy in identifying discharge destinations, with a reported accuracy rate of around 75-89% in various studies. While it is not perfect and may vary based on individual patient circumstances or specific healthcare settings, the tool is generally considered reliable for this purpose. Therefore, I conclude that discharge destinations can be accurately predicted using RAPT in most cases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is AZD5153 active in prostate cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether AZD5153 is active in prostate cancer, I first consider what AZD5153 is. AZD5153 is a bivalent BET inhibitor, which targets bromodomain and extraterminal (BET) proteins involved in gene expression regulation, often implicated in cancer. Next, I analyze if there is evidence of its activity specifically in prostate cancer. Prostate cancer is known to be driven by androgen receptor signaling, and BET inhibitors have been studied for their potential to disrupt this pathway. Research and clinical studies suggest that BET inhibitors, including AZD5153, have shown preclinical activity in prostate cancer models by inhibiting tumor growth and reducing androgen receptor-driven gene expression. However, I must consider if this translates to clinical efficacy in humans. While preclinical data is promising, I recall that clinical trials are still ongoing or limited in scope for AZD5153 in prostate cancer, and definitive clinical activity may not be fully established yet. Given the question's phrasing, which does not specify clinical or preclinical context, I lean towards acknowledging the evidence of activity in preclinical settings. Therefore, based on available knowledge, I conclude that AZD5153 is active in prostate cancer in preclinical models.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is GRG5 involved only in late embryonic mouse development?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether GRG5 is involved only in late embryonic mouse development, I need to consider the role of GRG5 (also known as AES, Amino-terminal Enhancer of Split), a member of the Groucho/Transducin-like Enhancer of split (TLE) family of transcriptional co-repressors. GRG5 is known to interact with various transcription factors and play a role in developmental processes by repressing gene expression. Research indicates that GRG5 is expressed in multiple stages of mouse embryonic development, not just the late stages. Studies have shown its expression and functional importance in early embryonic patterning and organogenesis, as well as in later stages. For instance, GRG5 has been implicated in early neural development and somitogenesis, which occur before late embryonic stages. Therefore, it is not exclusively involved in late embryonic development, as its activity spans across different developmental timelines. Based on this analysis, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does BNN27 promote memory loss?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether BNN27 promotes memory loss, I first consider the context and available information. BNN27 is a synthetic derivative of dehydroepiandrosterone (DHEA) and is being researched for its potential neuroprotective effects, particularly in relation to neurodegenerative diseases. Current studies suggest that BNN27 may have a protective role against neuronal damage and could potentially support cognitive functions, rather than promote memory loss. There is no substantial evidence or widely recognized research indicating that BNN27 causes or promotes memory loss. Instead, its mechanism appears to be linked with neuroprotection, possibly through interaction with neurotrophin receptors. Therefore, based on this analysis, it is unlikely that BNN27 promotes memory loss.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is BNN20 involved in Parkinson's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether BNN20 is involved in Parkinson's disease, I first consider what BNN20 is. BNN20, or 17β-spiro-(androst-5-en-3β-ol)-oxiran-2-one, is a synthetic analogue of dehydroepiandrosterone (DHEA) with potential neuroprotective properties. Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. I recall that research on BNN20 has explored its effects on neuroprotection, particularly in models of neurodegenerative diseases. Studies suggest that BNN20 may have beneficial effects by mimicking neurotrophic factors like BDNF, which could support neuronal survival. There is evidence from preclinical studies, such as those using animal models of Parkinson's disease, indicating that BNN20 can protect dopaminergic neurons and improve motor symptoms. Therefore, it appears that BNN20 is indeed involved in research related to Parkinson's disease as a potential therapeutic agent.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has istadefylline been considered as a treatment for Parkinson's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Istadefylline is a medication that acts as an adenosine A2A receptor antagonist. It has been studied and approved in some countries, such as Japan and the United States, as an adjunctive treatment for Parkinson's disease to help manage motor symptoms and reduce 'off' time in patients taking levodopa-based therapies. Therefore, it has indeed been considered and utilized as a treatment for Parkinson's disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is amantadine ER the first approved treatment for akinesia?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether amantadine ER (extended release) is the first approved treatment for akinesia, I need to consider the context of akinesia, which is a symptom often associated with Parkinson's disease, characterized by the inability to initiate movement. Amantadine, in its immediate-release form, has been used for decades to treat symptoms of Parkinson's disease, including akinesia, and was first approved by the FDA in the 1960s for influenza, with later recognition for Parkinson's symptoms. Amantadine ER, specifically, was approved more recently (around 2017) for the treatment of dyskinesia in Parkinson's patients, not primarily for akinesia. However, treatments for Parkinson's often address multiple symptoms, including akinesia. Given that other treatments, such as levodopa, have been used for akinesia since the 1960s and are considered the gold standard, amantadine ER cannot be considered the first approved treatment for akinesia. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has amantadine ER been approved by the FDA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether amantadine ER (extended-release) has been approved by the FDA, I need to consider the current status of this medication. Amantadine is an antiviral and antiparkinsonian drug, and its extended-release formulation is primarily used for the treatment of dyskinesia in patients with Parkinson's disease. I recall that the FDA approved an extended-release formulation of amantadine under the brand name Gocovri in 2017 for the treatment of dyskinesia in Parkinson's patients. Additionally, another extended-release formulation, Osmolex ER, was approved in 2018 for Parkinson's disease and drug-induced extrapyramidal reactions. Therefore, based on this information, amantadine ER has indeed been approved by the FDA.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is pimavanserin a typical antipsychotic?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether pimavanserin is a typical antipsychotic, I need to consider the classification of antipsychotics. Antipsychotics are generally divided into two categories: typical (first-generation) and atypical (second-generation). Typical antipsychotics, such as haloperidol and chlorpromazine, primarily work by blocking dopamine D2 receptors and are often associated with extrapyramidal side effects. Atypical antipsychotics, like risperidone and olanzapine, affect both dopamine and serotonin receptors and have a lower risk of such side effects. Pimavanserin is a medication used primarily for treating hallucinations and delusions associated with Parkinson’s disease psychosis. It acts as a selective serotonin 5-HT2A receptor inverse agonist, without significant dopamine receptor antagonism, which differentiates it from typical antipsychotics. Therefore, pimavanserin does not fit the profile of a typical antipsychotic.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has ProSavin undergone phase IV clinical trials by 2018?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ProSavin has undergone Phase IV clinical trials by 2018, I need to consider what Phase IV trials are and the status of ProSavin's development. Phase IV trials are post-marketing studies conducted after a drug or therapy has been approved for public use to monitor long-term effects and efficacy in a larger population. ProSavin is a gene therapy developed by Oxford BioMedica for the treatment of Parkinson's disease. I recall that ProSavin had completed early-phase trials (Phase I/II) by around 2012, focusing on safety and preliminary efficacy. However, I am not aware of any information indicating that ProSavin had received regulatory approval for marketing by 2018, which is a prerequisite for Phase IV trials. There is also a possibility that ProSavin's development was succeeded by a related therapy called AXO-Lenti-PD, which might have shifted focus away from ProSavin itself. Without specific evidence or documentation confirming Phase IV trials for ProSavin by 2018, I must conclude that it likely did not reach that stage by the specified year.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does ProSavin use an adenoviral vector?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ProSavin uses an adenoviral vector, I first need to recall that ProSavin is a gene therapy developed for the treatment of Parkinson's disease. It is designed to deliver genes encoding enzymes involved in dopamine synthesis directly to the brain. Next, I consider the type of vector used for gene delivery in ProSavin. I remember that ProSavin utilizes a lentiviral vector, which is derived from HIV but modified to be non-pathogenic, as opposed to an adenoviral vector, which is based on adenovirus and commonly used in other gene therapies. Lentiviral vectors are often chosen for their ability to integrate into the host genome and provide long-term gene expression, which is beneficial for chronic conditions like Parkinson's. Adenoviral vectors, on the other hand, do not integrate into the genome and are more suited for transient expression. Given this, I conclude that ProSavin does not use an adenoviral vector.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is BCL11B involved in schizophrenia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether BCL11B is involved in schizophrenia, I first consider the role of BCL11B, which is a gene encoding a transcription factor primarily known for its involvement in brain development and immune system regulation. Schizophrenia is a complex psychiatric disorder with genetic and environmental factors. Recent studies and genetic research have identified numerous susceptibility genes for schizophrenia, and I recall that BCL11B has been implicated in neurodevelopmental processes. Upon analysis, I note that some genome-wide association studies (GWAS) and other genetic analyses have suggested a potential link between BCL11B variants and schizophrenia, as disruptions in neurodevelopmental pathways can contribute to the disorder. However, the evidence is not fully conclusive, and the exact mechanism remains under investigation. Given the current scientific literature and the association found in some studies, I lean towards affirming a connection, though it may not be definitive. Therefore, my answer will reflect this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are CD8+ (cytotoxic) T cells and  CD4+ Helper T cells generated in the thyroid and express the T-cell receptor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to break it down into two parts: (1) Are CD8+ cytotoxic T cells and CD4+ helper T cells generated in the thyroid? (2) Do they express the T-cell receptor? First, regarding the generation of T cells, I know that T cells, including both CD4+ and CD8+ subsets, are primarily generated in the thymus, not in the thyroid. The thymus is the primary lymphoid organ where T cell maturation occurs. The thyroid, on the other hand, is an endocrine gland responsible for producing thyroid hormones and is not involved in T cell generation. There might be some confusion with secondary lymphoid organs or local immune responses, but generation specifically refers to their development, which happens in the thymus. Second, regarding the expression of the T-cell receptor (TCR), both CD4+ and CD8+ T cells are defined as T cells because they express the TCR, which is essential for recognizing antigens presented by MHC molecules. So, yes, they do express the T-cell receptor. Since the question uses 'and,' both conditions must be true for a 'yes' answer. However, since T cells are not generated in the thyroid, the answer should be 'no.'\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do MAIT cells have a role in multiple myeloma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether MAIT (Mucosal-Associated Invariant T) cells have a role in multiple myeloma, I first consider the nature of MAIT cells and multiple myeloma. MAIT cells are a subset of T cells that play a role in innate-like immune responses, primarily recognizing microbial metabolites presented by the MR1 molecule. They are involved in mucosal immunity and can respond to bacterial and viral infections. Multiple myeloma, on the other hand, is a hematological cancer characterized by the proliferation of malignant plasma cells in the bone marrow, leading to immune suppression and bone lesions. I recall that the tumor microenvironment in multiple myeloma often involves immune dysregulation, with various immune cells, including T cells, playing roles in either promoting or suppressing tumor growth. While MAIT cells are not typically highlighted in multiple myeloma research compared to other T cell subsets like CD8+ T cells or regulatory T cells, there is emerging evidence suggesting they might be involved. Studies indicate that MAIT cells can be altered in frequency or function in cancer patients, including hematological malignancies, potentially contributing to immune surveillance or dysfunction. Given this, I believe there is a plausible role for MAIT cells in multiple myeloma, likely related to their immune-modulatory functions in the tumor microenvironment. Therefore, my answer leans towards 'yes,' acknowledging their potential involvement based on current immunological understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the BAGEL algorithm used for arrayed CRISPR screens?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the BAGEL algorithm is used for arrayed CRISPR screens, I first need to understand the purpose of the BAGEL algorithm and the context of arrayed CRISPR screens. BAGEL (Bayesian Analysis of Gene Essentiality) is a computational tool designed to analyze CRISPR-Cas9 screening data, particularly to identify essential genes by calculating a Bayes Factor for gene essentiality based on guide RNA (gRNA) fold changes. CRISPR screens can be conducted in two formats: pooled and arrayed. Pooled screens involve a mixture of cells with different gRNAs, analyzed via next-generation sequencing, while arrayed screens test individual gRNAs in separate wells, allowing for more controlled experiments. BAGEL was originally developed and is primarily documented for use with pooled CRISPR screens, as it processes fold change data from sequencing results. However, the algorithm's core functionality—calculating gene essentiality based on gRNA effects—could theoretically be adapted to arrayed screens if fold change or similar data is available. Upon reviewing the primary literature and documentation for BAGEL, there is no explicit mention of its application to arrayed screens, and its training data and workflows are tailored to pooled screen outputs. Therefore, while it might be possible to use BAGEL for arrayed screens with significant customization, it is not standard or directly intended for that purpose.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Ubrogepant effective for migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Ubrogepant is effective for migraine, I first consider the context of the question. Ubrogepant is a medication specifically developed for the acute treatment of migraine. It is a calcitonin gene-related peptide (CGRP) receptor antagonist, which works by blocking CGRP, a protein involved in migraine attacks. Clinical studies and FDA approval in 2019 support its use for migraine treatment in adults, with or without aura. Trials have shown that Ubrogepant can provide pain relief and reduce migraine-associated symptoms like nausea and sensitivity to light or sound within two hours for many patients. While effectiveness can vary individually, the general consensus based on available data is that it is effective for many people. Therefore, the answer should reflect this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is modified vaccinia Ankara effective for smallpox?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether modified vaccinia Ankara (MVA) is effective for smallpox, I need to consider the background of MVA and its use in vaccination. MVA is a highly attenuated strain of vaccinia virus, developed as a safer alternative to traditional smallpox vaccines. It was initially created by passaging vaccinia virus multiple times in chick embryo fibroblasts, resulting in a virus that does not replicate efficiently in human cells, thus reducing the risk of adverse effects. Studies and clinical trials have shown that MVA induces a strong immune response, including the production of neutralizing antibodies and T-cell responses, which are critical for protection against smallpox. It has been tested as a vaccine candidate, particularly in scenarios where traditional vaccinia-based vaccines pose risks, such as in immunocompromised individuals. The FDA has approved an MVA-based vaccine (under the name JYNNEOS) for the prevention of smallpox and monkeypox, indicating its efficacy based on clinical data and animal studies. While it may not be as immunogenic as traditional replicating vaccinia vaccines in some contexts, it is still considered effective, especially given its safety profile. Therefore, based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Apremilast effective for Behçet’s Syndrome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Apremilast is effective for Behçet’s Syndrome, I first consider the nature of the condition and the drug. Behçet’s Syndrome is a rare, chronic inflammatory disorder characterized by recurrent oral and genital ulcers, skin lesions, and potential involvement of the eyes, joints, and vascular system. Apremilast is a phosphodiesterase-4 inhibitor, primarily used for treating psoriasis and psoriatic arthritis due to its anti-inflammatory properties. I recall that Apremilast has been studied for Behçet’s Syndrome, particularly for managing oral ulcers, which are a hallmark of the disease. Clinical trials, such as the phase 2 and phase 3 studies, have shown that Apremilast can significantly reduce the number of oral ulcers and associated pain in patients with Behçet’s Syndrome. The drug was approved by the FDA in 2019 for this specific indication, marking it as the first targeted oral therapy for Behçet’s Syndrome in the United States. While it may not address all manifestations of the disease (e.g., severe ocular or vascular involvement), it is considered effective for the mucocutaneous symptoms. Therefore, based on available evidence and regulatory approval, Apremilast is effective for Behçet’s Syndrome, particularly for oral ulcers.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Selinexor effective for multiple myeloma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Selinexor is effective for multiple myeloma, I first consider the context of the question. Multiple myeloma is a type of blood cancer affecting plasma cells, and treatment effectiveness depends on clinical evidence. Selinexor is a drug known as a selective inhibitor of nuclear export, and I recall that it has been approved by the FDA for use in relapsed or refractory multiple myeloma in combination with other drugs like dexamethasone. Clinical trials, such as the STORM trial, have shown that Selinexor can be effective in patients who have failed other therapies, demonstrating a response rate in heavily pretreated patients. However, effectiveness can vary based on individual patient factors, and side effects are notable. Since the question is general and does not specify a particular context or patient group, I will base my answer on the general evidence of its approval and documented efficacy in clinical settings. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does teplizumab hold promise for diabetes prevention?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether teplizumab holds promise for diabetes prevention, I first consider the context of diabetes, particularly Type 1 diabetes, which is an autoimmune condition where the immune system attacks insulin-producing beta cells. Teplizumab is a monoclonal antibody that targets the immune system, specifically T-cells, to delay or prevent the onset of Type 1 diabetes in at-risk individuals. Clinical trials, such as those conducted by TrialNet, have shown that teplizumab can delay the progression to clinical Type 1 diabetes in high-risk individuals by modulating the immune response. While it is not a cure and long-term effects are still under study, the results suggest it holds significant potential for prevention or delay of the disease. Therefore, based on current evidence, it appears to hold promise.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does nintedanib hold promise for lung disease associated with systemic sclerosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether nintedanib holds promise for lung disease associated with systemic sclerosis, I first consider the context of systemic sclerosis, a chronic autoimmune disease that can lead to interstitial lung disease (ILD), a major cause of morbidity and mortality. Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF), which shares similarities with systemic sclerosis-associated ILD in terms of fibrotic processes. Clinical studies, such as the SENSCIS trial, have shown that nintedanib can slow the decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated ILD, indicating a reduction in disease progression. While it does not cure the condition, the evidence suggests it offers a therapeutic benefit by mitigating lung function decline. Therefore, it appears to hold promise for this condition.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is mesothelioma caused by asbestos exposure?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Mesothelioma is a rare and aggressive form of cancer that primarily affects the lining of the lungs, abdomen, or heart. It is widely documented in medical literature that the primary cause of mesothelioma is exposure to asbestos, a naturally occurring mineral used in various industries for its heat-resistant properties. Asbestos fibers, when inhaled or ingested, can become lodged in the mesothelium, leading to inflammation and genetic damage over time, which can result in mesothelioma. While other factors like genetics or radiation may play a role in rare cases, asbestos exposure is the most significant and well-established cause, often linked to occupational or environmental exposure. Therefore, the answer to whether mesothelioma is caused by asbestos exposure is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Hemochromatosis type 4 is caused by a mutation in a recessive gene?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Hemochromatosis type 4, also known as ferroportin disease, is a form of hereditary hemochromatosis caused by mutations in the SLC40A1 gene, which encodes the ferroportin protein. Unlike other types of hemochromatosis that are typically autosomal recessive, type 4 is characterized by an autosomal dominant inheritance pattern. This means that a mutation in just one copy of the gene is sufficient to cause the disorder, rather than requiring mutations in both copies as in recessive conditions. Therefore, it is not caused by a mutation in a recessive gene.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Huntington's disease is caused by expansion of a CTG repeat in the HTT gene on Chromosome 4?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Huntington's disease is a genetic disorder, and I need to confirm whether it is caused by the expansion of a CTG repeat in the HTT gene on Chromosome 4. I recall that Huntington's disease is indeed caused by a mutation in the HTT gene, which is located on Chromosome 4. The mutation involves an expansion of a trinucleotide repeat, specifically CAG, not CTG. CTG repeat expansions are associated with other disorders like myotonic dystrophy. Since the question specifies CTG, which is incorrect, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can radiation induced meningiomas be treated with radiosurgery?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether radiation-induced meningiomas can be treated with radiosurgery, I first consider the nature of meningiomas and the context of radiation-induced cases. Meningiomas are typically benign tumors arising from the meninges, the protective layers surrounding the brain and spinal cord. Radiosurgery, such as stereotactic radiosurgery (e.g., Gamma Knife or CyberKnife), is a non-invasive treatment that delivers focused radiation to a specific target, often used for small to medium-sized meningiomas, especially in locations difficult to access surgically. For radiation-induced meningiomas, which occur as a late complication of prior radiation therapy (often for other conditions like childhood cancers), the treatment approach might differ due to the tumor's etiology and potential differences in behavior or surrounding tissue damage from prior radiation. However, literature and clinical guidelines suggest that radiosurgery can still be an effective option for these tumors, particularly when surgical resection is not feasible, provided that the radiation dose and field can be managed to avoid excessive toxicity to already irradiated tissues. After analyzing this, I conclude that radiosurgery is a viable treatment option in many cases, though it must be tailored to the patient’s history of radiation exposure.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an increased risk of meningiomas in atomic bomb survivors?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether there is an increased risk of meningiomas in atomic bomb survivors, I first consider the context of radiation exposure. Atomic bomb survivors were exposed to high levels of ionizing radiation, which is a known risk factor for various cancers and tumors due to its ability to cause DNA damage. Meningiomas are tumors that arise from the meninges, the protective layers surrounding the brain and spinal cord. Studies on radiation exposure, particularly from events like Hiroshima and Nagasaki, have been extensively documented. Research, including data from the Life Span Study of atomic bomb survivors, indicates that exposure to ionizing radiation is associated with an increased risk of developing meningiomas, especially with higher doses of radiation. The latency period for such tumors can be long, often decades. Therefore, based on this analysis, there appears to be evidence supporting an increased risk.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiation for tinea capitis increases brain tumor risk?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Tinea capitis is a fungal infection of the scalp, historically treated with low-dose radiation therapy, particularly in the mid-20th century. Studies and medical literature have investigated the long-term effects of this radiation exposure, especially concerning cancer risk. Research, including epidemiological studies, has shown that radiation to the head, even at low doses, can increase the risk of brain tumors later in life due to the sensitivity of brain tissue to ionizing radiation. Historical data from patients treated for tinea capitis with radiation have demonstrated a higher incidence of brain tumors compared to unexposed populations. Therefore, the evidence suggests a causal link between radiation treatment for tinea capitis and an increased risk of brain tumors.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can secondary glioblastoma be caused by brain irradiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether secondary glioblastoma can be caused by brain irradiation, I first need to consider the definition and characteristics of secondary glioblastoma. Secondary glioblastoma refers to a type of glioblastoma that develops from a pre-existing lower-grade glioma, as opposed to primary glioblastoma which arises de novo. Next, I evaluate the role of brain irradiation. Brain irradiation is a known risk factor for the development of brain tumors, including gliomas, due to its potential to cause DNA damage and mutations in brain cells. There is evidence in medical literature suggesting that radiation therapy, often used to treat other brain tumors or conditions, can contribute to the transformation of lower-grade gliomas into higher-grade tumors like glioblastoma, or even induce new tumors over time. Therefore, it is plausible and supported by studies that brain irradiation can be a contributing factor in the development of secondary glioblastoma, particularly in patients with a history of radiation exposure to the brain.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does head ct increase brain tumor risk?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether a head CT increases the risk of brain tumors, I need to consider the nature of CT scans and their associated radiation exposure. CT scans use ionizing radiation, which has the potential to damage DNA and, in theory, could increase the risk of cancer, including brain tumors. Studies, such as those published in journals like The Lancet, have suggested a small increased risk of brain tumors in children exposed to CT scans, particularly with multiple exposures. However, the risk is generally considered very low, especially with modern CT technology that uses lower doses of radiation. For adults, the risk is even smaller due to lower sensitivity to radiation. Guidelines from organizations like the American College of Radiology emphasize that the benefits of a medically necessary CT scan usually outweigh the small potential risk. Therefore, while there is a theoretical risk, it is minimal and context-dependent.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an increased risk for meningiomas in childhood leukemia survivors?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether there is an increased risk for meningiomas in childhood leukemia survivors, I first consider the context of childhood leukemia and its treatments. Childhood leukemia, particularly acute lymphoblastic leukemia (ALL), often involves treatments like cranial radiation and chemotherapy, which are known to potentially increase the risk of secondary neoplasms. Meningiomas are benign brain tumors that have been associated with prior radiation exposure, especially in pediatric populations. Studies and medical literature, such as those from the Childhood Cancer Survivor Study (CCSS), have indicated that survivors of childhood cancers, including leukemia, who received cranial radiation have a significantly higher risk of developing meningiomas later in life compared to the general population. The risk appears to be dose-dependent and related to the age at exposure. Therefore, based on this analysis, there is evidence to suggest an increased risk.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can radiotherapy cause radiation induced osteosarcoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Radiotherapy is a common treatment for various cancers, utilizing high-energy radiation to target and destroy cancer cells. However, exposure to radiation, especially in high doses, is a known risk factor for the development of secondary malignancies, including osteosarcoma, which is a type of bone cancer. Studies and clinical reports have documented cases of radiation-induced osteosarcoma, particularly in patients who received radiotherapy for other cancers, such as Hodgkin's lymphoma or breast cancer. The risk is generally associated with the dose of radiation and the age of the patient at the time of exposure, with younger patients being more susceptible. Therefore, it is plausible and supported by medical literature that radiotherapy can cause radiation-induced osteosarcoma.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Chernobyl survivors at increased risk for breast cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Chernobyl survivors are at increased risk for breast cancer, I am considering the exposure to ionizing radiation from the 1986 Chernobyl nuclear disaster. Ionizing radiation is a known risk factor for various cancers, including breast cancer, as it can cause DNA damage and mutations. Studies, such as those conducted on atomic bomb survivors in Hiroshima and Nagasaki, have shown a clear link between radiation exposure and increased breast cancer risk, particularly when exposure occurs at a young age. Similarly, research on Chernobyl survivors, including cleanup workers and residents of contaminated areas, has indicated elevated risks for certain cancers due to radiation exposure. Specific studies, like those published in journals such as the International Journal of Cancer, have reported a statistically significant increase in breast cancer incidence among women exposed to radiation from Chernobyl, especially in areas with higher contamination levels. Factors such as age at exposure, dose received, and time since exposure also play a role in determining risk. While other factors like lifestyle and genetics can influence breast cancer risk, the radiation exposure from Chernobyl is a significant contributing factor. Therefore, based on the available scientific evidence, it is reasonable to conclude that Chernobyl survivors are at an increased risk for breast cancer.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiotherapy for Hodgkin disease increases risk for lung cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether radiotherapy for Hodgkin disease increases the risk for lung cancer, I am considering the known effects of radiation therapy. Radiotherapy is a common treatment for Hodgkin lymphoma, often targeting the chest area where the lymph nodes are located. Exposure to radiation, especially in the chest, is a well-documented risk factor for secondary cancers, including lung cancer, due to the potential for radiation to cause DNA damage in healthy tissues over time. Studies have shown that survivors of Hodgkin lymphoma who received chest radiotherapy have a higher incidence of lung cancer compared to the general population, with the risk increasing with higher doses and longer follow-up periods. Factors such as smoking can further amplify this risk. Therefore, based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiotherapy for cervical cancer increases risk of colon cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether radiotherapy for cervical cancer increases the risk of colon cancer, I am considering the potential effects of radiation exposure on nearby organs. Radiotherapy for cervical cancer targets the pelvic area, which is close to the colon. Radiation can cause long-term damage to healthy tissues and may increase the risk of secondary cancers in the exposed area due to DNA damage and mutations. Studies and medical literature suggest that pelvic radiotherapy can indeed elevate the risk of developing secondary malignancies, including colon cancer, especially over a long period post-treatment. Therefore, based on this analysis, the answer should reflect an increased risk.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does radiotherapy for prostate cancer increase bladder cancer risk?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether radiotherapy for prostate cancer increases the risk of bladder cancer, I am considering the potential effects of radiation exposure on nearby organs. Radiotherapy for prostate cancer involves targeting the prostate gland, which is located close to the bladder. Radiation can cause damage to surrounding tissues, potentially leading to secondary malignancies over time. Studies and medical literature suggest that there is an increased risk of bladder cancer in patients who have undergone radiotherapy for prostate cancer due to this exposure. Therefore, based on this analysis, the answer should reflect this association.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for MRPL53 in cancer?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether there is a role for MRPL53 in cancer, I first consider what MRPL53 is. MRPL53 is a mitochondrial ribosomal protein involved in the synthesis of mitochondrial proteins, which are crucial for cellular energy production and metabolism. Cancer cells often exhibit altered metabolism, including changes in mitochondrial function, to support rapid growth and proliferation. Therefore, it is plausible that MRPL53, as a component of mitochondrial ribosomes, could play a role in cancer by influencing mitochondrial protein synthesis and cellular energy dynamics. Research in this area might indicate whether MRPL53 expression is altered in cancer cells or if it contributes to tumorigenesis through metabolic reprogramming or other mechanisms. While I am not referencing specific studies here, the general understanding of mitochondrial involvement in cancer suggests a potential role. Thus, I lean towards 'yes,' there is likely a role for MRPL53 in cancer, even if it might be indirect or context-dependent.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is there a role for TET proteins in invariant natural killer T cells (iNKT) cell fate?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about the role of TET proteins in invariant natural killer T (iNKT) cell fate, I first consider the biological context. TET proteins are enzymes involved in DNA demethylation, which plays a critical role in epigenetic regulation and gene expression during cell development and differentiation. iNKT cells are a subset of T cells with unique functions in immune responses, and their development and fate are influenced by epigenetic mechanisms. Research in immunology and epigenetics suggests that TET proteins, particularly TET2, are implicated in regulating T cell lineage commitment and function through DNA demethylation at key gene loci. Studies have shown that TET proteins can impact the differentiation and effector functions of various T cell subsets, including iNKT cells, by modulating the expression of transcription factors and cytokines critical for their fate. Therefore, it is reasonable to conclude that TET proteins likely have a role in iNKT cell fate.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Uc.63+ promote sensitivity to treatment in prostate cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether Uc.63+ promotes sensitivity to treatment in prostate cancer, I first consider the context of Uc.63+, which is a long non-coding RNA (lncRNA) that has been studied in relation to cancer progression. Research suggests that Uc.63+ is overexpressed in prostate cancer and may contribute to tumor growth and resistance to therapies by regulating cellular pathways. However, specific studies directly linking Uc.63+ to increased sensitivity to treatment in prostate cancer are limited or inconclusive based on current knowledge. Most evidence points to its role in promoting resistance rather than sensitivity. Therefore, based on this analysis, it is unlikely that Uc.63+ promotes sensitivity to treatment in prostate cancer.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do de novo truncating mutations in WASF1 cause cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether de novo truncating mutations in WASF1 cause cancer, I first consider the role of WASF1. WASF1, also known as WAVE1, is a gene involved in actin cytoskeleton reorganization, which plays a role in cell motility and signaling pathways. Mutations, especially truncating ones, could potentially disrupt normal protein function, leading to aberrant cellular behavior. De novo mutations are new mutations not inherited from parents, and truncating mutations often result in a shortened, non-functional protein. In the context of cancer, such mutations could act as drivers if they contribute to uncontrolled cell growth or metastasis. However, I need to evaluate if there is specific evidence linking WASF1 truncating mutations to cancer. While WASF1 has been implicated in cancer progression and metastasis in some studies, particularly in breast cancer, the direct causality of de novo truncating mutations in WASF1 as a primary driver of cancer initiation is not well-established in the literature I recall. Most cancer-related mutations are associated with well-known oncogenes or tumor suppressors, and WASF1 does not appear to be a primary target. Therefore, while it may contribute to cancer progression in specific contexts, it is unlikely to be a direct cause of cancer through de novo truncating mutations alone.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does the Mcm2-Ctf4-Polα axis play a role in transfer of histones to leading strand DNA at the replication forks?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the biological context of the Mcm2-Ctf4-Polα axis and its role at replication forks. Mcm2 is a component of the replicative helicase, Ctf4 is a protein that links the helicase to other replication factors, and Polα (DNA polymerase alpha) is involved in initiating DNA synthesis, particularly on the lagging strand. The question specifically asks about the transfer of histones to leading strand DNA. Histone transfer and deposition during replication are typically managed by histone chaperones like Asf1, which interacts with Mcm2, and other factors. Recent studies suggest that the Mcm2-Ctf4-Polα axis may facilitate histone transfer to both leading and lagging strands by coordinating histone chaperone activity with replication fork progression. Given this, it is plausible that this axis plays a role in histone transfer to the leading strand.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is AND-1/Ctf4 essential for proliferation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether AND-1/Ctf4 is essential for proliferation, I first consider the biological context. AND-1, also known as Ctf4 in yeast, is a protein involved in DNA replication and sister chromatid cohesion. It plays a critical role in the replisome complex, facilitating the coordination of DNA polymerase activity and the recruitment of other replication factors. Studies in yeast and mammalian cells suggest that loss of AND-1/Ctf4 leads to severe defects in DNA replication, cell cycle progression, and ultimately cell viability. In yeast, Ctf4 mutants are often inviable or show significant growth defects, indicating it is essential for proliferation. Similarly, in human cells, knockdown of AND-1 results in impaired proliferation and increased genomic instability. Based on this analysis, it appears that AND-1/Ctf4 is indeed essential for proliferation in most cellular contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a BRCA mutation analysis in the Greek population?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether there is a BRCA mutation analysis in the Greek population, I first consider the context of the question. BRCA mutations are genetic alterations associated with increased risk of breast and ovarian cancer, and population-specific studies are often conducted to understand the prevalence and types of mutations in different ethnic groups. Greece, as a distinct population with unique genetic characteristics due to historical and geographical factors, likely has been the subject of such studies. I recall that there have been genetic studies focusing on Mediterranean populations, including Greeks, for BRCA1 and BRCA2 mutations. Research has identified specific founder mutations in the Greek population, such as the BRCA1 5382insC mutation, which is relatively common. Additionally, genetic testing and research infrastructure in Greece, including collaborations with international cancer research networks, support the likelihood of such analyses. Therefore, it is reasonable to conclude that BRCA mutation analysis has been conducted in the Greek population.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Patient-derived organoids (PDOs) recapitulate patient responses in the clinic?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Patient-derived organoids (PDOs) are 3D cell cultures derived from patient tissues that aim to mimic the physiological and pathological characteristics of the original tissue. They have been increasingly used in personalized medicine to predict patient responses to treatments. Research shows that PDOs can often recapitulate patient-specific responses to drugs, reflecting tumor heterogeneity and drug sensitivity or resistance observed in the clinic. Studies, particularly in cancers like colorectal and pancreatic cancer, have demonstrated a high correlation between PDO responses and clinical outcomes. However, limitations exist, such as the lack of a complete tumor microenvironment (e.g., immune cells, stroma) in PDO models, which can influence treatment responses in vivo. Additionally, not all patient tissues can successfully generate viable organoids, and long-term culture may lead to genetic drift. Despite these challenges, the evidence suggests that PDOs can recapitulate patient responses in many cases, though not universally. Therefore, the answer leans toward 'yes,' acknowledging their potential with caveats.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Verubecestat effective for Alzheimer's Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Verubecestat is effective for Alzheimer's Disease, I need to consider the available scientific evidence and clinical trial results. Verubecestat is a BACE1 inhibitor developed to reduce amyloid-beta production, which is implicated in Alzheimer's pathology. However, clinical trials, particularly Phase 3 studies like the EPOCH trial, showed that Verubecestat did not significantly improve cognitive decline in patients with mild-to-moderate Alzheimer's Disease compared to placebo. Additionally, the trials were halted early due to lack of efficacy and some safety concerns. Based on this, the evidence suggests that Verubecestat is not effective for treating Alzheimer's Disease.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "The LINCS L1000 data set contains gene expression data for drug treated human cells, yes or no?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"The LINCS L1000 dataset is a large-scale gene expression dataset generated by the Library of Integrated Network-Based Cellular Signatures (LINCS) program. It specifically includes gene expression profiles from human cells treated with various perturbations, including drugs and other chemical compounds. The dataset is widely used for studying the effects of drugs on gene expression. Therefore, it is accurate to confirm that the LINCS L1000 dataset contains gene expression data for drug-treated human cells.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is bortezomib a Proteasome inhibitor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether bortezomib is a proteasome inhibitor, I first consider the definition of a proteasome inhibitor. Proteasome inhibitors are drugs that block the activity of proteasomes, which are protein complexes responsible for degrading unneeded or damaged proteins in cells. This inhibition can disrupt various cellular processes, often leading to cell death, and is particularly useful in treating certain cancers. Next, I recall that bortezomib is a medication commonly used in the treatment of multiple myeloma and mantle cell lymphoma. I believe it works by inhibiting the proteasome, specifically targeting the 26S proteasome, which leads to the accumulation of unwanted proteins and induces apoptosis in cancer cells. To confirm, I think about its classification and mechanism of action as described in medical literature or pharmacology resources, which consistently identify bortezomib as a first-in-class proteasome inhibitor. Therefore, based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are breaks in double stranded DNA associated with ionizing radiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are breaks in double stranded DNA associated with ionizing radiation?', I first consider the nature of ionizing radiation and its effects on biological molecules. Ionizing radiation, such as X-rays and gamma rays, has enough energy to remove tightly bound electrons from atoms, creating ions. This process can directly damage DNA by breaking chemical bonds or indirectly by producing free radicals that attack DNA. Double-strand breaks (DSBs) are a severe form of DNA damage where both strands of the DNA helix are severed. Scientific literature and studies in radiobiology confirm that DSBs are a hallmark of damage caused by ionizing radiation, as the high energy can disrupt the DNA structure at multiple points. Therefore, there is a clear association between double-strand DNA breaks and exposure to ionizing radiation.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Thymoquinone is ineffective against radiation induced enteritis, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether thymoquinone is ineffective against radiation-induced enteritis, I first consider the context and available knowledge. Thymoquinone is a bioactive compound derived from Nigella sativa (black seed) and is known for its antioxidant, anti-inflammatory, and protective properties in various conditions. Radiation-induced enteritis is inflammation of the intestines caused by radiation therapy, often involving oxidative stress and inflammation. Research suggests that thymoquinone may have protective effects against radiation damage due to its ability to scavenge free radicals and reduce inflammation. Some studies in animal models have shown that thymoquinone can mitigate radiation-induced damage in tissues, including the intestines, by reducing oxidative stress markers and inflammatory cytokines. However, clinical evidence in humans is limited, and the effectiveness can depend on dosage, timing, and specific conditions. The question asks if thymoquinone is ineffective, which implies a negative stance. Based on preclinical evidence, it appears that thymoquinone may have potential benefits, so it is not necessarily ineffective. Therefore, the answer should lean towards 'no,' indicating that it is not ineffective, though conclusive human data is lacking.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Autophagy is the process where a virus obtains nutrients from it's host, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Autophagy is a cellular process where cells degrade and recycle their own components to maintain homeostasis or respond to stress. It is not related to a virus obtaining nutrients from its host. Viruses do rely on host cells for replication and nutrients, but this is not termed autophagy. Autophagy can sometimes play a role in the host's defense against viral infections or, conversely, be exploited by viruses, but the definition provided in the question is incorrect. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are stretch enhancers transcribed more than super-enhancers?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are stretch enhancers transcribed more than super-enhancers?', I need to consider the definitions and characteristics of both stretch enhancers and super-enhancers. Stretch enhancers are large genomic regions associated with high levels of enhancer activity and are often linked to tissue-specific gene expression. Super-enhancers, on the other hand, are clusters of enhancers that drive the expression of genes critical for cell identity and are typically associated with high levels of transcription. Research indicates that super-enhancers are generally more transcriptionally active due to their dense clustering of transcription factors and co-activators, leading to higher expression of target genes compared to other enhancer types, including stretch enhancers. While stretch enhancers are significant in certain contexts, they are not typically described as being more transcribed than super-enhancers. Therefore, based on this analysis, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the FIP virus thought to be a mutated strain for the Feline enteric Coronavirus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the relationship between FIP (Feline Infectious Peritonitis) virus and Feline Enteric Coronavirus (FECV). FIP is indeed caused by a mutated form of FECV. FECV is a common virus in cats, often causing mild gastrointestinal issues. However, in some cases, FECV can mutate into a more virulent form known as FIPV (Feline Infectious Peritonitis Virus), which leads to the severe and often fatal disease FIP. This mutation typically occurs within the host, and while not all cats infected with FECV develop FIP, the connection between the two is well-established in veterinary science. Therefore, the FIP virus is thought to be a mutated strain of Feline Enteric Coronavirus.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is poliosis circumscripta another term for a white or unpigmented patch of hair or skin?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to analyze the term 'poliosis circumscripta.' Poliosis refers to a condition characterized by a localized patch of white or unpigmented hair, often due to a lack of melanin. The term 'circumscripta' suggests a specific, well-defined area. Therefore, poliosis circumscripta likely describes a distinct, localized patch of white hair, which aligns with the description of a white or unpigmented patch of hair. However, it typically pertains to hair rather than skin. Since the question includes both hair and skin, I must consider if the term could apply to skin as well. Upon reflection, poliosis is primarily associated with hair depigmentation, not skin, so it may not fully cover unpigmented skin patches. Given the phrasing of the question, which includes 'hair or skin,' and knowing that poliosis relates to hair, I believe the answer should be affirmative since it matches at least part of the description.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are stem cell transplants used to treat acute kidney injury?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether stem cell transplants are used to treat acute kidney injury (AKI), I first consider the nature of AKI, which is a sudden loss of kidney function often caused by injury, infection, or reduced blood flow. Current standard treatments for AKI typically involve supportive care, such as dialysis, managing fluid balance, and addressing underlying causes, rather than regenerative therapies. Stem cell therapy, on the other hand, is an emerging field often explored for its potential to repair damaged tissues. I recall that stem cells have been studied in preclinical and early clinical trials for kidney repair due to their ability to differentiate into various cell types or release protective factors. However, I need to determine if this has translated into standard clinical practice for AKI. Upon reflection, while there is promising research, stem cell transplants are not yet a widely accepted or routine treatment for AKI in clinical settings. Most studies are still experimental, and there are concerns about safety, efficacy, and long-term outcomes. Therefore, based on the current state of medical practice, I believe the answer should be 'no', as stem cell transplants are not a standard treatment for AKI at this time.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Do circular exons increase gene expression?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether circular exons increase gene expression, I first consider the biological context. Circular exons are part of circular RNAs (circRNAs), which are non-coding RNAs formed by back-splicing events. Unlike linear RNAs, circRNAs do not have a 5' cap or poly-A tail, and their role in gene expression is complex. Research suggests that circRNAs can act as miRNA sponges, sequestering miRNAs and thereby indirectly increasing the expression of target genes by reducing miRNA-mediated repression. However, this effect is context-dependent and not universal across all genes or cell types. Additionally, some studies indicate that the formation of circRNAs might compete with linear mRNA splicing, potentially reducing the expression of the corresponding linear transcript. Given the variability in outcomes and the lack of a definitive, consistent mechanism showing a direct increase in gene expression, I lean towards a negative answer but acknowledge the complexity. After weighing the evidence, I conclude that circular exons do not universally or directly increase gene expression.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are there lncRNAs that control the extent of neuronal outgrowth?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether there are long non-coding RNAs (lncRNAs) that control the extent of neuronal outgrowth, I first consider the role of lncRNAs in cellular processes. LncRNAs are a class of RNA molecules that do not code for proteins but are known to regulate gene expression, chromatin modification, and other cellular functions. Neuronal outgrowth refers to the extension of axons and dendrites during neuronal development or regeneration, a process tightly regulated by various molecular mechanisms. Research in neuroscience and molecular biology indicates that lncRNAs play significant roles in neuronal development, including differentiation, synapse formation, and plasticity. Specific studies have identified lncRNAs such as MALAT1 and NEAT1 that influence neuronal growth by modulating gene expression or interacting with signaling pathways. For instance, some lncRNAs are implicated in regulating cytoskeletal dynamics or neurotrophic factor expression, both critical for neuronal outgrowth. While the exact mechanisms and specific lncRNAs may vary across contexts, the cumulative evidence suggests that lncRNAs do indeed contribute to controlling neuronal outgrowth. Therefore, the answer should affirm the existence of such lncRNAs.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Selumetinib effective for low-grade glioma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Selumetinib is effective for low-grade glioma, I first consider the context of the question. Low-grade glioma is a type of brain tumor that grows slowly and is often found in children. Selumetinib is a MEK inhibitor, a targeted therapy drug that has been studied for various cancers, including those with specific genetic mutations like BRAF mutations often seen in low-grade gliomas. Recent clinical trials and studies, particularly in pediatric patients with neurofibromatosis type 1 (NF1)-associated low-grade gliomas, have shown promising results. The drug has demonstrated the ability to shrink tumors or stabilize disease progression in a significant number of patients. For instance, a phase 2 trial published in major medical journals reported a high response rate. While it may not work for every patient and long-term outcomes are still under investigation, the current evidence suggests that Selumetinib is effective for many cases of low-grade glioma, especially in the context of NF1. Therefore, based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does gavestinel improve outcomes of stroke patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether gavestinel improves outcomes in stroke patients, I first consider the context of gavestinel as a drug. Gavestinel is a glycine site antagonist of the NMDA receptor, which was investigated for its potential neuroprotective effects in acute ischemic stroke. I recall that clinical trials, such as the GAIN International trial, were conducted to evaluate its efficacy. Upon analysis, the results of these trials showed that gavestinel did not significantly improve functional outcomes or reduce mortality in stroke patients compared to placebo. There was no substantial evidence of benefit in terms of recovery or survival rates. Therefore, based on the available data, it does not appear to improve outcomes in stroke patients.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Enlimomab improve stroke outcomes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Enlimomab can improve stroke outcomes, I first consider what Enlimomab is. Enlimomab is an anti-ICAM-1 antibody that was investigated for its potential to reduce inflammation in acute ischemic stroke by inhibiting leukocyte adhesion to endothelial cells. I recall that clinical trials, particularly the Enlimomab Acute Stroke Trial conducted in the late 1990s, tested its efficacy. The results of this trial showed that Enlimomab did not improve outcomes in stroke patients and, in fact, was associated with worse outcomes, including increased mortality and disability, possibly due to adverse immune responses or other complications. Based on this, it appears that Enlimomab does not improve stroke outcomes and may even be harmful. Therefore, my answer will reflect the lack of positive impact on stroke outcomes.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should tirilazad be used for treatment of ischemic stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether tirilazad should be used for the treatment of ischemic stroke, I first considered the nature of ischemic stroke, which involves a blockage in blood flow to the brain, leading to tissue damage due to oxygen deprivation. Tirilazad is a drug that was investigated for its potential neuroprotective effects, primarily as a lipid peroxidation inhibitor, which could theoretically reduce damage from oxidative stress during stroke. However, I recall that clinical trials and research on tirilazad, particularly in the context of stroke, have not shown consistent or significant benefits. Major studies, such as those conducted in the 1990s, indicated that tirilazad did not improve outcomes in patients with acute ischemic stroke and may even have been associated with worse outcomes in some subgroups. Guidelines from organizations like the American Heart Association do not recommend its use for this condition. Given the lack of evidence supporting efficacy and potential risks, the use of tirilazad for ischemic stroke is not supported by current medical consensus.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Aptiganel effective for treatment of stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Aptiganel is effective for the treatment of stroke, I first consider the context of Aptiganel as a drug. Aptiganel, also known as Cerestat, is an NMDA receptor antagonist that was investigated for its potential neuroprotective effects in acute ischemic stroke. I recall that NMDA receptor antagonists were studied for their ability to reduce excitotoxicity, a process that contributes to neuronal damage during stroke. However, clinical trials for Aptiganel, particularly in the late 1990s, did not demonstrate significant efficacy in improving outcomes for stroke patients. In fact, some studies were halted due to lack of benefit or potential adverse effects. Based on this, it appears that Aptiganel is not considered effective for stroke treatment in clinical practice. Therefore, my answer will reflect this understanding.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should Lubeluzole be used for treatment of ischemic stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Lubeluzole should be used for the treatment of ischemic stroke, I first consider the context of ischemic stroke treatment, which focuses on restoring blood flow and protecting brain tissue. Lubeluzole is a neuroprotective agent that was investigated for its potential to limit brain damage after stroke by inhibiting glutamate release and nitric oxide synthesis. However, clinical trials, such as those conducted in the late 1990s, showed mixed results. While early studies suggested a potential benefit in reducing mortality and improving outcomes in some subgroups, larger randomized controlled trials failed to demonstrate a significant overall benefit in terms of functional recovery or mortality reduction. Additionally, Lubeluzole is not currently recommended in major clinical guidelines (e.g., American Heart Association/American Stroke Association) for ischemic stroke treatment, as thrombolytic therapy (e.g., tPA) and mechanical thrombectomy are the primary interventions. Potential side effects, such as cardiac arrhythmias, also raise concerns. Based on the lack of conclusive evidence supporting its efficacy and its absence from standard treatment protocols, I conclude that Lubeluzole should not be used for the treatment of ischemic stroke.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a vaccine for peanut allergy?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Is there a vaccine for peanut allergy?', I first need to consider the current state of medical research regarding peanut allergies. Peanut allergies are a type of food allergy that can cause severe reactions, and traditionally, management has involved avoidance and emergency treatments like epinephrine. However, recent advancements in allergy treatment, such as desensitization therapies (e.g., oral immunotherapy), have been developed to help build tolerance to peanuts. There is also a specific treatment called Palforzia, which is an FDA-approved oral immunotherapy for peanut allergy, but it is not classified as a traditional vaccine. A vaccine typically works by preventing a disease through immunization, often against infectious agents, whereas current peanut allergy treatments focus on reducing sensitivity rather than preventing the allergy outright. I am considering if there are any experimental or upcoming treatments labeled as vaccines. Upon reflection, while there are research efforts into developing a true vaccine for peanut allergy (e.g., using DNA-based or peptide-based approaches to train the immune system), none have been widely approved or are available to the public as of the latest information I have. Therefore, based on the current understanding, there is no vaccine for peanut allergy in the conventional sense or as an approved treatment.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Have toll-like receptor 2 activators been found in food?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Have toll-like receptor 2 activators been found in food?', I first need to consider what toll-like receptor 2 (TLR2) activators are. TLR2 is a protein involved in the innate immune system, recognizing specific molecular patterns associated with pathogens, such as lipopeptides, peptidoglycans, and lipoteichoic acids from bacteria. Activators of TLR2 are typically components or molecules that can bind to and stimulate this receptor. The question asks whether such activators have been identified in food. Food can contain microorganisms, their byproducts, or other natural compounds that might interact with TLR2. For instance, fermented foods like yogurt or kimchi contain lactic acid bacteria, which have cell wall components like peptidoglycans that are known to activate TLR2. Additionally, certain dietary lipids or contaminants in food might also have TLR2-activating properties, as some studies suggest saturated fatty acids can stimulate TLR2 under specific conditions. Therefore, there is evidence in scientific literature indicating that TLR2 activators, particularly from microbial sources or specific molecular components, are present in certain foods.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Rad4/XPC a DNA damage sensing protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Rad4/XPC is a DNA damage sensing protein, I first consider its role in the nucleotide excision repair (NER) pathway. Rad4 in yeast, and its human homolog XPC, are known to be involved in the initial recognition of DNA damage, particularly bulky lesions caused by UV light or chemical agents. These proteins bind to damaged DNA sites, initiating the repair process by recruiting other NER factors. This function aligns with the definition of a DNA damage sensing protein, as it detects and responds to structural distortions in DNA. Therefore, it seems appropriate to classify Rad4/XPC as a DNA damage sensing protein. I conclude that the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there interactions between short and long noncoding RNAs?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether there are interactions between short and long noncoding RNAs, I first consider the biological context. Noncoding RNAs (ncRNAs) are RNA molecules that do not code for proteins but play crucial roles in gene regulation and other cellular processes. Short ncRNAs, such as microRNAs (miRNAs) and small interfering RNAs (siRNAs), are typically less than 200 nucleotides, while long ncRNAs (lncRNAs) are longer than 200 nucleotides. Research in molecular biology indicates that ncRNAs can interact with each other through various mechanisms. For instance, lncRNAs can act as sponges or decoys for miRNAs, sequestering them and preventing their interaction with target mRNAs. Additionally, some studies suggest that lncRNAs can be processed into smaller ncRNAs or interact with them in regulatory networks. Based on this understanding, it is evident that interactions do occur between short and long noncoding RNAs in cellular processes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is indinavir effective for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether indinavir is effective for the treatment of amyotrophic lateral sclerosis (ALS), I first consider the nature of both the drug and the disease. Indinavir is a protease inhibitor primarily used in the treatment of HIV/AIDS. It works by inhibiting the protease enzyme necessary for the replication of the HIV virus. On the other hand, ALS is a neurodegenerative disease characterized by the progressive loss of motor neurons, leading to muscle weakness and paralysis, with no known cure and limited treatment options that mainly focus on symptom management. There is no established connection between HIV protease inhibitors and ALS treatment in mainstream medical literature. I also reflect on whether there might be any off-label use or emerging research suggesting indinavir's efficacy for ALS. However, I find no credible evidence or clinical guidelines supporting indinavir's use for ALS. Current ALS treatments, such as riluzole or edaravone, target different mechanisms, and indinavir's mechanism of action does not align with ALS pathology. Therefore, based on this analysis, indinavir is not considered effective for the treatment of ALS.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is golimumab effective for sarcoidosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether golimumab is effective for sarcoidosis, I first consider what sarcoidosis is—a chronic inflammatory disease that can affect multiple organs, often treated with anti-inflammatory or immunosuppressive drugs. Golimumab is a monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), commonly used for conditions like rheumatoid arthritis and ankylosing spondylitis. Since TNF-alpha plays a role in the inflammation associated with sarcoidosis, golimumab could theoretically be effective. However, I recall that while some TNF inhibitors like infliximab have shown promise in treating refractory sarcoidosis, golimumab specifically has limited evidence in this context. Clinical studies or guidelines do not widely support its use for sarcoidosis, and it is not an FDA-approved indication for this drug. Therefore, based on the lack of substantial evidence or endorsement in medical literature for golimumab in sarcoidosis treatment, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is marimastat effective for small-cell lung cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether marimastat is effective for small-cell lung cancer, I first consider what marimastat is. Marimastat is a matrix metalloproteinase inhibitor (MMPI) that was developed as a potential anti-cancer drug due to its ability to inhibit enzymes involved in tumor growth and metastasis. I recall that it has been studied in various cancers, but I need to focus on small-cell lung cancer (SCLC) specifically. SCLC is an aggressive form of lung cancer with limited treatment options, often treated with chemotherapy and radiation. I think marimastat was tested in clinical trials for lung cancer, but I believe the results were not promising. I remember that in trials for SCLC, marimastat did not show significant improvement in survival or disease progression when added to standard treatments. There were also concerns about side effects like musculoskeletal toxicity. Based on this, I conclude that marimastat is not considered effective for small-cell lung cancer.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are astronauts in higher risk for developing cancer?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether astronauts are at a higher risk for developing cancer, I need to consider the unique environment they are exposed to in space. Astronauts are subjected to higher levels of cosmic radiation, which includes galactic cosmic rays and solar particle events, unlike the protection offered by Earth's atmosphere and magnetic field. Studies and data from space agencies like NASA suggest that prolonged exposure to this radiation can damage DNA and increase the risk of cancer over time. Additionally, research on astronauts and analogous populations (like nuclear workers) indicates a potential correlation between radiation exposure and cancer risk, though long-term data is still being collected. Factors like mission duration and protective measures (shielding, etc.) also play a role, but the consensus in scientific literature leans toward an elevated risk. Therefore, I conclude that astronauts are at a higher risk for developing cancer due to their exposure to space radiation.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is g-H2AX a marker for double strand breaks?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Is g-H2AX a marker for double strand breaks?', I need to consider what g-H2AX represents in the context of cellular biology. g-H2AX refers to the phosphorylated form of the histone variant H2AX, which occurs at serine 139 in response to DNA damage. This phosphorylation is one of the earliest events following the induction of double-strand breaks (DSBs) in DNA, which are severe forms of DNA damage. The formation of g-H2AX foci at the sites of DSBs is widely recognized as a sensitive and specific marker for these breaks. It is used in research to detect and quantify DSBs in cells exposed to genotoxic stress, such as radiation or certain chemicals. While g-H2AX is primarily associated with DSBs, I should note that it can also be induced by other forms of DNA damage or cellular stress to a lesser extent, but its predominant and most reliable association is with DSBs. Therefore, it is accurate to consider g-H2AX as a marker for double-strand breaks.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether natalizumab improves the disease course of secondary progressive multiple sclerosis (SPMS), I first consider the nature of SPMS, which is characterized by a steady progression of disability with or without relapses, following an initial relapsing-remitting phase. Natalizumab is a monoclonal antibody primarily used in relapsing-remitting multiple sclerosis (RRMS) to reduce relapse rates and slow disability progression by preventing immune cells from crossing the blood-brain barrier. However, its efficacy in SPMS is less clear since SPMS involves more neurodegenerative processes rather than active inflammation. Clinical studies, such as the ASCEND trial, have investigated natalizumab in SPMS and found no significant benefit in slowing disability progression as measured by the Expanded Disability Status Scale (EDSS). While there might be some effect on reducing relapses in patients with active disease, the overall impact on the progressive course of SPMS appears limited. Therefore, based on current evidence, natalizumab does not significantly improve the disease course of SPMS.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are multipotent adult progenitor cells effective for treatment of stroke?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether multipotent adult progenitor cells (MAPCs) are effective for the treatment of stroke, I need to consider the current scientific understanding and evidence. MAPCs are a type of adult stem cell with the potential to differentiate into various cell types and have been studied for their regenerative properties. Research, including preclinical studies, has shown promise in using MAPCs for stroke treatment due to their ability to reduce inflammation, promote tissue repair, and improve functional recovery in animal models. However, clinical trials in humans are still limited, and while some early-phase trials suggest safety and potential efficacy, there is not yet conclusive evidence or widespread regulatory approval for their use in stroke treatment. The effectiveness is still under investigation, and more robust clinical data is needed. Given the question's binary nature and the promising but inconclusive evidence, I lean toward a positive response based on potential, acknowledging the lack of definitive proof. Thus, my answer will be 'yes' with the understanding that this is based on current potential rather than established fact.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is ozanezumab effective for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ozanezumab is effective for amyotrophic lateral sclerosis (ALS), I need to consider the current state of medical research and clinical trials related to this drug. Ozanezumab is a monoclonal antibody that targets Nogo-A, a protein thought to inhibit nerve regeneration. It has been investigated for its potential to slow the progression of ALS, a neurodegenerative disease. Based on available data up to my knowledge cutoff in October 2023, clinical trials, including a notable Phase II study, have not demonstrated significant efficacy of ozanezumab in improving survival or functional outcomes in ALS patients. The drug did not meet primary endpoints in these studies, and there is no widespread clinical approval or consensus on its effectiveness for ALS treatment. Therefore, the answer should reflect the lack of proven efficacy.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are gut microbiota profiles altered by irradiation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether gut microbiota profiles are altered by irradiation, I first consider the biological impact of irradiation. Irradiation, often used in medical treatments like radiotherapy or in experimental settings, involves exposure to ionizing radiation, which can damage cells and tissues. The gut microbiota, a complex community of microorganisms in the digestive tract, is sensitive to environmental changes, including stress, diet, and external factors like radiation. Studies in both animals and humans have shown that radiation exposure, particularly to the abdominal or pelvic area, can disrupt the balance of gut bacteria, leading to dysbiosis. This is likely due to direct damage to microbial cells, inflammation, or changes in the gut environment. Research published in scientific journals often reports shifts in microbial diversity, with a decrease in beneficial bacteria and an increase in pathogenic ones post-irradiation. Therefore, it seems clear that irradiation does alter gut microbiota profiles.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are genomic regulatory blocks (GRBs) any different than TADs?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether genomic regulatory blocks (GRBs) are different from topologically associating domains (TADs), I first need to clarify the definitions of both terms. GRBs are regions in the genome where gene regulation is coordinated, often involving long-range interactions between regulatory elements and target genes, typically conserved across species. TADs, on the other hand, are structural units of the genome defined by chromatin interactions, where regions within a TAD interact more frequently with each other than with regions outside the TAD, as identified through techniques like Hi-C. While both concepts relate to genome organization and regulation, GRBs are more functionally defined based on regulatory relationships, often spanning or overlapping with TADs but not necessarily identical to them. TADs are primarily structural, and their boundaries are defined by interaction frequencies, whereas GRBs focus on the regulatory logic and conservation. Therefore, they are related but distinct concepts, and the answer should reflect that they are different.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is Nivolumab (Opdivo) a PD-L1 inhibitor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Nivolumab (Opdivo) is a PD-L1 inhibitor, I need to recall or verify the mechanism of action of this drug. Nivolumab is a monoclonal antibody used in cancer immunotherapy. I remember that it targets the PD-1 receptor on T-cells, blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are often expressed on tumor cells. This blockade helps to restore T-cell activity against cancer cells. However, a PD-L1 inhibitor specifically targets PD-L1 on tumor cells, not PD-1 on T-cells. Drugs like Atezolizumab or Durvalumab are examples of PD-L1 inhibitors. Since Nivolumab targets PD-1 and not PD-L1 directly, it should not be classified as a PD-L1 inhibitor. Therefore, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is PF-05190457 an inverse agonist of the ghrelin receptor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether PF-05190457 is an inverse agonist of the ghrelin receptor, I need to consider the pharmacological definition of an inverse agonist and the specific properties of PF-05190457. An inverse agonist is a compound that binds to a receptor and reduces its basal activity, as opposed to a neutral antagonist which simply blocks the receptor without affecting basal activity, or an agonist which activates it. The ghrelin receptor, also known as the growth hormone secretagogue receptor (GHSR), is a G protein-coupled receptor involved in appetite regulation and energy balance. PF-05190457 is a compound developed by Pfizer, and based on available scientific literature and drug development data, it has been characterized as an inverse agonist of the ghrelin receptor. Studies indicate that it reduces the constitutive activity of GHSR, which aligns with the definition of an inverse agonist. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients, I first consider the role of LY6K, a cancer-testis antigen often overexpressed in various cancers, including NSCLC. Research suggests that LY6K overexpression is generally linked to tumor progression, invasion, and metastasis in NSCLC, which typically correlates with poorer prognosis. Studies have shown that high LY6K expression is associated with worse overall survival and disease-free survival in NSCLC patients due to its role in promoting cancer cell proliferation and resistance to therapy. There is no substantial evidence indicating that LY6K overexpression leads to a better prognosis; instead, it is often considered a potential biomarker for poor outcomes and a target for immunotherapy. Therefore, based on the available scientific literature, overexpression of LY6K is not associated with better prognosis in NSCLC patients.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does the BRAFV600E mutation have an effect on clinical response to radioiodine therapy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the BRAFV600E mutation affects clinical response to radioiodine therapy, I first consider the context of the mutation and the therapy. BRAFV600E is a common mutation in thyroid cancer, particularly papillary thyroid carcinoma, and is associated with more aggressive disease behavior. Radioiodine therapy is a standard treatment for thyroid cancer, aimed at destroying residual thyroid tissue or metastatic cells by targeting iodine uptake. Research suggests that BRAFV600E mutation may be linked to reduced expression of the sodium-iodide symporter (NIS), which is crucial for iodine uptake in thyroid cells. This could potentially lead to a poorer response to radioiodine therapy in patients with this mutation. Studies have shown mixed results, but there is evidence indicating that BRAFV600E-positive tumors may exhibit radioiodine resistance. Therefore, it is reasonable to conclude that the mutation does have an effect on the clinical response to this therapy.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does metformin has as an antitumor effect?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether metformin has an antitumor effect, I first consider the context of metformin as a widely used drug for type 2 diabetes that works by improving insulin sensitivity and reducing glucose production in the liver. Recent research has explored its potential effects beyond diabetes management, including possible antitumor properties. Studies suggest that metformin may inhibit cancer cell growth by activating the AMPK pathway, which regulates cellular energy and can suppress tumor development. Additionally, observational studies and meta-analyses have indicated a potential reduction in cancer incidence and improved outcomes in diabetic patients using metformin. However, while preclinical and epidemiological data are promising, definitive clinical evidence from randomized controlled trials is still lacking to confirm its efficacy as an antitumor agent. The question asks specifically if metformin 'has' an antitumor effect, which can be interpreted as whether there is evidence supporting this effect. Given the substantial body of research suggesting a potential effect, even if not fully conclusive, I lean towards affirming this based on current scientific literature. Therefore, my answer will reflect this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS), I first consider the nature of ALS, a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and eventual respiratory failure. Prognosis in ALS typically refers to survival time or disease progression rate. Xaliproden is a drug that was investigated for its potential neuroprotective effects, as it may promote neurotrophic factor activity. I recall that clinical trials, particularly a large Phase III trial, were conducted to assess xaliproden's efficacy in ALS. The results, as far as I remember, showed no significant improvement in survival or functional outcomes compared to placebo. There was a slight effect on some secondary endpoints, like vital capacity, but overall, it did not meet the primary endpoints for improving prognosis. Therefore, based on this analysis, the answer should be 'no', as the drug does not appear to significantly improve the prognosis of ALS.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is celecoxib effective for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether celecoxib is effective for amyotrophic lateral sclerosis (ALS), I first consider that ALS is a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and paralysis. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-2, reducing inflammation and pain. I recall that inflammation is thought to play a role in ALS progression, so there might be a theoretical basis for using anti-inflammatory drugs like celecoxib. However, I need to think about whether there is clinical evidence supporting its effectiveness. I remember that some studies have investigated celecoxib in ALS, particularly because of its anti-inflammatory properties and potential neuroprotective effects. A notable clinical trial around the early 2000s tested celecoxib in ALS patients but found no significant benefit in slowing disease progression or improving survival. I also consider that current ALS treatments focus on drugs like riluzole and edaravone, which have shown some efficacy, while celecoxib is not listed in standard ALS treatment guidelines. There might be ongoing research or preclinical studies suggesting potential, but based on available evidence, celecoxib does not appear to be effective for ALS. Therefore, my answer should reflect the lack of proven clinical benefit.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should Pentoxifylline be used for treatment of amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Pentoxifylline should be used for the treatment of amyotrophic lateral sclerosis (ALS), I first considered the nature of ALS, which is a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and paralysis. Currently, there are limited treatment options, with Riluzole and Edaravone being the primary FDA-approved drugs to slow disease progression. Pentoxifylline, on the other hand, is a medication primarily used for improving blood flow in conditions like peripheral vascular disease, and it has anti-inflammatory properties. I then analyzed whether there is evidence supporting its use in ALS. Upon reviewing available medical literature and guidelines, I found that Pentoxifylline has been studied in preclinical models for its potential neuroprotective and anti-inflammatory effects, which could theoretically benefit ALS patients. However, clinical trials and systematic reviews, such as those referenced in PubMed, indicate that there is insufficient evidence to support its efficacy in ALS treatment. Major ALS treatment guidelines, like those from the American Academy of Neurology, do not recommend Pentoxifylline as a standard or experimental therapy for ALS. Therefore, based on the lack of robust clinical evidence and guideline support, it should not be used for ALS treatment at this time.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does clinical trial data support the use of minocycline for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether clinical trial data supports the use of minocycline for amyotrophic lateral sclerosis (ALS), I first consider the context of ALS as a progressive neurodegenerative disease with limited treatment options. Minocycline, an antibiotic with anti-inflammatory and neuroprotective properties, has been investigated for ALS due to its potential to reduce neuroinflammation. I recall that early preclinical studies in animal models showed promise, suggesting minocycline could slow disease progression. However, I also remember that a significant clinical trial, a randomized controlled trial published around 2007, tested minocycline in ALS patients and found no benefit in terms of survival or disease progression. In fact, there was a trend toward faster decline in some measures of function in the minocycline group, raising concerns about potential harm. I believe this trial was conducted by Gordon et al. and published in a major journal like The Lancet Neurology. Given that this is a key piece of evidence and no subsequent large-scale trials have overturned these findings to my knowledge, the clinical trial data does not support the use of minocycline for ALS. Therefore, my answer is based on the outcome of this pivotal trial and the lack of positive evidence in humans despite earlier preclinical optimism.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Dexmecamylamine effective for depression?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Dexmecamylamine is effective for depression, I first consider what Dexmecamylamine is. It is a nicotinic acetylcholine receptor antagonist, historically studied for various conditions, including hypertension. I recall that nicotinic receptors are involved in mood regulation, and there has been some research into nicotinic antagonists for depression. However, I am not aware of conclusive evidence or widespread clinical use of Dexmecamylamine specifically for treating depression. There were studies around the early 2000s exploring its potential, but I believe the results were not definitive enough to establish it as a standard treatment. I also consider that current guidelines for depression treatment, such as those from the APA or NICE, do not list Dexmecamylamine as a recommended therapy. Given the lack of strong, widely accepted evidence or approval for this use, I lean towards a negative answer. However, I acknowledge the possibility of niche or experimental uses, but without specific, up-to-date data, I must err on the side of caution.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is NicVAX vaccine effective for smoking cessation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether NicVAX, a vaccine designed for smoking cessation, is effective, I need to consider the available information and research. NicVAX works by stimulating the immune system to produce antibodies that bind to nicotine, preventing it from reaching the brain and reducing the rewarding effects of smoking. Clinical trials and studies, particularly those conducted around the early 2000s to 2010s, are critical to evaluate its efficacy. Phase III trials for NicVAX, conducted by Nabi Biopharmaceuticals, showed that while the vaccine did generate antibodies in many participants, it did not significantly improve long-term smoking cessation rates compared to placebo in the general population. Specifically, the trials failed to meet primary endpoints for sustained abstinence. However, there were indications that individuals with the highest antibody responses had better outcomes, suggesting potential efficacy in a subset of users. Despite this, the overall results led to the discontinuation of its development for widespread use. Given the lack of consistent evidence supporting its effectiveness across a broad population and the failure in late-stage trials, I conclude that NicVAX is not considered effective for smoking cessation as a general treatment.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Figitumumab effective for non-small cell lung cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Figitumumab is effective for non-small cell lung cancer (NSCLC), I first consider the context of the drug. Figitumumab is a monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), which has been investigated for its potential in treating various cancers, including NSCLC. I recall that clinical trials, particularly phase III studies, have been conducted to evaluate its efficacy in NSCLC. Upon analysis, I remember that a significant trial was halted due to lack of efficacy and potential safety concerns, as the drug did not show a survival benefit and may have increased toxicity when combined with standard chemotherapy. Therefore, based on available data, Figitumumab does not appear to be effective for NSCLC.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Semagacestat effective for Alzheimer's Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Semagacestat is effective for Alzheimer's Disease, I first consider the context of the drug. Semagacestat is a gamma-secretase inhibitor that was developed to reduce amyloid-beta production, a key factor in Alzheimer's pathology. However, clinical trials, particularly the Phase III trials, showed that Semagacestat not only failed to improve cognitive function in patients with Alzheimer's Disease but also worsened cognitive decline and was associated with significant side effects, such as skin cancer and infections. The trials were halted due to these adverse outcomes. Based on this analysis, the drug is not effective for treating Alzheimer's Disease.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Systemic Lupus Erythematosus cause seizures?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect multiple organs and systems in the body, including the nervous system. Seizures are a known neurological manifestation of SLE, often occurring due to lupus-related brain inflammation, vasculitis, or other complications like antiphospholipid syndrome which can lead to blood clots or strokes. Studies and medical literature confirm that seizures can be a symptom in some patients with SLE, particularly in those with active disease or central nervous system involvement. Therefore, the answer to whether SLE can cause seizures is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is MAGE-A3 immunotherapeutic effective for non-small-cell lung cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether MAGE-A3 immunotherapeutic is effective for non-small-cell lung cancer (NSCLC), I am considering the available clinical evidence. MAGE-A3 is a cancer-testis antigen targeted in immunotherapy to stimulate an immune response against cancer cells. Clinical trials, such as the MAGRIT trial, which was a large phase III study, evaluated MAGE-A3 immunotherapy as an adjuvant treatment for NSCLC patients with MAGE-A3 expression after surgical resection. The trial results, published around 2014, showed that MAGE-A3 immunotherapy did not significantly improve disease-free survival compared to placebo. Subsequent analyses and studies have also failed to demonstrate a clear survival benefit or consistent efficacy in NSCLC. While there might be specific subgroups or contexts where some effect was observed, the overall evidence suggests it is not effective as a standard treatment for NSCLC. Therefore, based on the current understanding and trial outcomes, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Impetigo a viral infection that affects the skin?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Impetigo is a common skin infection, but I need to confirm whether it is caused by a virus or something else. Upon analysis, I recall that Impetigo is primarily a bacterial infection, often caused by Staphylococcus aureus or Streptococcus pyogenes. It is not caused by a virus. Therefore, the statement that Impetigo is a viral infection is incorrect.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is αCGRP a member of the CGRP family?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether αCGRP is a member of the CGRP family, I first need to consider what CGRP stands for and the context of the family. CGRP, or Calcitonin Gene-Related Peptide, is a neuropeptide involved in various physiological processes, including vasodilation and pain transmission. The CGRP family typically includes different isoforms or related peptides, such as αCGRP and βCGRP, which are derived from alternative splicing of the calcitonin gene or related genes. αCGRP is specifically one of the primary isoforms of CGRP, often associated with sensory neurons. Given this, it seems logical to conclude that αCGRP is indeed a member of the CGRP family, as it is a direct variant of CGRP itself. Therefore, my answer should reflect this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do genes with monoallelic expression contribute proportionally to genetic diversity in humans?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether genes with monoallelic expression contribute proportionally to genetic diversity in humans, I first need to understand the terms. Monoallelic expression refers to genes that are expressed from only one allele, often due to mechanisms like genomic imprinting or random monoallelic expression. Genetic diversity, on the other hand, refers to the variation in genetic makeup among individuals in a population, which is influenced by mutations, recombination, and other factors. Genes with monoallelic expression might contribute less to diversity because only one allele is active, potentially masking variation from the other allele. However, the inactive allele can still carry variants that could be passed on or become active in certain contexts or future generations. Proportionally, since monoallelic genes are a small subset of the genome (e.g., imprinted genes are only about 1% of human genes), their overall contribution to genetic diversity might not be proportional compared to biallelically expressed genes, where both alleles can contribute to phenotypic variation. After considering this, I believe the answer is no, as their contribution is likely not proportional due to limited expression and smaller number of such genes.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is deletion at 6q24.2-26 associated with shorter survival for ovarian cancer patients?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether deletion at 6q24.2-26 is associated with shorter survival for ovarian cancer patients, I am considering the genetic and clinical context. Deletions in the 6q region, particularly 6q24-26, have been studied in ovarian cancer as potential markers of prognosis. Research suggests that loss of heterozygosity (LOH) or deletions in this region may be linked to tumor progression and poorer outcomes due to the potential loss of tumor suppressor genes. Studies, such as those referenced in cancer genomics literature, indicate that 6q deletions are frequent in ovarian cancer and may correlate with advanced disease stages or reduced survival. However, the exact impact can vary based on specific patient cohorts, tumor subtypes, and other genetic alterations. Given the evidence from multiple studies supporting an association between 6q deletions and worse prognosis, I lean towards affirming the connection. Therefore, my answer will reflect this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does promoter shape vary across populations?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether promoter shape varies across populations, I first consider the biological context. Promoters are regions of DNA that initiate transcription of a particular gene, and their 'shape' could refer to structural characteristics or sequence variations that influence gene expression. Genetic variation across populations is well-documented, including single nucleotide polymorphisms (SNPs) and other mutations that can occur in promoter regions. Studies in population genetics suggest that such variations can affect promoter function and gene regulation, potentially leading to differences in expression patterns across populations. For instance, research on human populations has identified population-specific SNPs in promoter regions that correlate with disease susceptibility or phenotypic traits. Therefore, it is reasonable to conclude that promoter shape, interpreted as sequence or structural variation, does vary across populations due to genetic diversity.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the CADM2 gene associated with differences in information processing speed?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the CADM2 gene is associated with differences in information processing speed, I first consider the role of CADM2. CADM2 is a gene involved in cell adhesion, particularly in the brain, and has been linked to synaptic function and neural connectivity. Recent studies in genetics and neuroscience have explored its association with cognitive traits. Research, including genome-wide association studies (GWAS), has identified CADM2 as a candidate gene related to individual differences in cognitive performance, including processing speed. For instance, some studies suggest that variations in CADM2 may influence brain structure and function, which could impact how quickly individuals process information. While the evidence is not entirely conclusive and more research is needed to establish causality, the current body of literature supports an association. Therefore, based on this analysis, I conclude that there is evidence linking CADM2 to differences in information processing speed.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is KAT2A involved in Acute myeloid leukemia (AML)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether KAT2A is involved in Acute Myeloid Leukemia (AML), I first consider the role of KAT2A. KAT2A, also known as GCN5, is a histone acetyltransferase involved in epigenetic regulation by acetylating histones, which can influence gene expression. AML is a type of blood cancer characterized by abnormal proliferation of myeloid cells, often driven by genetic and epigenetic alterations. Research indicates that epigenetic regulators, including histone acetyltransferases, can play a role in AML pathogenesis. Specifically, KAT2A has been implicated in various cancers due to its role in regulating transcription and cell growth. Studies suggest that KAT2A may contribute to leukemogenesis by altering the expression of genes involved in cell differentiation and proliferation, which are critical in AML. Therefore, there appears to be a connection between KAT2A and AML based on its epigenetic regulatory functions and emerging research evidence.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, yes or no?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, I need to consider the role of AhR (Aryl hydrocarbon receptor) and Cyp1a1. AhR is a transcription factor that, when activated by ligands, can regulate the expression of genes like Cyp1a1, which is involved in the metabolism of xenobiotics and drugs. The induction of Cyp1a1 can be a double-edged sword: it may help in detoxifying harmful substances, but it can also lead to the activation of procarcinogens into carcinogenic forms, potentially increasing toxicity or cancer risk. Therefore, while AhR ligands can modulate important metabolic pathways via Cyp1a1 induction, this same mechanism might pose risks, making their attractiveness as drug targets questionable without specific therapeutic contexts or safety considerations. Given the potential adverse effects tied to Cyp1a1 induction, I lean towards a negative assessment unless the question implies a specific beneficial context not provided.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Glucoraphanin from broccoli can help reduce obesity , yes or no?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether glucoraphanin from broccoli can help reduce obesity, I first consider the scientific context. Glucoraphanin is a compound found in broccoli and other cruciferous vegetables, known for its role as a precursor to sulforaphane, which has antioxidant and anti-inflammatory properties. Research suggests that sulforaphane may influence metabolic processes, including fat metabolism and insulin sensitivity, which are relevant to obesity. Some animal studies and preliminary human research indicate potential benefits in reducing weight gain or improving metabolic health. However, conclusive evidence from large-scale, long-term human clinical trials is lacking, and the direct impact on obesity reduction remains uncertain. Given the question's phrasing and the existing suggestive evidence, I lean toward a positive response but acknowledge the need for caution due to limited definitive proof.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has saracatinib been tested in clinical trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether saracatinib has been tested in clinical trials, I need to consider the context and available information. Saracatinib is a drug initially developed as a potential treatment for cancer, specifically as a Src kinase inhibitor. It has also been investigated for other conditions like Alzheimer's disease due to its potential effects on certain pathways. Given that it is a pharmaceutical compound under investigation, it is highly likely that it has undergone clinical trials to evaluate its safety and efficacy in humans. Clinical trials are a standard part of drug development, and saracatinib, having been mentioned in scientific literature, should have been tested in such settings. I recall that there have been trials for saracatinib in cancer and possibly Alzheimer's, though I should confirm the exact status. However, the question is simply whether it has been tested, not whether it was successful or is currently in trials. Based on this reasoning, I believe the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does saracatinib promote oncogenesis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether saracatinib promotes oncogenesis, I first consider that saracatinib is a drug known as a Src kinase inhibitor, primarily investigated for its potential anti-cancer properties. Oncogenesis refers to the process of tumor formation or cancer development. Given that saracatinib is designed to inhibit Src kinases, which are often overactive in cancer cells and contribute to tumor growth, metastasis, and angiogenesis, it is unlikely to promote oncogenesis. Instead, it is intended to suppress pathways that drive cancer progression. However, I must also consider if there are any studies or evidence suggesting off-target effects or paradoxical promotion of cancer under certain conditions. Upon reflection, most literature indicates saracatinib's role as an anti-cancer agent, with clinical trials focusing on its potential to inhibit tumor growth in various cancers, such as breast and lung cancer. There is no substantial evidence suggesting it promotes oncogenesis. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has MLE4901 been tested in phase III clinical trials?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether MLE4901 has been tested in phase III clinical trials, I first need to consider what MLE4901 is. MLE4901 is a drug candidate, specifically an NK1 receptor antagonist, that was under investigation for the treatment of conditions like depression or anxiety. Phase III clinical trials are large-scale studies conducted to confirm a drug's efficacy and safety before regulatory approval. My knowledge indicates that MLE4901 was discontinued in development by Merck after phase II trials due to insufficient efficacy or other strategic reasons. There is no widely available or documented evidence in public databases up to my knowledge cutoff that suggests MLE4901 progressed to phase III trials. Therefore, the answer should be based on the lack of progression beyond phase II.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does ESN364 activate the hypothalamic-pituitary-gonadal axis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ESN364 activates the hypothalamic-pituitary-gonadal (HPG) axis, I first consider the nature of ESN364. ESN364 is a selective neurokinin-3 receptor (NK3R) antagonist, often studied for its role in modulating reproductive hormone release. The HPG axis involves the hypothalamus releasing gonadotropin-releasing hormone (GnRH), which stimulates the pituitary gland to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately regulating gonadal function. NK3R antagonists like ESN364 are known to suppress GnRH release by inhibiting kisspeptin-neurokinin B signaling in the hypothalamus, which typically reduces LH and FSH levels. Therefore, rather than activating the HPG axis, ESN364 likely inhibits it. I conclude that the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is traditional Chinese medicine associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the context and available evidence regarding traditional Chinese medicine (TCM) and its potential effects on heart failure risk in breast cancer patients treated with doxorubicin, a chemotherapy drug known for cardiotoxicity. Doxorubicin can cause heart damage, leading to heart failure in some patients. TCM, which includes herbal remedies, acupuncture, and other practices, is often used as a complementary therapy in cancer treatment. Some studies suggest that certain TCM interventions, such as specific herbal formulas, may have cardioprotective effects by reducing oxidative stress or inflammation, which are mechanisms involved in doxorubicin-induced cardiotoxicity. However, the evidence is not conclusive, as clinical trials are often limited by small sample sizes, lack of standardization in TCM practices, and variability in study design. Without specific, high-quality evidence directly linking TCM to a decreased risk of heart failure in this patient population, I must rely on the general understanding that while TCM may offer supportive benefits, it is not universally established as a definitive protective factor against heart failure in this context. Therefore, I will answer based on the current lack of robust, widely accepted evidence.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the protein ABCG2 (ATP-Binding Cassette, subfamily G, member 2, transporter) excreting uric acid?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the protein ABCG2 (ATP-Binding Cassette, subfamily G, member 2, transporter) excretes uric acid, I need to consider its known biological functions. ABCG2 is a transmembrane transporter protein primarily associated with the efflux of various substrates, including drugs and endogenous compounds, from cells. It is expressed in tissues like the kidney, liver, and intestine. Research indicates that ABCG2 plays a significant role in the excretion of uric acid, particularly in the kidneys and gut. Mutations or dysfunctions in ABCG2 are linked to hyperuricemia and gout, conditions caused by elevated uric acid levels, suggesting that ABCG2 is indeed involved in uric acid excretion. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the protein ABCG2 transmembrane?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ABCG2 is a transmembrane protein, I first consider what a transmembrane protein is: a protein that spans the lipid bilayer of a cell membrane, typically involved in transport or signaling. ABCG2, also known as Breast Cancer Resistance Protein (BCRP), is part of the ATP-binding cassette (ABC) transporter family. These proteins are often involved in the transport of molecules across membranes. I recall that ABCG2 is indeed located in the plasma membrane and functions to efflux various substrates, including drugs, which suggests it must span the membrane to facilitate this transport. Structurally, ABC transporters generally have transmembrane domains. Based on this reasoning, ABCG2 should be a transmembrane protein. I confirm this by considering that its role in drug resistance and transport across membranes aligns with the characteristics of transmembrane proteins. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can brain derived exosomes carry APP molecules?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether brain-derived exosomes can carry APP (Amyloid Precursor Protein) molecules, I first consider the nature of exosomes and their role in cellular communication. Exosomes are small extracellular vesicles released by cells, including neurons in the brain, and they carry various cargos such as proteins, lipids, and nucleic acids. APP is a transmembrane protein associated with Alzheimer's disease, and its cleavage products, like amyloid-beta, are often transported via exosomes. Research suggests that exosomes derived from neuronal cells can indeed contain APP and its fragments, as they play a role in intercellular transfer of these molecules, potentially contributing to the spread of pathology in neurodegenerative diseases. Studies have shown that brain-derived exosomes isolated from biological fluids or cell cultures often carry APP or its derivatives. Therefore, it seems plausible that brain-derived exosomes can carry APP molecules.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Flotillin be used as exosomal marker?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Flotillin can be used as an exosomal marker, I first consider the role of Flotillin. Flotillin is a protein associated with lipid rafts and is commonly found in exosomes, which are small extracellular vesicles involved in cell communication. Exosomal markers are typically proteins or molecules consistently present in exosomes, used to identify or isolate them. Research and literature often mention Flotillin-1 and Flotillin-2 as being enriched in exosomes, alongside other markers like CD63, CD81, and TSG101. While Flotillin is not as universally used as some tetraspanins (e.g., CD63), it is still considered a reliable marker in many studies for detecting exosomes. However, the specificity of Flotillin as an exosomal marker can vary depending on the cell type and context, as it is also present in other cellular membranes. Despite this, its frequent association with exosomes in scientific studies supports its use as a marker. Therefore, I conclude that Flotillin can be used as an exosomal marker.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has the Spanich flu virus been reconstructed?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the Spanish flu virus has been reconstructed, I need to consider the historical and scientific context. The Spanish flu, which caused a devastating pandemic in 1918-1919, was caused by an H1N1 influenza virus. I recall that in the early 2000s, scientists were able to recover genetic material from preserved tissue samples of victims of the 1918 flu. This was done by researchers like Jeffery Taubenberger and Ann Reid, who sequenced the virus's genome. Furthermore, in 2005, a team led by Terrence Tumpey at the CDC successfully reconstructed the 1918 virus in a secure laboratory setting to study its properties and understand why it was so deadly. This reconstruction was controversial due to biosafety and bioterrorism concerns, but it was indeed accomplished. Therefore, based on this information, the Spanish flu virus has been reconstructed.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Li–Fraumeni syndrome a rare, autosomal recessive, hereditary disorder that predisposes carriers to cancer development?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Li-Fraumeni syndrome is a rare hereditary disorder that predisposes individuals to a higher risk of developing various types of cancer. However, it is important to analyze the specific characteristics mentioned in the question. Li-Fraumeni syndrome is indeed rare and hereditary, and it does predispose carriers to cancer development. However, it is typically inherited in an autosomal dominant manner, not autosomal recessive as stated in the question. In autosomal dominant disorders, a single copy of the mutated gene (inherited from one parent) is sufficient to cause the disorder, whereas autosomal recessive disorders require two copies of the mutated gene (one from each parent). Since the question specifies 'autosomal recessive,' which is incorrect, the answer should reflect this inaccuracy.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are ICAMS, Intracellular Adhesion Molecules, part of the immunoglobulin superfamily?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ICAMs (Intercellular Adhesion Molecules) are part of the immunoglobulin superfamily, I need to consider their structural characteristics. The immunoglobulin superfamily is a group of proteins that share a common structural domain similar to immunoglobulins (antibodies), often involved in cell-cell recognition and adhesion. ICAMs are cell adhesion molecules that facilitate interactions between cells, particularly in immune responses. I recall that ICAM-1, for instance, has immunoglobulin-like domains in its structure, which suggests it belongs to the immunoglobulin superfamily. Upon further reflection, I confirm that ICAMs, including ICAM-1 through ICAM-5, are indeed classified as members of the immunoglobulin superfamily due to their Ig-like domains. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the Paramyxovirus genome is segmented, negative-sense RNA, I need to recall the characteristics of this virus family. Paramyxoviruses are a family of viruses that include pathogens like measles, mumps, and respiratory syncytial virus (RSV). I remember that their genome is typically RNA, and I believe it is negative-sense, meaning the RNA strand cannot be directly translated into proteins and requires transcription into a positive-sense strand first. Additionally, I think the genome of Paramyxoviruses is non-segmented, meaning it consists of a single piece of RNA rather than multiple segments. To confirm, I recall that viruses like influenza have segmented genomes, but Paramyxoviruses do not. Therefore, the genome is negative-sense RNA but not segmented. The question asks if it is both segmented and negative-sense, so since it is not segmented, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a vaccine for rotavirus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I am considering the question: 'Is there a vaccine for rotavirus?' Rotavirus is a common virus that causes severe diarrhea, especially in young children. I recall that vaccines have been developed to prevent rotavirus infections, as they are a significant cause of childhood illness and mortality in many parts of the world. The World Health Organization recommends rotavirus vaccination as part of routine childhood immunizations. There are specific vaccines like Rotarix and RotaTeq that are widely used. Therefore, I believe the answer to this question is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors(MPNST) rare in neurofibromatosis patients?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors (MPNST) are rare in neurofibromatosis patients, I first considered the nature of MPNST and its association with neurofibromatosis. MPNSTs are aggressive sarcomas that arise from peripheral nerves or their sheath elements. Neurofibromatosis type 1 (NF1) is a genetic disorder that predisposes individuals to various tumors, including MPNSTs. Research indicates that while MPNSTs are more common in NF1 patients compared to the general population, spinal intradural MPNSTs specifically are less frequently reported. Most MPNSTs in NF1 patients occur in peripheral nerves rather than in the spinal intradural space. Case reports and studies suggest that spinal intradural MPNSTs are indeed uncommon, even among NF1 patients, due to the specific anatomical location. Therefore, they can be considered rare in this population.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does AZD3759 cross the blood brain barrier?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether AZD3759 crosses the blood-brain barrier, I first consider the nature of the question. AZD3759 is a drug, specifically an EGFR inhibitor, often studied in the context of treating brain metastases in non-small cell lung cancer. The blood-brain barrier (BBB) is a protective barrier that restricts the passage of many substances into the brain. Drugs that can cross the BBB are often designed or selected for their ability to penetrate this barrier, especially for treating brain-related conditions. Research and clinical studies on AZD3759 indicate that it has been specifically developed to have improved BBB penetration compared to other EGFR inhibitors, as it is intended to target brain metastases. Based on available data and studies, such as those published in medical journals, it is documented that AZD3759 demonstrates the ability to cross the BBB effectively. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is PTEN a tumour suppressor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether PTEN is a tumor suppressor, I first consider the role of PTEN in cellular processes. PTEN (Phosphatase and Tensin homolog) is a gene that encodes a protein with phosphatase activity, which negatively regulates the PI3K/AKT signaling pathway. This pathway is crucial for cell growth and survival. When PTEN functions properly, it inhibits excessive cell proliferation by dephosphorylating PIP3, thus preventing overactivation of AKT. Mutations or loss of PTEN are commonly associated with various cancers, as they lead to uncontrolled cell growth due to hyperactivation of the PI3K/AKT pathway. Therefore, PTEN acts to suppress tumor formation by regulating cell growth and apoptosis. Based on this analysis, PTEN is indeed classified as a tumor suppressor gene.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is MLL3 part of the ASCOM complex?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether MLL3 is part of the ASCOM complex, I first need to clarify the terms. MLL3, also known as KMT2C, is a histone methyltransferase involved in epigenetic regulation, specifically in the methylation of histone H3 at lysine 4 (H3K4). The ASCOM complex, or Activating Signal Cointegrator-2 Complex, is a multi-subunit protein complex that includes histone methyltransferases and is involved in transcriptional coactivation. Research indicates that MLL3 (along with MLL4) is indeed a component of the ASCOM complex, where it contributes to the complex's methyltransferase activity. Therefore, based on this understanding, MLL3 is part of the ASCOM complex.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are astrocytes part of the blood brain barrier?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether astrocytes are part of the blood-brain barrier (BBB), I need to recall the components of the BBB. The BBB is a protective barrier that regulates the passage of substances from the bloodstream into the brain. It is primarily formed by endothelial cells of the brain's capillaries, which are tightly joined by tight junctions. However, other cell types, including astrocytes, play a crucial role in supporting and maintaining the BBB. Astrocytes are glial cells in the central nervous system that extend their endfeet to cover the blood vessels, contributing to the barrier's integrity by inducing the formation of tight junctions in endothelial cells and regulating the barrier's function. While astrocytes are not the primary structural component of the BBB (that role belongs to endothelial cells), they are indeed an essential part of the system that constitutes and supports the BBB. Therefore, it is accurate to consider astrocytes as part of the blood-brain barrier in a functional and supportive context.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the protein MCL-1 anti-apoptotic?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the protein MCL-1 is anti-apoptotic, I first consider the role of MCL-1 in cellular processes. MCL-1, or Myeloid Cell Leukemia 1, is a member of the BCL-2 family of proteins, which are key regulators of apoptosis (programmed cell death). The BCL-2 family includes both pro-apoptotic and anti-apoptotic members. MCL-1 is known to inhibit apoptosis by binding to and sequestering pro-apoptotic proteins like BAX and BAK, preventing the release of cytochrome c from mitochondria, which is a critical step in the apoptotic cascade. Research and literature consistently describe MCL-1 as an anti-apoptotic protein, often overexpressed in various cancers, contributing to cell survival and resistance to chemotherapy. There are no significant controversies or conflicting data suggesting otherwise in standard biological contexts. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are bacteria in the genus Clostridium facultative anaerobes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether bacteria in the genus Clostridium are facultative anaerobes, I need to recall the definition of facultative anaerobes and the characteristics of Clostridium. Facultative anaerobes are organisms that can grow in both the presence and absence of oxygen, switching between aerobic and anaerobic metabolism. Clostridium, however, is a genus of bacteria known for being obligate anaerobes, meaning they cannot tolerate oxygen and can only grow in its absence. Most species, like Clostridium botulinum and Clostridium tetani, are strictly anaerobic, and oxygen is toxic to them. There might be rare exceptions or misclassifications in some studies, but generally, the genus is characterized as obligate anaerobes. Therefore, the answer should be no, they are not facultative anaerobes.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has ORMD-0801 been tested in patients?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ORMD-0801 has been tested in patients, I need to consider the context and available information. ORMD-0801 is an oral insulin candidate developed by Oramed Pharmaceuticals for the treatment of diabetes. Based on publicly available data up to my knowledge cutoff, ORMD-0801 has undergone clinical trials, including Phase 2 and Phase 3 studies, which involve testing in human patients. For instance, Oramed has reported results from trials assessing its efficacy and safety in patients with type 2 diabetes. Therefore, it is reasonable to conclude that ORMD-0801 has been tested in patients.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Was vivotif licensed in Europe and the US at the same time?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Vivotif, an oral typhoid vaccine, was licensed in Europe and the US at the same time, I need to consider the historical context of its approval. Vivotif was developed by the Swiss Serum and Vaccine Institute (now part of Crucell). It was first licensed in Europe in the 1980s, with approvals in various European countries starting around 1983. In the US, the FDA approved Vivotif in 1989. Comparing these timelines, there is a clear gap of several years between the initial European licensing and the US approval. Therefore, they were not licensed at the same time.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can AGY be used as antidiuretic replacement therapy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether AGY can be used as antidiuretic replacement therapy, I first need to consider what AGY refers to in this context. AGY is not a widely recognized abbreviation for a specific drug or therapy in medical literature. It might be a typo or refer to something specific like Arginine-Glycine-Aspartate (a peptide sequence) or something else. Antidiuretic replacement therapy typically involves medications like desmopressin, which mimics the action of vasopressin to reduce urine production in conditions like diabetes insipidus. Without clear evidence or context that AGY is a substance or treatment related to antidiuretic effects, I cannot confirm its use for this purpose. Given the lack of information or standard recognition of AGY in this role, the answer should be based on the most likely assumption that it is not a known antidiuretic agent.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Have the rotavirus vaccines changed the predominant rotavirus genotypes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether rotavirus vaccines have changed the predominant rotavirus genotypes, I need to consider the impact of vaccination on viral evolution and strain distribution. Rotavirus vaccines, such as Rotarix and RotaTeq, target specific genotypes (e.g., G1P[8] and others). Widespread vaccination can create selective pressure, potentially leading to the emergence or dominance of genotypes not covered by the vaccine. Studies and surveillance data suggest that in some regions, after vaccine introduction, there has been a shift in predominant genotypes, with non-vaccine strains becoming more common. For instance, in some areas, G2P[4] or other genotypes have increased in prevalence post-vaccination. However, this varies by region and time, and vaccine effectiveness remains high overall. Based on this analysis, it appears that rotavirus vaccines have indeed influenced the distribution of genotypes in certain contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can leuprorelin acetate be used as androgen deprivation therapy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) agonist, which works by initially stimulating and then suppressing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression leads to a decrease in testosterone production in males, effectively reducing androgen levels. Androgen deprivation therapy (ADT) is a treatment used primarily in prostate cancer to lower androgen levels, as androgens can fuel the growth of prostate cancer cells. Since leuprorelin acetate achieves this reduction in androgen levels, it is indeed used as a form of ADT in clinical settings, particularly for the management of hormone-sensitive prostate cancer. Therefore, the answer to whether leuprorelin acetate can be used as androgen deprivation therapy is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can MVA85A confer immunity against smallpox?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether MVA85A can confer immunity against smallpox, I first need to understand what MVA85A is. MVA85A is a vaccine candidate primarily developed to boost immunity against tuberculosis (TB) as a booster to the BCG vaccine. It is based on a modified vaccinia virus Ankara (MVA), which is a highly attenuated strain of vaccinia virus. Smallpox, on the other hand, is caused by the variola virus, and the smallpox vaccine historically used is based on vaccinia virus, which provides cross-protection against variola due to their close relation. Since MVA85A uses a modified vaccinia virus, it might theoretically offer some level of cross-protection against smallpox, as vaccinia-based vaccines have done so in the past. However, MVA85A is specifically engineered to express antigens targeting Mycobacterium tuberculosis, not variola virus. There is no direct evidence or clinical data suggesting that MVA85A has been tested or proven effective against smallpox. Its primary design and testing have been focused on TB. Therefore, while the backbone of MVA85A is related to vaccinia, its specific modifications and purpose do not align with conferring immunity to smallpox.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the drug Exubera currently (March 2020) available?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Exubera is currently available as of March 2020, I need to consider the history of the drug. Exubera was an inhaled insulin product introduced by Pfizer for the treatment of diabetes. However, it was discontinued in 2007 due to poor sales and concerns over cost and convenience. There have been no widely reported updates or reintroductions of Exubera into the market since then. Additionally, no new developments or re-launches of Exubera are known to have occurred by March 2020. Therefore, it is reasonable to conclude that Exubera is not available as of that date.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has the drug Afrezza been approved by the FDA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Afrezza has been approved by the FDA, I first consider what Afrezza is. Afrezza is an inhaled insulin product used for managing diabetes. Next, I recall or verify the status of its approval. I remember that Afrezza was developed by MannKind Corporation and faced some challenges during its approval process. However, I believe it was eventually approved by the FDA. To confirm, I think about the timeline— it was approved in 2014 for use in adults with type 1 and type 2 diabetes. Since the question is a straightforward factual one and my recollection points to approval, I will answer accordingly. If there were any doubts, I would consider the need to check the latest FDA updates, but for this context, I am confident in the information.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Fluzone intradermal and the Fluzone intradermal quadrivalent vaccine produced by different companies?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question, I need to determine if Fluzone Intradermal and Fluzone Intradermal Quadrivalent vaccines are produced by different companies. After analyzing the question, I recall that both vaccines are variations of the Fluzone brand, which is manufactured by Sanofi Pasteur, a well-known pharmaceutical company specializing in vaccines. Fluzone Intradermal was an earlier version of the influenza vaccine administered via the intradermal route, while Fluzone Intradermal Quadrivalent is a newer version that protects against four strains of the influenza virus. Since both are under the Fluzone brand and produced by Sanofi Pasteur, they are not produced by different companies. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Daptacel be used instead of IPOL?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Daptacel can be used instead of IPOL, I need to consider the purpose and composition of each vaccine. Daptacel is a combination vaccine that protects against diphtheria, tetanus, and pertussis (whooping cough). It is used to immunize children against these bacterial diseases. On the other hand, IPOL is an inactivated poliovirus vaccine specifically designed to protect against polio, a viral disease. Since Daptacel does not contain any component to protect against polio, it cannot serve as a substitute for IPOL. The two vaccines target entirely different pathogens and diseases, so they are not interchangeable. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can CMB305 be used against sarcomas?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether CMB305 can be used against sarcomas, I first considered what CMB305 is. CMB305 is an investigational immunotherapy designed to target NY-ESO-1, a cancer-testis antigen often expressed in certain tumors. It is primarily studied for its potential in treating cancers like synovial sarcoma and myxoid/round cell liposarcoma, which are types of sarcomas that frequently express NY-ESO-1. Clinical trials and research data suggest that CMB305 has been evaluated in patients with these specific sarcomas, showing some immune response and potential therapeutic benefit. However, its efficacy and approval for broad use against all sarcomas are not established, as sarcomas are a diverse group of cancers, and not all express NY-ESO-1. Given that the question is general and does not specify a subtype of sarcoma, I must consider if CMB305 has a recognized application against sarcomas in a broader sense. Since there is evidence of its use in specific sarcoma subtypes, I lean towards a positive response, acknowledging that it is not universally applicable to all sarcomas. Therefore, my answer will reflect that it can be used against certain sarcomas.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has ZP-PTH been tested in a phase II clinical trial?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ZP-PTH has been tested in a Phase II clinical trial, I need to consider the context and available information. ZP-PTH refers to a parathyroid hormone analog developed by Zealand Pharma, often for conditions like hypoparathyroidism. Phase II trials are typically conducted to evaluate the efficacy and safety of a drug in a larger group of patients after initial safety has been established in Phase I. Without specific data or access to clinical trial registries like ClinicalTrials.gov at this moment, I must rely on general knowledge. I recall that Zealand Pharma has advanced some of their PTH analogs into clinical development, but I am unsure about the exact stage for ZP-PTH. Given the uncertainty and lack of specific evidence confirming a Phase II trial for ZP-PTH, I will err on the side of caution and assume it has not been confirmed in the public domain or my knowledge base.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is SARS virus interacting with ACE2 encoded protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the SARS virus interacts with the ACE2 encoded protein, I need to consider the biological mechanism of the SARS virus, specifically SARS-CoV, which caused the outbreak in 2002-2003. I recall that the SARS-CoV virus enters human cells by binding to a specific receptor on the cell surface. Research has shown that the spike protein of SARS-CoV binds to the angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in various human tissues, particularly in the lungs. This interaction is critical for the virus to gain entry into host cells. Multiple studies, including those published during and after the SARS outbreak, have confirmed that ACE2 is the functional receptor for SARS-CoV. Therefore, the SARS virus does interact with the ACE2 encoded protein.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ACE2 expressed on cell surfaces?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ACE2 is expressed on cell surfaces, I need to consider what ACE2 is and its biological role. ACE2, or Angiotensin-Converting Enzyme 2, is a protein known to act as a receptor for certain coronaviruses, including SARS-CoV-2. For it to function as a receptor, it must be present on the cell surface to interact with viral particles. Scientific literature and studies, such as those related to COVID-19, consistently indicate that ACE2 is a transmembrane protein, meaning it is embedded in the cell membrane with parts exposed on the cell surface. It is particularly expressed in cells of the lungs, heart, kidneys, and intestines. Therefore, based on this understanding, ACE2 is indeed expressed on cell surfaces.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cathepsin L active in endosomes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether cathepsin L is active in endosomes, I need to consider the biological context. Cathepsin L is a lysosomal cysteine protease primarily active in lysosomes, where it functions in protein degradation under acidic conditions. Endosomes, while also acidic, are distinct compartments involved in sorting and trafficking of molecules. Research indicates that cathepsin L can be present and active in endosomes under certain conditions, particularly in antigen processing and presentation in immune cells. Studies have shown that cathepsin L contributes to the cleavage of proteins in endosomal compartments, especially in dendritic cells. Therefore, while its primary site of activity is lysosomes, cathepsin L can indeed be active in endosomes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is endotrophin derived from collagen?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether endotrophin is derived from collagen, I first need to recall that endotrophin is a peptide associated with adipose tissue and metabolic processes. It is known to be a cleavage product of a specific type of collagen, namely collagen VI. Collagen VI is a component of the extracellular matrix, and during its processing or remodeling, endotrophin is released as a bioactive fragment. This fragment has been linked to inflammation and insulin resistance in obesity. Therefore, since endotrophin is indeed a derivative of collagen VI, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Protoporphyrinogen oxidase localized to the mitochondrium?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Protoporphyrinogen oxidase (PPO) is localized to the mitochondrion, I need to recall its role and location in cellular processes. PPO is an enzyme involved in the heme biosynthesis pathway, specifically in the conversion of protoporphyrinogen IX to protoporphyrin IX. Heme synthesis occurs partially in the mitochondria and partially in the cytosol. I remember that the early steps of heme synthesis, starting with the formation of delta-aminolevulinic acid (ALA), occur in the mitochondria, then some intermediate steps occur in the cytosol, and the final steps return to the mitochondria. PPO is one of the later enzymes in the pathway. Upon checking my knowledge, I confirm that PPO is indeed located in the inner mitochondrial membrane, where it catalyzes its reaction. Therefore, it is localized to the mitochondrion.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is aggrephagy a variant of autophagy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether aggrephagy is a variant of autophagy, I first need to clarify the terms. Autophagy is a cellular process where cells degrade and recycle their own components through lysosomal machinery, crucial for maintaining cellular homeostasis. It includes various forms like macroautophagy, microautophagy, and chaperone-mediated autophagy. Aggrephagy, on the other hand, refers specifically to the selective autophagic degradation of protein aggregates, which are often associated with neurodegenerative diseases. Upon analysis, aggrephagy is indeed a specialized form of autophagy, focusing on the clearance of aggregated proteins via the autophagosomal-lysosomal pathway, typically through macroautophagy mechanisms with specific receptors like p62/SQSTM1. Therefore, it can be classified as a variant or subtype of autophagy due to its selective nature within the broader autophagy framework.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does protein ALEX1 contain armadillo repeats?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether protein ALEX1 contains armadillo repeats, I first consider what armadillo repeats are: they are a type of protein domain consisting of tandem repeats of a motif that forms a superhelix of alpha-helices, often involved in protein-protein interactions. ALEX1, also known as Armadillo repeat-containing X-linked protein 1 (ARMCX1), is a protein encoded by the ARMCX1 gene. The name itself suggests a connection to armadillo repeats, as 'Arm' in the name likely refers to armadillo. I recall that proteins in the ARMCX family are characterized by the presence of armadillo repeat motifs. To confirm, I think about the function and structure of ALEX1, which is involved in mitochondrial dynamics and apoptosis, and literature often describes it as containing armadillo repeats. Since the question is straightforward and the protein's nomenclature and family classification strongly indicate the presence of armadillo repeats, I conclude that the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Bcl-2-like protein 1 an pro apoptotic protein?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Bcl-2-like protein 1 is a pro-apoptotic protein, I first consider the role of the Bcl-2 family of proteins in apoptosis regulation. The Bcl-2 family includes both pro-apoptotic and anti-apoptotic members. Bcl-2 itself is anti-apoptotic, inhibiting cell death by preventing the release of cytochrome c from mitochondria. Bcl-2-like protein 1, also known as Bcl-xL, is structurally similar to Bcl-2 and is generally considered to have an anti-apoptotic function, as it also inhibits apoptosis by stabilizing the mitochondrial membrane. Pro-apoptotic proteins, on the other hand, like Bax and Bak, promote mitochondrial outer membrane permeabilization. Since Bcl-2-like protein 1 (Bcl-xL) functions to prevent apoptosis, it is not a pro-apoptotic protein.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do nematodes contain a CTCF gene?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether nematodes contain a CTCF gene, I first consider that CTCF (CCCTC-binding factor) is a protein involved in regulating gene expression and chromatin structure, primarily studied in vertebrates and some invertebrates. Nematodes, such as Caenorhabditis elegans, are a well-studied model organism in biology. I recall that CTCF is conserved across many species, but its presence in nematodes is uncertain. Upon reflection, research indicates that while CTCF is found in many bilaterian animals, nematodes like C. elegans lack a clear ortholog of the CTCF gene. Studies suggest that nematodes may use different mechanisms or proteins for similar chromatin organization functions. Therefore, based on this analysis, I conclude that nematodes do not contain a CTCF gene.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does steroid 5A-Reductase deficiency lead to hermaphroditism?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether steroid 5A-Reductase deficiency leads to hermaphroditism, I first need to clarify the terms and the condition. Steroid 5A-Reductase deficiency is a genetic disorder that affects the conversion of testosterone to dihydrotestosterone (DHT), a more potent androgen, crucial for the development of male external genitalia during fetal development. Individuals with this deficiency are genetically male (46,XY) but may be born with ambiguous genitalia or female-appearing external genitalia due to insufficient DHT. At puberty, increased testosterone can lead to masculinization. Hermaphroditism, or more accurately termed intersex conditions in humans, refers to individuals with both male and female gonadal tissue or ambiguous sexual characteristics. In 5A-Reductase deficiency, affected individuals have testes (male gonads) and no female reproductive structures, so they do not have true hermaphroditism. However, the ambiguous genitalia at birth might be mistaken for an intersex condition. After analyzing this, the precise answer hinges on the definition: since hermaphroditism typically implies the presence of both ovarian and testicular tissue, which is not the case here, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is the TFR1 gene dispensable for erythropoiesis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the TFR1 gene is dispensable for erythropoiesis, I first consider the role of TFR1 (Transferrin Receptor 1) in this process. Erythropoiesis is the production of red blood cells, which requires iron for hemoglobin synthesis. TFR1 is crucial for iron uptake into cells by binding to transferrin, the iron-transporting protein in blood. In erythroid precursors, TFR1 is highly expressed to ensure sufficient iron supply for hemoglobin production. Studies in molecular biology and hematology suggest that without TFR1, iron uptake would be severely impaired, likely disrupting erythropoiesis. There might be alternative pathways or receptors like TFR2, but TFR1 is considered the primary mechanism for iron acquisition in erythroid cells. Knockout studies in mice have shown that TFR1 deficiency leads to severe anemia, indicating it is not dispensable. Therefore, based on this analysis, TFR1 is essential for erythropoiesis.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are somatic mutations positioned towards the nuclear periphery?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether somatic mutations are positioned towards the nuclear periphery, I first consider the biological context. Somatic mutations are genetic alterations that occur in non-germline cells after conception. The nuclear periphery refers to the region near the nuclear envelope in a cell's nucleus, often associated with heterochromatin, which is transcriptionally inactive. Research in nuclear architecture suggests that gene positioning within the nucleus can influence mutation rates or repair mechanisms. Some studies indicate that DNA near the nuclear periphery might be more prone to damage or less efficiently repaired due to its association with heterochromatin. However, there is no definitive consensus that somatic mutations are specifically positioned towards the nuclear periphery across all cell types or conditions. The question seems to ask for a general trend, and based on current understanding, while there may be some correlation in specific contexts, it is not a universal rule. Therefore, I lean towards a negative answer but acknowledge the complexity of the topic.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is Mediator present at super enhancers?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Mediator is present at super enhancers, I first consider the biological context. Mediator is a multi-subunit protein complex that plays a critical role in transcriptional regulation by facilitating communication between transcription factors and RNA polymerase II. Super enhancers are large clusters of enhancers that drive high levels of gene expression, often associated with key cell identity genes. Research indicates that Mediator is indeed recruited to enhancer regions, including super enhancers, where it helps assemble the transcriptional machinery. Studies, such as those using ChIP-seq, have shown that Mediator subunits like MED1 are enriched at super enhancer regions, particularly in cell-specific contexts. Therefore, it is reasonable to conclude that Mediator is present at super enhancers.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Tcf3 associated with the Wnt pathway?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Tcf3 is associated with the Wnt pathway, I first consider the biological context. Tcf3, or Transcription Factor 3, is a member of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors. The Wnt signaling pathway is a key regulator of cell fate and development, and it often involves TCF/LEF family members as downstream effectors. In the canonical Wnt pathway, when Wnt ligands bind to Frizzled receptors, it leads to the stabilization of beta-catenin, which then translocates to the nucleus and interacts with TCF/LEF proteins to activate target gene expression. Tcf3 is known to interact with beta-catenin in this pathway, often acting as a transcriptional repressor in the absence of Wnt signaling and as an activator when Wnt signaling is active. Research and literature, such as studies on embryonic development and cancer, frequently mention Tcf3 in the context of Wnt signaling. Therefore, based on this understanding, Tcf3 is indeed associated with the Wnt pathway.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Nanog repressed in pluripotent stem cells?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Nanog is repressed in pluripotent stem cells, I first consider the role of Nanog in stem cell biology. Nanog is a key transcription factor associated with maintaining pluripotency in embryonic stem cells. It is highly expressed in pluripotent stem cells and is critical for self-renewal and preventing differentiation. Repression of Nanog typically occurs during differentiation, when cells lose pluripotency. Therefore, in pluripotent stem cells, Nanog should not be repressed; instead, it should be actively expressed. Based on this understanding, the answer should be 'no', as Nanog is not repressed in pluripotent stem cells.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do nematodes contain architectural proteins like CTCF?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether nematodes contain architectural proteins like CTCF, I first need to consider what CTCF is and its role in organisms. CTCF (CCCTC-binding factor) is a highly conserved zinc-finger protein in vertebrates that plays a critical role in chromatin organization, acting as an insulator and helping to form topologically associating domains (TADs) in the genome. The question is whether nematodes, such as Caenorhabditis elegans, possess a similar protein with comparable functions. Upon analysis, while nematodes do have proteins involved in chromatin organization, research indicates that CTCF homologs are not present in most invertebrates, including nematodes. Studies on C. elegans suggest that they lack a direct CTCF ortholog and instead rely on other mechanisms and proteins for chromatin looping and organization. Therefore, based on current understanding, nematodes do not contain architectural proteins like CTCF.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do polycomb group proteins (PcG) mediate the formation of chromatin loops?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether polycomb group proteins (PcG) mediate the formation of chromatin loops, I first consider their primary function. PcG proteins are known for their role in epigenetic regulation, particularly in silencing gene expression by modifying chromatin structure. They form complexes like PRC1 and PRC2, which are involved in histone modification and chromatin compaction. Recent studies suggest that PcG proteins, especially through components like CBX proteins in PRC1, can contribute to the formation of chromatin loops by facilitating long-range interactions between genomic regions, often at polycomb-repressed domains. These loops help in maintaining a repressed state by physically bringing distant regulatory elements together. While their role is not as direct as architectural proteins like CTCF or cohesin, evidence from Hi-C and other chromatin conformation capture techniques indicates their involvement in loop formation. Therefore, I conclude that PcG proteins do mediate the formation of chromatin loops, albeit in a context-specific manner.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are super enhancers structurally insulated in chromatin loops?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether super enhancers are structurally insulated in chromatin loops, I first consider the definition and characteristics of super enhancers. Super enhancers are large clusters of transcriptional enhancers that drive the expression of genes critical for cell identity. They are often associated with high levels of transcription factor binding and histone modifications like H3K27ac. Regarding chromatin structure, research in genomics and epigenetics, including studies using Hi-C and other chromosome conformation capture techniques, suggests that super enhancers are frequently located within topologically associating domains (TADs) or chromatin loops. These structures can insulate regulatory elements, restricting interactions to within the loop or TAD, thereby potentially insulating super enhancers from other genomic regions. However, insulation is not absolute, as some super enhancers may interact across TAD boundaries under specific conditions. Given the predominant evidence, it seems that super enhancers are often structurally insulated within chromatin loops as part of the genome's 3D organization to ensure specific gene regulation. Therefore, the answer leans towards affirmative based on current understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are there negative enhancers?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are there negative enhancers?', I first need to interpret the term 'negative enhancers' in a likely context, as it is not specified. In biology, enhancers are DNA sequences that increase the transcription of genes. The term 'negative enhancers' could refer to regulatory elements that decrease gene expression, which are more commonly known as silencers. Silencers function oppositely to enhancers by repressing transcription. Therefore, if 'negative enhancers' is meant to describe elements that inhibit gene expression, the answer would be yes, as silencers exist. Alternatively, in other contexts like psychology or education, 'negative enhancers' could imply something that worsens a situation or performance, which could also exist. Given the ambiguity, I lean towards the biological context as it is a common usage of the term 'enhancer.' After analysis, I conclude that the answer is yes, interpreting 'negative enhancers' as silencers or similar repressive elements.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are enhancers directional in their targeting of gene promoters?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether enhancers are directional in their targeting of gene promoters, I first consider the biological context. Enhancers are regulatory DNA sequences that can activate transcription of a gene by interacting with its promoter. They can function over long distances and are often located far from the genes they regulate. The key question is whether their effect is specific to a particular direction or orientation relative to the promoter. Research indicates that enhancers are generally not directional in the sense of their physical orientation; they can function in either orientation (forward or reverse) relative to the gene. However, their targeting can be influenced by the spatial organization of chromatin and specific interactions with promoters, which might give an appearance of directionality in certain contexts. Despite this, the consensus in molecular biology is that enhancers are not inherently directional in their sequence orientation, as their function depends on the binding of transcription factors and looping mechanisms rather than a fixed directional requirement. Therefore, the answer should be 'no', enhancers are not directional in their targeting of gene promoters in terms of sequence orientation, though their functional interaction can be context-specific.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is the zelda transcription factor a chromatin remodeller?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the Zelda transcription factor is a chromatin remodeler, I first need to clarify the roles of transcription factors and chromatin remodelers. Transcription factors are proteins that bind to specific DNA sequences to regulate gene expression, typically by promoting or inhibiting the transcription of target genes. Chromatin remodelers, on the other hand, are proteins or protein complexes that alter chromatin structure by repositioning, ejecting, or restructuring nucleosomes, thereby influencing DNA accessibility for transcription. Zelda, also known as Zld, is a transcription factor in Drosophila melanogaster, crucial for early embryonic development and zygotic genome activation. It binds to specific DNA motifs and activates the transcription of many genes. However, there is no evidence in the literature suggesting that Zelda directly modifies chromatin structure or possesses enzymatic activity typical of chromatin remodelers like SWI/SNF or ISWI complexes. While Zelda may indirectly influence chromatin accessibility by recruiting other factors, its primary role is as a pioneer transcription factor, not a remodeler. Therefore, based on this analysis, Zelda is not classified as a chromatin remodeler.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is methotrexate used for the treatment of Rheumatoid Arthritis (RA)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly prescribed for the treatment of Rheumatoid Arthritis (RA). It works by reducing inflammation and slowing the progression of the disease. It is often considered a first-line treatment for RA due to its efficacy and relatively well-understood safety profile. Therefore, the answer to the question is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can ATAC-Seq be employed in single-cell mode?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"ATAC-Seq, or Assay for Transposase-Accessible Chromatin using sequencing, is a technique used to study chromatin accessibility. The question asks whether it can be applied in a single-cell mode. Upon analysis, I recall that single-cell ATAC-Seq (scATAC-Seq) is indeed a well-established method that allows researchers to assess chromatin accessibility at the single-cell level. This adaptation of the original ATAC-Seq protocol involves isolating single cells and performing the assay on individual cells to capture cell-to-cell variability in chromatin structure. Therefore, it is possible to employ ATAC-Seq in single-cell mode.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is yeast fbp1 affected by glucose starvation stress?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether yeast FBP1 is affected by glucose starvation stress, I first consider the biological context. FBP1 in yeast (Saccharomyces cerevisiae) encodes fructose-1,6-bisphosphatase, an enzyme involved in gluconeogenesis, which is the process of generating glucose from non-carbohydrate sources. Gluconeogenesis is typically activated under conditions of glucose scarcity, as the cell needs to produce its own glucose. Glucose starvation stress would likely induce the expression of FBP1 to facilitate this process. Research indicates that FBP1 expression is repressed in the presence of glucose (via glucose repression mechanisms) and derepressed during glucose starvation. Therefore, it is reasonable to conclude that FBP1 is indeed affected by glucose starvation stress, as its expression is upregulated under such conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does an antiphlogistic promotes inflammation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether an antiphlogistic promotes inflammation, I first need to understand the term 'antiphlogistic.' The prefix 'anti-' suggests something that opposes or counters, and 'phlogistic' relates to inflammation (from the Greek 'phlogistos,' meaning inflamed). Therefore, an antiphlogistic should logically be something that reduces or prevents inflammation, such as an anti-inflammatory drug or treatment. Promoting inflammation would be the opposite of its purpose. After analyzing this, the answer should be 'no,' as an antiphlogistic does not promote inflammation but rather works against it.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can SMAD6 variants cause craniosynostosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SMAD6 variants can cause craniosynostosis, I first consider the role of SMAD6 in biological processes. SMAD6 is a gene involved in the TGF-beta/BMP signaling pathway, which regulates bone and cartilage development. Craniosynostosis is a condition characterized by the premature fusion of cranial sutures, often linked to genetic mutations affecting bone growth. Research indicates that mutations in genes related to the BMP signaling pathway can contribute to craniosynostosis. Specifically, studies have identified SMAD6 variants as being associated with non-syndromic midline craniosynostosis, suggesting a causal relationship. Therefore, based on this analysis, SMAD6 variants can indeed cause craniosynostosis.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can propofol cause green urine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I am considering the question of whether propofol, a commonly used anesthetic, can cause green urine. I recall that propofol is metabolized in the liver and excreted through urine, and there have been rare reports of unusual urine discoloration associated with its use. Upon further reflection, I remember that propofol can indeed cause green urine due to the presence of phenolic metabolites that are excreted in the urine. This is a documented, though uncommon, side effect. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can radiosurgery be used for the DNET tumors?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether radiosurgery can be used for DNET (Dysembryoplastic Neuroepithelial Tumor) tumors, I first need to consider the nature of DNET tumors and the applicability of radiosurgery. DNET tumors are typically benign, low-grade brain tumors often associated with epilepsy, most commonly found in children and young adults. The primary treatment for DNET tumors is usually surgical resection, which can be curative if the tumor is completely removed. Radiosurgery, such as stereotactic radiosurgery (e.g., Gamma Knife), is a non-invasive treatment that delivers focused radiation to a specific area, often used for small, well-defined tumors or in cases where surgery is not feasible. While radiosurgery is more commonly used for malignant tumors, metastases, or arteriovenous malformations, it can sometimes be considered for benign tumors like DNET if they are inoperable due to location or if the patient is not a surgical candidate. However, evidence on the effectiveness of radiosurgery for DNET is limited, as it is not the standard of care. Studies and clinical guidelines suggest that radiosurgery might be an option in rare, recurrent, or residual cases after incomplete resection, but it is not typically the first-line treatment. Given this, while it is technically possible to use radiosurgery for DNET tumors in specific circumstances, the answer hinges on whether it is generally considered a standard or recommended approach. Based on the preference for surgical resection and limited data supporting radiosurgery as a primary treatment, I lean toward 'no' as the answer, indicating it is not commonly used or recommended as a standard treatment for DNET tumors.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Was golimumab tested for diabetes?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether golimumab was tested for diabetes, I first consider what golimumab is. Golimumab is a monoclonal antibody used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis by inhibiting tumor necrosis factor-alpha (TNF-alpha). Diabetes, however, is a metabolic disorder typically related to insulin regulation, not directly linked to TNF-alpha inhibition in the same way as autoimmune diseases. I recall that some studies on TNF-alpha inhibitors suggest a potential indirect effect on insulin sensitivity, but I am not aware of specific clinical trials testing golimumab directly for diabetes treatment or management. A quick mental review of medical literature and drug indications shows that golimumab's approved uses and clinical trials focus on inflammatory and autoimmune conditions, not diabetes. There might be exploratory studies or off-label investigations, but without specific evidence or recollection of such trials, I lean towards a negative response. Therefore, based on the primary indications and known research focus of golimumab, it is unlikely that it was tested specifically for diabetes.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Nelson's syndrome is a condition that can occur after bilateral adrenalectomy in patients with Cushing's disease, characterized by rapid enlargement of a pituitary tumor and increased ACTH production. Cabergoline is a dopamine agonist primarily used to treat hyperprolactinemia by inhibiting prolactin secretion from the pituitary gland. In some cases, it has been explored for managing ACTH-secreting tumors due to its potential to reduce ACTH levels. There is limited but emerging evidence suggesting that cabergoline may be effective in controlling ACTH hypersecretion in Nelson's syndrome, particularly in patients who do not respond to other treatments. Therefore, while not a first-line treatment, it can be used in specific cases based on clinical judgment and patient response.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is proton beam therapy used for treatment of craniopharyngioma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether proton beam therapy is used for the treatment of craniopharyngioma, I first consider the nature of craniopharyngioma, which is a rare, benign brain tumor typically located near the pituitary gland. Treatment often involves surgery and radiation therapy due to the tumor's proximity to critical structures. Proton beam therapy is a type of radiation therapy that uses protons instead of X-rays, offering the advantage of delivering radiation more precisely to the tumor while minimizing damage to surrounding healthy tissue. This is particularly important in brain tumors like craniopharyngioma, where nearby structures such as the optic nerves and hypothalamus are at risk. Upon reflection, I recall that proton beam therapy is indeed used in some cases for craniopharyngioma, especially in pediatric patients or when conventional radiation poses a higher risk of side effects. Clinical studies and medical guidelines support its use as an effective option in certain scenarios, although it may not be the first-line treatment for all cases. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can Panitumumab cause trichomegaly?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Panitumumab can cause trichomegaly, I first need to consider what Panitumumab is and its known side effects. Panitumumab is a monoclonal antibody used primarily in the treatment of metastatic colorectal cancer. It targets the epidermal growth factor receptor (EGFR), which can affect skin and hair growth. Trichomegaly refers to the abnormal lengthening of eyelashes. I recall that EGFR inhibitors, including drugs like Panitumumab, are associated with dermatologic side effects such as rash, dry skin, and sometimes changes in hair growth, including trichomegaly. Upon reflection, there are documented cases and studies linking EGFR inhibitors to trichomegaly as a side effect due to the disruption of normal hair growth cycles. Therefore, it seems plausible and supported by medical literature that Panitumumab can indeed cause trichomegaly.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do exon 38 or 39 KMT2D missense variants cause Kabuki syndrome type 1 (KS1)?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether exon 38 or 39 KMT2D missense variants cause Kabuki syndrome type 1 (KS1), I first consider the background of KS1. Kabuki syndrome is a rare genetic disorder characterized by distinctive facial features, developmental delay, and other anomalies. KS1 is primarily associated with mutations in the KMT2D gene, which encodes a histone methyltransferase involved in epigenetic regulation. Mutations in KMT2D are known to disrupt normal gene expression, leading to the phenotypic features of KS1. Many pathogenic variants in KMT2D are loss-of-function mutations, such as nonsense or frameshift mutations, but missense variants, which result in a single amino acid change, can also be pathogenic if they affect critical functional domains of the protein. Exons 38 and 39 of KMT2D are located in regions that encode parts of the SET domain, which is crucial for the methyltransferase activity of the protein. Missense variants in these exons could potentially disrupt this activity, leading to KS1. Studies and clinical reports have identified pathogenic missense variants in various exons of KMT2D, including exons 38 and 39, associated with KS1. Therefore, it is reasonable to conclude that missense variants in these exons can cause KS1, provided they impact the protein's function. I will answer 'yes' based on this analysis.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is tirabrutinib effective for lymphoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether tirabrutinib is effective for lymphoma, I first consider the context of the question. Tirabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, a class of drugs often used in the treatment of certain B-cell malignancies, including types of lymphoma such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Clinical studies and data suggest that tirabrutinib has shown efficacy in treating relapsed or refractory B-cell lymphomas, particularly in Japan where it has been approved for such indications. However, effectiveness can vary based on the specific type of lymphoma, patient condition, and other factors. Since the question is general and does not specify a subtype of lymphoma or context (e.g., first-line treatment or relapsed cases), I will base my answer on the general evidence of its use in lymphoma treatment. Given the available information and its approval for certain lymphomas, I conclude that tirabrutinib is effective for lymphoma in the contexts where it has been studied and approved.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is fusobacterium associated with Lemierre's syndrome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Lemierre's syndrome is a rare condition characterized by septic thrombophlebitis of the internal jugular vein, often following an oropharyngeal infection, and is typically associated with anaerobic bacteria. Fusobacterium, particularly Fusobacterium necrophorum, is indeed a primary pathogen linked to this syndrome. It is frequently isolated in cases of Lemierre's syndrome, and its association is well-documented in medical literature. Therefore, the answer should affirm the connection between Fusobacterium and Lemierre's syndrome.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is progeria caused by an autosomal recessive gene?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare genetic disorder characterized by accelerated aging in children. To determine if it is caused by an autosomal recessive gene, I need to recall the genetic basis of the condition. Progeria is primarily caused by a mutation in the LMNA gene, which is responsible for producing a protein called lamin A. This mutation is typically a de novo mutation, meaning it occurs spontaneously and is not inherited in most cases. Furthermore, the mutation is autosomal dominant, not recessive, because a single copy of the mutated gene is sufficient to cause the disorder. Therefore, progeria is not caused by an autosomal recessive gene.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there a genetic cause of craniostenosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Craniostenosis, also known as craniosynostosis, is a condition where the sutures in an infant's skull close prematurely, leading to abnormal skull shape and potential brain growth issues. I am considering whether there is evidence linking this condition to genetic causes. Research indicates that craniosynostosis can indeed have genetic origins in many cases. Specific genetic mutations, such as those in the FGFR (fibroblast growth factor receptor) genes, are associated with syndromic forms of craniosynostosis, like Apert, Crouzon, and Pfeiffer syndromes. Additionally, family history and twin studies suggest a hereditary component in some non-syndromic cases. While environmental factors may also play a role, the genetic link is well-established in medical literature. Therefore, the answer should affirm the presence of a genetic cause.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is acupotomy used to treat muscle stiffness?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether acupotomy is used to treat muscle stiffness, I first need to understand what acupotomy is. Acupotomy is a therapeutic technique that combines principles of acupuncture with minor surgical procedures, often involving a small needle-knife to release adhesions or scar tissue in muscles and tendons. It is commonly used in traditional Chinese medicine and integrative therapies to address chronic pain, muscle tension, and stiffness by targeting specific trigger points or areas of restriction. Muscle stiffness, often caused by tension, injury, or poor posture, could theoretically be alleviated by such a technique if it involves releasing tight or adhered tissues. Research and clinical practice suggest that acupotomy is indeed applied for conditions like myofascial pain syndrome, which includes muscle stiffness as a symptom. Therefore, it seems reasonable to conclude that acupotomy can be used for treating muscle stiffness in certain contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is carpal tunnel syndrome a type of nerve entrapment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Carpal tunnel syndrome is a condition caused by compression of the median nerve as it passes through the carpal tunnel in the wrist. Nerve entrapment refers to a condition where a nerve is compressed or pinched, leading to pain, numbness, or other symptoms. Since carpal tunnel syndrome involves the compression of the median nerve, it fits the definition of a nerve entrapment condition. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any role of genotoxic pks + E. coli in cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about the role of genotoxic pks+ E. coli in cancer, I first need to consider what pks+ E. coli refers to. Pks stands for polyketide synthase, a gene island in certain strains of Escherichia coli that enables the production of a genotoxin called colibactin. Colibactin is known to cause DNA damage by inducing double-strand breaks in host cells, which can lead to genomic instability—a hallmark of cancer. Research has shown that pks+ E. coli is more prevalent in the gut microbiota of colorectal cancer patients compared to healthy individuals. Studies, including those using animal models, have demonstrated that pks+ E. coli can promote tumorigenesis by causing DNA damage and inflammation in the intestinal epithelium. Therefore, there is evidence suggesting a role of genotoxic pks+ E. coli in cancer, particularly colorectal cancer.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is avelumab effective for urothelial carcinoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether avelumab is effective for urothelial carcinoma, I first consider the context of the question. Urothelial carcinoma is a type of cancer that typically occurs in the bladder or other parts of the urinary tract. Avelumab is a monoclonal antibody and a type of immune checkpoint inhibitor, specifically targeting PD-L1, which is often used in cancer immunotherapy. I recall that avelumab has been studied and approved for certain indications in cancer treatment. Upon reflection, I remember that avelumab is indeed approved by regulatory bodies like the FDA for the treatment of locally advanced or metastatic urothelial carcinoma, particularly as a maintenance therapy following platinum-based chemotherapy, based on clinical trial results showing improved overall survival in some patient populations (e.g., the JAVELIN Bladder 100 trial). However, effectiveness can depend on specific patient conditions, such as PD-L1 status or prior treatments. Since the question is general and does not specify a particular context or subgroup, I will base my answer on the established approval and evidence of efficacy in the indicated population. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does a comet assay measure radiation induced mutations?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether a comet assay measures radiation-induced mutations, I first need to understand what a comet assay is and what it measures. A comet assay, also known as single-cell gel electrophoresis, is a technique used to detect DNA damage in individual cells. It visualizes DNA strand breaks by embedding cells in agarose, lysing them, and subjecting them to electrophoresis. Damaged DNA migrates away from the nucleus, forming a 'comet' shape, where the tail represents fragmented DNA. Radiation is known to cause DNA damage, including strand breaks, which the comet assay can detect. However, mutations are specific changes in the DNA sequence, such as point mutations or insertions/deletions, which are not directly measured by the comet assay. The assay primarily quantifies DNA strand breaks and alkali-labile sites, not the specific sequence alterations that define mutations. While radiation-induced DNA damage detected by the comet assay could lead to mutations if not repaired properly, the assay itself does not measure mutations directly. Therefore, the answer should be 'no', as the comet assay measures DNA damage, not mutations per se.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is MIS-C or Multisystem  Inflammatory syndrome in children a complication of Covid-19?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether MIS-C (Multisystem Inflammatory Syndrome in Children) is a complication of Covid-19, I need to consider the current medical understanding. MIS-C is a rare but serious condition that has been observed in children and adolescents following a Covid-19 infection. It involves inflammation of multiple organ systems, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. According to health organizations like the CDC and WHO, MIS-C is associated with Covid-19, often appearing weeks after the initial infection, even in children who had mild or asymptomatic cases. The exact cause is not fully understood, but it is believed to be a delayed immune response to the virus. Therefore, it is reasonable to classify MIS-C as a complication of Covid-19, as it arises as a consequence of the infection.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SLIC-CAGE used for quantification of translation?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether SLIC-CAGE is used for quantification of translation, I first need to understand what SLIC-CAGE is. SLIC-CAGE (Super-Resolution Localization and Identification of Capped RNA Transcripts by CAGE) is a technique related to CAGE (Cap Analysis of Gene Expression), which is primarily used for mapping transcription start sites and quantifying gene expression at the transcriptional level by capturing the 5' ends of capped RNAs. Translation, however, refers to the process of protein synthesis from mRNA, which is a post-transcriptional event. Techniques for quantifying translation typically involve methods like ribosome profiling or polysome profiling, which directly assess mRNA association with ribosomes. SLIC-CAGE, being a variant of CAGE, is more focused on transcriptional analysis rather than translation. Therefore, it is unlikely to be directly used for quantifying translation.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is adenosine signaling prognostic for cancer outcome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether adenosine signaling is prognostic for cancer outcome, I first consider the role of adenosine in the tumor microenvironment. Adenosine is a purine nucleoside that accumulates in the tumor microenvironment and is known to have immunosuppressive effects, potentially promoting tumor growth by inhibiting immune responses. It interacts with adenosine receptors on immune cells, which can dampen anti-tumor immunity. Several studies have suggested that high levels of adenosine or increased expression of adenosine-related pathways (like CD73 and CD39, enzymes that generate adenosine) are associated with worse prognosis in various cancers, including breast, colorectal, and lung cancer. These studies often link adenosine signaling to tumor progression, metastasis, and resistance to therapies like immunotherapy. However, the prognostic value might vary depending on cancer type, stage, and specific patient cohorts, as not all studies universally confirm this association. There are also emerging therapies targeting adenosine pathways (e.g., anti-CD73 or adenosine receptor inhibitors), which indirectly support its relevance to cancer outcomes. On balance, while not universally conclusive across all contexts, the majority of evidence points to adenosine signaling being a negative prognostic factor in many cancers. Therefore, I lean towards 'yes,' it is prognostic for cancer outcome, acknowledging that further research might refine this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does bleomycin cause lung toxicity?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Bleomycin is a chemotherapeutic agent commonly used in the treatment of certain cancers, such as Hodgkin's lymphoma and testicular cancer. One of the well-documented and serious side effects of bleomycin is pulmonary toxicity, which can manifest as pneumonitis or pulmonary fibrosis. This toxicity is dose-dependent and can be life-threatening in some cases. Risk factors include higher cumulative doses, older age, and pre-existing lung conditions. Therefore, the answer to whether bleomycin causes lung toxicity is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there sex differences in oncogenic mutational processes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are there sex differences in oncogenic mutational processes?', I first consider the biological context. Oncogenic mutational processes refer to the mechanisms by which mutations occur in genes that drive cancer development. Sex differences could imply variations between males and females in how these mutations arise or accumulate, potentially due to genetic, hormonal, or environmental factors. Research in cancer genomics suggests that there are indeed differences in mutation rates, types, and affected pathways between sexes in certain cancers. For instance, studies have shown that mutation burdens and specific driver mutations can vary by sex in cancers like lung cancer or melanoma, possibly influenced by hormonal differences or sex chromosome-specific genes. While the extent and mechanisms are still under investigation, evidence supports the existence of sex differences in these processes. Therefore, my answer is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is co-loss of BRCA2-RB1 associated with better prognosis for prostate cancer patients?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether co-loss of BRCA2-RB1 is associated with a better prognosis for prostate cancer patients, I first consider the biological roles of these genes. BRCA2 is involved in DNA repair, and its loss is often linked to genomic instability and aggressive cancer behavior. RB1, a tumor suppressor gene, regulates cell cycle progression, and its loss is also associated with poor outcomes in various cancers, including prostate cancer. Co-loss of both genes might suggest a more aggressive tumor phenotype due to combined defects in DNA repair and cell cycle control. I recall that studies in prostate cancer have shown that loss of RB1, especially in combination with other genetic alterations, often correlates with resistance to therapy and worse prognosis. However, I also consider if there are specific contexts or studies suggesting a paradoxical benefit, such as synthetic lethality or enhanced response to certain treatments like PARP inhibitors in BRCA-deficient tumors. Upon reflection, while BRCA2 loss might sensitize tumors to specific therapies, the co-loss with RB1 likely exacerbates tumor aggressiveness rather than improving prognosis. Most literature points to worse outcomes with such dual losses, particularly in advanced or castration-resistant prostate cancer. Therefore, I conclude that co-loss of BRCA2-RB1 is not associated with a better prognosis.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for Dickkopf-1 (DKK1) in prostate cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether there is a role for Dickkopf-1 (DKK1) in prostate cancer, I first consider the biological context. DKK1 is a known inhibitor of the Wnt signaling pathway, which is implicated in various cancers due to its role in cell proliferation and differentiation. In prostate cancer, aberrant Wnt signaling has been associated with tumor progression and metastasis. Research suggests that DKK1 may have a dual role, potentially acting as a tumor suppressor by inhibiting Wnt signaling or, conversely, promoting cancer progression under certain conditions by influencing the tumor microenvironment or bone metastasis, which is common in prostate cancer. Studies have shown elevated DKK1 levels in the serum of prostate cancer patients, particularly those with bone metastases, indicating a possible biomarker role or involvement in disease progression. Therefore, based on this analysis, there appears to be evidence supporting a role for DKK1 in prostate cancer.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Benralizumab effective for Chronic Spontaneous Urticaria?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Benralizumab is effective for Chronic Spontaneous Urticaria (CSU), I first consider the purpose of Benralizumab. It is a monoclonal antibody that targets the interleukin-5 receptor, primarily used for severe eosinophilic asthma by reducing eosinophil levels. Chronic Spontaneous Urticaria, on the other hand, is a skin condition characterized by recurrent hives and itching, often linked to autoimmune mechanisms or histamine release, not necessarily eosinophil-driven pathways. Current treatments for CSU typically involve antihistamines or Omalizumab, another monoclonal antibody targeting IgE. There is limited evidence or clinical guideline support for Benralizumab in CSU treatment, as its mechanism does not directly address the primary drivers of CSU. I conclude that it is unlikely to be effective for this condition based on its known therapeutic targets.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is belimumab effective for the lupus nephritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether belimumab is effective for lupus nephritis, I first consider the context of the question. Lupus nephritis is a serious kidney complication of systemic lupus erythematosus (SLE), and treatment often involves immunosuppressive therapies. Belimumab is a monoclonal antibody that inhibits B-cell activating factor (BAFF), approved for SLE. I recall that clinical studies, such as the BLISS-LN trial, have investigated its efficacy specifically for lupus nephritis. The trial results showed that belimumab, when added to standard therapy, improved renal response rates compared to placebo. Therefore, based on this evidence, it appears to be effective for lupus nephritis in certain patients, though individual responses may vary and it should be considered under medical guidance.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is liraglutide effective for weight reduction?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Liraglutide is a medication primarily used to treat type 2 diabetes, but it has also been approved for weight management in certain patients. Clinical studies, such as those leading to its approval under the brand name Saxenda, have shown that liraglutide can lead to significant weight loss in overweight or obese individuals when combined with a reduced-calorie diet and increased physical activity. It works by mimicking the effects of GLP-1, a hormone that regulates appetite and food intake, thereby reducing hunger and promoting a feeling of fullness. Therefore, based on available evidence, liraglutide is effective for weight reduction in the appropriate patient population.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Eflornithine and Sulindac are effective for prevention of progression in Familial Adenomatous Polyposis?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Eflornithine and Sulindac are effective for the prevention of progression in Familial Adenomatous Polyposis (FAP), I am considering the medical context and available evidence. FAP is a genetic condition characterized by the development of numerous polyps in the colon and rectum, which can progress to colorectal cancer if untreated. Eflornithine is an ornithine decarboxylase inhibitor that may reduce cell proliferation, and Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) known to reduce polyp formation in some contexts. Studies, including clinical trials, have suggested that the combination of these drugs may be effective in reducing polyp burden and delaying progression in FAP patients. For instance, research published in medical journals indicates that this combination can significantly decrease polyp number and size compared to placebo. However, effectiveness can vary based on individual patient factors, and long-term outcomes like cancer prevention are still under investigation. Based on the current evidence, it appears that this combination is considered effective for preventing progression in FAP, at least in terms of polyp reduction.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is ofatumumab effective for multiple sclerosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ofatumumab is effective for multiple sclerosis (MS), I first consider the context of the question. Ofatumumab is a monoclonal antibody that targets CD20 on B-cells, used in the treatment of certain conditions. I recall that it has been approved under the brand name Kesimpta for relapsing forms of multiple sclerosis. Clinical trials, such as the ASCLEPIOS I and II studies, have shown that ofatumumab reduces the annualized relapse rate, slows disability progression, and decreases the number of brain lesions in patients with relapsing MS compared to other treatments like teriflunomide. While effectiveness can vary based on individual patient factors, the general evidence supports its efficacy for relapsing MS. Since the question does not specify a subtype of MS, I will base my answer on its established use for relapsing forms, which is a significant portion of MS cases. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Olaparib effective for prostate cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Olaparib is effective for prostate cancer, I first consider the context of the drug. Olaparib is a PARP inhibitor, primarily used in the treatment of certain cancers with specific genetic mutations, such as BRCA mutations. It has been approved for use in ovarian, breast, and pancreatic cancers with these mutations. For prostate cancer, I recall that Olaparib has been studied and approved for metastatic castration-resistant prostate cancer (mCRPC) in patients with specific DNA repair gene mutations, particularly BRCA1/2 or ATM mutations, based on clinical trials like the PROfound study. This study showed improved progression-free survival in patients with these mutations compared to standard treatments. However, its effectiveness is not universal for all prostate cancer patients, as it depends on the presence of these genetic alterations. Since the question does not specify a subtype or genetic profile, I must consider the general context. Given that Olaparib is effective for a significant subset of prostate cancer patients with certain mutations, and it has regulatory approval for this indication, I lean towards a positive response. However, I acknowledge the limitation of the question's broad phrasing. After weighing this, I conclude that the answer should be 'yes' based on its proven efficacy in a specific, clinically relevant group of prostate cancer patients.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has tocilizumab been assessed against Covid-19?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether tocilizumab has been assessed against Covid-19, I am considering the context of medical research and clinical trials. Tocilizumab is an immunosuppressive drug, primarily used to treat rheumatoid arthritis, and it works by inhibiting the interleukin-6 (IL-6) receptor. Given the cytokine storm observed in severe Covid-19 cases, where excessive inflammation can lead to critical conditions, it is plausible that tocilizumab has been evaluated for its potential to mitigate this response. I recall that during the Covid-19 pandemic, several drugs originally developed for other conditions were repurposed and tested for efficacy against the virus. Reports and studies, including those from 2020 and 2021, indicate that tocilizumab was indeed assessed in clinical trials for Covid-19 patients, particularly those with severe symptoms. The RECOVERY trial, for instance, included tocilizumab and found it reduced mortality in certain hospitalized patients. Therefore, the answer should affirm that it has been assessed.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is tocilizumab a tumor necrosis factor inhibitor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Is tocilizumab a tumor necrosis factor inhibitor?', I need to recall or research what tocilizumab is and its mechanism of action. Tocilizumab is a monoclonal antibody used primarily in the treatment of rheumatoid arthritis and other inflammatory conditions. It targets the interleukin-6 (IL-6) receptor, thereby inhibiting the IL-6 signaling pathway, which plays a role in inflammation. Tumor necrosis factor (TNF) inhibitors, on the other hand, are a different class of drugs that specifically block TNF-alpha, another cytokine involved in inflammation. Since tocilizumab targets IL-6 and not TNF-alpha, it is not classified as a TNF inhibitor. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is tofacitinib a JAK inhibitor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Is tofacitinib a JAK inhibitor?', I need to recall or verify the pharmacological classification of tofacitinib. Tofacitinib is a medication commonly used for treating conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. I remember that it works by inhibiting Janus kinase (JAK) enzymes, which are involved in the signaling pathways of various cytokines and growth factors important in immune responses. Therefore, it should be classified as a JAK inhibitor. To confirm, I consider if there is any chance it belongs to another class of drugs, but I am confident based on its mechanism of action that it is indeed a JAK inhibitor. Thus, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does the use of bDMARDs during pregnancy impact neonatal development?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the use of bDMARDs (biologic Disease-Modifying Antirheumatic Drugs) during pregnancy impacts neonatal development, I first consider the nature of bDMARDs. These are medications used to treat autoimmune conditions by targeting specific components of the immune system. Pregnancy introduces a complex scenario where the mother's health needs must be balanced with potential risks to the fetus. Some bDMARDs, like certain TNF inhibitors, have been studied in pregnant women with autoimmune diseases, and data suggest that they may not significantly increase the risk of adverse neonatal outcomes when used appropriately, especially if discontinued before the third trimester to minimize placental transfer. However, other bDMARDs might pose risks due to limited data or known effects on immune development. The impact can vary based on the specific drug, timing of exposure, and dosage. Given the question's general nature without specifying a particular bDMARD or context, I lean towards acknowledging a potential impact, as there is evidence of risk with some agents or in certain scenarios. Therefore, I conclude that there can be an impact on neonatal development.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is tocilizumab a csDMARD?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether tocilizumab is a csDMARD, I need to clarify the definitions. csDMARDs, or conventional synthetic Disease-Modifying Antirheumatic Drugs, are traditional medications like methotrexate, leflunomide, or sulfasalazine, which modify the course of autoimmune diseases such as rheumatoid arthritis through non-specific immunosuppression. Tocilizumab, however, is a biologic DMARD (bDMARD) that specifically targets the interleukin-6 receptor, inhibiting its signaling pathway. Biologic DMARDs are distinct from csDMARDs due to their targeted mechanism and biologic origin. Therefore, tocilizumab does not fall under the category of csDMARDs.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is vocimagene amiretrorepvec effective for glioblastoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether vocimagene amiretrorepvec is effective for glioblastoma, I first consider the context of the question. Vocimagene amiretrorepvec, also known as Toca 511, is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma, by delivering a gene that converts a prodrug into a cytotoxic agent to kill cancer cells. I recall that clinical trials, such as the Toca 5 trial, have been conducted to evaluate its efficacy. However, the results of the Phase 3 trial (reported around 2019) showed that it did not meet the primary endpoint of overall survival compared to standard care. While there may be specific subgroups or conditions under which it shows promise, the general consensus based on available data leans toward it not being effective as a standalone treatment for glioblastoma at this time. I must answer with a binary 'yes' or 'no,' and based on the most recent and widely reported trial outcomes, the answer should reflect the lack of proven efficacy in improving survival rates.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does addition of valproic acid improve survival of patients with diffuse intrinsic pontine glioma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the addition of valproic acid improves survival in patients with diffuse intrinsic pontine glioma (DIPG), I first consider the nature of DIPG, a rare and aggressive pediatric brain tumor with a poor prognosis, typically located in the brainstem. Standard treatment often involves radiation therapy, but survival rates remain low, with median survival around 9-12 months. Valproic acid, primarily an anticonvulsant, has been investigated for potential anti-cancer properties, including histone deacetylase inhibition, which may affect tumor growth. However, I must evaluate if there is clinical evidence supporting its efficacy in DIPG. Upon reflection, I recall that while preclinical studies might suggest some benefit of histone deacetylase inhibitors in gliomas, specific clinical trials or robust evidence for valproic acid in DIPG are limited or inconclusive. Most studies focus on its role in managing seizures in these patients rather than as a primary therapeutic agent for survival benefit. Without definitive randomized controlled trials or meta-analyses showing improved survival outcomes with valproic acid in DIPG, I lean towards a negative response. However, I acknowledge the possibility of emerging research, but based on current widely accepted medical knowledge, the addition of valproic acid does not have a proven impact on improving survival in DIPG patients.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is capmatinib effective for glioblastoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether capmatinib is effective for glioblastoma, I first consider what capmatinib is and its intended use. Capmatinib is a targeted therapy drug, specifically a MET inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) with specific MET gene alterations. Glioblastoma, on the other hand, is a type of brain cancer, and its treatment typically involves surgery, radiation, and chemotherapy like temozolomide. I am not aware of any widely recognized clinical evidence or FDA approval indicating that capmatinib is effective for glioblastoma. While MET alterations can play a role in some glioblastomas, the efficacy of capmatinib in this context is not established in standard medical guidelines or large-scale clinical trials as of my last update. There might be ongoing research or off-label use, but without specific data, I cannot assume effectiveness. Therefore, based on current general knowledge, the answer should be 'no', pending any new evidence or context provided.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should cerebrolysin be used for aneurysmal subarachnoid hemorrhage?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Cerebrolysin is a neurotrophic agent that has been studied for various neurological conditions due to its potential neuroprotective and neuroregenerative effects. However, aneurysmal subarachnoid hemorrhage (aSAH) is a specific type of stroke caused by the rupture of an intracranial aneurysm, leading to bleeding into the subarachnoid space. The primary management of aSAH focuses on securing the aneurysm (via clipping or coiling), managing intracranial pressure, preventing vasospasm, and addressing complications like hydrocephalus. While Cerebrolysin has shown some promise in ischemic stroke and traumatic brain injury for improving neurological outcomes, there is limited high-quality evidence or clinical guidelines supporting its use specifically for aSAH. Most studies and reviews indicate that its role in hemorrhagic stroke, including aSAH, is not well-established, and it is not a standard of care in current neurosurgical or neurocritical care protocols (e.g., guidelines from the American Heart Association or European Stroke Organization). Potential risks, such as increased cerebral edema or unknown interactions with the pathophysiology of aSAH (e.g., vasospasm or rebleeding), also need consideration. Therefore, based on the lack of robust evidence and guideline support, Cerebrolysin should not be routinely used for aneurysmal subarachnoid hemorrhage.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Tranexamic acid effective for intracerebral haemorrhage?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Tranexamic acid is effective for intracerebral haemorrhage, I need to consider the current medical evidence and clinical guidelines. Tranexamic acid is an antifibrinolytic agent that helps reduce bleeding by inhibiting the breakdown of blood clots. In the context of intracerebral haemorrhage (ICH), which is a type of stroke caused by bleeding within the brain, the primary concern is to control bleeding and prevent further hematoma expansion. Studies, such as the TICH-2 trial, have investigated the use of Tranexamic acid in ICH. The results showed that while it may reduce hematoma growth in some cases, there was no significant improvement in functional outcomes or mortality rates at 90 days. Additionally, there are concerns about potential risks, such as thromboembolism. Based on this analysis, while Tranexamic acid might have a mechanistic benefit in reducing bleeding, the overall clinical effectiveness in improving patient outcomes for ICH is not conclusively supported by evidence at this time.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can thiotepa be recommended for treatment of osteosarcoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether thiotepa can be recommended for the treatment of osteosarcoma, I first considered the nature of thiotepa and osteosarcoma. Thiotepa is a chemotherapeutic agent, classified as an alkylating agent, used in the treatment of various cancers, including breast cancer, ovarian cancer, and certain lymphomas. Osteosarcoma, on the other hand, is a type of bone cancer that primarily affects children and young adults. Standard treatment for osteosarcoma typically involves a combination of surgery and chemotherapy regimens that include drugs like methotrexate, doxorubicin, and cisplatin. I then analyzed whether thiotepa is part of the standard or experimental protocols for osteosarcoma. Upon reflection, thiotepa is not commonly mentioned in guidelines or clinical protocols for osteosarcoma treatment, such as those from the National Comprehensive Cancer Network (NCCN) or the American Society of Clinical Oncology (ASCO). It is more frequently associated with high-dose chemotherapy regimens followed by stem cell transplantation in other malignancies. There is limited evidence or clinical trial data supporting its use specifically for osteosarcoma. Therefore, based on current medical knowledge and standard practices, thiotepa is not typically recommended for osteosarcoma treatment.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does hypofractionated radiotherapy offers any benefit for DIPG?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether hypofractionated radiotherapy offers any benefit for Diffuse Intrinsic Pontine Glioma (DIPG), I first consider the nature of DIPG, a highly aggressive pediatric brain tumor with a poor prognosis, typically located in the brainstem. Standard treatment often involves conventional radiotherapy, but hypofractionated radiotherapy, which delivers higher doses per fraction over fewer sessions, has been explored as an alternative to reduce treatment burden and potentially improve quality of life. Studies and clinical trials suggest that hypofractionated radiotherapy may provide comparable survival outcomes to conventional fractionation while shortening treatment duration, which is a significant benefit for patients with limited life expectancy. However, it is not universally superior in terms of tumor control or long-term outcomes, and the primary benefit lies in convenience and reduced treatment time rather than improved survival. Based on this analysis, I conclude that hypofractionated radiotherapy does offer a benefit for DIPG, particularly in terms of treatment efficiency and patient comfort.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is isradipine effective for Parkinson's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether isradipine is effective for Parkinson's disease, I first consider the nature of the question, which seeks a direct evaluation of a drug's efficacy for a specific condition. Isradipine is a calcium channel blocker primarily used for hypertension. Research and clinical trials have explored its potential neuroprotective effects in Parkinson's disease due to its ability to block L-type calcium channels, which may reduce neuronal stress in the substantia nigra, a region affected in Parkinson's. However, as of the latest widely available data, while some preclinical studies and early-phase clinical trials (like the STEADY-PD III trial) have shown promise, the results are not conclusive. The phase 3 trial results published around 2020 indicated that isradipine did not significantly slow the progression of Parkinson's disease. Therefore, based on current evidence, it is not considered effective for treating or slowing Parkinson's disease progression in a clinical setting. I will answer 'no' to reflect the lack of definitive positive outcomes in human trials.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should nerinetide be used for treatment of ischaemic stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether nerinetide should be used for the treatment of ischaemic stroke, I first consider the context of the question. Ischaemic stroke occurs when blood flow to the brain is blocked, often by a clot, leading to brain tissue damage. Treatment typically focuses on restoring blood flow (e.g., thrombolysis or mechanical thrombectomy) and protecting brain tissue from further damage (neuroprotection). Nerinetide is a drug that has been investigated for its neuroprotective properties, specifically in reducing brain damage during acute ischaemic stroke by interfering with harmful signaling pathways. Recent clinical trials, such as the ESCAPE-NA1 trial, have shown mixed results. In patients not treated with alteplase (a thrombolytic agent), nerinetide appeared to improve outcomes, but in those receiving alteplase, there was no significant benefit, possibly due to drug interactions. Given this, the use of nerinetide is not universally recommended in current clinical guidelines, as its efficacy depends on specific patient conditions and treatment combinations. It is not yet widely approved or adopted as a standard treatment for ischaemic stroke. Therefore, based on the current evidence and lack of broad endorsement in medical practice, I lean toward 'no' for general use, though it may have potential in specific scenarios.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Lanabecestat effective for Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Lanabecestat is effective for Alzheimer's disease, I need to consider the available information on this drug. Lanabecestat is a BACE1 inhibitor developed to reduce amyloid-beta plaque formation, which is a hallmark of Alzheimer's disease. Clinical trials, particularly Phase 3 studies, have been conducted to evaluate its efficacy. However, reports indicate that these trials were terminated early due to lack of efficacy and potential safety concerns, including cognitive worsening in some patients compared to placebo. Major studies, such as the AMARANTH and DAYBREAK-ALZ trials, showed no significant benefit in slowing cognitive decline in patients with early or mild Alzheimer's disease. Based on this, it appears that Lanabecestat is not effective for treating Alzheimer's disease.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should minocycline be used for mild Alzheimer disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether minocycline should be used for mild Alzheimer's disease, I first consider the nature of minocycline, which is a tetracycline antibiotic primarily used for bacterial infections and sometimes for its anti-inflammatory properties. Alzheimer's disease is a neurodegenerative condition characterized by cognitive decline, and its treatment typically focuses on symptom management with drugs like cholinesterase inhibitors or memantine. I recall that there has been some research into minocycline's potential neuroprotective and anti-inflammatory effects in neurodegenerative diseases, including Alzheimer's, due to its ability to cross the blood-brain barrier and reduce microglial activation. However, I also consider that clinical evidence supporting its use in Alzheimer's, especially in mild stages, is limited. Most studies are preclinical or early-phase trials, and there is no widespread clinical guideline or approval for minocycline in Alzheimer's treatment. Potential side effects, such as gastrointestinal issues or dizziness, and the risk of antibiotic resistance also weigh against its routine use without strong evidence. After analyzing this, I conclude that minocycline should not be used for mild Alzheimer's disease based on current evidence and standard medical practice.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is MK-1602 a CGRP antagonist?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether MK-1602 is a CGRP antagonist, I first need to consider what a CGRP antagonist is. CGRP (Calcitonin Gene-Related Peptide) antagonists are a class of drugs designed to block the action of CGRP, a neuropeptide involved in migraine pathophysiology. These drugs are often used for the prevention or treatment of migraines. Now, regarding MK-1602, I recall that it is an investigational drug developed by Merck for the treatment of migraines. Based on available information and clinical trial data, MK-1602 is indeed designed to target the CGRP pathway, specifically acting as a CGRP receptor antagonist. Therefore, it fits the definition of a CGRP antagonist. I will confirm this understanding and conclude with a definitive answer.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has ubrogepant entered clinical phase III trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ubrogepant has entered clinical phase III trials, I need to consider the current status of this drug. Ubrogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist developed for the treatment of migraine. I recall that ubrogepant has been studied extensively and has progressed through various phases of clinical trials. Phase III trials are large-scale studies conducted to confirm the efficacy and safety of a drug before it is submitted for regulatory approval. Based on available information, ubrogepant has indeed completed phase III trials, as evidenced by studies like ACHIEVE I and ACHIEVE II, which were pivotal trials leading to its approval by the FDA in 2019 under the brand name Ubrelvy. Therefore, it is accurate to confirm that ubrogepant has entered and completed phase III trials.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there small molecule CGRPs under development for the treatment of migraine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether there are small molecule CGRPs under development for the treatment of migraine, I first need to clarify that CGRP stands for Calcitonin Gene-Related Peptide, which is a neuropeptide involved in migraine pathophysiology. The question likely refers to small molecule CGRP receptor antagonists or inhibitors, as CGRP itself is a peptide and not typically a small molecule. I recall that there are indeed small molecule CGRP receptor antagonists, such as rimegepant and ubrogepant, which have been developed and approved for migraine treatment. Additionally, there may be others in various stages of clinical development. Given this, it seems that there are small molecule therapies targeting CGRP pathways under development or already available for migraine treatment. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is eptinezumab a small molecule?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether eptinezumab is a small molecule, I first need to consider what constitutes a small molecule in the context of pharmaceuticals. Small molecules are typically low molecular weight compounds, often less than 900 daltons, that can easily penetrate cell membranes. They are usually chemically synthesized. On the other hand, biologics, such as monoclonal antibodies, are large, complex molecules often produced through biotechnology. Upon researching, I find that eptinezumab is a monoclonal antibody used for the preventive treatment of migraine. Monoclonal antibodies are large molecules, with molecular weights often exceeding 100,000 daltons, far beyond the threshold for small molecules. Therefore, eptinezumab does not qualify as a small molecule.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is gabapentin effective for chronic pelvic pain?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether gabapentin is effective for chronic pelvic pain, I first consider the nature of gabapentin as a medication. Gabapentin is an anticonvulsant drug often used to treat neuropathic pain, which is pain caused by nerve damage or dysfunction. Chronic pelvic pain can have various causes, including neuropathic components, musculoskeletal issues, or visceral pain from organs. I recall that gabapentin has been studied for neuropathic pain conditions like diabetic neuropathy and postherpetic neuralgia with positive results. However, chronic pelvic pain is a complex condition, and its effectiveness might depend on the underlying cause. Upon reflection, I remember that some studies and clinical guidelines suggest gabapentin as a potential treatment for chronic pelvic pain, especially when there is a suspected neuropathic component, but the evidence is not as robust as for other conditions. There are mixed results in the literature, with some patients reporting relief while others do not. Given this, I lean towards a cautious affirmation, acknowledging that it can be effective for some individuals, particularly where nerve-related pain is involved, but it is not universally effective. After weighing this, I conclude that the answer should be 'yes' with the understanding that effectiveness varies based on individual cases and pain etiology.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether trimetazidine protects from myocardial injury after percutaneous coronary intervention (PCI), I am considering the context and available medical knowledge up to my last update. Trimetazidine is an anti-ischemic drug that works by optimizing cardiac energy metabolism, often used in angina treatment. Studies and clinical trials have explored its potential cardioprotective effects during procedures like PCI, which can cause myocardial injury due to ischemia-reperfusion. Some evidence suggests that trimetazidine may reduce myocardial injury markers (like troponin levels) post-PCI by mitigating oxidative stress and improving endothelial function. However, results are not universally conclusive, as some studies show limited or no significant benefit. Given the balance of evidence leaning towards a protective effect in certain contexts, I will answer affirmatively, acknowledging that this may depend on specific patient conditions and study designs.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does inactivation of CYLD help in colorectal cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether inactivation of CYLD helps in colorectal cancer, I first need to consider the role of CYLD in cellular processes. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB signaling, a pathway often hyperactivated in cancers, including colorectal cancer, leading to increased cell survival and inflammation. Inactivation of CYLD could theoretically enhance NF-kappaB signaling, potentially promoting tumor growth and progression. Research suggests that loss of CYLD function is associated with increased tumorigenesis in various cancers, including colorectal cancer, as it may contribute to chronic inflammation and uncontrolled cell proliferation. However, 'help' in this context likely refers to a beneficial effect for the patient, such as treatment or prognosis improvement. From this perspective, inactivation of CYLD would not be helpful, as it may worsen the disease. Therefore, the answer should be based on the interpretation that 'help' means a positive outcome for the patient.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for TFII-I in megakaryopoiesis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about the role of TFII-I in megakaryopoiesis, I first consider what megakaryopoiesis is: the process by which megakaryocytes, the cells responsible for platelet production, are formed from hematopoietic stem cells. TFII-I is a transcription factor known to be involved in various cellular processes, including gene regulation and signaling pathways. I recall that TFII-I has been studied in the context of hematopoiesis, and there is evidence suggesting its involvement in the regulation of genes important for megakaryocyte differentiation and platelet production. Studies have indicated that TFII-I interacts with signaling pathways like those involving GATA-1, a key regulator in megakaryopoiesis. Therefore, it seems plausible that TFII-I plays a role in this process. After analyzing this, I conclude that the answer should be affirmative based on the existing scientific literature and known functions of TFII-I in related cellular processes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is istiratumab effective for pancreatic cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether istiratumab is effective for pancreatic cancer, I first considered the nature of istiratumab. Istiratumab is an investigational bispecific antibody designed to target IGF-1R and ErbB3, which are involved in tumor growth and survival pathways. I then analyzed available information on its clinical development. As of the latest data, istiratumab has been studied in various solid tumors, including pancreatic cancer, in early-phase clinical trials. However, there is limited publicly available evidence from large-scale, randomized controlled trials demonstrating its efficacy specifically for pancreatic cancer. The results from Phase 1/2 trials suggest some activity in combination therapies, but definitive conclusions on effectiveness cannot be drawn without further data from advanced trials. Given the current lack of conclusive evidence or regulatory approval for this indication, I lean towards a negative response, acknowledging the potential for future research to alter this assessment.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does erenumab target the calcitonin gene-related peptide?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Erenumab is a monoclonal antibody used for the prevention of migraine. It specifically targets the calcitonin gene-related peptide (CGRP) receptor, blocking the action of CGRP, which is involved in migraine pathophysiology. Therefore, the answer to whether erenumab targets CGRP is affirmative, as it directly interacts with the CGRP receptor.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is there a link between rare variants in PPARG and type 1 diabetes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question about a link between rare variants in PPARG and type 1 diabetes, I first consider the biological context. PPARG (Peroxisome Proliferator-Activated Receptor Gamma) is a gene primarily associated with lipid metabolism and insulin sensitivity, often linked to type 2 diabetes and metabolic syndrome. Type 1 diabetes, on the other hand, is an autoimmune condition characterized by the destruction of insulin-producing beta cells. Given the distinct mechanisms of type 1 and type 2 diabetes, a direct link between PPARG variants and type 1 diabetes seems unlikely at first glance. However, rare variants could potentially influence immune regulation or inflammation, which are relevant to type 1 diabetes. I recall that most genetic studies on type 1 diabetes focus on HLA regions and other immune-related genes, not PPARG. A quick mental review of literature suggests that while PPARG variants are well-studied in type 2 diabetes, there is little to no evidence connecting them to type 1 diabetes. Therefore, I conclude that there is likely no established link.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there an association of alterations in ADCY7 and ulcerative colitis?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question about an association between alterations in ADCY7 and ulcerative colitis, I first consider the biological context. ADCY7 encodes adenylate cyclase 7, an enzyme involved in the production of cyclic AMP (cAMP), which plays a role in cellular signaling pathways, including those related to inflammation and immune response. Ulcerative colitis is a chronic inflammatory bowel disease, and genetic factors are known to contribute to its pathogenesis. I recall that genome-wide association studies (GWAS) and other genetic research have identified numerous susceptibility loci for inflammatory bowel diseases, including ulcerative colitis. While I am not immediately aware of specific studies directly linking ADCY7 to ulcerative colitis, alterations in genes involved in cAMP signaling could plausibly influence inflammatory pathways relevant to the disease. However, without specific evidence or data from studies confirming this association, I must rely on the lack of widely recognized connection in current medical literature. Therefore, I conclude that there is likely no established association unless proven by specific research.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there high nucleotide diversity in the Drosophila suzukii species?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about high nucleotide diversity in Drosophila suzukii, I first consider the context of nucleotide diversity, which refers to the variation in DNA sequences among individuals within a species. High nucleotide diversity typically indicates a large amount of genetic variation, often due to a large population size, historical population dynamics, or other evolutionary factors. Drosophila suzukii, commonly known as the spotted wing drosophila, is a fruit fly species known for its invasive nature and agricultural impact. Research on this species suggests that it exhibits significant genetic diversity, particularly due to its rapid global expansion and adaptation to diverse environments. Studies have shown that populations of D. suzukii often have high levels of genetic variation, which could be attributed to multiple introductions and large effective population sizes in some regions. Therefore, based on this analysis, it seems likely that there is high nucleotide diversity in this species.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Αre plants from the genus Strychnos the original source of curare?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether plants from the genus Strychnos are the original source of curare, I need to consider the historical and botanical context. Curare is a plant-based poison used by indigenous peoples in South America, primarily as a paralyzing agent for hunting. It is derived from various plants, but the most well-known sources are species from the genus Strychnos, such as Strychnos toxifera, as well as plants from the genus Chondrodendron, like Chondrodendron tomentosum. While multiple plants contribute to curare preparations, Strychnos species are often cited as a primary source in historical and scientific literature due to their potent alkaloids, such as strychnine and curarine, which have paralytic effects. Therefore, it is reasonable to conclude that plants from the genus Strychnos are indeed among the original sources of curare, even if not the sole source.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Curare function by stimulating the acetylcholine receptor?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Curare is a plant-derived poison historically used as a paralyzing agent. It functions as a neuromuscular blocking agent by competitively inhibiting acetylcholine receptors at the neuromuscular junction. This means it binds to the receptors without activating them, preventing acetylcholine from binding and thus blocking muscle contraction. The question asks if Curare stimulates the acetylcholine receptor. Since Curare inhibits rather than stimulates the receptor, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is AZD9668 a VEGF mRNA drug?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether AZD9668 is a VEGF mRNA drug, I first need to consider what is known about AZD9668. AZD9668 is a drug developed by AstraZeneca, and based on available information, it is primarily recognized as a neutrophil elastase inhibitor, used in the context of respiratory diseases like chronic obstructive pulmonary disease (COPD) or cystic fibrosis. VEGF (Vascular Endothelial Growth Factor) mRNA drugs, on the other hand, typically target or modulate VEGF expression for conditions like cancer or macular degeneration, often through mechanisms like RNA interference or mRNA therapy. There is no widely available evidence or documentation suggesting that AZD9668 functions as an mRNA-based therapy or specifically targets VEGF pathways. Therefore, it does not appear to fit the description of a VEGF mRNA drug.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has AZD9668 been tested in clinical trials?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether AZD9668 has been tested in clinical trials, I need to consider the context and available information. AZD9668 is a drug candidate developed by AstraZeneca, primarily investigated for its potential in treating respiratory conditions like chronic obstructive pulmonary disease (COPD) due to its action as a neutrophil elastase inhibitor. Clinical trials are formal studies conducted to evaluate the safety and efficacy of such drugs in humans. Given that AZD9668 is a known investigational drug from a major pharmaceutical company, it is highly likely that it has undergone or is undergoing clinical testing. I recall that there are records of clinical trials for AZD9668, particularly in phases like Phase 1 or Phase 2, focusing on respiratory diseases. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are TAMs good anticancer therapeutic targets?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether TAMs (Tumor-Associated Macrophages) are good anticancer therapeutic targets, I first need to consider their role in the tumor microenvironment. TAMs are a type of immune cell often found in high numbers within tumors. They can promote tumor growth, angiogenesis, and metastasis by secreting growth factors and cytokines, and they often suppress anti-tumor immune responses. This suggests that targeting TAMs could disrupt these tumor-supporting activities. There are ongoing studies and therapies aimed at either depleting TAMs or reprogramming them to adopt an anti-tumor phenotype (e.g., from M2 to M1 macrophages). Some preclinical and early clinical trials have shown promise, such as using CSF1R inhibitors to reduce TAM populations. However, challenges remain, including the heterogeneity of TAMs, potential off-target effects, and the complexity of the tumor microenvironment, which might limit the efficacy of TAM-targeted therapies as a standalone approach. Despite these challenges, the evidence suggests that TAMs are a viable target for anticancer therapies, especially in combination with other treatments like immunotherapy. Therefore, I conclude that TAMs are good therapeutic targets.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Tocilizumab (Actemra) used to block/antagonize the  IL-6 receptor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Tocilizumab, also known as Actemra, is a monoclonal antibody used in the treatment of certain inflammatory conditions such as rheumatoid arthritis. It works by specifically targeting and binding to the interleukin-6 (IL-6) receptor, thereby blocking the activity of IL-6, a cytokine involved in inflammatory and immune responses. By inhibiting the IL-6 receptor, Tocilizumab prevents the downstream effects of IL-6 signaling, which contributes to inflammation. Therefore, it is accurate to say that Tocilizumab is used to block or antagonize the IL-6 receptor.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are PDXK mutations linked to polyneuropathy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether PDXK mutations are linked to polyneuropathy, I first consider the role of PDXK, which encodes pyridoxal kinase, an enzyme involved in vitamin B6 metabolism. Vitamin B6 is crucial for nerve function, and deficiencies or disruptions in its metabolism could theoretically lead to neuropathic conditions. I recall that mutations in genes related to vitamin B6 metabolism have been associated with neurological disorders. Upon further reflection, I remember that recent studies have identified PDXK mutations in patients with axonal polyneuropathy, particularly in cases of hereditary neuropathy. This suggests a potential link, as impaired pyridoxal kinase activity might lead to reduced levels of active vitamin B6, impacting nerve health. However, I must consider if this association is well-established or still under investigation. Given the evidence from genetic studies and clinical reports, I believe there is a credible link, though it may not be universally present in all polyneuropathy cases. Therefore, my answer leans towards affirming the connection.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do bacteria release extracellular vesicles?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Do bacteria release extracellular vesicles?', I first consider what extracellular vesicles are. Extracellular vesicles are small membrane-bound structures released by cells, often carrying proteins, lipids, and nucleic acids, and they play roles in communication and material transfer. I recall that while this phenomenon is well-documented in eukaryotic cells, there is also evidence in prokaryotes like bacteria. I think about studies showing that both Gram-negative and Gram-positive bacteria release outer membrane vesicles or other types of vesicles, which are involved in processes like toxin delivery, communication, and stress response. I confirm this by recalling that research in microbiology has identified these vesicles as a common feature across many bacterial species. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Gram positive bacteria able to release extracellular vesicles?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Gram-positive bacteria can release extracellular vesicles, I first consider the biological context. Extracellular vesicles (EVs) are small membrane-bound structures released by cells, often involved in communication, nutrient acquisition, or pathogenicity. While EVs are well-documented in Gram-negative bacteria, where they are often called outer membrane vesicles (OMVs) due to their origin from the outer membrane, the situation with Gram-positive bacteria is different because they lack an outer membrane. Instead, they have a thick peptidoglycan cell wall. Recent research, however, has shown that Gram-positive bacteria can indeed release EVs, which are derived from their cytoplasmic membrane. Studies have identified EVs in species like Staphylococcus aureus and Bacillus subtilis, suggesting this is a conserved mechanism across bacterial types. Therefore, the answer should be affirmative based on current scientific understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the apilimod inhibitor effective against SARS-CoV-2?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the apilimod inhibitor is effective against SARS-CoV-2, I first consider the context of apilimod as a drug that inhibits the PIKfyve kinase, which is involved in cellular processes like endosomal trafficking. Research and studies, particularly those from 2020, have suggested that apilimod may have antiviral properties by disrupting the endosomal pathway that SARS-CoV-2 uses to enter cells. Some in vitro studies have shown promising results, indicating that apilimod can reduce viral replication in cell cultures. However, effectiveness in clinical settings or in vivo studies is less clear, as there is limited data on human trials or definitive evidence of its efficacy against SARS-CoV-2 in patients. Given the question's general phrasing, I lean towards a positive response based on preliminary research, but I acknowledge the uncertainty in real-world application. After weighing this, I will answer based on the available scientific evidence suggesting potential effectiveness.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Hunter's disease is associated with the X Chromosome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Hunter's disease, also known as Mucopolysaccharidosis Type II (MPS II), is a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. This enzyme deficiency leads to the accumulation of glycosaminoglycans in the body, causing various symptoms. The gene responsible for producing this enzyme, IDS, is located on the X chromosome. Since it is an X-linked recessive disorder, it primarily affects males, who have only one X chromosome, while females, with two X chromosomes, are typically carriers. Therefore, Hunter's disease is indeed associated with the X chromosome.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Toll-like receptors (TLRs) induced by microbes?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Toll-like receptors (TLRs) are induced by microbes, I need to consider the biological role of TLRs. TLRs are a type of pattern recognition receptor in the innate immune system, crucial for detecting pathogen-associated molecular patterns (PAMPs) from microbes such as bacteria, viruses, and fungi. The question seems to ask if microbes trigger the expression or activation of TLRs. Upon reflection, TLRs are generally constitutively expressed on immune cells like macrophages and dendritic cells, meaning they are already present and not necessarily 'induced' in terms of upregulated expression by microbes. However, their activation is indeed triggered by microbial components. The term 'induced' might imply an increase in expression, which can happen in some contexts due to inflammatory signals, but it's not the primary mechanism. I think the most accurate interpretation is that TLRs are not induced (as in newly expressed) by microbes but are activated by them. Therefore, the answer should be 'no' if 'induced' refers to expression rather than activation.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can Freund's complete adjuvant induce arthritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Freund's complete adjuvant (FCA) is a mixture often used in research to boost immune responses. It contains inactivated Mycobacterium tuberculosis, which can stimulate a strong inflammatory response. In animal models, particularly in rats and mice, FCA is commonly used to induce arthritis as part of experimental models like adjuvant-induced arthritis (AIA). This model mimics aspects of human rheumatoid arthritis. Therefore, FCA can indeed induce arthritis in certain contexts, specifically in laboratory settings for research purposes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can saponins be used as adjuvant?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether saponins can be used as adjuvants, I first need to understand the context. Saponins are naturally occurring compounds found in various plants, known for their soap-like foaming properties. In the context of immunology, adjuvants are substances that enhance the body's immune response to an antigen, often used in vaccines. Research indicates that saponins, particularly those derived from the Quillaja saponaria tree (like QS-21), have been widely studied and used as adjuvants due to their ability to stimulate both humoral and cellular immune responses. They can enhance antibody production and activate T-cell responses, making them effective in vaccine formulations. Clinical trials and approved vaccines, such as those for shingles and malaria, include saponin-based adjuvants, confirming their practical application. Therefore, saponins can indeed be used as adjuvants.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is phosphoenolpyruvate carboxykinase 1 (PCK1) the rate-limiting enzyme in gluconeogenesis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether phosphoenolpyruvate carboxykinase 1 (PCK1) is the rate-limiting enzyme in gluconeogenesis, I need to consider the biochemical pathway of gluconeogenesis and the role of PCK1 within it. Gluconeogenesis is the process of synthesizing glucose from non-carbohydrate precursors, primarily occurring in the liver and kidneys. PCK1 catalyzes the conversion of oxaloacetate to phosphoenolpyruvate (PEP), which is a critical and irreversible step in this pathway. Rate-limiting enzymes are typically those that control the flux through a metabolic pathway, often due to their regulation and the irreversibility of the reaction they catalyze. PCK1 is indeed a key regulatory point in gluconeogenesis, as its activity is modulated by hormonal signals such as glucagon and insulin, and it commits the pathway towards glucose production. While other enzymes, like fructose-1,6-bisphosphatase, also play significant roles and are sometimes considered rate-limiting, PCK1 is frequently highlighted in literature as a primary control point due to its position in the pathway and regulatory mechanisms. Therefore, it is reasonable to conclude that PCK1 is a rate-limiting enzyme in gluconeogenesis.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is histone variant H3.3K27M associated with gliomas?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether histone variant H3.3K27M is associated with gliomas, I am considering the scientific context. H3.3K27M is a specific mutation in the histone H3.3 protein, where lysine at position 27 is replaced by methionine. Research indicates that this mutation is frequently found in pediatric high-grade gliomas, particularly diffuse intrinsic pontine gliomas (DIPG) and other midline gliomas. It is known to disrupt normal histone methylation patterns, leading to altered gene expression that contributes to tumorigenesis. Therefore, there is a clear association between H3.3K27M and gliomas, especially in specific subtypes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do honey contain diastases/amylases?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether honey contains diastases/amylases, I first need to clarify that diastase is a general term for enzymes that break down starch into simpler sugars, and amylase is a specific type of diastase enzyme. Honey is a natural product produced by bees from nectar, and during this process, bees add enzymes to the nectar. One of these enzymes is indeed amylase, which helps in converting the complex sugars in nectar into simpler sugars like glucose and fructose. Scientific literature and studies on honey composition confirm that honey contains small amounts of enzymes, including amylase (often referred to as diastase in older texts). The presence of diastase in honey is even used as an indicator of its freshness and quality in some standards, as the enzyme activity can decrease over time or with heat treatment. Therefore, honey does contain diastases/amylases, though the levels can vary based on factors like floral source, processing, and storage conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is HbA1c an ideal biomarker of well-controlled diabetes?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether HbA1c is an ideal biomarker for well-controlled diabetes, I first consider what HbA1c represents. HbA1c, or glycated hemoglobin, measures the average blood glucose levels over the past 2-3 months by reflecting the percentage of hemoglobin that is bound to glucose. It is widely used in clinical practice to assess long-term glycemic control in diabetes management. An ideal biomarker should be accurate, reliable, and reflective of the condition's status. HbA1c meets many of these criteria as it correlates well with average blood glucose levels and is predictive of diabetes-related complications. However, it has limitations: it may not reflect short-term glucose fluctuations, can be affected by conditions like anemia or hemoglobinopathies, and may not be equally accurate across all populations due to genetic or environmental factors. Despite these limitations, it remains the gold standard for monitoring diabetes control in most cases. Given its widespread acceptance and utility, I believe it can be considered an ideal biomarker, though not perfect.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is erabutoxin b usually found in plants?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether erabutoxin b is usually found in plants, I first need to identify what erabutoxin b is. Erabutoxin b is a neurotoxic protein derived from the venom of the sea snake Laticauda semifasciata, commonly known as the erabu sea krait. It belongs to the family of three-finger toxins, which are typically found in snake venoms and are not associated with plant sources. Plants generally produce different types of toxins, such as alkaloids or glycosides, for defense mechanisms, but not protein-based neurotoxins like erabutoxin b. There is no scientific evidence or documentation suggesting that erabutoxin b or similar toxins are produced by or found in plants. Therefore, it is not usually found in plants.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is autism thought to be related to the  Arginine Vasopressin Peptide (AVP)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether autism is thought to be related to Arginine Vasopressin Peptide (AVP), I first consider the role of AVP, which is a hormone involved in social behavior, stress response, and bonding, primarily through its action in the brain. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Research in neuroscience has explored various biological factors, including neuropeptides like AVP, due to their influence on social behaviors. Studies have suggested that AVP and its receptors might play a role in social deficits observed in autism. For instance, animal models and some human studies have indicated differences in AVP levels or receptor expression in individuals with autism. Additionally, AVP is closely related to oxytocin, another peptide heavily studied in autism for its role in social bonding. While the evidence is not conclusive, there is a growing body of research linking AVP to autism, particularly in the context of social behavior regulation. Therefore, it is reasonable to conclude that autism is thought to be related to AVP in scientific discussions and research.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Ixodes a species of tick?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Ixodes is a species of tick, I first need to clarify the taxonomic classification. Ixodes is actually a genus of ticks, not a specific species. It belongs to the family Ixodidae, which includes hard ticks. Within the genus Ixodes, there are many species, such as Ixodes scapularis (the deer tick) and Ixodes ricinus (the castor bean tick), which are known vectors for diseases like Lyme disease. Since the question asks if Ixodes is a species, and it is a genus, the accurate answer should reflect this distinction. Therefore, the answer should be 'no', as Ixodes is not a species but a genus of ticks.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are mucins glycosylated proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are mucins glycosylated proteins?', I first need to recall the definition of mucins. Mucins are a family of high molecular weight proteins produced by epithelial tissues, and they are known for their role in forming mucus, which provides lubrication and protection. A key characteristic of mucins is that they are heavily glycosylated, meaning they have a large number of carbohydrate (sugar) molecules attached to their protein backbone. This glycosylation is essential for their function, as it contributes to their gel-like properties. Therefore, based on this understanding, mucins are indeed glycosylated proteins.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are mucin overexpression associated with disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether mucin overexpression is associated with disease, I first consider the role of mucins. Mucins are a family of high molecular weight, heavily glycosylated proteins produced by epithelial tissues. They play a critical role in forming protective barriers on mucosal surfaces and are involved in cell signaling. Overexpression of mucins, particularly certain types like MUC1, MUC2, or MUC5AC, has been documented in various pathological conditions. For instance, in cancer, mucin overexpression is often linked to tumor progression, metastasis, and poor prognosis in diseases such as breast, pancreatic, and colorectal cancers. Additionally, in respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), mucin overproduction contributes to airway obstruction and inflammation. In gastrointestinal disorders, altered mucin expression is associated with inflammatory bowel disease and infections. Based on this analysis, there is substantial evidence in medical literature that mucin overexpression is indeed associated with various diseases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are interferons defensive proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Interferons are a group of signaling proteins produced and released by host cells in response to the presence of pathogens such as viruses, bacteria, parasites, or tumor cells. They play a crucial role in the immune system by interfering with viral replication and activating immune cells. Therefore, they can be classified as defensive proteins because their primary function is to protect the body from infections and diseases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether YKL-40 is used as a biomarker for Alzheimer's disease, I first consider the context of biomarkers in medical diagnostics. Biomarkers are measurable indicators used to examine normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. In the case of Alzheimer's disease, biomarkers are often used to detect the presence of the disease, monitor its progression, or predict its onset. YKL-40, also known as chitinase-3-like protein 1, is a glycoprotein associated with inflammation and tissue remodeling. Research suggests that YKL-40 levels are elevated in the cerebrospinal fluid and blood of patients with Alzheimer's disease, potentially reflecting neuroinflammation, which is a hallmark of the condition. Several studies have explored its role as a potential biomarker, indicating that it might be used to differentiate Alzheimer's disease from other neurodegenerative disorders or to track disease severity. However, while promising, YKL-40 is not yet a standard or widely accepted clinical biomarker for Alzheimer's disease, as more validation and standardization are needed. It is often studied in research settings rather than routine clinical practice. Given the question's phrasing, which implies current usage, and considering the evidence of its investigation in Alzheimer's research, I lean towards a positive response but acknowledge the lack of definitive clinical adoption. After weighing this, I conclude that YKL-40 is indeed discussed and used in research contexts as a potential biomarker for Alzheimer's disease, even if not universally in clinical settings.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is G3BP1 found in stress granules?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether G3BP1 is found in stress granules, I first consider the biological context. Stress granules are cytoplasmic aggregates of RNA and proteins that form in response to cellular stress, such as heat shock or oxidative stress, and are involved in regulating mRNA translation. G3BP1, or Ras GTPase-activating protein-binding protein 1, is a known RNA-binding protein. I recall that G3BP1 is often cited as a core component of stress granules and plays a critical role in their assembly. Research indicates that G3BP1 interacts with other stress granule components and is essential for their formation under stress conditions. Therefore, it is reasonable to conclude that G3BP1 is indeed found in stress granules.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has FTY720  been considered for the treatment of stroke?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether FTY720 has been considered for the treatment of stroke, I first need to recall that FTY720, also known as fingolimod, is a sphingosine-1-phosphate receptor modulator primarily used for treating multiple sclerosis. Its mechanism involves immunomodulation and potential neuroprotective effects, which could theoretically be relevant to stroke, a condition involving brain ischemia or hemorrhage leading to cell death. Stroke treatment often focuses on neuroprotection and reducing inflammation, areas where FTY720 might have a role. I am considering if there is any research or clinical discussion around FTY720 for stroke. Upon reflection, I recall that there have been preclinical studies in animal models suggesting that FTY720 may reduce ischemic brain injury by decreasing inflammation and promoting recovery. Additionally, there might be some early-phase clinical studies or reviews discussing its potential. Given this, it seems that FTY720 has indeed been considered for stroke treatment in research contexts, even if it is not yet a standard clinical therapy. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is FTY720 FDA approved?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether FTY720 is FDA approved, I first need to clarify that FTY720 is also known as fingolimod, a medication used to treat multiple sclerosis. I recall that fingolimod, under the brand name Gilenya, was approved by the FDA in 2010 as the first oral treatment for relapsing forms of multiple sclerosis. To confirm, I consider that this approval is well-documented in medical and pharmaceutical resources. There are no recent controversies or withdrawals of this approval that I am aware of. Therefore, based on this analysis, FTY720 (fingolimod) is indeed FDA approved.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does the royal jelly contain proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Royal jelly is a secretion produced by honeybees to nourish larvae and the queen bee. It is known to be rich in nutrients, including proteins, vitamins, and minerals. Scientific studies and nutritional analyses confirm that royal jelly contains a significant amount of proteins, primarily in the form of major royal jelly proteins (MRJPs), which play a crucial role in its biological functions. Therefore, the answer to the question is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are the major royal jelly proteins similar to the yellow proteins?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the major royal jelly proteins are similar to the yellow proteins, I first consider the context of both protein groups. Major royal jelly proteins (MRJPs) are a family of proteins found in royal jelly, a secretion produced by honeybees, and they play a crucial role in the development of queen bees. Yellow proteins, on the other hand, are a family of proteins also found in insects, including honeybees, and are often associated with pigmentation and other physiological functions. Research indicates that MRJPs and yellow proteins share a common evolutionary origin and belong to the same protein superfamily, often referred to as the Yellow/MRJP family. They exhibit structural and sequence similarities, suggesting a functional or evolutionary relationship. Therefore, based on this analysis, I conclude that they are similar.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the Apis mellifera genome available?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the Apis mellifera genome is available, I am considering the context of genomic research. Apis mellifera, commonly known as the Western honey bee, is a well-studied species due to its ecological and agricultural importance. I recall that its genome was sequenced and published in the early 2000s, specifically in 2006, by the Honey Bee Genome Sequencing Consortium. This information is publicly accessible through databases like NCBI and Ensembl. Therefore, the genome is indeed available for research and study.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has the olive tree pollen proteome been studied?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the olive tree pollen proteome has been studied, I first consider the context of proteome studies, which involve the comprehensive analysis of proteins in a specific biological sample. Olive tree pollen is a common allergen, particularly in Mediterranean regions, so it is likely that researchers have investigated its protein composition to understand allergenic components. I recall that studies on pollen proteomes, especially for allergenic plants like olive trees, have been conducted using techniques like mass spectrometry. There are specific allergens identified in olive pollen, such as Ole e 1, which suggests that proteomic analysis has been performed. While I am not citing a specific paper, the prevalence of olive pollen allergies and the advancement of proteomic technologies make it highly probable that such studies exist. Therefore, I conclude that the olive tree pollen proteome has been studied.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is hemoglobin antimicrobial?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether hemoglobin is antimicrobial, I first need to consider the primary function of hemoglobin, which is to transport oxygen in the blood of vertebrates. It binds oxygen in the lungs and releases it to tissues. However, I should also explore if it has any secondary roles, such as antimicrobial properties. Upon reflection, I recall that certain derivatives of hemoglobin, like heme, can generate reactive oxygen species that might have antimicrobial effects under specific conditions. Additionally, there are studies suggesting that hemoglobin-derived peptides may exhibit antimicrobial activity by disrupting bacterial membranes. However, hemoglobin itself, in its native form, is not primarily recognized as an antimicrobial agent; its main role remains oxygen transport. To confirm, I consider if there are contexts, such as in certain organisms or under specific physiological conditions, where hemoglobin directly acts against microbes. While there is evidence of indirect antimicrobial contributions through its breakdown products or in combination with other immune factors, hemoglobin alone is not classified as an antimicrobial substance in the same way as dedicated antimicrobial peptides or proteins like defensins. Therefore, based on this analysis, I conclude that hemoglobin is not inherently antimicrobial.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are there antimicrobial proteins in royal jelly?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Royal jelly is a secretion produced by honeybees to nourish larvae and the queen bee. It is known to have various bioactive components, including proteins. Research indicates that royal jelly contains antimicrobial proteins such as royalisin and jelleines, which have been shown to exhibit antibacterial properties against a range of pathogens. Studies have identified these proteins as part of royal jelly's defense mechanism, contributing to its antimicrobial activity. Therefore, the presence of antimicrobial proteins in royal jelly is supported by scientific evidence.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does Amblyopia affect the eye?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Amblyopia, commonly known as lazy eye, is a vision development disorder where an eye fails to achieve normal visual acuity, even with prescription lenses. It typically affects one eye and can result from various causes such as strabismus (misaligned eyes), significant differences in refractive errors between the eyes, or visual deprivation (e.g., cataracts). Since Amblyopia directly impacts the functioning of the eye by reducing its ability to see clearly, it does affect the eye.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is atenolol metabolized by CYP2D6?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether atenolol is metabolized by CYP2D6, I need to consider the pharmacological properties of atenolol, a beta-blocker used primarily for hypertension and angina. CYP2D6 is a cytochrome P450 enzyme involved in the metabolism of many drugs. Atenolol is known for being primarily excreted unchanged in the urine, with minimal hepatic metabolism compared to other beta-blockers like metoprolol, which is extensively metabolized by CYP2D6. Research and clinical pharmacology resources indicate that atenolol does not significantly rely on CYP2D6 for its metabolism. Therefore, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is cadherin a plasma membrane marker?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether cadherin is a plasma membrane marker, I need to consider its biological role. Cadherins are a family of transmembrane proteins that mediate cell-cell adhesion, primarily through calcium-dependent interactions. They are integral components of the plasma membrane, specifically located at adherens junctions. A plasma membrane marker is typically a molecule used to identify or label the plasma membrane in experimental settings, often due to its specific localization. While cadherins are indeed located on the plasma membrane, they are not commonly used as general markers for the plasma membrane in research, as other proteins or lipids (like Na+/K+ ATPase or certain fluorescent dyes) are more frequently utilized for this purpose. However, in specific contexts, especially in studies of cell adhesion or epithelial tissues, cadherins like E-cadherin are used to indicate plasma membrane localization at cell junctions. Given this, while cadherin is associated with the plasma membrane, it is not a universal marker for it in the way other molecules are. Therefore, the answer should lean towards 'no' in a general sense, unless the context specifies otherwise.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there an upper limit on the functional fraction of the human genome?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To address the question of whether there is an upper limit on the functional fraction of the human genome, I first consider the definition of 'functional fraction.' This refers to the portion of the genome that has a biological role, such as coding for proteins, regulating gene expression, or other non-coding functions. Current research suggests that while only about 1-2% of the human genome codes for proteins, a much larger portion—potentially up to 80-90%—may have some functional role, as indicated by projects like ENCODE. However, there is debate over what constitutes 'function,' with some arguing that much of this activity might be biochemical noise without evolutionary significance. Theoretically, there could be an upper limit due to constraints like energy costs of maintaining functional elements, evolutionary pressures, or the need for non-functional regions as buffers for mutations. Yet, science has not definitively established a fixed upper limit, as our understanding of genomic function is still evolving. Given the question's phrasing, which implies a yes or no answer, and considering that there are likely practical or theoretical constraints even if not precisely defined, I lean toward 'yes,' there is an upper limit, even if it is not yet quantifiable.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are synonymous sites in primates and rodents functionally constrained?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether synonymous sites in primates and rodents are functionally constrained, I first consider the biological context. Synonymous sites are positions in the DNA sequence where a nucleotide change does not alter the amino acid sequence of the protein due to the redundancy of the genetic code. Historically, these sites were thought to be neutral, evolving without selective pressure. However, recent research suggests that synonymous sites can be under functional constraint due to factors like codon usage bias, mRNA stability, and splicing regulation. In primates and rodents, which are both mammals but differ in evolutionary divergence and life history traits, studies have shown evidence of purifying selection at synonymous sites, indicating some level of constraint. For instance, codon bias and the need for translational efficiency or accuracy can impose selection pressures. While the degree of constraint may vary between the two groups, the general consensus in evolutionary biology is that synonymous sites are not entirely neutral in either primates or rodents. Therefore, I conclude that synonymous sites in these organisms are functionally constrained to some extent.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does IL18 signaling have a role in thymus?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether IL18 signaling has a role in the thymus, I first consider the biological context. IL18 (Interleukin-18) is a pro-inflammatory cytokine involved in immune responses, primarily associated with the activation of T cells and natural killer (NK) cells. The thymus is a primary lymphoid organ responsible for T cell development and maturation. Given that IL18 influences T cell activity and is linked to immune regulation, it is plausible that IL18 signaling could play a role in thymic functions, such as T cell differentiation or selection. Research suggests that IL18 is expressed in the thymus and may contribute to thymocyte development or immune tolerance mechanisms. However, its exact role might not be as central as other cytokines like IL7. After analyzing this, I conclude that IL18 signaling does have a role in the thymus, even if it might be context-specific or less prominent compared to other signaling pathways.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is metoprolol metabolized by CYP2D6?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether metoprolol is metabolized by CYP2D6, I need to consider the pharmacological properties of metoprolol, a beta-blocker used primarily for hypertension and heart conditions. CYP2D6 is a cytochrome P450 enzyme involved in the metabolism of many drugs. I recall that metoprolol is indeed metabolized in the liver, and CYP2D6 plays a significant role in its metabolism. Genetic polymorphisms in CYP2D6 can affect the metabolism of metoprolol, leading to variations in drug efficacy and side effects among individuals (e.g., poor metabolizers vs. extensive metabolizers). Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the glucocorticoid receptor a transcription factor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the glucocorticoid receptor is a transcription factor, I need to consider its biological role. The glucocorticoid receptor (GR) is a type of nuclear receptor that binds to glucocorticoid hormones. Upon binding, it translocates to the nucleus and interacts with specific DNA sequences, known as glucocorticoid response elements, to regulate gene expression. Transcription factors are proteins that bind to DNA and influence the transcription of genetic information from DNA to mRNA. Since the glucocorticoid receptor directly binds to DNA and modulates gene expression, it fits the definition of a transcription factor. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has dupilumab been FDA approved for atopic dermatitis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether dupilumab has been FDA approved for atopic dermatitis, I first consider the context of dupilumab as a medication. Dupilumab is a monoclonal antibody used to treat certain inflammatory conditions. I recall that it is commonly associated with the treatment of atopic dermatitis, also known as eczema, particularly in moderate to severe cases. My understanding is that dupilumab was indeed approved by the FDA for this indication. I believe the approval came in 2017 for adults, and later extended to adolescents and children. To confirm, I think about the brand name Dupixent, which is marketed for atopic dermatitis among other conditions like asthma and chronic rhinosinusitis with nasal polyposis. Since the question is a straightforward factual query and my recollection aligns with this, I conclude that the answer should be affirmative. However, if I had any doubt, I would consider the need to verify with an official source like the FDA website, but based on my knowledge, I am confident in this response.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Has the companion diagnostic HercepTest received FDA approval?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the companion diagnostic HercepTest has received FDA approval, I first consider the purpose and history of HercepTest. HercepTest is a diagnostic test used to determine HER2 protein overexpression in breast cancer patients, often guiding treatment decisions with drugs like Herceptin (trastuzumab). I recall that HercepTest was developed by Dako and has been in use for many years. I believe it was one of the early companion diagnostics to be approved by the FDA, specifically around the late 1990s or early 2000s, coinciding with the approval of Herceptin. To confirm, I think about the regulatory pathway for companion diagnostics, which typically requires FDA approval to ensure accuracy and reliability in identifying eligible patients for specific therapies. Given that HercepTest is widely used and referenced in clinical guidelines, it is highly likely that it has received FDA approval. I can conclude that the answer should be affirmative based on this analysis.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is FKBP52 encoding a chaperone ?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether FKBP52 encodes a chaperone, I first need to understand what FKBP52 is. FKBP52, also known as FK506-binding protein 52, is a protein that belongs to the immunophilin family. It is known to interact with steroid hormone receptors and assist in their proper folding and function, which is a characteristic role of a chaperone protein. Chaperones help in protein folding and prevent misfolding, often under stress conditions. Given that FKBP52 plays a role in stabilizing and modulating the activity of other proteins, it can be classified as a chaperone. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is colistin an antibiotic?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Colistin is a polymyxin antibiotic used to treat certain bacterial infections, particularly those caused by Gram-negative bacteria. It is often considered a last-resort treatment due to its potential toxicity. Based on this, it is indeed classified as an antibiotic.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Keutel syndrome a common genetic disorder?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Keutel syndrome is a common genetic disorder, I first need to consider the prevalence of the condition. Keutel syndrome is a rare autosomal recessive disorder characterized by abnormal cartilage calcification, hearing loss, and other features. It is caused by mutations in the MGP gene. Based on available medical literature and databases, Keutel syndrome is extremely rare, with only a small number of cases reported worldwide. Therefore, it cannot be considered a common genetic disorder.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Daprodustat effective for anemia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Daprodustat is effective for anemia, I first consider that Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia, particularly in patients with chronic kidney disease. Clinical trials and studies, such as those published in medical journals, have shown that Daprodustat can effectively increase hemoglobin levels in patients with anemia associated with chronic kidney disease. It works by stimulating erythropoiesis, similar to the body's natural response to low oxygen levels. While effectiveness may vary based on individual patient conditions and specific types of anemia, the general evidence supports its efficacy in the context of chronic kidney disease-related anemia. Therefore, based on this analysis, I conclude that Daprodustat is effective for anemia in relevant cases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an association between pyostomatitis vegetans and Crohn's disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about an association between pyostomatitis vegetans and Crohn's disease, I first consider the nature of both conditions. Pyostomatitis vegetans is a rare inflammatory condition characterized by pustules and vegetating plaques in the oral mucosa. Crohn's disease is a type of inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract. I recall that pyostomatitis vegetans is often linked with underlying gastrointestinal disorders, particularly IBD. Research and clinical studies suggest that pyostomatitis vegetans is strongly associated with Crohn's disease and ulcerative colitis, often considered a cutaneous manifestation of these conditions. Given this connection, it appears there is indeed an association between pyostomatitis vegetans and Crohn's disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Sotrovimab effective for COVID-19?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Sotrovimab is effective for COVID-19, I need to consider the available information up to my knowledge cutoff in October 2023. Sotrovimab is a monoclonal antibody treatment developed for COVID-19. Clinical trials and real-world data have shown that it can reduce the risk of hospitalization or death in high-risk patients with mild to moderate COVID-19, particularly when administered early. It was granted emergency use authorization by the FDA and other health authorities for this purpose. However, its effectiveness can vary depending on the circulating variants of the virus, as some variants may be less susceptible to this treatment. Given the general evidence of its efficacy in appropriate contexts, I will answer affirmatively, acknowledging that effectiveness is context-dependent.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Ozanimod effective for Ulcerative Colitis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Ozanimod is effective for Ulcerative Colitis, I first consider the context of the question. Ozanimod is a medication known as a sphingosine 1-phosphate receptor modulator, primarily used in the treatment of multiple sclerosis. However, it has also been studied for inflammatory bowel diseases, including Ulcerative Colitis. Clinical trials, such as the TOUCHSTONE study, have shown that Ozanimod can induce and maintain remission in patients with moderate to severe Ulcerative Colitis. The drug was approved by the FDA in 2021 for this indication under the brand name Zeposia. Based on this information, it appears that Ozanimod is indeed effective for Ulcerative Colitis in certain patient populations, as supported by clinical evidence and regulatory approval.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Cabotegravir effective for HIV prevention?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Cabotegravir is effective for HIV prevention, I first consider the context of the drug. Cabotegravir is an antiretroviral medication, and recent studies and clinical trials, such as those reported by the NIH and WHO, have shown that it is highly effective as a pre-exposure prophylaxis (PrEP) for preventing HIV infection. It is administered as a long-acting injectable, which offers an alternative to daily oral PrEP. The HPTN 083 and HPTN 084 trials demonstrated that Cabotegravir significantly reduces the risk of HIV acquisition compared to standard oral PrEP in high-risk populations. Based on this evidence, I conclude that it is effective for HIV prevention.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is sacituzumab govitecan effective for breast cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether sacituzumab govitecan is effective for breast cancer, I first consider the context of the drug. Sacituzumab govitecan is an antibody-drug conjugate specifically approved for the treatment of metastatic triple-negative breast cancer (TNBC) in patients who have received prior therapies. Clinical trials, such as the ASCENT trial, have demonstrated its efficacy in improving progression-free survival and overall survival in this specific subgroup compared to standard chemotherapy. However, its effectiveness is not universal across all types of breast cancer, as it is primarily indicated for TNBC and not necessarily for other subtypes like HER2-positive or hormone receptor-positive breast cancers unless specified in ongoing research or off-label use. Given the question's general phrasing, 'breast cancer,' without specifying a subtype, I must weigh whether to answer based on its proven efficacy in TNBC or consider the broader context. Since the drug has shown significant effectiveness in a specific, challenging type of breast cancer, and it is FDA-approved for that indication, I lean towards a positive response. However, I acknowledge the limitation in scope. Ultimately, based on available evidence and the general intent of the question, I conclude that it is effective for breast cancer, specifically in the context of TNBC.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is rilonacept effective for pericarditis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether rilonacept is effective for pericarditis, I first consider the nature of pericarditis, which is inflammation of the pericardium, often caused by viral infections, autoimmune conditions, or other triggers. Treatment typically involves anti-inflammatory drugs like NSAIDs, colchicine, or corticosteroids. Rilonacept is a medication that inhibits interleukin-1 (IL-1), a cytokine involved in inflammatory responses. It is primarily approved for conditions like cryopyrin-associated periodic syndromes (CAPS). Recent studies and clinical trials, such as the RHAPSODY trial, have shown that rilonacept can be effective in treating recurrent pericarditis by reducing inflammation and preventing recurrences in patients who are refractory to standard treatments. Based on this evidence, it appears that rilonacept is effective for pericarditis, particularly in specific cases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Sotatercept effective for Pulmonary Arterial Hypertension?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Sotatercept is effective for Pulmonary Arterial Hypertension (PAH), I first consider the context of the question. Sotatercept is a novel therapeutic agent that has been investigated for its potential in treating PAH, a condition characterized by high blood pressure in the arteries of the lungs. Recent clinical trials, such as the STELLAR trial, have shown promising results, indicating that Sotatercept can improve exercise capacity and reduce pulmonary vascular resistance in patients with PAH. The drug works by targeting the activin signaling pathway, which is implicated in the disease's pathology. Based on the available data and trial outcomes reported in medical literature up to my knowledge cutoff, it appears to be effective in improving key clinical endpoints for PAH patients. Therefore, my answer will reflect this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Belimumab used for lupus nephritis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Belimumab is used for lupus nephritis, I first consider that Belimumab is a monoclonal antibody that inhibits B-cell activating factor (BAFF), used primarily in the treatment of systemic lupus erythematosus (SLE). Lupus nephritis is a common and serious complication of SLE, involving kidney inflammation. I recall that Belimumab has been studied and approved for use in lupus nephritis in addition to standard therapy, based on clinical trials showing efficacy in reducing disease activity and proteinuria in patients with active lupus nephritis. Therefore, it is reasonable to conclude that Belimumab is indeed used for lupus nephritis.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there an association between Guillain–Barré syndrome and covid vaccine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about an association between Guillain-Barré syndrome (GBS) and the COVID-19 vaccine, I first considered the nature of GBS, which is a rare neurological disorder where the body's immune system attacks the peripheral nerves. I then reviewed available information and studies up to my knowledge cutoff in October 2023. Some studies and reports, including data from the CDC and FDA, have noted a small number of GBS cases following certain COVID-19 vaccinations, particularly with viral vector vaccines like Johnson & Johnson's Janssen vaccine. The incidence appears to be slightly higher than the background rate in the general population, suggesting a potential link, though causality is not definitively established. However, the risk remains extremely low, and the benefits of vaccination in preventing severe COVID-19 outcomes generally outweigh this risk. Given that there is evidence of a possible association, even if rare, I will answer affirmatively.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do mutations in KCNT2 only cause phenotypes with epilepsy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether mutations in KCNT2 only cause phenotypes with epilepsy, I need to consider the role of the KCNT2 gene. KCNT2 encodes a potassium channel subunit involved in regulating neuronal excitability. Mutations in this gene have been associated with neurological disorders, particularly epilepsy, due to their impact on channel function leading to abnormal neuronal firing. However, I should check if there are reports of KCNT2 mutations causing other phenotypes without epilepsy. Upon reflection, while epilepsy is a prominent feature in many cases, there are instances where mutations in related potassium channel genes lead to developmental delays or other neurological symptoms without seizures. Specifically for KCNT2, the literature suggests a strong link to epilepsy, but I recall some studies mentioning phenotypes like intellectual disability or movement disorders that may not always be accompanied by seizures. Therefore, it seems that mutations in KCNT2 do not exclusively cause phenotypes with epilepsy, as other neurological manifestations can occur independently or alongside epilepsy.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do only changes in coding regions of MEF2C cause developmental disorders?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Do only changes in coding regions of MEF2C cause developmental disorders?', I need to consider the role of the MEF2C gene in development and the impact of genetic changes. MEF2C is a transcription factor critical for brain development, and mutations in this gene are associated with developmental disorders such as intellectual disability and epilepsy. Coding regions of a gene are the parts that are transcribed into mRNA and translated into proteins, so changes in these regions can directly affect the protein's function. However, non-coding regions, such as promoters or intronic regulatory elements, can also influence gene expression and lead to disorders. Research indicates that while coding mutations in MEF2C are a primary cause of MEF2C haploinsufficiency syndrome, deletions or disruptions in regulatory regions upstream or downstream of the gene can also result in similar developmental phenotypes by affecting MEF2C expression. Therefore, it is not only changes in the coding regions that cause developmental disorders; changes in non-coding regions can also contribute.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Algenpantucel-L effective for pancreatic cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Algenpantucel-L is effective for pancreatic cancer, I first considered the context of the question, which likely seeks information on the therapeutic efficacy of this drug based on clinical evidence. Algenpantucel-L is an investigational immunotherapy designed to stimulate an immune response against pancreatic cancer cells. I recall that it has been studied in clinical trials, particularly for resected pancreatic cancer as an adjuvant therapy. However, based on available data up to my knowledge cutoff, Phase III trials, such as the IMPRESS trial, did not demonstrate a statistically significant improvement in overall survival compared to standard care. There might be ongoing research or subgroup analyses suggesting potential benefits in specific patient populations, but the general consensus appears to be that it has not met primary endpoints for broad efficacy. Given this, I lean towards a 'no' in terms of proven effectiveness as a standard treatment at this time. I must note that new studies or approvals post my cutoff could alter this conclusion, but I must adhere to the binary 'yes' or 'no' format requested. Therefore, based on the most widely reported trial outcomes, my answer will reflect the lack of definitive efficacy.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is tivantinib effective for MET-high hepatocellular carcinoma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether tivantinib is effective for MET-high hepatocellular carcinoma (HCC), I first consider the context of tivantinib as a drug. Tivantinib is a small molecule inhibitor initially developed as a selective MET inhibitor, targeting the MET receptor tyrosine kinase, which is often overexpressed in certain cancers, including HCC. MET-high HCC refers to tumors with high expression of the MET protein, which is associated with poor prognosis and aggressive disease. Clinical trials, particularly phase II and III studies, have investigated tivantinib in this context. A phase II trial showed promising results, with improved progression-free survival and overall survival in MET-high HCC patients treated with tivantinib compared to placebo. However, subsequent phase III trials, such as the METIV-HCC trial, failed to confirm these benefits, showing no significant improvement in overall survival. The discrepancy may be due to differences in patient selection, study design, or the drug's mechanism, as later research suggested tivantinib may not be a pure MET inhibitor and could have off-target effects, including cytotoxicity via microtubule inhibition. Given the lack of consistent evidence from large, confirmatory trials demonstrating efficacy in MET-high HCC, the current consensus leans against its effectiveness for this specific indication. Therefore, my answer is based on the most recent and comprehensive clinical data.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Isradipine slow progression of Early Parkinson Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Isradipine can slow the progression of Early Parkinson Disease, I first consider the context of the question. Isradipine is a calcium channel blocker primarily used to treat high blood pressure. Recent research has explored its potential neuroprotective effects in Parkinson’s Disease due to its ability to block L-type calcium channels, which may reduce neuronal stress in the substantia nigra, a region affected in Parkinson’s. I recall that a significant clinical trial, the STEADY-PD III trial, investigated this specific question. The trial results, published around 2019-2020, showed that Isradipine did not significantly slow the progression of early Parkinson’s Disease compared to placebo, as measured by clinical outcomes like the Unified Parkinson’s Disease Rating Scale (UPDRS). While preclinical studies in animal models suggested a protective effect, the translation to human patients did not hold up in this large, randomized, double-blind study. Therefore, based on the available evidence, the answer should be 'no', as the clinical data does not support Isradipine’s efficacy in slowing disease progression in early Parkinson’s.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is nerinetide effective for ischaemic stroke?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether nerinetide is effective for ischaemic stroke, I first consider the context of the question. Nerinetide is a drug that has been investigated for its potential neuroprotective effects in acute ischaemic stroke. I recall that clinical trials, such as the ESCAPE-NA1 trial, have evaluated its efficacy. The results of this trial, published in recent years, showed that nerinetide did not significantly improve outcomes in the overall population of patients with ischaemic stroke undergoing endovascular thrombectomy. However, there was a subgroup of patients who did not receive alteplase (a thrombolytic agent) where nerinetide showed a potential benefit in reducing infarct volume and improving functional outcomes. Despite this, the overall evidence does not support its broad effectiveness for ischaemic stroke, as the primary endpoint in major trials was not met. Regulatory bodies have not widely approved it for this indication based on current data. Therefore, while there may be specific contexts or subgroups where it shows promise, the general answer based on available evidence leans toward it not being broadly effective for ischaemic stroke at this time.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should perampanel be used for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether perampanel should be used for amyotrophic lateral sclerosis (ALS), I first considered the nature of perampanel and ALS. Perampanel is an antiepileptic drug, primarily used to treat epilepsy by acting as a non-competitive AMPA receptor antagonist. ALS, on the other hand, is a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and atrophy. There is ongoing research into glutamate excitotoxicity as a potential mechanism in ALS, and since perampanel targets AMPA receptors involved in glutamate signaling, there might be a theoretical basis for its use. However, I analyzed whether there is clinical evidence or guideline support for its use in ALS. Currently, perampanel is not an approved or recommended treatment for ALS. Standard treatments for ALS include drugs like riluzole and edaravone, which have demonstrated efficacy in slowing disease progression. While some studies or trials may explore perampanel's potential in ALS due to its mechanism of action, there is no conclusive evidence or widespread clinical consensus supporting its use for this condition at this time. Therefore, based on the lack of established evidence and approval, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are variants in FHF2 (also known as FGF13) associated with encephalopathy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether variants in FHF2 (also known as FGF13) are associated with encephalopathy, I first need to consider the role of FGF13. FGF13, or Fibroblast Growth Factor 13, is a member of the fibroblast growth factor family and is known to be involved in neuronal development and function, particularly in regulating voltage-gated sodium channels in neurons. Encephalopathy refers to a broad category of brain dysfunction, often linked to genetic mutations, infections, or metabolic issues. I recall that mutations in genes related to neuronal excitability and sodium channel function, such as SCN1A, are well-documented causes of encephalopathy, particularly in conditions like Dravet syndrome. Given FGF13's role in modulating sodium channels, it is plausible that variants in this gene could disrupt neuronal excitability and lead to encephalopathy. Upon further reflection, I remember that there have been studies and case reports linking FGF13 mutations to developmental and epileptic encephalopathies, especially in the context of X-linked inheritance, as FGF13 is located on the X chromosome. Therefore, I conclude that there is an association between variants in FGF13 and encephalopathy.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Adamts18 deficiency associated with cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Adamts18 deficiency is associated with cancer, I first consider the role of Adamts18, which is a member of the ADAMTS family of metalloproteinases involved in extracellular matrix remodeling and tissue development. Research suggests that Adamts18 plays a role in tumor suppression, as studies have shown that its deficiency or downregulation may contribute to tumor progression in certain cancers, such as lung cancer or colorectal cancer, due to impaired matrix regulation and increased angiogenesis. There is evidence from scientific literature indicating that mutations or reduced expression of Adamts18 are linked to cancer development in preclinical models. However, the association may not be universal across all cancer types, and more clinical data might be needed to confirm a direct causal relationship in humans. Based on the available information, it appears there is an association in specific contexts, so I lean towards 'yes', but I must ensure the answer reflects the current understanding. After analyzing, I conclude that there is indeed an association supported by research.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Erythropoietin effective for neuroprotection of Preterm Infants.",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Erythropoietin (EPO) is effective for neuroprotection in preterm infants, I first consider the context of preterm infants, who are at high risk for neurological impairments due to brain immaturity and potential injuries like intraventricular hemorrhage or hypoxia-ischemia. Erythropoietin, a hormone primarily known for stimulating red blood cell production, has been studied for its neuroprotective properties due to its anti-inflammatory, anti-apoptotic, and neurotrophic effects in preclinical models. Clinical studies and meta-analyses, such as those published in recent pediatric and neonatology journals, have shown mixed results. Some randomized controlled trials suggest that EPO may reduce the risk of neurodevelopmental impairment in preterm infants, particularly when administered early. However, other studies indicate no significant long-term benefit or raise concerns about potential risks like retinopathy of prematurity. Given the current evidence, while there is promising data supporting EPO's neuroprotective role, the consensus is not definitive, and guidelines do not universally recommend its use for this purpose. Therefore, I lean towards a cautious affirmation but acknowledge the need for further research.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Should Intepirdine be used for Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Intepirdine is a drug that was investigated for the treatment of Alzheimer's disease, specifically targeting cognitive symptoms. It acts as a 5-HT6 receptor antagonist, with the hypothesis that this mechanism could improve cognition by increasing acetylcholine levels in the brain. However, clinical trials, including the MINDSET Phase 3 trial, showed that Intepirdine did not meet primary endpoints for improving cognition or daily function in patients with mild-to-moderate Alzheimer's disease compared to placebo. The drug failed to demonstrate significant efficacy, and its development for Alzheimer's was largely discontinued by Axovant Sciences in 2017. Based on the lack of evidence supporting its effectiveness and the results of failed trials, it should not be used for Alzheimer's disease. Therefore, the answer is no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should istiratumab be used for Pancreatic Cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether istiratumab should be used for pancreatic cancer, I first considered the nature of istiratumab. Istiratumab is an investigational bispecific antibody designed to target specific pathways in cancer cells, often studied in the context of various solid tumors. I then analyzed whether there is established evidence or clinical guidelines supporting its use specifically for pancreatic cancer. Upon reflection, istiratumab has been primarily investigated in other cancer types, such as colorectal or gastric cancer, with limited data or approval for pancreatic cancer. There are no widely recognized clinical trials or FDA approvals indicating its efficacy or safety specifically for pancreatic cancer. Given the lack of substantial evidence or standard recommendations for its use in this context, I conclude that it should not be used for pancreatic cancer at this time, pending further research or clinical validation.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is vocimagene amiretrorepvec effective for recurrent high-grade glioma?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether vocimagene amiretrorepvec is effective for recurrent high-grade glioma, I first consider the nature of the treatment and the condition. Vocimagene amiretrorepvec, also known as Toca 511, is a gene therapy designed to deliver a cytosine deaminase gene to cancer cells, which then converts the prodrug 5-fluorocytosine (5-FC) into the active chemotherapeutic agent 5-fluorouracil (5-FU) directly at the tumor site. This approach aims to target cancer cells selectively. Recurrent high-grade glioma, such as glioblastoma, is an aggressive brain cancer with limited treatment options and poor prognosis after recurrence. I recall that clinical trials, including a phase 3 trial (Toca 5), have investigated this therapy. The results of the phase 3 trial, reported around 2019-2020, showed that vocimagene amiretrorepvec did not meet the primary endpoint of overall survival compared to standard of care in patients with recurrent high-grade glioma. While there were some indications of durable responses in a subset of patients, the overall efficacy was not statistically significant. Therefore, based on the available evidence, it does not appear to be broadly effective for this condition.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Was ALVAC-HIV effective for HIV prevention in the HVTN 702 trial?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ALVAC-HIV was effective for HIV prevention in the HVTN 702 trial, I need to consider the context and results of the trial. The HVTN 702 trial was a large-scale study conducted in South Africa to test a vaccine regimen that included ALVAC-HIV (a canarypox vector) combined with a protein subunit vaccine. The trial aimed to build on the modest success of the RV144 trial in Thailand. However, in early 2020, the trial was halted because interim results showed that the vaccine regimen did not provide statistically significant protection against HIV acquisition. The data indicated that the incidence of HIV infection was similar in both the vaccine and placebo groups, meaning the vaccine was not effective in preventing HIV in this trial. Therefore, the answer should be based on the trial's outcome.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does αCGRP have amyloidogenic properties?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether αCGRP (alpha-Calcitonin Gene-Related Peptide) has amyloidogenic properties, I first consider the definition of amyloidogenic properties, which refers to the ability of a protein or peptide to form amyloid fibrils—insoluble protein aggregates associated with diseases like Alzheimer's or Parkinson's. αCGRP is a neuropeptide involved in vasodilation and pain transmission, primarily studied in the context of migraine and cardiovascular functions. I recall that some neuropeptides can exhibit amyloid-like behavior under certain conditions, but I need to evaluate if there is specific evidence for αCGRP. Upon reflection, I remember that studies have suggested that CGRP, including its alpha isoform, can form amyloid-like structures in vitro, particularly under specific pH or concentration conditions, as noted in research related to its aggregation behavior. However, it is not primarily classified as an amyloidogenic peptide like amyloid-beta or islet amyloid polypeptide (IAPP). Given the evidence of amyloid-like aggregation in controlled settings, I lean towards affirming that it does have such properties, though not necessarily pathological in vivo. Therefore, my answer will be based on the scientific findings of its potential to form amyloid-like structures.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do SETD1A mutations predispose to schizophrenia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SETD1A mutations predispose to schizophrenia, I first consider the role of SETD1A, a gene involved in histone methylation and epigenetic regulation, which are processes linked to neurodevelopment and psychiatric disorders. Research, including studies published in journals like Nature Neuroscience, has identified that rare loss-of-function mutations in SETD1A are associated with an increased risk of schizophrenia. These mutations are found more frequently in individuals with schizophrenia compared to controls, suggesting a genetic predisposition. However, such mutations are not common causes of schizophrenia and are only one of many genetic and environmental factors contributing to the disorder. After analyzing this, I conclude that SETD1A mutations do predispose to schizophrenia, though they are not a sole or primary cause.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is covid-19 induced anosmia caused by disruption of nuclear architecture?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether COVID-19-induced anosmia is caused by disruption of nuclear architecture, I first consider the nature of anosmia in COVID-19 patients. Anosmia, or loss of smell, is a common symptom of COVID-19. Research suggests it is primarily linked to the virus affecting the olfactory epithelium, where the virus may infect supporting cells like sustentacular cells rather than directly impacting olfactory neurons. The mechanism often involves inflammation and damage to these supporting cells, disrupting the olfactory system's function. Nuclear architecture refers to the organization of the cell nucleus, including chromatin structure and gene expression regulation. While some studies indicate that SARS-CoV-2 can cause cellular stress and potentially affect nuclear processes, there is no direct, widely accepted evidence linking disruption of nuclear architecture specifically to anosmia in COVID-19. Current literature points more towards local inflammation and cellular damage in the nasal cavity as the primary cause of smell loss. Therefore, based on the available information, it seems unlikely that nuclear architecture disruption is the direct cause of COVID-19-induced anosmia.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there any role of the 'Greek islands' in olfactory receptor choice?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"The question asks about the role of 'Greek islands' in olfactory receptor choice. At first glance, 'Greek islands' likely refers to a geographical or cultural context, which seems unrelated to olfactory receptor choice, a biological process involving the selection of specific odorant receptors by olfactory neurons. There is no known scientific connection between the Greek islands and olfactory biology. It is possible that 'Greek islands' might be a typo or metaphor, but without further context, it appears irrelevant. A search of scientific literature or biological concepts does not reveal any direct or indirect link. Therefore, the answer should be based on the lack of evidence or relevance of Greek islands in this context.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is HDAC1 required for GATA-1 transcriptional activity?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether HDAC1 is required for GATA-1 transcriptional activity, I first consider the roles of both components. HDAC1, or Histone Deacetylase 1, is an enzyme that removes acetyl groups from histones, generally leading to transcriptional repression by condensing chromatin structure. GATA-1 is a transcription factor critical for erythroid and megakaryocytic differentiation, activating genes involved in these processes. The question is whether HDAC1 is necessary for GATA-1 to function in transcriptional activation. Research indicates that GATA-1 can interact with co-repressors and co-activators, including histone deacetylases like HDAC1, often in the context of gene repression rather than activation. However, some studies suggest that HDAC1 might be involved in fine-tuning GATA-1 activity by modulating chromatin structure at specific loci. Despite this, the core transcriptional activity of GATA-1, particularly in activation, is more directly linked to co-activators like CBP/p300, which have histone acetyltransferase activity, counteracting HDAC effects. There is evidence from literature, such as studies on erythroid differentiation, showing that while HDAC1 can associate with GATA-1 in certain repressive complexes, it is not essential for GATA-1's primary role in transcriptional activation. Therefore, based on this analysis, HDAC1 is not strictly required for GATA-1 transcriptional activity.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there a dependence between chromatin organization and dorsoventral gene expression in Drosophila?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I first consider the biological context. Chromatin organization refers to the structure and packaging of DNA within the nucleus, which can influence gene accessibility and expression. Dorsoventral gene expression in Drosophila relates to the patterning of gene activity along the dorsal-ventral axis during embryonic development, which is critical for establishing body plan. Research in developmental biology suggests that chromatin structure can regulate gene expression by controlling access to transcription factors. In Drosophila, studies have shown that epigenetic modifications and chromatin remodeling are involved in the regulation of key dorsoventral patterning genes like 'dorsal' and 'twist.' Therefore, there appears to be a connection between chromatin organization and the spatial regulation of gene expression in this context. After analyzing this, I conclude that there is a dependence.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does atemoya juice inhibit the CYP1A2 enzyme?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether atemoya juice inhibits the CYP1A2 enzyme, I first consider the nature of atemoya, a hybrid fruit from the Annona family, known for its sweet, creamy flesh. CYP1A2 is a cytochrome P450 enzyme involved in metabolizing various drugs and compounds in the liver. Fruit juices, like grapefruit juice, are known to inhibit certain CYP enzymes (notably CYP3A4), leading to drug interactions. However, there is limited specific research or widely recognized data on atemoya juice and its effects on CYP1A2. I recall that some tropical fruits contain bioactive compounds like flavonoids or alkaloids that could potentially interact with CYP enzymes, but without concrete studies on atemoya juice specifically, I cannot confirm inhibition. Given the lack of evidence or documentation in scientific literature about atemoya juice inhibiting CYP1A2, the most accurate response based on current knowledge is negative.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does atemoya juice inhibit tye CYP3A4 enzyme?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether atemoya juice inhibits the CYP3A4 enzyme, I first consider what is known about atemoya, a hybrid fruit from the Annona family, and its potential interactions with enzymes like CYP3A4, which is crucial for metabolizing many drugs. CYP3A4 inhibition is often associated with certain fruits, such as grapefruit, due to compounds like furanocoumarins. However, there is limited specific research or widely recognized evidence directly linking atemoya or its juice to CYP3A4 inhibition. Atemoya is not commonly listed among fruits known for such interactions, unlike grapefruit or Seville oranges. Without concrete scientific studies or data confirming this effect for atemoya, I lean towards a negative response, acknowledging the lack of evidence as the basis for my conclusion.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether daily atemoya juice intake changes the pharmacokinetics of CYP1A2 substrates, I first consider the nature of atemoya, a tropical fruit hybrid of sugar apple and cherimoya. Pharmacokinetics involves how drugs are absorbed, distributed, metabolized, and excreted, and CYP1A2 is a liver enzyme responsible for metabolizing certain drugs. Fruit juices, like grapefruit juice, are known to interact with enzymes such as CYP3A4, altering drug metabolism, but I am unsure about atemoya's specific effects on CYP1A2. There is limited research on atemoya juice compared to more studied juices like grapefruit or orange. Atemoya contains various bioactive compounds, but I am not aware of any specific inhibitors or inducers of CYP1A2 in this fruit. Without concrete evidence or studies demonstrating an interaction, I lean toward a negative answer, but I acknowledge the possibility of unknown effects. Given the lack of specific data or widely recognized interactions, I conclude that there is no established evidence to suggest atemoya juice affects CYP1A2 substrates.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can bergapten cross the blood-brain barrier?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether bergapten can cross the blood-brain barrier, I first consider that bergapten is a furanocoumarin compound found in certain plants like bergamot. The blood-brain barrier (BBB) is a selective barrier that protects the brain by limiting the passage of substances from the bloodstream. Factors determining whether a molecule can cross the BBB include its lipophilicity, molecular size, and whether it is a substrate for efflux transporters like P-glycoprotein. Bergapten is a relatively small, lipophilic molecule, which suggests it might have the potential to cross the BBB passively. However, furanocoumarins are known to interact with cytochrome P450 enzymes and possibly transporters, which could affect their distribution. Without specific studies or data on bergapten's BBB permeability, I lean towards a tentative 'yes' based on its chemical properties, but acknowledge the uncertainty due to potential transporter interactions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can bergapten cause phototoxicity?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Bergapten is a naturally occurring compound found in certain plants, such as bergamot orange, and belongs to a class of chemicals known as furanocoumarins. These compounds are known to cause phototoxicity, a condition where exposure to ultraviolet (UV) light after contact with the substance leads to skin irritation or burns. Bergapten, in particular, is well-documented in scientific literature for its phototoxic effects, as it can absorb UV light and transfer energy to skin cells, causing damage. Therefore, the answer to whether bergapten can cause phototoxicity is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can whole genome sequencing be used for diagnosis of mitochondrial disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Whole genome sequencing (WGS) involves sequencing the entire DNA content of an individual, including both nuclear and mitochondrial DNA. Mitochondrial diseases are often caused by mutations in mitochondrial DNA (mtDNA) or nuclear DNA that affects mitochondrial function. WGS can detect mutations in mtDNA as well as nuclear genes related to mitochondrial function, making it a potential tool for diagnosing mitochondrial diseases. However, challenges such as heteroplasmy (the presence of both normal and mutated mtDNA in cells) and the need for specialized analysis tools may affect its diagnostic accuracy. Despite these challenges, WGS is increasingly used in clinical settings for comprehensive genetic analysis, including for mitochondrial disorders. Therefore, it can be used for diagnosis of mitochondrial disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is AGO2 related to cytokinesis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether AGO2 is related to cytokinesis, I first consider what AGO2 is. AGO2, or Argonaute 2, is a protein primarily known for its role in RNA interference and the regulation of gene expression through small RNAs like microRNAs and siRNAs. It is a key component of the RNA-induced silencing complex (RISC). Cytokinesis, on the other hand, is the process during cell division where the cytoplasm of a parent cell is divided into two daughter cells. At first glance, AGO2's primary function seems unrelated to cell division processes like cytokinesis, as it is more associated with post-transcriptional gene regulation. However, I recall that some studies have suggested roles for RNA interference machinery in cell cycle regulation or other cellular processes beyond gene silencing. I consider if there is any direct evidence linking AGO2 to cytokinesis. Upon reflection, there are studies indicating that AGO2 may localize to the midbody during cytokinesis and could play a role in regulating local translation or RNA stability at that site, potentially affecting the process. For instance, some research has shown that AGO2 and associated RNAs are involved in the final stages of cell division. Given this, there appears to be a connection, albeit not as central as AGO2's role in RNA silencing. Therefore, I conclude that AGO2 is related to cytokinesis based on emerging evidence of its involvement in the process.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does TIMELESS-TIPIN participate in replisome disassembly?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether TIMELESS-TIPIN participates in replisome disassembly, I first consider the role of TIMELESS-TIPIN in DNA replication. TIMELESS-TIPIN is a protein complex known to be involved in the stabilization of the replication fork and the coordination of DNA replication under stress conditions. It interacts with components of the replisome, such as DNA polymerases and helicases, to ensure proper fork progression. However, replisome disassembly is a distinct process that occurs during the termination of DNA replication, involving specific proteins like CRL2-LRR1 in eukaryotes to ubiquitylate and remove the replisome components. Based on current biological knowledge, TIMELESS-TIPIN is primarily associated with fork stability and checkpoint signaling rather than the active disassembly of the replisome at termination. There is no direct evidence or widely accepted research indicating that TIMELESS-TIPIN plays a role in replisome disassembly. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is METTL1 overexpression associated with better patient survival?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether METTL1 overexpression is associated with better patient survival, I first consider the role of METTL1, which is a methyltransferase involved in RNA modification, particularly in cancer contexts. Research suggests that METTL1 can be overexpressed in various cancers, often linked to tumor progression and poor prognosis due to its role in promoting cell proliferation and metastasis. However, the exact impact on survival may vary depending on cancer type and specific studies. Without specific data or context provided in the question, I rely on general trends in oncology research. Most studies indicate that METTL1 overexpression correlates with worse survival outcomes, not better. Therefore, based on this analysis, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has CPX-351 been approved by the FDA and the EMA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether CPX-351 has been approved by both the FDA and the EMA, I need to consider the regulatory status of this drug. CPX-351, also known as Vyxeos, is a liposomal formulation of cytarabine and daunorubicin used for the treatment of certain types of acute myeloid leukemia (AML). I recall that the FDA approved CPX-351 in August 2017 for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. Regarding the EMA, I believe it was also approved in 2018 for similar indications in the European Union under the name Vyxeos. Since the question asks if it has been approved by both agencies, and based on my recollection, it seems that the answer should be affirmative for both. However, I must ensure accuracy, and since my knowledge confirms approvals from both, I will conclude with a positive response.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is REGN5458 a single-targeted antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether REGN5458 is a single-targeted antibody, I first need to consider what a single-targeted antibody is. A single-targeted antibody, or monoclonal antibody, is designed to bind to one specific antigen or target. REGN5458 is a bispecific antibody developed by Regeneron, specifically targeting BCMA (B-cell maturation antigen) and CD3, which means it binds to two different targets simultaneously. Bispecific antibodies are distinct from single-targeted antibodies because they engage multiple targets. Therefore, REGN5458 does not fit the definition of a single-targeted antibody.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is MEDI2228 a bispecific antibody?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether MEDI2228 is a bispecific antibody, I first need to consider what a bispecific antibody is. Bispecific antibodies are engineered proteins that can bind to two different antigens or epitopes simultaneously, often used in therapeutic applications like cancer treatment to target multiple pathways or cell types. Now, regarding MEDI2228, I recall that it is a drug candidate developed by MedImmune (a subsidiary of AstraZeneca). Based on available information, MEDI2228 is an antibody-drug conjugate (ADC) targeting BCMA (B-cell maturation antigen), primarily for multiple myeloma. ADCs are typically monoclonal antibodies conjugated to a cytotoxic drug, not bispecific antibodies, which would target two different antigens. There is no indication in the public domain or my knowledge base that MEDI2228 has bispecific properties; it appears to be a targeted ADC. Therefore, I conclude that MEDI2228 is not a bispecific antibody.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is there a role for CADM1 in Myelodysplastic syndrome (MDS)?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about the role of CADM1 in Myelodysplastic Syndrome (MDS), I first consider what CADM1 and MDS are. CADM1 (Cell Adhesion Molecule 1) is a gene that encodes a protein involved in cell adhesion, often studied in the context of cancer for its potential tumor suppressor role. Myelodysplastic Syndrome (MDS) is a group of disorders caused by poorly formed blood cells, often linked to genetic and epigenetic alterations. I recall that CADM1 has been implicated in various hematological malignancies due to its role in cell signaling and adhesion, which could affect bone marrow function. There is evidence suggesting that CADM1 expression might be altered in MDS, potentially contributing to abnormal cell interactions or apoptosis resistance in the bone marrow. Studies have shown that CADM1 can be epigenetically silenced in MDS, which may play a role in disease progression. Therefore, it seems plausible that CADM1 has a role in MDS, likely as a tumor suppressor or through its impact on cellular interactions. Based on this analysis, I conclude that there is a role for CADM1 in MDS.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Does UBE4B promote renal cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether UBE4B promotes renal cancer, I first consider the role of UBE4B, which is a ubiquitin conjugation factor involved in the ubiquitination process, potentially targeting proteins for degradation. Ubiquitination can influence cancer development by regulating cell cycle, apoptosis, and DNA repair. I recall that studies have linked UBE4B to certain cancers, possibly through its interaction with p53, a tumor suppressor protein, where it may facilitate p53 degradation, thus promoting tumorigenesis. For renal cancer specifically, I think there is evidence suggesting UBE4B overexpression in renal cell carcinoma, potentially contributing to tumor progression by disrupting normal cellular controls. However, I must note that the exact mechanisms and consistency of this effect across studies might vary, and I should ideally confirm with specific research data. Based on the general understanding and recalled associations, it seems plausible that UBE4B does promote renal cancer.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can IFNg induce the expression of IDO?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether IFNg (Interferon-gamma) can induce the expression of IDO (Indoleamine 2,3-dioxygenase), I need to consider the biological context. IFNg is a cytokine known for its role in immune response, particularly in activating macrophages and inducing various genes involved in immune regulation. IDO is an enzyme that plays a role in tryptophan metabolism and is often associated with immune suppression and tolerance. From my knowledge, IFNg is one of the primary inducers of IDO expression, especially in dendritic cells and macrophages, as part of its immunomodulatory effects. This induction helps in regulating T-cell responses by depleting tryptophan, which is necessary for T-cell proliferation. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Mycobacterium abscessus a human pathogen?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Mycobacterium abscessus is a human pathogen, I first consider the definition of a pathogen as an organism capable of causing disease in humans. Mycobacterium abscessus is a species of rapidly growing, non-tuberculous mycobacteria known to cause infections, particularly in individuals with compromised immune systems or underlying lung conditions like cystic fibrosis. It is associated with skin, soft tissue, and pulmonary infections, often resistant to many antibiotics, making it a significant clinical concern. Based on this, it is clear that Mycobacterium abscessus can cause disease in humans and should be classified as a human pathogen.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do we find bacteriophages in the gut?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Do we find bacteriophages in the gut?', I first consider the biological context. Bacteriophages are viruses that infect bacteria, and the gut is known to host a vast community of bacteria, especially in the intestines. Given this, it is logical to expect that bacteriophages would also be present in the gut as they target bacteria for their life cycle. Research in microbiology and gut microbiome studies confirms that bacteriophages are indeed abundant in the human gut, playing a significant role in regulating bacterial populations and contributing to gut health. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is NfL (neurofilament light chain) a biomarker of neurodegeneration?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether NfL (neurofilament light chain) is a biomarker of neurodegeneration, I first consider the scientific context. NfL is a protein component of the neuronal cytoskeleton, released into the cerebrospinal fluid and blood upon axonal damage or neuronal injury. Numerous studies have shown elevated NfL levels in conditions like Alzheimer's disease, multiple sclerosis, and traumatic brain injury, correlating with disease progression and neuronal loss. This suggests NfL is indeed associated with neurodegeneration. However, I also note that NfL is not specific to a single disease and can be elevated in other conditions involving neuronal damage. Despite this, its widespread use in research and clinical settings as a marker of neuronal injury supports the conclusion that it is a biomarker of neurodegeneration.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do the proteins Talin and Amot interact?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether the proteins Talin and Amot interact, I first consider the biological context. Talin is a cytoskeletal protein that links integrins to the actin cytoskeleton, playing a key role in cell adhesion and mechanotransduction. Amot (Angiomotin) is involved in regulating cell polarity and Hippo signaling, often associated with tight junctions and endothelial cell migration. There is no widely recognized direct interaction between Talin and Amot in the literature or protein interaction databases I can recall. They operate in somewhat distinct pathways, with Talin being more focal adhesion-related and Amot tied to junctional complexes and signaling. However, indirect interactions or context-specific interactions in certain cell types or conditions might exist, though I lack specific evidence for this. After analyzing, I conclude that there is no established direct interaction between Talin and Amot based on current knowledge.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is serotonin transported by platelets?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Is serotonin transported by platelets?', I need to consider the biological role of platelets and serotonin. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter involved in mood regulation, among other functions. Platelets, which are small blood cells, play a key role in blood clotting. However, they also store and transport serotonin in the bloodstream. Platelets take up serotonin from the plasma via a specific transporter and store it in dense granules. When activated, platelets release serotonin, which can influence vascular tone and other physiological processes. Therefore, it is accurate to say that platelets do transport serotonin.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Otolin-1 a matrix protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Otolin-1 is a matrix protein, I first consider the definition of a matrix protein, which typically refers to proteins that form or are associated with the extracellular matrix or structural components in tissues like bone, cartilage, or otoliths in the inner ear. Otolin-1 is known to be a protein specifically associated with otoliths, which are calcium carbonate structures in the inner ear of vertebrates, aiding in balance and hearing. Research indicates that Otolin-1 is a collagen-like protein that contributes to the organic matrix of otoliths, playing a role in their formation and structure. Given this, it seems appropriate to classify Otolin-1 as a matrix protein since it is integral to the structural matrix of otoliths.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the protein HOXA11 associated with endometrial disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the protein HOXA11 is associated with endometrial disease, I first consider the role of HOXA11. HOXA11 is a homeobox gene involved in the development and regulation of the reproductive system, particularly in uterine and endometrial tissue formation. Research indicates that altered expression of HOXA11 is linked to conditions like endometriosis and endometrial cancer, where it may affect implantation, tissue growth, or cellular differentiation. Studies have shown that decreased HOXA11 expression is often observed in women with endometriosis, suggesting a potential role in the disease's pathology. Therefore, there appears to be a connection between HOXA11 and endometrial disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Lysozyme abundant in human tears?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Lysozyme is an enzyme known for its antibacterial properties, as it breaks down bacterial cell walls. It is found in various bodily fluids, including tears, saliva, and mucus. In human tears, lysozyme is indeed a significant component, playing a crucial role in protecting the eyes from infection by inhibiting bacterial growth. Research and biological studies confirm that lysozyme is abundant in tears as part of the eye's natural defense mechanism. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SMOC2 expressed during wound healing?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SMOC2 is expressed during wound healing, I first consider the biological context. SMOC2 (SPARC-related modular calcium-binding protein 2) is a matricellular protein involved in extracellular matrix interactions and tissue repair processes. Wound healing involves inflammation, proliferation, and remodeling phases, during which various genes and proteins are upregulated to facilitate tissue regeneration. Research suggests that SMOC2 plays a role in modulating cell-matrix interactions and angiogenesis, which are critical during wound healing. Studies, particularly in skin and other tissues, have indicated that SMOC2 expression increases in response to injury as part of the repair mechanism. Therefore, based on this analysis, it is likely that SMOC2 is expressed during wound healing.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is esophageal adenocarcinoma associated with aberrant glycosylation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether esophageal adenocarcinoma is associated with aberrant glycosylation, I first consider the nature of esophageal adenocarcinoma, which is a type of cancer affecting the esophagus, often linked to chronic acid reflux and Barrett's esophagus. Aberrant glycosylation refers to abnormal patterns of sugar molecule attachment to proteins or lipids, which can play a role in cancer development by affecting cell signaling, adhesion, and immune evasion. Research in oncology suggests that many cancers, including adenocarcinomas, exhibit altered glycosylation patterns that contribute to tumor progression and metastasis. Specifically, studies have shown that esophageal adenocarcinoma is associated with changes in glycosylation, such as increased expression of certain glycan structures like sialyl-Lewis antigens, which are implicated in cancer cell behavior. Therefore, there appears to be a connection based on available scientific literature and understanding of cancer biology.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is cytokeratin a tumor marker?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether cytokeratin is a tumor marker, I first need to consider what a tumor marker is. Tumor markers are substances, often proteins, produced by cancer cells or by the body in response to cancer, used to help detect, diagnose, or monitor cancer. Cytokeratins are a family of intermediate filament proteins found in epithelial cells, and they are often used in immunohistochemistry to identify the origin of tumors, particularly carcinomas. Certain cytokeratins, like CK19, are associated with specific cancers and can be measured in blood as fragments (e.g., CYFRA 21-1) to monitor diseases like non-small cell lung cancer. While cytokeratins are not tumor markers in the classical sense for all cancers, specific cytokeratin fragments are indeed used as tumor markers in certain contexts. Therefore, it is reasonable to conclude that cytokeratin can be considered a tumor marker in specific cases.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there any R packages that help with visualizing data on spirals?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I need to consider whether there are R packages specifically designed or commonly used for visualizing data on spirals. Spirals are a unique way to represent data, often used for cyclical or periodic patterns, such as in time series or polar coordinates. I recall that R has packages like 'ggplot2' which is highly flexible for custom visualizations, and it might support spiral plots through extensions or custom geoms. Additionally, there could be specialized packages like 'spiralize' which is designed for creating spiral visualizations, especially for genomic data or other sequential data. After thinking through this, I believe there are indeed R packages that can help with spiral visualizations, either directly or through customization.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are there roles for cohesin mutations in AML?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Are there roles for cohesin mutations in AML?', I first consider that AML stands for Acute Myeloid Leukemia, a type of blood cancer. Cohesin is a protein complex involved in chromosome segregation, DNA repair, and gene regulation. Mutations in cohesin complex genes, such as SMC1A, SMC3, RAD21, and STAG2, have been implicated in various cancers. Research indicates that cohesin mutations are recurrent in AML, particularly in certain subtypes, and are associated with altered gene expression and chromosomal instability, contributing to leukemogenesis. Studies suggest these mutations may play a role in disease progression and could be potential therapeutic targets. Therefore, there is evidence supporting a role for cohesin mutations in AML.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 epoxygenases from arachidonic acid?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question, I need to consider the biochemical pathway involved in the synthesis of Epoxyeicosatrienoic acids (EETs). EETs are signaling molecules derived from arachidonic acid, a polyunsaturated fatty acid. Cytochrome P450 enzymes, specifically the epoxygenase subfamily, are known to catalyze the epoxidation of arachidonic acid, forming EETs. This is a well-established pathway in lipid metabolism, particularly in the context of cardiovascular and inflammatory regulation. Therefore, the statement in the question aligns with scientific understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Epistaxis associated with dental implant placement?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Epistaxis, or nosebleed, is not commonly associated with dental implant placement under normal circumstances. Dental implant procedures typically involve the jawbone and surrounding oral tissues, which are anatomically distant from the nasal cavity. However, in rare cases, if the implant placement is in the upper jaw (maxilla) and involves the sinus area, there could be a potential risk of complications that might indirectly lead to nasal issues, including epistaxis, especially if there is perforation of the sinus membrane or infection. Additionally, if a patient has a pre-existing condition like a bleeding disorder or is on anticoagulant therapy, the risk of bleeding, including epistaxis, might be higher. After reviewing the general medical and dental literature context, the association seems minimal and not direct unless specific complications or patient conditions are present. Therefore, the answer leans towards 'no' for a general association.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Are Tregs CD4(+)CD25(+) regulatory T cells a positive regulator of the immune response?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Tregs, specifically CD4(+)CD25(+) regulatory T cells, are a positive regulator of the immune response, I need to consider their role in the immune system. Tregs are a subset of T cells known for their immunosuppressive function. They play a critical role in maintaining immune homeostasis by suppressing excessive immune responses, preventing autoimmunity, and promoting tolerance. The term 'positive regulator' typically implies something that enhances or activates a response. However, Tregs generally dampen or inhibit immune activity to prevent overactivation, which could be seen as a negative regulatory role. On the other hand, by controlling inflammation and preventing damage, they indirectly support a balanced immune response, which could be interpreted as a positive contribution. After analyzing this, I conclude that Tregs are not a positive regulator in the direct sense of amplifying the immune response, but rather act as a negative regulator by suppressing it. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Unlike DNA, RNA is not methylated, yes or no?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question 'Unlike DNA, RNA is not methylated, yes or no?', I need to consider the biochemical properties of DNA and RNA. DNA methylation is a well-known epigenetic modification that occurs on cytosine bases, typically in CpG dinucleotides, and plays a role in gene regulation. RNA, on the other hand, can also undergo methylation, such as N6-methyladenosine (m6A) modification, which is common in mRNA and affects RNA stability and translation. Since both DNA and RNA can be methylated, the statement 'RNA is not methylated' is incorrect. Therefore, the answer to the question, which seems to ask for confirmation of the statement, should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do RNA binding Proteins  that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs (AU-RBPs) regulate the DNA Damage Response?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the role of RNA-binding proteins (RBPs) that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs, often referred to as AU-RBPs. These proteins are typically involved in post-transcriptional regulation, affecting mRNA stability, translation, and localization. The question specifically asks if AU-RBPs in the 5' UTR regulate the DNA Damage Response (DDR), which is a cellular mechanism to detect and repair DNA damage. While AU-RBPs are more commonly associated with the 3' UTR for stability and decay of mRNAs related to inflammation or stress responses, their role in the 5' UTR might influence translation initiation. There is emerging evidence that some RBPs can indirectly influence DDR by regulating the expression of DDR-related genes through mRNA binding. However, direct evidence linking AU-RBPs in the 5' UTR to DDR regulation is limited or unclear in standard biological knowledge. I will lean towards a cautious 'no' unless specific studies suggest otherwise, but I must acknowledge that specialized research might provide a different perspective. For the purpose of this answer, based on general knowledge, I conclude that AU-RBPs in the 5' UTR are not primarily known for regulating DDR.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are G-quadruplexes(G4) possible drug targets for glioblastoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether G-quadruplexes (G4) are possible drug targets for glioblastoma, I first consider the nature of G-quadruplexes and their relevance to glioblastoma, a highly aggressive brain cancer. G-quadruplexes are secondary DNA structures formed in guanine-rich regions, often found in telomeres and oncogene promoters, which can influence gene expression and genomic stability. In cancer, including glioblastoma, these structures are implicated in regulating key processes like telomere maintenance and oncogene activation. Research suggests that stabilizing or destabilizing G4 structures with small molecules could interfere with cancer cell proliferation, making them potential therapeutic targets. Studies have shown that G4-targeting compounds can induce DNA damage and apoptosis in glioblastoma cells, and there is growing interest in their role in cancer therapy. However, challenges remain, such as specificity, off-target effects, and delivery across the blood-brain barrier. Despite these hurdles, the existing evidence supports the potential of G4 as drug targets for glioblastoma, though further research and clinical validation are needed. Therefore, my answer is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is CircRNA produced by back splicing of exon, intron or both, forming exon or intron circRNA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question, I need to recall the biological process of circular RNA (circRNA) formation. CircRNA is a type of non-coding RNA that forms a closed loop structure. It is primarily produced through a process called back-splicing, where a downstream splice donor site is joined to an upstream splice acceptor site. This process can involve exons, introns, or both. Exonic circRNA is formed from back-splicing of exons, which is the most common type. Intronic circRNA can also be formed from intronic sequences, though less frequently. Additionally, there are cases where circRNA includes both exonic and intronic regions. Therefore, circRNA can be produced by back-splicing of exons, introns, or both, forming either exonic or intronic circRNA, or a combination. Since the question asks if circRNA is produced by back-splicing of exon, intron, or both, and whether it forms exon or intron circRNA, the answer should affirm that both scenarios are possible.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are circRNAs susceptible to degradation by RNase R?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether circRNAs (circular RNAs) are susceptible to degradation by RNase R, I need to consider the properties of circRNAs and the function of RNase R. CircRNAs are a type of non-coding RNA that form a closed loop structure due to back-splicing, which makes them resistant to exonucleases that degrade linear RNAs from their ends. RNase R is a 3' to 5' exonuclease that specifically degrades linear RNAs but is known to have limited activity on circular RNAs due to the lack of free ends in circRNAs. Research indicates that circRNAs are generally resistant to RNase R, which is often used in experiments to enrich circRNAs by degrading linear RNAs. Therefore, circRNAs are not typically susceptible to degradation by RNase R.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is RUNX1T1 associate with obesity?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether RUNX1T1 is associated with obesity, I first consider the biological context. RUNX1T1, also known as ETO, is a gene often linked to hematological malignancies, such as acute myeloid leukemia, due to its role in chromosomal translocations like t(8;21). It is primarily involved in transcriptional regulation and hematopoiesis. Obesity, on the other hand, is a metabolic condition influenced by genetic, environmental, and lifestyle factors, often associated with genes related to energy metabolism, appetite regulation, or fat storage (e.g., FTO, MC4R). There is no widely recognized direct link between RUNX1T1 and obesity in current scientific literature. I reflect on whether there might be indirect associations, such as through inflammatory pathways or epigenetic modifications, but no concrete evidence or studies come to mind linking RUNX1T1 specifically to obesity. A quick mental check of relevant databases or research trends also does not suggest a connection. Therefore, based on the available knowledge, it is unlikely that RUNX1T1 is associated with obesity.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can FTO promote pancreatic cancer development?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether FTO (Fat Mass and Obesity-Associated protein) can promote pancreatic cancer development, I first consider the biological role of FTO. FTO is an RNA demethylase that regulates mRNA stability and translation by removing N6-methyladenosine (m6A) modifications. Recent studies suggest that FTO is overexpressed in various cancers, including pancreatic cancer, and may contribute to tumorigenesis by altering the expression of oncogenes or tumor suppressor genes through m6A modification. Research indicates that FTO can promote cancer cell proliferation, invasion, and metastasis by dysregulating key signaling pathways. For instance, in pancreatic cancer, FTO has been linked to enhanced tumor growth and poor prognosis in some studies. However, the exact mechanisms and context-specific effects are still under investigation, and not all studies may conclusively prove causation. Based on the available evidence, it appears that FTO can indeed play a role in promoting pancreatic cancer development, so my answer leans toward 'yes'.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is Ameloblastoma (AB) a common benign tumor occurring in the brain?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Ameloblastoma (AB) is a common benign tumor occurring in the brain, I first need to recall what Ameloblastoma is. Ameloblastoma is a rare, benign tumor that typically arises in the jaw, particularly in the mandible or maxilla, and is associated with odontogenic epithelium, which is related to tooth development. It is not commonly associated with the brain or intracranial regions. Brain tumors, on the other hand, include entities like meningiomas, gliomas, or pituitary adenomas, none of which are related to Ameloblastoma. There might be rare cases or misclassifications, but generally, Ameloblastoma is not considered a brain tumor, nor is it common in that location. Therefore, the answer should be based on its typical location and prevalence in the brain, which is not the case.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is disruption of immune regulation mechanisms associated with adverse pregnancy outcomes, including preeclampsia (PE)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I first consider the role of immune regulation mechanisms in pregnancy. Pregnancy involves a delicate balance of immune tolerance to prevent rejection of the fetus while maintaining protection against infections. Disruption of these mechanisms, such as imbalances in regulatory T cells, cytokines, or other immune components, could lead to adverse outcomes. Preeclampsia (PE) is a pregnancy complication characterized by high blood pressure and often proteinuria, and research suggests it may involve immune dysregulation, including excessive inflammation or impaired maternal-fetal tolerance. Studies have shown associations between altered immune responses and PE, such as increased pro-inflammatory cytokines or reduced regulatory immune cells. Therefore, it seems plausible that disruption of immune regulation is associated with adverse pregnancy outcomes like PE.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can METTL3 methylate long noncoding RNAs?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether METTL3 can methylate long noncoding RNAs (lncRNAs), I first consider the role of METTL3. METTL3 is a key component of the m6A methyltransferase complex, which is responsible for adding N6-methyladenosine (m6A) modifications to RNA molecules. This modification is well-studied in messenger RNAs (mRNAs), where it affects RNA stability, translation, and other processes. However, m6A modifications are not exclusive to mRNAs; they have also been identified in other RNA types, including lncRNAs. Research indicates that lncRNAs can indeed be targets of m6A modification, and METTL3, as a primary methyltransferase, is involved in this process. Studies have shown that m6A modification of lncRNAs by METTL3 can influence their structure, stability, and interactions with proteins, thereby affecting their biological functions. Therefore, based on this understanding, METTL3 can methylate lncRNAs.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is PCAT6 a microRNA?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether PCAT6 is a microRNA, I first need to consider what microRNAs are and what PCAT6 is classified as. MicroRNAs are small, non-coding RNA molecules that regulate gene expression. PCAT6, or Prostate Cancer-Associated Transcript 6, is a long non-coding RNA (lncRNA) associated with prostate cancer. Since lncRNAs are distinct from microRNAs due to their length and function—lncRNAs are typically longer than 200 nucleotides while microRNAs are about 22 nucleotides—I can conclude that PCAT6 does not fall under the category of microRNAs. Therefore, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can autophagy related lncRNAs be used for colorectal cancer prognosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether autophagy-related lncRNAs can be used for colorectal cancer prognosis, I first consider the role of autophagy in cancer. Autophagy is a cellular process that can both promote and inhibit tumor progression, depending on the context. Long non-coding RNAs (lncRNAs) are known to regulate various biological processes, including autophagy, by interacting with genes and proteins. In colorectal cancer, dysregulation of autophagy has been linked to tumor development and progression. Recent studies suggest that specific lncRNAs associated with autophagy pathways may serve as biomarkers for prognosis, as they can influence tumor behavior, metastasis, and response to therapy. There is emerging evidence in scientific literature that certain autophagy-related lncRNAs are correlated with patient outcomes in colorectal cancer, indicating their potential as prognostic markers. However, challenges such as specificity, validation in large cohorts, and clinical applicability need to be addressed. Based on this analysis, I conclude that while promising, the use of autophagy-related lncRNAs for colorectal cancer prognosis is still under investigation but shows potential.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are circular RNAs implicated in diseases of the eye?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether circular RNAs (circRNAs) are implicated in diseases of the eye, I first consider the nature of circRNAs. Circular RNAs are a type of non-coding RNA that form a closed loop structure, making them more stable than linear RNAs. They have been increasingly recognized for their roles in gene regulation, acting as miRNA sponges, protein scaffolds, or even coding for small peptides. Research in recent years has linked circRNAs to various diseases, including cancer, cardiovascular diseases, and neurological disorders, by influencing cellular processes like proliferation, apoptosis, and inflammation. Regarding eye diseases, I recall that the eye is a complex organ with unique molecular environments in tissues like the retina, cornea, and lens. Diseases such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and cataracts involve intricate molecular pathways where non-coding RNAs, including circRNAs, could play a role. I consider specific studies or evidence: there is emerging research suggesting that circRNAs are differentially expressed in ocular tissues under pathological conditions. For instance, circRNAs have been implicated in regulating oxidative stress and angiogenesis in diabetic retinopathy, and some studies have identified specific circRNAs associated with retinal degeneration or glaucoma progression. While the field is still developing, and direct causal links may not be fully established, the involvement of circRNAs in eye diseases is supported by preliminary research. Therefore, I conclude that circRNAs are indeed implicated in diseases of the eye based on current scientific understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Ameloblastoma (AB) a benign tumor that never metastasizes?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Ameloblastoma (AB) is a benign tumor that never metastasizes, I first consider the definition and characteristics of Ameloblastoma. Ameloblastoma is a rare, benign odontogenic tumor originating from the enamel-forming cells of the teeth, typically occurring in the jaw. It is classified as benign because it does not usually spread to other parts of the body. However, I recall that while it is generally benign, there are rare cases where Ameloblastoma can metastasize, particularly in its malignant variant known as malignant Ameloblastoma or Ameloblastic carcinoma. These rare cases can spread to distant sites like the lungs. Therefore, it is not accurate to say it 'never' metastasizes, as exceptions exist. Based on this analysis, the answer should reflect that it is not entirely true that Ameloblastoma never metastasizes.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Acute Necrotizing Encephalopathy (ANE) which typically affects young, healthy children usually triggered by exposure to air pollution?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Acute Necrotizing Encephalopathy (ANE), which typically affects young, healthy children, is usually triggered by exposure to air pollution, I need to consider the known causes and triggers of ANE. ANE is a rare, severe brain disorder often associated with viral infections, particularly influenza, and is characterized by rapid onset of brain damage following a febrile illness. It is thought to result from an exaggerated immune response or cytokine storm rather than direct viral invasion of the brain. Environmental factors like air pollution are known to exacerbate respiratory conditions and may contribute to overall health risks, but there is no widely recognized or established link between air pollution and the onset of ANE in medical literature. Most studies and clinical reports focus on viral triggers and genetic predispositions (such as mutations in the RANBP2 gene) as the primary causes. While air pollution could theoretically worsen a respiratory infection that might precede ANE, it is not considered a direct or usual trigger for the condition. Therefore, the answer should be based on the predominant understanding of ANE's etiology, which does not include air pollution as a typical trigger.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is retinol binding protein 4 an adipokine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether retinol binding protein 4 (RBP4) is an adipokine, I first need to define what an adipokine is. Adipokines are cytokines or cell-signaling proteins secreted by adipose tissue, which play roles in metabolism, inflammation, and other physiological processes. RBP4 is a protein primarily known for transporting retinol (vitamin A) in the blood. Recent research has shown that RBP4 is secreted by adipocytes (fat cells) and is associated with insulin resistance and metabolic disorders, which aligns with the characteristics of adipokines. Studies have confirmed that RBP4 levels are elevated in obesity and type 2 diabetes, further supporting its classification as an adipokine. Therefore, based on this analysis, RBP4 can be considered an adipokine.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do Afamin bind Vitamin E?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Afamin binds Vitamin E, I first consider the biological role of Afamin. Afamin is a glycoprotein in the albumin family, primarily found in human plasma, and it is known to act as a carrier protein. Research indicates that Afamin specifically binds and transports Vitamin E, a fat-soluble antioxidant, in the bloodstream. Studies have shown that Afamin has a high affinity for Vitamin E, particularly alpha-tocopherol, which is the most biologically active form of Vitamin E. This binding helps in the distribution of Vitamin E to various tissues and protects it from degradation. Therefore, based on this understanding, Afamin does bind Vitamin E.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is HYDIN (Hydrocephalus-inducing protein homolog) an axonemal protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether HYDIN (Hydrocephalus-inducing protein homolog) is an axonemal protein, I first consider the definition of an axonemal protein. Axonemal proteins are components of the axoneme, the central structure of cilia and flagella, which is responsible for their motility. HYDIN is a protein associated with ciliary function, and mutations in the HYDIN gene are linked to primary ciliary dyskinesia (PCD), a disorder caused by defective cilia. Research indicates that HYDIN is located in the central pair apparatus of the axoneme, specifically in motile cilia, where it plays a role in ciliary motility. Therefore, based on this information, HYDIN can be classified as an axonemal protein since it is a structural or functional component of the axoneme.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is ASF1 phopshorylated by  the Tousled-like kinases?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ASF1 is phosphorylated by Tousled-like kinases, I first consider the biological context. ASF1 (Anti-Silencing Function 1) is a histone chaperone involved in chromatin assembly and disassembly. Tousled-like kinases (TLKs) are known to play roles in DNA replication, repair, and chromatin assembly by phosphorylating various substrates. Research indicates that TLKs phosphorylate ASF1 to regulate its activity in chromatin assembly during DNA replication and repair. Studies have shown that TLK1 and TLK2 target ASF1, specifically at certain serine residues, to modulate its function. Therefore, based on this understanding, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is paxillin affected by RANKL?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether paxillin is affected by RANKL, I first need to consider the biological context. RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) is a cytokine involved in bone remodeling and immune cell regulation, primarily known for its role in osteoclast differentiation and activation. Paxillin is a focal adhesion protein involved in cell adhesion, migration, and signaling, often linked to integrin signaling pathways. There is evidence in scientific literature suggesting that RANKL signaling can influence focal adhesion proteins indirectly through pathways like Src kinase, which interacts with paxillin. Studies have shown that RANKL stimulation in osteoclasts can lead to cytoskeletal reorganization, where paxillin plays a role. Therefore, it is reasonable to conclude that paxillin is affected by RANKL, at least in specific cellular contexts such as osteoclasts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is taxilin a cancer marker?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether taxilin is a cancer marker, I first need to consider what a cancer marker is. Cancer markers are substances, often proteins, that are produced by cancer cells or by the body in response to cancer, and their presence or levels can indicate the presence of cancer. Now, regarding taxilin, I recall that it is a protein involved in intracellular vesicle trafficking and possibly in cellular signaling pathways. However, I am not aware of any widely recognized or established research directly linking taxilin to cancer diagnosis or prognosis as a marker. It might be studied in specific contexts or experimental research, but it is not commonly used in clinical settings for cancer detection. Therefore, based on general knowledge, I would conclude that taxilin is not considered a standard cancer marker.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can parasite infections by Schistosoma japonicum prevent or improve asthma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether parasite infections by Schistosoma japonicum can prevent or improve asthma, I first consider the biological context. Schistosoma japonicum is a parasitic worm that causes schistosomiasis, primarily affecting the liver and intestines. Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways. There is a hypothesis in immunology called the 'hygiene hypothesis,' which suggests that exposure to certain infections or parasites early in life might modulate the immune system and reduce the likelihood of allergic diseases like asthma. Some studies on other helminths, such as hookworms, have shown a potential protective effect against asthma due to their ability to shift the immune response from a Th2-dominated (allergy-prone) to a more balanced or regulatory response. However, specific evidence for Schistosoma japonicum is less clear. Research indicates that while Schistosoma infections can induce a strong Th2 response (which is also associated with asthma), chronic infections might lead to immune regulation through mechanisms like increased IL-10 production, potentially dampening allergic responses. Some epidemiological studies in endemic areas suggest a lower prevalence of asthma, but causality is not definitively established, and other factors like genetics or environment could play a role. There are also conflicting studies showing no significant protective effect or even exacerbation of allergic conditions. Given the mixed evidence, I lean towards a cautious 'yes' based on the potential immune-modulatory effects, though the effect is not universally proven or consistent across all contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does sphingosine-1 phosphoate suppress epiregulin?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether sphingosine-1-phosphate (S1P) suppresses epiregulin, I first consider the biological context. S1P is a bioactive lipid mediator involved in various cellular processes, including cell growth, survival, and inflammation, primarily through its interaction with G protein-coupled receptors. Epiregulin, on the other hand, is a member of the epidermal growth factor (EGF) family, known for promoting cell proliferation and differentiation by binding to EGFR. I recall that S1P can modulate signaling pathways like MAPK and PI3K/Akt, which overlap with pathways activated by epiregulin. However, I am not aware of direct evidence or studies specifically showing that S1P suppresses epiregulin expression or activity. It is possible that S1P might indirectly influence epiregulin through downstream signaling, but without specific data or literature to confirm this interaction, I must conclude based on the lack of direct evidence. Therefore, my answer leans towards 'no' unless proven otherwise by specific research.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is telomestatin, a novel statin drug used to treat high cholesterol?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether telomestatin is a novel statin drug used to treat high cholesterol, I first need to clarify what telomestatin is. Telomestatin is a natural product isolated from Streptomyces anulatus and is known primarily as a telomerase inhibitor, often studied for its potential anti-cancer properties due to its ability to interfere with telomere maintenance in cancer cells. Statins, on the other hand, are a class of drugs that inhibit HMG-CoA reductase, an enzyme involved in cholesterol synthesis, and are widely used to lower cholesterol levels. Based on this, telomestatin does not belong to the statin class of drugs, nor is it used for treating high cholesterol. Its primary research focus is in oncology, not lipid management. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Satb1 a transcription factor?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Satb1 is a transcription factor, I first need to recall that transcription factors are proteins that bind to specific DNA sequences to regulate gene expression. Satb1, or Special AT-rich sequence-binding protein 1, is known to be involved in chromatin organization and gene regulation. It binds to AT-rich DNA sequences and can influence the expression of multiple genes by organizing chromatin into loops, often acting as a global regulator. Given this role in directly interacting with DNA and modulating gene expression, Satb1 fits the definition of a transcription factor.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is the 22-item sino-nasal outcome test (SNOT-22) a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS)?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the 22-item Sino-Nasal Outcome Test (SNOT-22) is a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS), I am considering the context and background of the SNOT-22. The SNOT-22 is a patient-reported outcome measure specifically designed to assess the impact of sino-nasal disorders, particularly chronic rhinosinusitis, on quality of life. It covers a range of symptoms and functional limitations, including nasal, emotional, and sleep-related issues. Based on its frequent mention in clinical research, guidelines, and practice for evaluating CRS treatment outcomes and patient experiences, it appears to be a standard tool in this field. It is often referenced in studies and used by clinicians to quantify HRQOL in CRS patients. Therefore, I conclude that it is widely used for this purpose.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SOX10 expressed in melanoma cells?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n\n\n    \"draft\": \"To answer whether SOX10 is expressed in melanoma cells, I first consider the biological context. SOX10 is a transcription factor known to play a critical role in the development of neural crest cells, which give rise to melanocytes, the cells from which melanoma originates. Research and clinical studies have shown that SOX10 is often highly expressed in melanoma cells, as it is involved in melanocyte differentiation and survival. It is also used as a diagnostic marker in pathology to identify melanoma. While expression levels can vary depending on the specific type or stage of melanoma, the general consensus in scientific literature is that SOX10 is indeed expressed in most melanoma cells. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is EuroQol 5-Dimension Health Assessment (EQ-5D) [a widely used, simple instrument that monitors the general health-related quality of life (HRQoL) in chronic disease] a 5 question assessment?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the EuroQol 5-Dimension Health Assessment (EQ-5D) is a 5-question assessment, I need to consider what the EQ-5D entails. The EQ-5D is a standardized instrument used to measure health-related quality of life, often in chronic disease contexts. It is known for its simplicity and wide application. The name '5-Dimension' suggests it covers five specific areas or dimensions of health. Upon reflection, these dimensions are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension typically corresponds to a single question or item where the respondent rates their level of difficulty or severity. Therefore, it seems logical that the EQ-5D consists of 5 questions, one for each dimension. However, I should also consider if there are additional components, like the visual analogue scale (VAS) for overall health, which is sometimes included but is not part of the core 5 dimensions. Since the question specifies '5-Dimension Health Assessment,' it likely refers to the core part of the tool, which is indeed based on 5 questions. Thus, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is neurofilament light marker for disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Neurofilament light (NfL) is a protein found in neurons and is released into the blood and cerebrospinal fluid when neuronal damage occurs. It has been studied as a biomarker for various neurological diseases, including multiple sclerosis, Alzheimer's disease, and traumatic brain injury, as elevated levels often indicate neuronal injury or degeneration. Therefore, it can be considered a marker for disease in the context of neurological conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Phospholemman a membrane protein?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Phospholemman is a membrane protein, I first consider what Phospholemman is. Phospholemman, also known as FXYD1, is a small protein associated with the regulation of ion transport, particularly in cardiac and skeletal muscle cells. It is known to interact with the Na+/K+-ATPase pump, which is embedded in the cell membrane. Given this association, it is likely that Phospholemman is either embedded in or closely associated with the membrane. Upon further reflection, I recall that Phospholemman is indeed an integral membrane protein with a single transmembrane domain. Therefore, it fits the definition of a membrane protein. Based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Mical an oxidoreductase?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Mical is an oxidoreductase, I first need to clarify what Mical refers to in this context. Mical is likely referring to a protein or enzyme, specifically 'Molecule Interacting with CasL,' which is known in biological contexts. Research indicates that Mical is a flavoprotein monooxygenase, an enzyme that catalyzes oxidation-reduction reactions by incorporating oxygen into substrates. Oxidoreductases are a broad class of enzymes that facilitate the transfer of electrons from one molecule to another, which includes monooxygenases like Mical. Since Mical's function involves redox activity, it fits within the oxidoreductase category under the enzyme classification system (EC 1). Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is resistance training usually associated with increasing muscle hypertrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether resistance training is usually associated with increasing muscle hypertrophy, I first consider the definition of resistance training and muscle hypertrophy. Resistance training involves exercises that cause muscles to work against an external force, such as weights or resistance bands, with the goal of improving strength, endurance, or muscle size. Muscle hypertrophy refers to the increase in muscle size due to the growth of muscle fibers, often as a result of mechanical tension, muscle damage, and metabolic stress. Scientific literature and fitness studies consistently show that resistance training, especially when performed with progressive overload (gradually increasing weight or intensity), is a primary stimulus for muscle hypertrophy. While other factors like nutrition (protein intake) and recovery play a role, resistance training is widely recognized as a key driver for hypertrophy in most individuals, assuming proper program design (e.g., volume, intensity, and rest). There are exceptions, such as when resistance training focuses on endurance with very light weights and high reps, which may not significantly induce hypertrophy. However, in general usage and context, resistance training is indeed associated with increasing muscle size. Therefore, the answer should reflect this common association.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is periampullary carcinoma (PAC) a relatively rare genitourinary malignancy",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether periampullary carcinoma (PAC) is a relatively rare genitourinary malignancy, I first need to clarify the nature of PAC. Periampullary carcinoma refers to cancers that arise in the region around the ampulla of Vater, which includes parts of the duodenum, pancreas, bile duct, and ampulla itself. These are typically considered gastrointestinal or pancreaticobiliary malignancies, not genitourinary, as the genitourinary system involves the reproductive and urinary organs (e.g., kidneys, bladder, prostate). Therefore, PAC does not fall under the category of genitourinary malignancies. Additionally, while PAC is less common compared to other cancers like colorectal or breast cancer, the question's classification is incorrect. Since it is not a genitourinary malignancy, the answer to the question as posed should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is pRETRO-SUPER an adenoviral vector?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether pRETRO-SUPER is an adenoviral vector, I first need to consider what pRETRO-SUPER is. From my knowledge, pRETRO-SUPER is a plasmid vector commonly used in RNA interference studies, particularly for expressing short hairpin RNAs (shRNAs) in mammalian cells. It is based on a retroviral system, as the name suggests ('RETRO' indicates retrovirus). Adenoviral vectors, on the other hand, are derived from adenoviruses and are used for gene delivery with different characteristics, such as non-integration into the host genome. Since pRETRO-SUPER is retroviral and not adenoviral, it does not fall under the category of adenoviral vectors. Therefore, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can epigenetic modifications be heritable?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Epigenetic modifications refer to changes in gene expression that do not involve alterations to the underlying DNA sequence, such as DNA methylation or histone modification. The question asks whether these modifications can be passed from one generation to the next. Research shows that while most epigenetic marks are reset during reproduction (e.g., during gamete formation and early embryonic development), there is evidence in some organisms and under specific conditions that certain epigenetic changes can be transmitted across generations. For example, studies in plants, worms, and even mammals have demonstrated transgenerational epigenetic inheritance in response to environmental factors like diet or stress. However, the extent and mechanisms of heritability in humans are still under investigation and not fully conclusive. Given the evidence of heritability in various species, the answer leans toward affirmation.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the likelihood of severe COVID-19?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether ACE inhibitors and ARBs increase the likelihood of severe COVID-19, I first consider the biological context. ACE inhibitors and ARBs are medications used to treat hypertension and other cardiovascular conditions. They affect the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure. There was initial concern during the COVID-19 pandemic that these drugs might increase the risk of severe disease because the SARS-CoV-2 virus uses the ACE2 receptor to enter cells, and these medications can upregulate ACE2 expression in some tissues. However, I recall that multiple studies and clinical data have since investigated this hypothesis. Observational studies and meta-analyses, including those published in major medical journals, have largely found no consistent evidence that ACE inhibitors or ARBs increase the risk of severe COVID-19 outcomes. In fact, some studies suggest a potential protective effect, though this is not conclusive. Guidelines from organizations like the American Heart Association and European Society of Cardiology have recommended continuing these medications in patients with COVID-19 unless otherwise contraindicated. Based on this analysis, the answer should be 'no', as the current evidence does not support an increased likelihood of severe COVID-19 with these drugs.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does p85α homodimerize?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether p85α homodimerizes, I first consider the context of p85α, which is a regulatory subunit of the phosphoinositide 3-kinase (PI3K) enzyme complex. p85α typically forms heterodimers with the catalytic subunit p110 to regulate PI3K activity. The question of homodimerization refers to whether two p85α subunits can bind to each other to form a dimer. Based on current biochemical knowledge, p85α is not generally reported to form homodimers under physiological conditions; its primary role is to interact with p110 or other signaling molecules via its SH2 and SH3 domains. Some studies might suggest potential interactions under specific experimental conditions, but these are not standard or widely accepted. Therefore, the most accurate answer, based on prevailing scientific understanding, is that p85α does not homodimerize in a biologically relevant context.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is thalidomide used as an immunomodulatory drug nowadays?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Thalidomide, originally infamous for causing severe birth defects in the 1950s and 1960s, has been repurposed in modern medicine. I need to consider whether it is currently used as an immunomodulatory drug. After recalling relevant information, I know that thalidomide has been found to have anti-inflammatory and immunomodulatory properties, particularly in the treatment of conditions like multiple myeloma and certain complications of leprosy, such as erythema nodosum leprosum. It is also used in some cases for graft-versus-host disease and other inflammatory conditions. Given this, it seems that thalidomide is indeed used as an immunomodulatory drug today, under strict regulations to prevent its teratogenic effects. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are functional tests a good biomarker for Duchenne Muscular Dystrophy?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether functional tests are a good biomarker for Duchenne Muscular Dystrophy (DMD), I first need to consider what constitutes a biomarker and the role of functional tests in DMD. A biomarker is a measurable indicator used to examine normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. In the context of DMD, a genetic disorder characterized by progressive muscle degeneration and weakness, biomarkers are crucial for diagnosis, monitoring disease progression, and evaluating treatment efficacy. Functional tests, such as the 6-minute walk test, timed function tests (e.g., time to stand or climb stairs), and strength assessments, measure physical capabilities and are often used to assess the functional impact of DMD. These tests are non-invasive, relatively easy to perform, and can provide valuable data on disease progression and treatment effects. However, they may be influenced by factors like patient effort, motivation, fatigue, or learning effects, which could affect their reliability as a consistent biomarker. Additionally, functional tests might not directly reflect the underlying biological changes in muscle tissue, which are central to DMD pathology. While they are useful in clinical assessments, they may not fully meet the criteria for an ideal biomarker, which should be specific, sensitive, and directly linked to the disease mechanism. After weighing these points, I conclude that while functional tests are valuable tools, they are not the most ideal biomarkers for DMD compared to molecular or imaging biomarkers that directly measure dystrophin levels or muscle damage.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, particularly influenza?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider whether there are clinical methods or characteristics that can reliably differentiate COVID-19 from other respiratory illnesses like influenza. COVID-19, caused by the SARS-CoV-2 virus, shares many symptoms with influenza, such as fever, cough, and fatigue. However, there are some distinguishing features. For instance, loss of taste or smell (anosmia) is more commonly associated with COVID-19 than with influenza. Additionally, COVID-19 may present with more severe respiratory distress in certain cases and has a different pattern of transmission and incubation. Despite these differences, overlapping symptoms make it challenging to distinguish them solely based on clinical presentation without diagnostic testing. Testing, such as PCR or antigen tests for COVID-19, is often necessary for a definitive diagnosis. Therefore, while there are clinical clues, a clear distinction often requires laboratory confirmation. The answer should be 'yes' because there are some clinical differences, even if they are not always definitive.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is lumbar puncture the first test that should be performed on a patient with increased intracranial pressure?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether a lumbar puncture should be the first test performed on a patient with increased intracranial pressure (ICP), I need to consider the medical context and guidelines. Increased ICP can be caused by conditions like brain tumors, hemorrhages, or infections such as meningitis. A lumbar puncture (LP) is a procedure to collect cerebrospinal fluid (CSF) for diagnostic purposes, but it carries risks, especially in patients with elevated ICP. Performing an LP in such cases can lead to brain herniation, a life-threatening complication, due to the sudden release of pressure. Therefore, imaging studies like a CT scan or MRI are typically recommended as the first step to identify the cause of increased ICP and rule out contraindications for LP. Only if imaging shows no signs of mass effect or herniation risk, and if there’s suspicion of infection or other conditions requiring CSF analysis, might an LP be considered. Based on this analysis, lumbar puncture should not be the first test in patients with suspected increased ICP due to the potential risks involved.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether mutation of the ARTEMIS gene causes severe combined immunodeficiency (SCID), I first consider the role of the ARTEMIS gene. The ARTEMIS gene, also known as DCLRE1C, is involved in the V(D)J recombination process, which is crucial for the development of T and B cells in the immune system. Mutations in genes involved in this process can lead to immune deficiencies. I recall that mutations in ARTEMIS are indeed associated with a form of SCID, specifically a type known as radiosensitive SCID, due to defects in DNA repair mechanisms. This condition results in a lack of functional T and B cells, leading to severe immune deficiency. Therefore, based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Cinpanemab effective for Parkinson’s Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Cinpanemab is effective for Parkinson’s Disease, I first consider the context of the question. Cinpanemab is a monoclonal antibody designed to target alpha-synuclein, a protein implicated in the pathology of Parkinson’s Disease. Its effectiveness would depend on clinical trial results and scientific evidence. Based on available information up to my knowledge cutoff in October 2023, Cinpanemab was investigated in clinical trials (e.g., by Biogen) for its potential to slow disease progression in Parkinson’s Disease. However, reports indicate that the Phase 2 SPARK study did not meet its primary or secondary endpoints, showing no significant improvement in motor or non-motor symptoms compared to placebo. Without newer evidence suggesting otherwise, it appears that Cinpanemab has not been proven effective for Parkinson’s Disease in the studies conducted so far. Therefore, my answer is based on this analysis of the current data.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Prasinezumab effective for Parkinson’s Disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Prasinezumab is effective for Parkinson’s Disease, I first consider the context of the question. Prasinezumab is a monoclonal antibody designed to target alpha-synuclein, a protein implicated in the pathology of Parkinson’s Disease. Current research, including clinical trials, suggests that while Prasinezumab has shown some potential in slowing disease progression in early-stage Parkinson’s patients (as seen in the PASADENA trial by Roche), the results are not conclusive across all endpoints. The primary endpoint of the trial did not meet statistical significance for overall motor improvement, though secondary endpoints indicated possible benefits in certain subgroups. Given the mixed results and ongoing research, I lean toward a cautious approach. Since the question asks for a definitive judgment and the evidence is not fully conclusive, I will answer 'no' at this stage, acknowledging that future studies might change this perspective.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does CIDEB mutation protect from liver disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether CIDEB mutation protects from liver disease, I first consider the role of CIDEB, a gene involved in lipid metabolism and apoptosis in liver cells. Mutations in CIDEB could theoretically alter lipid handling or cell death pathways, potentially impacting liver disease progression. Recent studies, particularly in the context of non-alcoholic fatty liver disease (NAFLD), suggest that certain CIDEB variants may confer protection by reducing hepatic steatosis or inflammation. However, the evidence is not fully conclusive across all populations or types of liver disease, such as viral hepatitis or alcoholic liver disease. After analyzing this, I lean towards a positive association based on emerging research, but I must confirm the context of the question is aligned with NAFLD or similar conditions where this protective effect has been noted.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there any association between Tripe palms and cancer?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Tripe palms, also known as acanthosis palmaris, is a rare dermatological condition characterized by thickened, velvety palms with pronounced ridges, resembling the appearance of tripe (the stomach lining of certain animals). Medical literature suggests that tripe palms are often associated with underlying malignancies, particularly gastric and lung cancers. Studies indicate that this condition can be a paraneoplastic syndrome, meaning it is a manifestation of an internal cancer. Therefore, the presence of tripe palms should prompt further investigation for potential cancer.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Was AAVS3 developed for hemophilia A?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether AAVS3 was developed for hemophilia A, I need to consider the context of AAVS3. AAVS3 likely refers to a type of adeno-associated virus (AAV) vector used in gene therapy. Hemophilia A is a genetic disorder caused by a deficiency in factor VIII, and gene therapy using AAV vectors has been explored as a treatment to deliver the factor VIII gene. I recall that certain AAV serotypes, like AAV5 and AAV8, have been used in clinical trials for hemophilia A. However, AAVS3 might be a specific variant or a typo. Upon reflection, AAVS3 is not a widely recognized serotype for hemophilia A therapy in current literature; it might refer to a specific construct or be a misnomer. Most hemophilia A gene therapies use AAV5 or AAV8. Therefore, I believe AAVS3 was not specifically developed for hemophilia A.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether DNX-2401 was tested for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), I first considered the nature of DNX-2401. It is an oncolytic virus therapy developed for treating gliomas, particularly glioblastoma, through targeted destruction of cancer cells. DIPG is a type of high-grade glioma affecting the brainstem, primarily in children, and is notoriously difficult to treat. Given that DNX-2401 targets glioma cells, it is plausible that it could be tested for DIPG. I recall that clinical trials and research studies have explored oncolytic viruses for various brain tumors, including pediatric cases. Upon reflection, I believe there have been specific studies or trials investigating DNX-2401 for DIPG, as its mechanism of action could theoretically apply to this tumor type. Therefore, I conclude that it has been tested for DIPG.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Baricitinib effective for Alopecia Areata?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Baricitinib is effective for Alopecia Areata, I first consider the context of the question. Alopecia Areata is an autoimmune condition causing hair loss, and Baricitinib is a JAK inhibitor used primarily for rheumatoid arthritis but has been studied for other autoimmune conditions. Recent clinical trials and FDA approvals in 2022 have indicated that Baricitinib (under the brand name Olumiant) is effective for severe Alopecia Areata, as it helps to reduce inflammation and promote hair regrowth in some patients. The evidence from studies like the BRAVE-AA1 and BRAVE-AA2 trials supports its efficacy in adults with severe cases. Therefore, based on current medical research and regulatory approvals, the answer should affirm its effectiveness.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is erenumab effective for trigeminal neuralgia?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether erenumab is effective for trigeminal neuralgia, I first consider what erenumab is and its approved uses. Erenumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, primarily used for the prevention of migraine in adults. Trigeminal neuralgia, on the other hand, is a chronic pain condition affecting the trigeminal nerve, characterized by sudden, severe facial pain. It is typically treated with anticonvulsants like carbamazepine or surgical interventions, not with migraine-specific treatments. I am not aware of any clinical guidelines or substantial evidence supporting the use of erenumab for trigeminal neuralgia. A quick mental review of medical literature suggests that while CGRP may play a role in some pain pathways, erenumab's mechanism is specifically studied and approved for migraine, not for neuropathic pain conditions like trigeminal neuralgia. There might be off-label use or ongoing research, but without specific data or studies to confirm efficacy, I cannot assume it is effective for this condition. Therefore, based on current knowledge, the answer should be no.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is alternative splicing associated with heart disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether alternative splicing is associated with heart disease, I first consider the biological context. Alternative splicing is a process where a single gene can produce multiple protein isoforms by including or excluding different exons during mRNA processing. This mechanism is crucial for protein diversity and can influence cellular function. Heart disease encompasses a range of conditions affecting the heart, including cardiomyopathy, heart failure, and coronary artery disease, often involving genetic and molecular factors. Research in molecular biology and cardiology suggests that dysregulation of alternative splicing can contribute to pathological conditions in the heart. For instance, studies have shown that specific splicing events in genes like titin (TTN) are linked to dilated cardiomyopathy, a type of heart disease. Aberrant splicing can lead to dysfunctional proteins critical for cardiac muscle function. Therefore, there is evidence supporting an association between alternative splicing and heart disease.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is PRP-40 involved in microexon splicing?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether PRP-40 is involved in microexon splicing, I first consider the role of PRP-40 in splicing processes. PRP-40 is a pre-mRNA processing factor known to be part of the spliceosome complex in yeast, where it facilitates early steps of spliceosome assembly by interacting with other splicing factors. Microexons are very short exons, often less than 30 nucleotides, and their splicing is regulated by specific factors due to their small size and unique recognition challenges. In higher organisms, factors like SR proteins and other RNA-binding proteins are often implicated in microexon recognition. While PRP-40's role in general splicing is established, its specific involvement in microexon splicing is less clear and may depend on the organism or context. Research in yeast might not directly translate to higher eukaryotes where microexon splicing is more prominent, such as in neuronal tissues. After considering this, I recall that in some studies, PRP-40 homologs in higher organisms have been linked to alternative splicing events, but direct evidence for microexon splicing is not definitive in my knowledge base. Given the lack of specific evidence tying PRP-40 directly to microexon splicing, I lean towards a negative answer, but acknowledge that emerging research might suggest otherwise. For the purpose of this response, I will conclude with 'no' based on the general understanding of PRP-40's role.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I first consider the role of microexons and alternative splicing in gene regulation. Microexons are very short exons, often just a few nucleotides long, that can be included or excluded during RNA splicing to create different protein isoforms. Alternative splicing of small GTPase regulators could affect their function, as small GTPases are critical for cellular processes like signal transduction, cytoskeletal dynamics, and vesicle trafficking, which are essential in the central nervous system (CNS). Disruptions in these processes are often linked to CNS diseases such as neurodegenerative disorders (e.g., Alzheimer's, Parkinson's) or neurodevelopmental disorders (e.g., autism). Research suggests that alternative splicing, including microexon splicing, is particularly prevalent in neuronal tissues and can influence synaptic function and plasticity. If microexon splicing alters the activity of small GTPase regulators, it could plausibly impact CNS function and contribute to disease pathology. Therefore, based on this reasoning, there is likely an implication.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does silencing of SRRM4 promote microexon inclusion?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether silencing of SRRM4 promotes microexon inclusion, I first consider the role of SRRM4, which is a splicing factor known to regulate the inclusion of microexons—short exons typically less than 27 nucleotides—in neuronal genes. Research indicates that SRRM4 enhances the inclusion of these microexons during splicing. Therefore, if SRRM4 is silenced, its positive regulatory effect on microexon inclusion would be lost, likely leading to reduced inclusion of microexons. Based on this understanding, silencing SRRM4 should not promote microexon inclusion; instead, it should inhibit it.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether silencing of SRRM4 inhibits tumor growth across cancers, I first consider the role of SRRM4 (Serine/Arginine Repetitive Matrix 4), a splicing factor involved in RNA processing and gene expression regulation. Research suggests that SRRM4 is overexpressed in certain cancers, such as lung and prostate cancer, where it may promote oncogenic splicing events that drive tumor progression. Silencing SRRM4 could disrupt these events, potentially inhibiting tumor growth in those specific cancers. However, cancer is highly heterogeneous, with different molecular drivers across types and even within subtypes of the same cancer. While silencing SRRM4 might be effective in cancers where it plays a critical role, it may not have a universal effect across all cancers due to varying dependencies on SRRM4-mediated splicing. Current literature, including studies on SRRM4 knockdown in specific cancer cell lines, shows promising results in reducing proliferation and tumor growth, but these studies are limited to specific cancer types. There is no comprehensive evidence or clinical data suggesting a pan-cancer effect. Therefore, while silencing SRRM4 may inhibit tumor growth in some cancers, it is unlikely to do so universally across all cancers.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether SRRM4 regulates neuronal-specific microexon splicing of TAF1 mRNA, I first consider the biological context. SRRM4 (Serine/Arginine Repetitive Matrix 4) is a splicing factor known to be involved in the regulation of alternative splicing, particularly in neuronal tissues. It has been implicated in the inclusion of microexons—short exons often found in neuronal transcripts—during mRNA processing. TAF1 (TATA-box binding protein associated factor 1) is a component of the transcription initiation complex, and its mRNA is known to undergo alternative splicing, including neuronal-specific isoforms. Research indicates that SRRM4 specifically promotes the inclusion of microexons in neuronal transcripts, and studies have identified TAF1 as one of the targets where microexon splicing is regulated in a neuronal-specific manner. Given this, it is likely that SRRM4 does regulate the neuronal-specific microexon splicing of TAF1 mRNA.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is PRP-40 regulation of microexons a conserved phenomenon?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether PRP-40 regulation of microexons is a conserved phenomenon, I first consider the biological context. PRP-40 is a splicing factor involved in the regulation of microexons, which are small exons often found in neuronal genes and critical for alternative splicing. The term 'conserved phenomenon' implies that this regulatory mechanism is maintained across different species or evolutionary lineages. Research in molecular biology suggests that microexon regulation is indeed important in various organisms, particularly in vertebrates, where it plays a role in neuronal development and function. Studies have shown that PRP-40 or its homologs are present in multiple species, including humans, mice, and potentially other organisms, indicating a possible conserved role. However, I must consider if there is direct evidence or studies confirming that PRP-40 specifically regulates microexons in a conserved manner across species. While the general mechanism of microexon splicing is conserved, the specific involvement of PRP-40 might vary or be substituted by other factors in different species. Given the lack of specific contradictory evidence in my knowledge base and the general understanding of splicing factor conservation, I lean towards affirming that it is conserved, but I acknowledge the need for precise studies to confirm this. For the purpose of this binary answer, based on the available understanding, I will conclude affirmatively.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does nintedanib improve response rate in patients with bladder cancer?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether nintedanib improves response rate in patients with bladder cancer, I first consider the nature of nintedanib. It is a tyrosine kinase inhibitor primarily used for treating idiopathic pulmonary fibrosis and some types of lung cancer, targeting pathways like VEGF, FGF, and PDGF, which are involved in angiogenesis and tumor growth. Bladder cancer, often treated with chemotherapy, immunotherapy, or targeted therapies, may involve similar pathways, suggesting a potential benefit. However, I am not aware of specific clinical trials or guidelines that confirm nintedanib's efficacy in bladder cancer. Upon reflection, most evidence for nintedanib relates to lung conditions and certain cancers like non-small cell lung cancer, not bladder cancer. Without concrete data or studies showing improved response rates in bladder cancer patients, I cannot confirm a positive effect. Therefore, based on current knowledge, the answer should be no, pending any new research or data that might suggest otherwise.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether prehospital transdermal glyceryl trinitrate (GTN) was effective for stroke in the RIGHT-2 trial, I need to consider the context and findings of the trial. The RIGHT-2 trial was a randomized, controlled study conducted in the UK to evaluate the efficacy and safety of GTN administered prehospital to patients with presumed stroke. The primary outcome was functional outcome at 90 days, measured by the modified Rankin Scale (mRS). The results, published in 2019, showed that GTN did not improve functional outcomes compared to the control group. There was no significant difference in the primary outcome between the GTN and sham groups, and there were concerns about potential harm in certain subgroups, such as those with intracerebral hemorrhage. Therefore, based on the trial results, GTN was not effective for stroke in this setting.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Was erythropoietin effective for optic neuritis in the TONE trial?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether erythropoietin was effective for optic neuritis in the TONE trial, I need to consider the context and findings of the trial. The TONE trial (Treatment of Optic Neuritis with Erythropoietin) was a clinical study investigating the potential neuroprotective effects of erythropoietin in patients with optic neuritis, often an early sign of multiple sclerosis. The primary endpoint of the trial was likely related to visual recovery or nerve damage prevention, measured through visual acuity or retinal nerve fiber layer thickness. Based on available data or general knowledge of the trial results, the study did not show a significant benefit of erythropoietin over placebo in improving visual outcomes or protecting against nerve damage. Therefore, it appears that erythropoietin was not effective for optic neuritis in this context.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can losartan reduce brain atrophy in Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether losartan can reduce brain atrophy in Alzheimer's disease, I first consider the nature of losartan as an angiotensin II receptor blocker (ARB) primarily used to treat high blood pressure. I then evaluate if there is any scientific evidence or clinical research linking losartan to neuroprotection or reduction of brain atrophy in Alzheimer's disease. Brain atrophy in Alzheimer's is associated with neuronal loss and cognitive decline, and some studies suggest that ARBs like losartan may have protective effects on the brain by reducing inflammation and improving cerebral blood flow. However, I recall that while there are preclinical studies and hypotheses supporting a potential benefit, there is no definitive clinical evidence or large-scale human trials confirming that losartan specifically reduces brain atrophy in Alzheimer's patients. Current treatments for Alzheimer's focus on symptom management rather than reversing atrophy, and losartan is not an approved treatment for this purpose. Therefore, based on the lack of conclusive evidence, my answer leans towards 'no' at this time, acknowledging that future research might provide different insights.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is levosimendan effective for amyotrophic lateral sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether levosimendan is effective for amyotrophic lateral sclerosis (ALS), I first consider the nature of ALS, a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and respiratory failure. Levosimendan is a calcium sensitizer primarily used for acute heart failure, enhancing cardiac contractility and vasodilation. Its potential role in ALS could relate to improving respiratory muscle function or diaphragm strength, as respiratory failure is a critical issue in ALS. I recall that there have been studies exploring levosimendan in ALS, particularly focusing on its effects on respiratory function. A notable clinical trial, the LEVALS study, investigated levosimendan in ALS patients and found some improvement in diaphragm function and respiratory parameters in certain doses, but the overall impact on disease progression or survival remains unclear. The drug is not a standard treatment for ALS, and current evidence does not conclusively establish it as effective for managing the disease broadly. Guidelines and reviews suggest that while there may be some benefit in specific contexts, it is not a primary or proven therapy for ALS. Therefore, based on the available information, I conclude that levosimendan is not considered definitively effective for ALS at this time.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether bexarotene should be used for relapsing-remitting multiple sclerosis (RRMS), I first considered the nature of RRMS, which is a form of multiple sclerosis characterized by episodes of new or worsening symptoms followed by periods of recovery. Current treatments for RRMS focus on disease-modifying therapies that reduce inflammation and prevent relapses. Bexarotene is a retinoid X receptor agonist primarily used for cutaneous T-cell lymphoma, and there is emerging research suggesting it may promote remyelination in animal models of MS by enhancing oligodendrocyte differentiation. However, I analyzed that there is currently no substantial clinical evidence or approval from regulatory bodies like the FDA or EMA for its use in RRMS. Clinical trials are limited, and potential side effects, such as hyperlipidemia and hypothyroidism, could pose risks. Without robust human data or guideline recommendations, it is not appropriate to recommend bexarotene for RRMS at this time.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Efgartigimod be used for myasthenia gravis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether Efgartigimod can be used for myasthenia gravis, I first consider the nature of the drug and the condition. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by muscle weakness due to autoantibodies targeting acetylcholine receptors. Efgartigimod, also known as Efgartigimod alfa-fcab, is a medication designed to reduce pathogenic IgG antibodies by binding to the neonatal Fc receptor, which is a novel approach for treating autoimmune diseases. Clinical trials and FDA approval data indicate that Efgartigimod has been approved for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive, as of December 2021. Therefore, it is indeed indicated for this condition in specific cases. The answer should be affirmative based on this information.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the current state of clinical research on pioglitazone and its potential effects on cognitive impairment in individuals at risk for Alzheimer's disease. Pioglitazone is a medication primarily used to treat type 2 diabetes by improving insulin sensitivity. Some preclinical studies and early-phase clinical trials have suggested that it may have neuroprotective effects, potentially reducing inflammation and improving brain metabolism, which could be relevant to Alzheimer's disease. Notably, the TOMMORROW study, a large phase 3 clinical trial, investigated pioglitazone's ability to delay the onset of mild cognitive impairment due to Alzheimer's disease in cognitively normal individuals at high risk. However, the trial was terminated early in 2018 due to lack of efficacy, as interim analyses showed no significant benefit in delaying cognitive decline. While some smaller studies or subgroup analyses might suggest potential benefits under specific conditions, the most robust clinical trial data currently available does not support the claim that pioglitazone can delay cognitive impairment in this population. Therefore, based on the predominant evidence from clinical trials, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is Tilavonemab effective for progressive supranuclear palsy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Tilavonemab is effective for progressive supranuclear palsy (PSP), I first consider the context of the question. PSP is a rare neurodegenerative disorder, and Tilavonemab is a monoclonal antibody targeting tau protein, which is implicated in PSP pathology. I recall that clinical trials have been conducted to evaluate its efficacy. Based on available data up to my knowledge cutoff in October 2023, Phase 2 trials, such as the one conducted by AbbVie, showed that Tilavonemab did not meet primary endpoints for slowing disease progression in PSP patients. The results indicated no significant clinical benefit compared to placebo. Therefore, current evidence suggests it is not effective for PSP, though further research might be ongoing or new data could emerge. For the purpose of this yes/no answer, I will base my response on the most recent trial outcomes I’m aware of.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether ocrelizumab is effective for primary progressive multiple sclerosis (PPMS), I am considering the available medical knowledge and clinical evidence. Ocrelizumab is a monoclonal antibody that targets CD20-positive B cells, and it has been studied for its efficacy in multiple sclerosis. Specifically, for PPMS, the ORATORIO clinical trial demonstrated that ocrelizumab significantly reduced the risk of disability progression compared to placebo in patients with PPMS. Based on this evidence, it appears that ocrelizumab is effective for PPMS, and it is one of the few treatments approved by regulatory bodies like the FDA for this condition. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is deucravacitinib effective for psoriasis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether deucravacitinib is effective for psoriasis, I first consider the context of the question. Psoriasis is a chronic autoimmune skin condition, and deucravacitinib is a medication recently studied for its potential in treating such conditions. I recall that deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor, which targets specific pathways involved in inflammation. Clinical trials, such as the POETYK PSO-1 and PSO-2 studies, have shown that deucravacitinib significantly improves skin clearance in patients with moderate to severe plaque psoriasis compared to placebo and even outperformed some existing treatments like apremilast. The data indicates a higher percentage of patients achieving PASI 75 (a 75% reduction in psoriasis severity) with deucravacitinib. Additionally, it has been approved by regulatory bodies like the FDA for this indication in 2022 under the brand name Sotyktu. While there may be variations in individual responses and potential side effects, the evidence supports its effectiveness. Therefore, based on this analysis, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is daridorexant effective for insomnia?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether daridorexant is effective for insomnia, I first consider the context of the question. Daridorexant is a medication classified as a dual orexin receptor antagonist, specifically developed for the treatment of insomnia. Clinical studies and trials, such as those published in medical journals, have shown that daridorexant helps improve sleep onset and maintenance in adults with insomnia. It works by blocking the action of orexin, a neurotransmitter that promotes wakefulness, thereby facilitating sleep. Regulatory bodies like the FDA have approved daridorexant (under the brand name Quviviq) for the treatment of insomnia based on evidence from randomized controlled trials demonstrating its efficacy and safety compared to placebo. While individual responses to medication can vary, and side effects or contraindications may exist, the general consensus from available data supports its effectiveness for insomnia. Therefore, based on this analysis, the answer should affirm its effectiveness.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is tebentafusp effective for uveal melanoma?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether tebentafusp is effective for uveal melanoma, I first consider the context of the question. Uveal melanoma is a rare cancer of the eye, and treatment options have historically been limited, especially for metastatic cases. Tebentafusp is a novel bispecific protein designed to target gp100, a protein expressed in melanoma cells, and redirect T-cells to attack the cancer. I recall that clinical trials, particularly the IMCgp100-202 trial, have shown promising results. In this phase 3 trial, tebentafusp demonstrated a significant improvement in overall survival compared to standard treatments like checkpoint inhibitors for patients with previously untreated metastatic uveal melanoma. Specifically, the trial results indicated a hazard ratio for death of 0.51, suggesting a substantial benefit. However, effectiveness can depend on factors like patient selection (HLA-A*02:01-positive patients were the target group in the trial) and the stage of the disease. Side effects, such as cytokine release syndrome, are also a consideration but do not negate the overall efficacy. Given the data from the trial and the FDA approval of tebentafusp (under the brand name Kimmtrak) in 2022 for unresectable or metastatic uveal melanoma, I conclude that it is effective for this condition in the specified patient population.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can lenacapavir be used for HIV?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Lenacapavir is a novel antiretroviral drug that has been developed for the treatment of HIV. It is a capsid inhibitor that works by interfering with the HIV capsid, a protein shell that protects the virus's genetic material. Clinical trials and studies have shown that lenacapavir is effective in treating HIV, particularly in individuals with multidrug-resistant strains. It has been approved by regulatory authorities like the FDA for use in heavily treatment-experienced adults with HIV who have limited treatment options. Therefore, it can be used for HIV treatment under specific conditions and guidelines.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Wilson's disease described as an iron storage disease?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Wilson's disease is a genetic disorder characterized by the accumulation of copper in the body, particularly in the liver, brain, and other organs, due to a mutation in the ATP7B gene. It is not related to iron storage. Iron storage diseases, such as hemochromatosis, involve the excessive accumulation of iron in the body. Therefore, Wilson's disease should not be described as an iron storage disease.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is medical hydrology the same as Spa therapy?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether medical hydrology is the same as spa therapy, I first need to clarify the definitions of both terms. Medical hydrology is the science of using water for therapeutic purposes, often in a clinical or medical context, focusing on the physiological effects of water on the body, such as in balneotherapy or hydrotherapy for specific health conditions. Spa therapy, on the other hand, generally refers to wellness treatments at a spa, which may include water-based therapies but often encompasses a broader range of relaxation and beauty treatments not necessarily focused on medical outcomes. While there is overlap, as both can involve water-based treatments, medical hydrology seems to be more scientifically grounded and medically oriented, whereas spa therapy is often more about general well-being and relaxation. Therefore, they are related but not identical.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the North Star Ambulatory Assessment (NSAA) score is a reliable clinical outcome for assessing disease progression in Duchenne Muscular Dystrophy (DMD), I first consider the purpose and design of the NSAA. The NSAA is a functional scale specifically developed for ambulant boys with DMD to measure motor performance through a series of tasks like standing, walking, and climbing stairs. It is widely used in clinical trials and clinical practice. Research and clinical studies suggest that the NSAA is sensitive to changes over time and correlates with disease progression in DMD, showing reliability and validity in capturing functional decline. However, factors such as variability in patient effort, age, and stage of disease might influence the consistency of results. Despite these considerations, the NSAA is generally accepted as a standard tool in DMD research and care, supported by evidence from multiple studies. Therefore, I conclude that it is reliable for this purpose.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can modulation of KCNQ1 splicing prevent arrhythmias?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether modulation of KCNQ1 splicing can prevent arrhythmias, I first consider the role of KCNQ1, a gene encoding a potassium channel protein critical for cardiac repolarization. Mutations or dysregulation in KCNQ1 are linked to Long QT Syndrome (LQTS), a condition that predisposes individuals to arrhythmias. Splicing modulation could theoretically correct aberrant splicing variants or enhance functional protein expression, potentially stabilizing cardiac electrical activity. Research suggests that alternative splicing of KCNQ1 can influence channel function, and targeted interventions (like antisense oligonucleotides) have shown promise in other genetic disorders by correcting splicing defects. However, direct evidence for preventing arrhythmias via KCNQ1 splicing modulation is limited and context-dependent, requiring specific mutations or conditions. Clinical translation and safety also remain unproven. Given the plausible mechanism and emerging research, I lean toward a positive potential but acknowledge the lack of definitive proof. Thus, my answer is based on theoretical and preliminary evidence.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can the concept of digital twins be applied in Precision Nutrition?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the concept of digital twins can be applied in Precision Nutrition, I first need to understand both concepts. A digital twin is a virtual representation of a physical entity or system, often used in industries like manufacturing or healthcare to simulate and predict behaviors or outcomes. Precision Nutrition involves tailoring dietary recommendations to an individual's unique genetic, lifestyle, and environmental factors. Applying digital twins in this context could mean creating a virtual model of a person's nutritional needs and responses based on real-time data like genetic profiles, gut microbiome, activity levels, and dietary intake. This model could simulate how different foods or diets might affect the individual's health, metabolism, or disease risk, allowing for highly personalized nutrition plans. There are already examples of digital twins in healthcare, such as virtual models of organs or patient physiology, so extending this to nutrition seems feasible, especially with advancements in wearable tech and AI for data integration. There are challenges, like ensuring data accuracy and privacy, but the concept itself appears applicable. Therefore, my answer is affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is prosopagnosia also known as lack of auditory recognition?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Prosopagnosia is a neurological condition characterized by the inability to recognize faces, often referred to as 'face blindness.' It is specifically related to visual recognition of faces and does not pertain to auditory recognition, which involves identifying or recognizing sounds or voices. Auditory recognition issues would fall under different conditions, such as auditory agnosia. Therefore, prosopagnosia is not known as a lack of auditory recognition.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do cells undergoing necroptosis show disruption of their cell membranes?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Necroptosis is a programmed form of necrosis, or cell death, that is distinct from apoptosis. It is characterized by the activation of specific signaling pathways, including the involvement of receptor-interacting protein kinases (RIPK1 and RIPK3) and mixed lineage kinase domain-like protein (MLKL). A hallmark of necroptosis is the loss of plasma membrane integrity, which leads to the release of intracellular contents and often triggers inflammation. This disruption of the cell membrane is a defining feature, distinguishing necroptosis from apoptosis, where the membrane typically remains intact until late stages. Therefore, cells undergoing necroptosis do indeed show disruption of their cell membranes.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Iron deficiency anemia a common complication of chronic kidney disease?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether iron deficiency anemia is a common complication of chronic kidney disease (CKD), I first consider the relationship between the two conditions. CKD often leads to reduced production of erythropoietin, a hormone produced by the kidneys that stimulates red blood cell production. This can result in anemia. Additionally, CKD patients may experience iron deficiency due to blood loss from dialysis, reduced dietary intake, or impaired iron absorption. Medical literature and clinical guidelines, such as those from the National Kidney Foundation, indicate that anemia, often related to iron deficiency, is indeed a frequent complication in CKD, especially in advanced stages. Therefore, it is reasonable to conclude that iron deficiency anemia is common in this context.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Anemia is not associated with chronic kidney failure",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether anemia is not associated with chronic kidney failure, I need to consider the medical relationship between the two conditions. Chronic kidney failure, or chronic kidney disease (CKD), often leads to a decrease in the production of erythropoietin, a hormone produced by the kidneys that stimulates red blood cell production. This reduction can result in anemia, which is a common complication of CKD. Therefore, anemia is indeed associated with chronic kidney failure. The statement in the question claims the opposite, so the correct response should reflect that the statement is incorrect.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is anaphylaxis a results of mast cell activation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Anaphylaxis is a severe allergic reaction that can be life-threatening. It occurs when the immune system overreacts to an allergen, leading to the release of chemicals that cause symptoms like difficulty breathing, swelling, and a drop in blood pressure. Mast cells, a type of immune cell, play a central role in this process. When activated by an allergen binding to IgE antibodies on their surface, mast cells release histamine and other mediators that trigger the symptoms of anaphylaxis. Therefore, anaphylaxis is indeed a result of mast cell activation.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is trichotillomania encountered with equali frequency in males and females?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether trichotillomania is encountered with equal frequency in males and females, I first considered the nature of trichotillomania, which is a mental health disorder characterized by the recurrent pulling out of one's hair. I recalled that research and clinical studies often discuss the prevalence of this condition across genders. Upon reflection, I remember that trichotillomania is generally reported to be more common in females than in males, with some studies suggesting a female-to-male ratio of approximately 4:1 in clinical settings. However, there might be underreporting or differences in help-seeking behavior among males, which could skew the data. Despite this, the consensus in psychological and psychiatric literature leans towards a higher frequency in females. Therefore, it does not appear to be encountered with equal frequency in both genders.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can skin picking phenotype present following methylphenidate treatment?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether skin picking phenotype can present following methylphenidate treatment, I first consider the nature of methylphenidate, a stimulant commonly used to treat ADHD. It works by increasing dopamine and norepinephrine levels in the brain, which can sometimes lead to side effects like anxiety, nervousness, or compulsive behaviors. Skin picking, or excoriation disorder, is a repetitive behavior often linked to stress, anxiety, or obsessive-compulsive tendencies. There is evidence in medical literature suggesting that stimulant medications like methylphenidate can exacerbate or trigger compulsive behaviors, including skin picking, in some individuals, particularly those with a predisposition to such behaviors or underlying psychiatric conditions. Case reports and studies have documented instances where methylphenidate use correlates with the onset or worsening of skin picking. Therefore, it is plausible and supported by clinical observations that this phenotype can present following treatment.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Optogenetics refers to the study of gene expression optimization",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Optogenetics is a field that combines optics and genetics to control and monitor the activities of individual neurons in living tissue using light. It does not refer to the study of gene expression optimization, which is more related to genetic engineering or synthetic biology aimed at enhancing or modifying gene expression. Therefore, the statement is incorrect.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the current status of CAR-T cell therapies in medical treatments. CAR-T cell therapies are a type of immunotherapy where T cells are genetically engineered to target specific cancer cells. I recall that several CAR-T therapies have been developed and approved by regulatory bodies like the FDA for certain types of B cell malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. For instance, therapies like Kymriah and Yescarta have been approved for these conditions. Since the question is specifically about B cell malignancies, and there are approved therapies targeting these, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether deflazacort is more efficient than prednisone or prednisolone for the treatment of Duchenne muscular dystrophy (DMD), I need to consider the available clinical evidence and expert consensus. Deflazacort is a corticosteroid specifically approved for DMD in some regions, and studies, such as those published in journals like Neurology (2016), have shown that it may offer similar efficacy to prednisone/prednisolone in terms of delaying loss of ambulation and maintaining muscle strength. Additionally, deflazacort is often associated with a better side effect profile, particularly with less weight gain compared to prednisone. However, 'efficiency' could refer to either clinical effectiveness or cost-effectiveness, and while deflazacort may have advantages in tolerability, it is often more expensive. Based on clinical guidelines and studies, deflazacort is generally considered at least as effective as, if not more tolerable than, prednisone/prednisolone for DMD treatment. Therefore, in the context of overall benefit to the patient, I lean towards 'yes', acknowledging that individual responses and access to medication may vary.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether casimersen is effective for the treatment of Duchenne muscular dystrophy (DMD), I first consider the nature of DMD, a genetic disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Casimersen is an antisense oligonucleotide designed to treat DMD in patients with a specific mutation amenable to exon 45 skipping. Clinical trials and FDA approval data indicate that casimersen increases dystrophin production in skeletal muscle, which is a surrogate endpoint for clinical benefit. The FDA granted accelerated approval to casimersen in February 2021 based on this data, though further studies are needed to confirm long-term clinical benefits. Given the evidence of increased dystrophin production and the targeted mechanism for specific DMD mutations, I conclude that casimersen is effective for certain patients with DMD.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether viltolarsen is effective for the treatment of Duchenne muscular dystrophy (DMD), I first consider the nature of DMD, a genetic disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Viltolarsen is an antisense oligonucleotide designed to treat DMD in patients with specific mutations amenable to exon 53 skipping, which allows for the production of a partially functional dystrophin protein. Clinical trials and studies, such as those leading to its accelerated approval by the FDA in 2020, have shown that viltolarsen can increase dystrophin production in skeletal muscle. However, the clinical benefit, such as improved motor function, is still under investigation with ongoing confirmatory trials. While there is evidence of biochemical efficacy (increased dystrophin levels), the long-term clinical effectiveness in significantly altering disease progression remains to be fully established. Given the question's broad phrasing and the context of 'effective' likely referring to its intended therapeutic purpose and regulatory approval, I lean towards a positive response, acknowledging its targeted efficacy for a subset of DMD patients.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether golodirsen is effective for the treatment of Duchenne muscular dystrophy (DMD), I first consider the nature of DMD, a genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle degeneration. Golodirsen is an antisense oligonucleotide designed to treat DMD in patients with a specific mutation amenable to exon 53 skipping, which allows for the production of a shorter but functional dystrophin protein. Clinical trials and studies, such as those reviewed by the FDA, have shown that golodirsen can increase dystrophin production in some patients. However, the clinical benefit, such as improved muscle function or delayed disease progression, is still under evaluation with mixed results in terms of significant functional improvement. While it was granted accelerated approval by the FDA in 2019 based on dystrophin increase as a surrogate endpoint, full confirmation of clinical efficacy requires further studies. Given the question's broad phrasing and the evidence of some positive effect on dystrophin levels, I lean towards a 'yes' for effectiveness in a specific subset of patients, though not universally for all DMD cases. Since the question does not specify a subgroup, I must consider the general context. Ultimately, based on available data, I conclude that golodirsen is considered effective for certain DMD patients under specific conditions.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether eteplirsen is effective for the treatment of Duchenne muscular dystrophy (DMD), I first consider the context of the disease and the drug. DMD is a genetic disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Eteplirsen is an antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, potentially allowing the production of a shorter but functional dystrophin protein in patients with specific mutations amenable to this skipping. Clinical trials and studies, such as those reviewed by the FDA, have shown mixed results. While there is evidence of increased dystrophin production in some patients, the clinical benefits, such as improved motor function or delayed disease progression, have been debated due to small sample sizes and limited long-term data. The FDA granted accelerated approval in 2016 based on dystrophin increase as a surrogate endpoint, but this does not conclusively confirm clinical effectiveness. Considering the available evidence, there is some indication of benefit for a subset of patients, so I lean toward a positive response, acknowledging the controversy and limitations.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is SARS-CoV-2 transmitted through breast milk?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether SARS-CoV-2 is transmitted through breast milk, I need to consider the current scientific understanding. Studies and health organizations like the WHO and CDC have indicated that there is no conclusive evidence showing that SARS-CoV-2 is transmitted through breast milk. While the virus has been detected in breast milk in rare cases, transmission to infants via this route has not been confirmed. The benefits of breastfeeding are well-documented, and guidelines generally support continued breastfeeding with precautions if the mother is infected. Therefore, based on the available data, the answer should be 'no', as there is no definitive proof of transmission through breast milk.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Do machine learning-based methods outperform statistical methods for survival analysis?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether machine learning-based methods outperform statistical methods for survival analysis, I need to consider the context and criteria for 'outperformance,' such as predictive accuracy, interpretability, and handling of complex data. Statistical methods, like the Cox proportional hazards model, are well-established, interpretable, and effective for survival analysis when assumptions (e.g., proportional hazards) are met. They often perform well with smaller datasets and provide clear insights into variable effects. On the other hand, machine learning methods, such as random survival forests or deep learning models, can capture non-linear relationships and handle high-dimensional data better, often leading to superior predictive performance in complex scenarios. However, they may lack interpretability and require larger datasets to avoid overfitting. Research and comparisons (e.g., studies in medical informatics) suggest that machine learning methods frequently outperform statistical methods in terms of predictive accuracy, especially with large, complex datasets, but this is not universal and depends on the specific problem and data characteristics. Given the general trend in recent literature favoring machine learning for predictive tasks in survival analysis, I lean towards 'yes,' but acknowledge that statistical methods can still be preferable in certain contexts.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Does iron regulate oligodendrocyte maturation?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether iron regulates oligodendrocyte maturation, I first consider the biological context. Oligodendrocytes are cells in the central nervous system responsible for producing myelin, which insulates nerve fibers. Iron is a crucial element in cellular processes, including energy metabolism and enzymatic functions. Research indicates that iron is essential for myelination, as it is a cofactor for enzymes involved in lipid synthesis, a key component of myelin. Studies have shown that iron deficiency can impair oligodendrocyte development and myelination, suggesting a regulatory role. Additionally, iron accumulation in oligodendrocytes during development supports the idea that iron availability influences their maturation. Based on this analysis, it appears that iron does play a role in regulating oligodendrocyte maturation.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are LOQ and LOD the same?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether LOQ (Limit of Quantification) and LOD (Limit of Detection) are the same, I need to consider their definitions in analytical chemistry. LOD is the lowest concentration of a substance that can be reliably detected by a method, indicating presence but not necessarily accurate measurement. LOQ, on the other hand, is the lowest concentration at which a substance can be quantitatively measured with acceptable precision and accuracy. Based on this, they are related but distinct concepts, as LOQ is typically higher than LOD and involves reliable quantification, not just detection. Therefore, they are not the same.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects motor neurons. Research has shown that mutations in the Superoxide Dismutase 1 (SOD1) gene are linked to a subset of familial ALS cases, which account for about 10-20% of all ALS cases. The SOD1 gene is involved in protecting cells from oxidative stress, and mutations can lead to toxic protein misfolding, contributing to motor neuron degeneration. Therefore, ALS can indeed be associated with mutations in the SOD1 gene.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether Quercetin-biapigenin nanoparticles have been shown to be effective in penetrating the blood-brain barrier, I first consider the context of the compounds involved. Quercetin and biapigenin are flavonoids known for their antioxidant and anti-inflammatory properties. Nanoparticles are often used to enhance the delivery of such compounds across biological barriers like the blood-brain barrier (BBB), which is notoriously difficult to penetrate due to its selective permeability. I am not immediately aware of specific studies or data directly addressing Quercetin-biapigenin nanoparticles and their ability to cross the BBB. My knowledge might be limited to general trends in nanoparticle research for drug delivery, where certain formulations (like lipid-based or polymeric nanoparticles) have shown promise in BBB penetration. However, without specific evidence or studies on this exact combination, I must conclude that there is no definitive information available in my knowledge base to confirm their effectiveness in this regard. Therefore, I will answer based on the lack of specific evidence.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"I need to analyze the question about whether OXLUMO (lumasiran) is used for the treatment of primary hyperoxaluria. First, I recall that primary hyperoxaluria is a rare genetic disorder that causes overproduction of oxalate, leading to kidney stones and potential kidney damage. OXLUMO is a medication that I believe targets the underlying cause of this condition by reducing oxalate production. It is an RNA interference (RNAi) therapeutic designed to decrease the levels of oxalate in the body by targeting the hydroxyacid oxidase 1 (HAO1) gene, which is involved in oxalate synthesis. Based on this understanding, OXLUMO should indeed be used for treating primary hyperoxaluria, specifically type 1, as it is approved for this indication by regulatory authorities like the FDA. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can untranslated regions (UTRs) regulate gene expression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Untranslated regions (UTRs) are sections of mRNA that are not translated into protein, located at the 5' and 3' ends of the coding sequence. The 5' UTR can influence the initiation of translation through elements like ribosome binding sites or secondary structures that affect ribosome access. The 3' UTR often contains binding sites for microRNAs or RNA-binding proteins that can regulate mRNA stability, localization, or translation efficiency. Therefore, UTRs play a significant role in post-transcriptional regulation of gene expression.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can the epigenetic status of introns affect gene expression?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether the epigenetic status of introns can affect gene expression, I first consider the role of introns and epigenetics. Introns are non-coding regions of DNA within a gene that are spliced out during RNA processing. Epigenetics refers to modifications, such as DNA methylation or histone modification, that influence gene expression without altering the DNA sequence. While introns themselves do not code for proteins, they can contain regulatory elements or influence chromatin structure. Research suggests that epigenetic modifications in intronic regions, like methylation patterns, can impact splicing efficiency, chromatin accessibility, or the recruitment of transcription factors, thereby indirectly affecting gene expression. Therefore, it seems plausible that the epigenetic status of introns can indeed influence gene expression.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider whether there are clinical methods or characteristics that can reliably differentiate COVID-19 from other respiratory illnesses like influenza. COVID-19, caused by the SARS-CoV-2 virus, shares many symptoms with influenza, such as fever, cough, and fatigue. However, there are some distinguishing features, such as the loss of taste or smell (anosmia) which is more specific to COVID-19. Additionally, COVID-19 can lead to more severe respiratory complications in certain cases, and the progression of symptoms might differ. Clinically, though, these differences are not always clear-cut, and definitive diagnosis often requires laboratory testing like PCR for SARS-CoV-2 or influenza-specific tests. Despite overlapping symptoms, there are clinical clues and patterns (e.g., epidemiological context, specific symptoms like anosmia) that can help distinguish them, even if not definitively without testing. Therefore, the answer should be 'yes', as there are ways to distinguish them clinically, though not always with complete certainty without diagnostic tests.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether COVID-19 caused by the Omicron variant is less severe than infections caused by other variants, I need to consider the available scientific evidence up to my knowledge cutoff in April 2023. The Omicron variant, first identified in late 2021, has been associated with a higher transmission rate but generally milder symptoms compared to earlier variants like Delta. Studies and data from various health organizations, including the WHO and CDC, suggest that Omicron often results in less severe illness, particularly in vaccinated individuals, with lower rates of hospitalization and death. However, severity can still vary based on factors like age, underlying health conditions, and vaccination status. While there are exceptions and ongoing research, the consensus leans toward Omicron being less severe on average than variants like Delta. Therefore, I will answer affirmatively, acknowledging that this is a generalization and not universally true for every case.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer this question, I need to consider the current medical guidelines and evidence regarding the use of inhaled glucocorticoids (ICS) in patients with asthma or COPD during the COVID-19 pandemic. Inhaled glucocorticoids are a cornerstone of treatment for controlling inflammation in these conditions. Stopping these medications could lead to exacerbations of asthma or COPD, which might increase the risk of severe illness if the patient contracts COVID-19. According to major health organizations like the CDC, WHO, and respiratory societies such as the American Thoracic Society, there is no evidence suggesting that ICS increase the risk of contracting COVID-19 or worsen outcomes. In fact, continuing these medications is recommended to maintain disease control. Some studies even suggest that ICS might have a protective effect against severe COVID-19 outcomes, though this is not conclusive. Therefore, advising patients to stop these medications to prevent COVID-19 is not supported by current evidence or guidelines.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is adenosine methylation an epigenetic modification?",
    "answer": "yes",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether adenosine methylation is an epigenetic modification, I first need to define epigenetic modifications. Epigenetic modifications are chemical changes to DNA or histone proteins that affect gene expression without altering the DNA sequence itself. Common examples include DNA methylation (typically on cytosine bases in mammals) and histone modifications. Adenosine methylation, specifically N6-methyladenosine (m6A), occurs on RNA molecules rather than DNA. It is a post-transcriptional modification that influences RNA stability, splicing, and translation. Since it does not directly modify DNA or histones and is not heritable in the same way as DNA methylation, it is generally not classified as an epigenetic modification in the traditional sense. However, some broader definitions of epigenetics might include RNA modifications under the umbrella of epigenetic regulation due to their role in gene expression control. Given the strict definition, I conclude that adenosine methylation is not considered a classic epigenetic modification.\",\n    \"answer\": \"no\"\n}",
    "correct": false
  },
  {
    "question": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether analgesics or antipyretics can be taken for side effects following COVID-19 vaccination, I first consider the common side effects of the vaccine, which include pain at the injection site, fever, fatigue, and muscle aches. Analgesics (pain relievers) and antipyretics (fever reducers) like acetaminophen or ibuprofen are often used to manage such symptoms. I recall that health authorities, such as the CDC and WHO, have stated that it is generally safe to take these medications to alleviate discomfort after vaccination, though they advise against taking them preemptively before vaccination as it might interfere with the immune response. However, for post-vaccination side effects, there is no strong evidence suggesting harm. I also consider that individual health conditions or allergies might affect this decision, but the question seems to ask about general use. Based on this analysis, I conclude that it is acceptable to take these medications for side effects after vaccination.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer the question, I first need to understand what Luminopsins are. Luminopsins are a class of proteins used in optogenetics, which are engineered fusion proteins combining a light-sensitive opsin (like channelrhodopsin) with a bioluminescent protein (like luciferase). The purpose is to allow control of neural activity using light generated internally via a chemical reaction, rather than external light sources. Now, considering the components mentioned in the question: luminol is a chemical compound used in chemiluminescence, often in forensic science to detect blood, but it is not a protein. Rhodopsin, on the other hand, is a light-sensitive protein found in the retina, involved in vision. However, Luminopsins typically involve opsins like channelrhodopsin, not necessarily rhodopsin, and they use proteins like luciferase, not luminol. Therefore, Luminopsins are not fusion proteins of luminol (a chemical, not a protein) and rhodopsin. The answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "In twin-twin transfusion syndrome, are the twins identical?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Twin-twin transfusion syndrome (TTTS) is a condition that occurs in monochorionic twin pregnancies, where twins share a single placenta. This condition typically affects identical twins because they are monozygotic, meaning they originate from a single fertilized egg that splits into two embryos. Since identical twins have the same genetic makeup and often share a placenta, the conditions for TTTS are met. It is extremely rare for non-identical (dizygotic) twins to share a placenta, so TTTS is almost exclusively associated with identical twins. Therefore, the answer should be affirmative.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Zanubrutinib is a first-generation BTK inhibitor approved by the US FDA, I need to consider the classification of BTK inhibitors and the approval status of Zanubrutinib. BTK inhibitors are categorized into generations based on their development and specificity. First-generation BTK inhibitors, like Ibrutinib, are less selective and have more off-target effects. Zanubrutinib is a second-generation BTK inhibitor, designed to be more selective with fewer side effects. Additionally, Zanubrutinib (under the brand name Brukinsa) has been approved by the FDA for certain indications, such as mantle cell lymphoma and Waldenström's macroglobulinemia. Since it is not a first-generation inhibitor, despite being FDA-approved, the answer should reflect its correct classification.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether CRISPR/Cas12a can be used for the detection of EGFR mutations in circulating DNA, I first consider the capabilities of CRISPR/Cas12a. CRISPR/Cas12a is a gene-editing tool that has been adapted for diagnostic purposes due to its ability to target specific DNA sequences and exhibit collateral cleavage activity on non-target DNA upon activation. This property has been leveraged in diagnostic assays like DETECTR, which can detect specific DNA or RNA sequences with high sensitivity. EGFR mutations are often point mutations or small insertions/deletions, and circulating DNA (cfDNA) from blood samples is a common source for non-invasive cancer diagnostics. Given that CRISPR/Cas12a-based systems have been successfully used to detect specific mutations in DNA, including in cfDNA, by designing guide RNAs to target mutation-specific sequences, it is feasible to apply this technology for EGFR mutation detection. Studies and protocols in the literature have demonstrated the use of Cas12a for detecting mutations in cancer-related genes with high specificity and sensitivity. Therefore, it is reasonable to conclude that CRISPR/Cas12a can indeed be used for this purpose.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether Functional Neurological Disorder (FND) is classified as a psychosomatic disorder, I first need to understand the definitions and classifications. FND is a condition where patients experience neurological symptoms such as weakness, tremors, or seizures that cannot be explained by a structural or organic neurological disease. Historically, FND has been linked to psychological factors and was often considered under the umbrella of conversion disorders or psychosomatic conditions, where physical symptoms are thought to arise from psychological stress or trauma. However, modern understanding, as reflected in the DSM-5 and ICD-11, emphasizes that FND is a distinct diagnosis that does not necessarily require a psychological cause, focusing instead on the mismatch between symptoms and known neurological pathways. While psychological factors can be relevant, they are not mandatory for diagnosis. The term 'psychosomatic' generally implies a direct causal link between mind and body, which is not always accurate for FND under current classifications. Therefore, while there is overlap in historical context and some clinical perspectives, FND is not strictly classified as a psychosomatic disorder in contemporary medical frameworks.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are any medications available to prevent COVID-19 following exposure?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether any medications are available to prevent COVID-19 following exposure, I first consider the context of post-exposure prophylaxis (PEP) for COVID-19. I recall that certain antiviral medications and monoclonal antibodies have been studied or authorized for use in specific scenarios to reduce the risk of developing severe disease after exposure. For instance, drugs like Paxlovid (nirmatrelvir/ritonavir) have been approved for early treatment in high-risk individuals shortly after exposure or symptom onset, which could be considered a form of prevention of severe outcomes. Additionally, there have been discussions and studies around other antivirals or therapies for PEP. However, I must clarify if these are officially recommended or widely available for prevention post-exposure as of the latest guidelines. Upon reflection, while treatments exist for early intervention, the availability of medications specifically labeled for prevention after exposure may depend on regional health policies, specific patient conditions, and evolving research. Given that there are indeed medications like Paxlovid used in such contexts for high-risk individuals, I lean towards a positive response, acknowledging that 'prevention' here likely refers to preventing severe disease rather than infection itself.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Can reinfection occur after SARS-CoV-2 infection?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether reinfection can occur after SARS-CoV-2 infection, I am considering the scientific evidence and reports available up to my knowledge cutoff. SARS-CoV-2 is the virus responsible for COVID-19, and studies have shown that while most individuals develop some level of immunity after infection, this immunity may wane over time. Additionally, the emergence of new variants can evade prior immunity to some extent. There have been documented cases of reinfection, especially with different variants of the virus. Therefore, reinfection is possible, though the likelihood and severity can vary based on factors like vaccination status, time since initial infection, and variant differences.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can other vaccines be given with COVID-19 vaccine?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether other vaccines can be given with the COVID-19 vaccine, I need to consider current medical guidelines and recommendations from health authorities like the CDC or WHO. Generally, the initial guidance during the rollout of COVID-19 vaccines suggested a separation of at least 14 days between the administration of the COVID-19 vaccine and other vaccines to monitor for side effects and ensure efficacy. However, updated recommendations from the CDC (as of the latest data) indicate that COVID-19 vaccines can be co-administered with other vaccines, including influenza and routine immunizations, without a waiting period, as there is no evidence of safety concerns or reduced effectiveness. This change was made to facilitate vaccination schedules and improve coverage. Therefore, based on the most current and widely accepted guidance, it is permissible to administer other vaccines alongside the COVID-19 vaccine.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is omaveloxolone a suppressor of Nrf2?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether omaveloxolone is a suppressor of Nrf2, I need to consider the role of omaveloxolone and its interaction with the Nrf2 pathway. Nrf2 (Nuclear factor erythroid 2-related factor 2) is a transcription factor that regulates the expression of antioxidant proteins, protecting against oxidative stress. Omaveloxolone, also known as RTA 408, is a synthetic triterpenoid compound developed for its potential therapeutic effects in conditions involving oxidative stress and inflammation, such as Friedreich's ataxia. Research indicates that omaveloxolone is actually an activator of Nrf2, not a suppressor. It works by inhibiting Keap1, a protein that normally suppresses Nrf2 activity by targeting it for degradation. By inhibiting Keap1, omaveloxolone allows Nrf2 to accumulate in the nucleus and activate the transcription of protective genes. Therefore, it does not suppress Nrf2 but rather enhances its activity. Based on this analysis, the answer should be 'no'.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Is omaveloxolone an activator of NFkB?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether omaveloxolone is an activator of NFkB, I first consider the nature of omaveloxolone and NFkB. Omaveloxolone is a synthetic triterpenoid compound known for its role in activating the Nrf2 pathway, which is involved in antioxidant and anti-inflammatory responses. NFkB, on the other hand, is a transcription factor primarily associated with pro-inflammatory responses. I recall that omaveloxolone's primary mechanism is through Nrf2 activation, which can sometimes indirectly suppress NFkB activity by reducing oxidative stress and inflammation. However, I am not aware of direct evidence suggesting that omaveloxolone activates NFkB; in fact, it might inhibit it indirectly. Given this analysis, I lean towards a negative answer, but I must confirm that there is no specific study or context indicating activation. Upon reflection, I conclude that omaveloxolone is not known as an activator of NFkB.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Has RTA 408 received FDA approval?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether RTA 408 has received FDA approval, I need to consider the current status of this drug. RTA 408, also known as omaveloxolone, is a compound developed by Reata Pharmaceuticals for the treatment of conditions like Friedreich's ataxia. As of the latest available information, omaveloxolone (under the brand name Skyclarys) received FDA approval on February 28, 2023, for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. This marks it as the first FDA-approved treatment for this condition. Therefore, the answer should reflect this approval status.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can salivary cortisol be used to evaluate pain in neonates?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether salivary cortisol can be used to evaluate pain in neonates, I first consider the nature of cortisol as a stress hormone that increases in response to physical and psychological stressors, including pain. Salivary cortisol is a non-invasive method to measure cortisol levels, which is particularly advantageous in neonates where blood sampling can be distressing and challenging. Research indicates that salivary cortisol levels correlate with plasma cortisol levels, suggesting it as a viable biomarker for stress and pain. Studies have shown that painful procedures in neonates, such as heel pricks, result in elevated salivary cortisol levels, supporting its potential use as an indirect measure of pain. However, there are limitations to consider, such as variability in cortisol responses due to individual differences, circadian rhythms, and other stressors unrelated to pain. Additionally, while salivary cortisol can indicate a stress response, it may not specifically isolate pain from other stressors. Despite these limitations, the non-invasive nature and the evidence from studies suggest that it can be used as part of a broader pain assessment strategy in neonates, often in conjunction with behavioral and physiological pain scales. Therefore, I conclude that salivary cortisol can be used to evaluate pain in neonates, acknowledging it is not a standalone measure but a useful component.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Can breastfeeding be used to alleviate the procedural pain in neonates?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question of whether breastfeeding can be used to alleviate procedural pain in neonates, I first consider the context and available evidence. Procedural pain in neonates refers to discomfort caused by medical interventions such as heel pricks or vaccinations. Breastfeeding is often associated with comfort and soothing for infants due to the physical closeness, skin-to-skin contact, and the release of calming hormones like oxytocin. Research in neonatal care suggests that breastfeeding during painful procedures can reduce pain responses, as evidenced by lower heart rates, reduced crying, and improved behavioral pain scores. Studies, including those published in pediatric journals, have shown that breastfeeding acts as a natural analgesic by providing distraction and comfort. However, it may not be feasible in all situations, such as when the mother is unavailable or the neonate cannot breastfeed due to medical conditions. Despite these limitations, the evidence leans toward breastfeeding being an effective non-pharmacological method for pain relief in many cases. Therefore, my analysis concludes that breastfeeding can indeed be used to alleviate procedural pain in neonates.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Is music therapy effective for pain management in neonates?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether music therapy is effective for pain management in neonates, I first consider the context and available evidence. Music therapy involves using music to address physical, emotional, and cognitive needs, and in neonates, it is often explored as a non-pharmacological intervention for pain relief during procedures or in neonatal intensive care units (NICUs). Research suggests that music can have calming effects, potentially reducing stress and pain perception by stimulating the release of endorphins or distracting from discomfort. Several studies, including systematic reviews, indicate that music therapy can lower heart rate, improve oxygen saturation, and reduce behavioral signs of pain in neonates during painful procedures like heel pricks or circumcisions. However, the evidence is not universally conclusive, as some studies note variability in response based on the type of music, duration, and individual differences among neonates. Despite these limitations, the majority of research leans toward a positive effect, with minimal risk or side effects associated with music therapy. Therefore, based on the balance of evidence, I conclude that music therapy is generally effective for pain management in neonates.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic muscle disorder characterized by progressive muscle weakness, primarily affecting the face, shoulders, and upper arms. Upon analysis, while there is currently no cure for FSHD, there are treatments and interventions aimed at managing symptoms and improving quality of life. These include physical therapy, occupational therapy, and sometimes surgical interventions to address complications like scapular winging. Additionally, ongoing research and clinical trials are exploring potential therapies, but no definitive disease-modifying treatment is widely available yet. Therefore, the answer to whether there is any treatment for FSHD is affirmative, as symptomatic treatments do exist.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Are there any other types of Spinal Muscular Atrophy except for types 1-4?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer the question about whether there are other types of Spinal Muscular Atrophy (SMA) besides types 1-4, I first considered the standard classification of SMA. SMA is a genetic disorder affecting motor neurons, and it is typically categorized into four main types (1, 2, 3, and 4) based on the age of onset and severity of symptoms. Type 1 is the most severe, with onset in infancy, while Type 4 is the mildest, often presenting in adulthood. However, I also recalled that there are rarer forms or variants of SMA that do not fit neatly into these categories, such as SMA Type 0, which is an extremely severe form with onset before birth, and other atypical forms linked to different genetic mutations. After reflecting on this, I conclude that there are indeed other types or variants of SMA beyond the standard 1-4 classification.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do all proteins start with methionine?",
    "answer": "no",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether all proteins start with methionine, I need to consider the process of protein synthesis in cells. In eukaryotic and prokaryotic organisms, protein synthesis begins with the translation of mRNA into a sequence of amino acids. The start codon, AUG, codes for methionine in eukaryotes and most prokaryotes (though in prokaryotes, it can sometimes be formylmethionine, a modified form of methionine). This means that the first amino acid in the nascent polypeptide chain is typically methionine. However, post-translational modifications can occur, where the initial methionine is cleaved off in many proteins. Despite this, the question likely refers to the initial amino acid during synthesis, not the final protein structure after modifications. Therefore, in the context of translation initiation, all proteins do start with methionine (or formylmethionine in prokaryotes). I will answer 'yes' based on this understanding.\",\n    \"answer\": \"yes\"\n}",
    "correct": false
  },
  {
    "question": "Do epigenetic changes change the DNA sequence?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Epigenetic changes refer to modifications in gene expression that do not involve alterations to the underlying DNA sequence. These changes can include DNA methylation, histone modification, and non-coding RNA interactions, which can turn genes on or off without changing the genetic code itself. Therefore, epigenetic changes do not alter the DNA sequence; they affect how the DNA is read and expressed.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are epigenetic changes heritable?",
    "answer": "yes",
    "llm_answer": "yes",
    "llm_response": "{\n    \"draft\": \"To answer whether epigenetic changes are heritable, I first need to consider the definition of epigenetic changes. Epigenetic changes are modifications to gene expression that do not involve alterations to the underlying DNA sequence, such as DNA methylation or histone modification. The question of heritability depends on whether these changes can be passed from one generation to the next. Research shows that some epigenetic marks can be transmitted through germline cells in certain organisms, like plants and animals, under specific conditions. For example, studies in mice have demonstrated that certain epigenetic modifications related to diet or stress can influence the phenotype of offspring. However, in humans, while there is evidence suggesting potential heritability of epigenetic changes (e.g., in cases of famine exposure across generations), the mechanisms and extent are still under investigation and not fully conclusive. Most epigenetic marks are reset during early embryonic development, which limits their heritability. Therefore, while some epigenetic changes can be heritable in specific contexts, it is not a universal rule. Given the question's general nature, I will answer affirmatively but acknowledge the complexity in my draft.\",\n    \"answer\": \"yes\"\n}",
    "correct": true
  },
  {
    "question": "Do enhancers have to be close to their gene targets?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"Enhancers are regulatory DNA sequences that can activate the transcription of specific genes. They do not need to be physically close to their target genes on the linear DNA sequence. Enhancers can be located far away, even on different chromosomes in some cases, and still influence gene expression through mechanisms like DNA looping, which brings the enhancer and promoter into close spatial proximity. Therefore, enhancers do not have to be close to their gene targets.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  },
  {
    "question": "Are accessible enhancers necessarily active?",
    "answer": "no",
    "llm_answer": "no",
    "llm_response": "{\n    \"draft\": \"To answer whether accessible enhancers are necessarily active, I first need to consider the definitions and relationship between accessibility and activity in the context of gene regulation. Enhancers are regulatory DNA sequences that can boost the transcription of associated genes. Accessibility refers to the physical state of the chromatin at the enhancer region—whether it is open and available for binding by transcription factors and other regulatory proteins, often marked by techniques like ATAC-seq or DNase-seq. Activity, on the other hand, typically implies that the enhancer is functionally engaged in promoting gene expression, often evidenced by specific histone modifications (like H3K27ac) or direct measurement of enhancer RNA production. While accessible enhancers are more likely to be active because open chromatin allows for protein binding, accessibility does not guarantee activity; an enhancer could be accessible but lack the necessary transcription factors or co-activators to drive gene expression. Therefore, accessible enhancers are not necessarily active.\",\n    \"answer\": \"no\"\n}",
    "correct": true
  }
]